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ABSTRACT 
 
ANNAH B. WYSS: Single Nucleotide Polymorphisms in Nucleotide Excision Repair Genes and Head 
and Neck Cancer Risk and Outcomes 
(Under the direction of Dr. Andrew Olshan) 
 
 An estimated 52,140 incident head and neck cancers (HNC), with 11,460 associated deaths 
occurred in the US during 2011. Cigarette smoke contributes to HNC risk by causing bulky DNA 
adducts. Such adducts are removed by nucleotide excision repair (NER) processes. Previous studies 
have suggested that polymorphisms in NER genes are independent risk factors for HNC, as well as 
modifiers of smoking-HNC associations.  Treatment of HNC with radiation and platinum-based 
chemotherapies also produce bulky DNA adducts, and previous studies suggest independent NER 
SNP and joint SNP-treatment associations with HNC survival.  
Race-specific (white and African American) odds ratios (ORs) and 95% intervals (Is) for the 
individual and joint effects of 84 single nucleotide polymorphisms (SNPs) in 15 NER genes and 
cigarette smoking on HNC risk were estimated from unconditional and hierarchical logistic 
regression models using data from the Carolina Head and Neck Cancer Epidemiology (CHANCE) 
Study (1,227 cases and 1,325 controls). Race-specific hazard ratios (HRs) and 95% confidence 
intervals (CIs) for the individual and joint effects of the same SNPs in NER genes and treatment 
(surgery, radiation, and chemotherapy) on survival among cases were estimated using Cox 
proportional hazards models, with Bonferroni corrected p-values to account for multiple 
comparisons. 
Among whites, rs4150403 on ERCC3 (XPB) was associated with increased HNC risk (OR=1.28, 
95% I=1.01, 1.61). Among African Americans, rs4253132 on ERCC6 was associated with decreased
iv 
 
HNC risk (OR=0.62, 95% I=0.45, 0.86). For HNC survival, no associations were significant at a 
Bonferroni-corrected alpha of 0.0006. However, rs3136038 and rs3136130 of ERCC4 and rs50871 of 
ERCC2 (XPD) were suggestively associated with similarly improved survival among whites at an 
uncorrected 0.05 alpha (overall survival HRs≈0.80 and disease-specific survival HRs≈0.70). Likewise, 
rs2607755 of XPC was suggestively associated with improved survival among African Americans 
(overall survival HR=0.62 and disease-specific survival HR=0.51). A few SNP-cigarette smoking and 
SNP-treatment interactions suggested possible additive effects.  
We conducted one of the largest and most comprehensive evaluations of SNPs in multiple 
NER genes, identifying only a few SNPs from biologically plausible genes associated with HNC risk or 
survival, and possibly interacting with cigarette smoking or treatment.
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CHAPTER 1 
BACKGROUND AND LITERATURE REVIEW 
1.1 SPECIFIC AIMS 
 In the United States an estimated 52,140 incident cases of oral cavity, pharyngeal and 
laryngeal cancers, with 11,460 associated deaths occured in 2011 (1). Tobacco is a well-established 
risk factor for head and neck cancer (HNC) incidence, with well over 20 cohort and case-control 
studies demonstrating strong associations (2). Nucleotide excision repair (NER) genes remove bulky 
DNA adducts caused by cigarettes smoking (3) and are therefore considered independent predictors 
for HNC, as well as important modifiers of associations between tobacco and HNC (4,5). With regard 
to HNC mortality, treatment is a strong prognostic factor and NER genes are believed to also modify 
the association between treatment and HNC survival through increased/decreased DNA repair 
activities (6,7). 
 Previous research indicates significant associations between polymorphisms in NER genes 
and HNC risk, but vary with regard to which particular genes are predictive of HNC, as well as the 
magnitude of associations (4,5,8-46). Studies regarding the joint effects of cigarette smoking and 
NER genes on HNC risk are more limited, but some indicate stronger effects among smokers with 
polymorphisms in NER genes (4,8-10,13,15,16,22,24,26-28,30,31,33,35-38,40,44). Studies on HNC 
survival have also demonstrated important effects of polymorphism in NER genes and treatment, 
especially with regard to radiation and platinum-based chemotherapy (7,47-55). 
 The impact of cigarette smoking and variation in NER genes on HNC incidence, as well as 
treatment and polymorphisms on survival, may be further modified by race. African Americans
2 
 
 experience higher smoking rates compared to whites in the US (56)  and a previous study using data 
from the Carolina Head and Neck Cancer (CHANCE) study reported higher magnitude odds ratios for 
cigarette smoking and HNC associations among African Americans compared to whites (57). In 
addition, HNC incidence and mortality rates vary by race in the US, and HNC survival is particularly 
low among African Americans men (58-62). Yet studies generally do not consider such associations 
stratified by race; only one study to date has reported NER variant-HNC estimates specific to African 
Americans (15). 
 The CHANCE study contains previously collected demographic, lifestyle and survival data, as 
well as DNA samples, for a large and racially diverse population (959 white and 330 African 
American cases and 1100 white and 261 African American controls) (57,63,64). DNA samples were 
recently genotyped for 1235 single nucleotide polymorphisms (SNPs) in 208 genes (64). Therefore, 
the CHANCE study is suitable to investigate the associations between polymorphisms in NER genes, 
cigarette smoking, and treatment and HNC outcomes by addressing the following dissertation aims: 
 Aim 1: Assess the individual and joint effects of polymorphisms in NER genes (15 genes, 84 
SNPs) and cigarette smoking (ever, frequency, and duration) on HNC risk. Hypothesis.  
Polymorphisms in NER genes will be associated with HNC incidence, with larger effects among 
smokers compared to never smokers. Methods. Unconditional logistic regression will be used to 
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for cigarette smoking, SNPs, and joint 
effects. Gene-environment interactions will be assessed for synergistic effects on the additive scale. 
Adjustment variables will be determined through a directed acyclic graph (DAG), as well as previous 
literature. Possible adjustment variables include: age, sex, education, family history of cancer, 
alcohol drinking, cigar and pipe smoking, smokeless tobacco use, marijuana smoking, nutrition, and 
oral health. Models will also be adjusted for ancestral informative markers (AIMS) and stratified by 
race (African American and white). P-values will be corrected for multiple testing using an alpha 
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adjustment method(s) such as the Bonferroni method. In addition, hierarchical regression will be 
employed to address correlation of exposures (i.e. SNPs in in linkage disequilibrium, LD). 
 Aim 2: Assess the individual and joint effects of polymorphisms in NER genes (15 genes, 84 
SNPs) and treatment (various types of chemotherapy, radiation therapy, and surgery) on risk of 
mortality among HNC cases. Hypothesis. Polymorphisms in NER genes will be associated with 
overall survival and disease-specific survival, with varying prognosis across treatment types.  
Methods. To assess survival, CHANCE data was linked with the National Death Index (NDI) to 
ascertain deaths through 2009. Cox proportional hazards models will be used to estimate hazard 
ratios (HRs) and 95% CIs to compare hazards of mortality among cases based on SNPs in NER, 
treatment (various types of chemotherapy, radiation therapy, and surgery), and their joint effects. 
Interactions will be assessed similar to aim 1. Adjustment variables will be determined using the 
methods described in aim 1, and will include clinical variables, such as tumor stage and site, in 
addition to demographic and behavioral covariates. Models will also be adjusted for ancestral 
informative markers (AIMS) and stratified by race (African American and white). The Bonferroni 
method will be used to account for multiple comparisons. Absolute differences in months of survival 
will also be assessed via Kaplan-Meier plots. 
1.2 HEAD AND NECK CANCER: OVERVIEW 
1.2.1 Definition 
 Head and neck cancer (HNC) is defined as cancers of the oral cavity (lips, gums, tongue, and 
floor and roof of the mouth, also known as the hard palate), pharynx (nasopharnynx, oropharynx, 
including tonsils and base of tongue, and hypopharynx), and larynx (65-67).  Nasopharyngeal cancers 
are generally considered separate from HNC given the different risk factor profile and global 
distribution of the cancer (68). In addition, most studies of HNC exclude lip cancers since the primary 
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risk factor for these cancers is sun exposure and not smoking and alcohol drinking (69). More than 
90% of HNC are squamous cell carcinomas (70). 
1.2.2 Natural progression 
 Although many HNCs arise without detectable premalignant conditions, the presence of 
leukoplakia and erythroplakia may indicate developing disease (71). Leukopakia is characterized by 
white lesions, while erythroplakia is characterized by red lesions (71). Several factors affect the 
likelihood and rate of progression of pre-malignant lesions to cancer, such as anatomic site, 
demographic profile of the individual (e.g., age) and behavioral risk factors (e.g., types of tobacco 
used)(71). For example, it has been suggested that premalignant lesions on the floor of the mouth 
are more likely to progress to cancer than other sites within the oral cavity (71). Likewise, some 
studies have reported higher rates of regression among pipe smokers or tobacco chewers compared 
to cigarette smokers, and smoking cessation has also been associated with a greater likelihood of 
tumor regression (71).  Genetic susceptibility is also an important factor in tumor progression (71). 
Alterations of tumor suppressor genes, including p53, are strongly associated with tumor 
progression (71) A complete description of molecular and clinical progression from hyperplasia to 
cancer can be found in Forastiere et al., 2001 (72).  
1.2.3 Global and US Burden 
Head and neck cancer is among the most common cancers worldwide with nearly 600,000 
incident cases and 300,000 deaths occurring globally each year (73). High incidence regions include 
India and other parts of Southeast Asia, Brazil, Russia, Australia (which is mostly due to lip cancers 
attributed to sun exposure), parts of Europe (mainly Spain and France), and the United 
States(72,74). In the United States, there were an estimated 52,140 new cases of oral cavity, 
pharyngeal and laryngeal cancers, with 11,460 associated deaths in 2011 (1). The age-adjusted 
incidence rate for oral cavity and pharyngeal cancers in the US is 10.6 per 100,000 people per year 
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and the mortality rate is 2.5 per 100,000 people per year (59) (tables 1 and 2). For laryngeal cancers, 
the US incidence and mortality rates are 3.4 per 100,000 and 1.2 per 100,000, respectively (60) 
(tables 1 and 2). HNC is a relatively fatal disease with poor survival. Within three years of diagnosis, 
approximately a third of patients have died; among African Americans more than 40-50% have died 
(61,62) (table 3 and 4). By five years, 40% of patients have died; among African Americans nearly 50-
60% (61,62) (table 3 and 4). As of January 1, 2008, the prevalence of HNC in the US was 
approximately 341,656 men and women (59,60). It is estimated that 1 in 98 people in the US will be 
diagnosed with oral cavity or pharyngeal cancer, and 1 in 277 with laryngeal cancer, during their 
lifetime (59,60).  
1.3 HEAD AND NECK CANCER: DEMOGRAPHIC RISK FACTORS 
1.3.1 Age 
 The median age of diagnosis among oral cavity and pharyngeal cancer cases in the US is 62 
years, with “approximately 0.6% diagnosed under age 20; 2.3% between 20 and 34 years; 6.3% 
between 35 and 44 years; 20.5% between 45 and 54 years; 27.5% between 55 and 64 years; 21.2% 
between 65 and 74 years; 15.6% between 75 and 84 years; and 6.0% 85+ years” (59). The median 
age at death among oral cavity and pharyngeal cancer cases in the US is 67 years, with 
“approximately 0.2% [dying] under age 20; 0.8% between 20 and 34 years; 3.3% between 35 and 44 
years; 14.6% between 45 and 54 years; 24.0% between 55 and 64 years; 23.8% between 65 and 74 
years; 22.1% between 75 and 84 years; and 11.3% 85+ years” (59). The median age at diagnosis and 
death among laryngeal cancer cases is 65 and 68, respectively, with age distributions similar to oral 
cavity and pharyngeal cancers (60).Survival decreases with increasing age (61) (table 3 and 4).  
1.3.2 Sex 
 Incidence and mortality of HNC is much higher in men compared to women in the US 
(59,60). As summarized in table 1, the age-adjusted incidence rates for oral cavity and pharyngeal 
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and laryngeal cancers in men were 2.5 and 4.6 times, respectively, the incidence rates in women 
(15.7 versus 6.2 and 6.0 versus 1.3 per 100,000, respectively) (59,60). With respect to mortality, the 
age-adjusted mortality rates for oral cavity and pharyngeal and laryngeal cancers in men were 2.8 
and 4.4 times, respectively, the mortality rates in women (3.9 versus 1.4 and 2.2 versus 0.5 per 
100,00 people, respectively, table 2) (59,60). 
1.3.3 Race 
 The incidence of oral cavity and pharyngeal cancers has historically been higher among 
African Americans compared to whites in the US; however, starting in 2005 incidence rates 
began to be higher among whites due to more rapid decline in incidence among African 
American men (58,75). In 2008, the age-adjusted incidence rates of oral cavity and pharyngeal 
cancers were 9.1 per 100,000 among African Americans and 11.0 per 100,000 among whites 
(58).  In contrast, age-adjusted mortality rates continue to be higher among African Americans 
compared to whites for all HNC subsites (59,60).  Incidence and mortality rates based on the 
2004-2008 Surveillance, Epidemiology and End Results (SEER) data are presented in tables 1 and 
2 according to HNC subsite, race, and gender. For African Americans, 5-year survival rates are 
30.7% for males and 50.6% for females (61,62,76) (tables 3 and 4). For whites, corresponding 
rates are 58.9% and 61.2%, respectively (tables 3 and 4) (61,62,76).  
1.3.4 Socioeconomic Status 
 As with many diseases, social determinants, such as income and education, are associated 
with HNC outcomes. Socioeconomic status is believed to influence a number of other risk factors for 
HNC, such as smoking and drinking habits, diet, human papillomavirus (HPV) infection, and exposure 
to harmful chemicals in the workplace and housing, but may also act through other mechanisms 
such as access to health information and health care, as well as levels of stress (77). A recent meta-
analysis of 41 case-control studies (15,344 oral cancer cases and 33,852 controls) considered 
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associations between various measures of SES and oral cavity cancer (77,78). Since the individual 
studies varied greatly with regard to measurement scale of income, occupation and education, 
Conway et al. (77) selected the lowest and highest categories for each variable as reported by the 
original authors and then collapsed across the heterogeneous definitions to form  ‘high’ and ‘low’ 
categories for the  meta-analysis. Of the 41 studies considered, five studies reported information on 
household income resulting in a summary OR (95% CI) for low income compared to high income of 
2.41 (1.59, 3.65) (77). Fourteen studies reported on occupation resulting in a summary OR (95% CI) 
of 1.84 (95%CI 1.47, 2.31) for low occupation social class compared to high occupation social class 
(77). Thirty-seven studies reported on education resulting in a summary OR (95% CI) of 1.85 (1.60, 
2.15) for low educational attainment compared to high educational attainment (77).  
1.3.5 Family History 
 Family history is often considered as a marker of inherited genetic susceptibility, which can 
play a strong role in cancer incidence and mortality (79). In 2004, International Head and Neck 
Cancer Epidemiology (INHANCE) Consortium began pooling HNC case-control studies throughout 
the world to better characterize risk factors (80).  In an INHANCE study on family history, having a 
relative diagnosed with HNC was associated with increased risk; OR (95% CI) was 1.62 (1.32, 1.98) 
for 1 affected relative and 2.65 (1.13, 6.22) for 2 or more affected relatives (79). Specifically, having 
a parent with HNC was associated with a 45% increase in risk [OR (95% CI0 = 1.45 (1.14, 1.84)] and 
having a sibling with HNC was associated with a 123% increase in risk [OR (95% CI) = 2.23 (1.61, 
3.08)] (79). 
1.3.6 Genetic Variation 
 In addition to variants in nucleotide excision repair (NER) genes (as will be discussed in detail 
in later sections), associations between variants in a number of other genes and HNC have been 
investigated. For example, the INHANCE consortium, in collaboration with the Central Europe study 
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and the Alcohol Related Cancers and Genetic susceptibility in Europe (ARCAGE) study, recently 
published a genome-wide analysis (GWA) detailing the association between 294,620 variants and 
upper-aerodigestive tract (UADT) cancers, including HNC (81). In the first phase of this study, 
associations between all 294,620 single nucleotide polymorphisms (SNPs) and UADT cancers were 
examined in the Central Europe and ARCAGE study populations (2,091 cases and 3,513 controls 
from the studies, plus an additional 4,821 genomic controls) (81). In the second phase, the top 
nineteen SNPs associated with UADT cancer, as identified in phase 1, were then examined for 
association with only HNC in the INHANCE population (6,514 cases and  7,892 controls) (81). From 
this paper it is unclear which NER variants were tested, but based on a Bonferroni corrected alpha 
level of (p ≤ 5x10-7), five SNPs were found to be significantly associated with UADT cancers: 
rs4767364 in ALDH2; rs1494961in HEL208 (related to the ADH genes); and rs1573496, rs1229984 
and rs698 in ADH7, AHD1B, and ADH1C, respectively (81). All of these genes are known to function 
in alcohol metabolism, and the individual and joint effects of variants in ALDH2 and ADH genes and 
alcohol on HNC incidence and survival in CHANCE were recently analyzed by Dr. Anne Hakenewerth 
as part of her dissertation (64,82).   
1.4 HEAD AND NECK CANCER: ENVIRONMENTAL AND BEHAVIORAL RISK FACTORS 
1.4.1 Cigarette Smoking  
 Although the cigarette smoking is on the decline in the US, an estimated 17.2% of 
individuals in the US smoke cigarettes (56). With regard to prevalence of smoking by race in the US, 
17.4% of whites and 19.1% of African Americans smoked in the US in 2010 (56). Cigarettes contain 
many IARC classified probable and known carcinogens, including tar, nicotine, nickel, arsenic, lead, 
benzene and a host of nitrosamines (2). The effects of tobacco use on the incidence and mortality of 
HNC is well established (2).  For example, the IARC Monograph on Tobacco Smoke (2) concluded that 
there is sufficient evidence for a casual association between cigarette smoking and head and neck 
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cancer based on biologic and epidemiologic evidence. The monograph summarizes the findings of 3 
cohort studies on cigarette smoking and HNC with risk ratios (RR) from 1.5 to 3.4 and over 15 case-
control studies with odds ratios (OR) ranging from approximately 2.0 to 10.0. Strong dose-response 
trends in frequency and duration were also noted across studies (2).  
 In one of the first studies published by INHANCE, which included data from 15 case-control 
studies at the time, investigators estimated the individual effects of cigarette smoking on HNC by 
focusing analyses on never alcohol drinkers to better understand the independent effects of 
cigarette smoking separate from other major risk factors (83). Among never alcohol drinkers, the 
summary OR (95% CI) for cigarette smoking and HNC was found to be 2.13 (1.52, 2.98), with 
individual study estimates ranging from 0.36 (0.07, 1.91) for Seattle to 11.53 (4.69, 28.31) for Milan 
(83). Given the heterogeneity of studies, which may reflect regional differences in smoking habits 
and products among other reasons, the authors considered the impact of removing the four most 
influential studies (including Seattle and Milan) which resulted in a summary OR of 2.02 (1.61, 2.53) 
for cigarette smoking and HNC (83). The effect estimate also did not change substantially when only 
large studies (i.e. more than 500 cases) were considered (83). The authors also noted strong dose-
response trends (p<0.001) across frequency (cigs/day), duration (years), and cumulative packyears 
of cigarette smoking, with ORs over 4.0 for the highest levels of frequency and packyears (83).  With 
regard to subsite, INHANCE reported the strongest association for cigarette smoking and laryngeal 
cancer. Among never alcohol drinkers, ORs (95% CIs) associated with cigarette smoking were 1.35 
(0.90, 2.01) for oral cavity cancer, 2.02 (1.34, 3.05) for oropharyngeal and hypopharyngeal cancer, 
and 6.84 (4.25 to 11.01) for laryngeal cancer (83). The estimated population attributable fraction of 
cigarette smokers among never drinkers was near 25%, and 75% of HNC were attributed to cigarette 
smoking and alcohol drinking combined (83,84).  
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 A recently published analysis from the Carolina Head and Neck Cancer Epidemiology 
(CHANCE) Study reported an adjusted OR (95% CI) for current cigarette smoking compared to never 
cigarette smoking was 3.92 (3.00, 5.13) which agreed with estimates from similarly powered studies 
included INHANCE (57). Likewise, risk appeared to increase with increasing frequency, duration, and 
packyears of use, with ORs over 3.0 for the highest levels of frequency and duration in CHANCE (57). 
CHANCE also provided an opportunity to consider race-stratified estimates. The adjusted ORs (95% 
CIs) for current cigarette smoking were 15.1 (7.11, 32.0) among African Americans and 3.14 (2.36, 
4.20) among whites (57). Increasing trends in frequency, duration, and packyears of use were noted 
for each race (57). 
 Cigarette smoking has also been linked to decreases in survival. In the National Institutes of 
Health – American Association of Retired Persons (NIH-AARP) cohort study, investigators from the 
National Cancer Institute (NCI) found adjusted hazard ratios (HRs) for former and current smokers, 
compared to never smokers,  of 3.47 (2.06, 5.87) and 12.96 (7.81, 21.52), respectively (85). Elevated 
risk of death among HNC cases who currently smoke compared to non-smokers was also noted in a 
Japanese study (86).  
 1.4.2 Use of Other Tobacco Products  
 Cigars and pipes contain carcinogens similar to cigarettes and delivered dosages of some 
carcinogens may even be higher in cigars than in cigarettes (2). Elevated risk of head and neck 
cancer among pipe and cigar smokers has been consistently reported in literature (2,87). For 
example, in an unpublished analysis of the INHANCE pooled case-control data, the adjusted ORs 
(95% CIs) among never-cigarette smokers were (2.54, 95% CI=1.93, 3.34) for ever cigar smoking and 
(2.08, 95% CI=1.55, 2.81) for ever pipe smoking (87). Risk of head and neck cancer also increased 
with increasing frequency and duration of cigar and pipe smoking (87) . 
11 
 
 Heavy daily use of smokeless tobacco products directly exposes the oral cavity to 
carcinogens and can result in exposure to nicotine comparable to that of heavy smokers (88). 
Previous estimates on the risk of HNC among smokeless tobacco users in the US are varied and 
often hard to interpret due to low frequencies of users and indistinct definitions of exposure (89). A 
review by Boffetta on smokeless tobacco and risk of head and neck cancer in the US (90), considered 
nine studies with risk estimates ranging from 0.9 (0.1, 6.7) to 11.2 (4.1, 30.7). The pooled relative 
risk (RR) and 95% CI for the nine studies was 2.6 (1.3, 5.2 (90). Likewise, studies summarized in the 
IARC Monograph on Smokeless Tobacco (88) varied between null and elevated ORs for ever tobacco 
chewers and ever snuff users. In an unpublished INHANCE study, the adjusted ORs (95% CIs) among 
never cigarette smokers were 1.40 (0.71, 2.09) for ever tobacco chewing and 1.56 (0.68, 2.44) for 
ever snuff use in the US (91). Internationally, betel quid and other regional forms of smokeless 
tobacco products have been more strongly associated with HNC (88). 
1.4.3 Environmental Tobacco Smoke 
 Environmental tobacco smoke (ETS), also known as involuntary, passive or secondhand 
smoke, occurs from sidestream and exhaled mainstream cigarette smoke (2,92). Although the 
composition and concentration of ETS varies based on the setting, experimental and observational 
studies have consistently demonstrated elevated levels of many tobacco-related carcinogens in the 
ambient air (2). Although IARC has classified ETS as a causal agent for lung cancer, relatively few 
studies have considered the effects of ETS on HNC risk (2,92). As of April 2012, only six studies were 
found to report on the association between ETS and HNC risk (92-97). Results have been somewhat 
mixed with smaller studies tending to find larger magnitude ORs for the association between ETS 
and HNC and larger studies more likely to report attenuated ORs (92-97). However, the conclusion 
of potentially modest increased risk of HNC associated with ETS was relatively uniform across 
studies. The two largest studies, both by Lee et al, reported ORs (95% CIs) for ever ETS exposure in 
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home or at work of 1.07 (0.85, 1.34) in the International Head and Neck Cancer Epidemiology 
(INHANCE) consortium (92) and 1.87 (1.08, 3.23) and 1.98 (0.77, 5.07) with respect to 
oral/oropharyngeal and laryngeal/hypopharngyeal cancer in the ARCAGE study (96). Both of these 
studies also found evidence for increasing HNC risk with increasing intensity of ETS exposure (92,96).  
1.4.4 Alcohol Consumption 
 Next to cigarette smoking, alcohol drinking is the second most established risk factor for 
HNC. Alcohol contains several possible, probable and known carcinogens, including nitrosamines 
(98). Further, genetic variants that help regulate the metabolism of alcohol can impact the levels of 
acetaldehyde which may cause DNA damage through several pathways, including the formation of 
DNA adducts (98). The IARC Monograph on Alcohol Consumption (98) concluded that there is 
sufficient evidence to classify alcohol as a carcinogen for HNC. Nearly 20 cohort and case-control 
studies have reported positive associations between alcohol and HNC, including dose-response 
relationships with highest risk among heaviest consumption (98).   
 In the first INHANCE study on alcohol drinking, investigators found the OR (95% CI) between 
ever drinking alcohol and HNC to be 1.18 (0.93 to 1.50) among never tobacco users, with the 
association being significantly elevated after ‘influential’ studies were dropped from the analysis 
(83). In addition, risk of HNC increased with increasing frequency of alcohol drinking (ptrend<0.0001), 
with elevated risk among individuals who consumed 3 or more drinks a day (83). In a subsequent 
INHANCE publication on the joint effects of alcohol and tobacco, the authors reported a greater 
than multiplicative effect with an interaction parameter [Ψ = OR11 / (OR01 * OR10)] and 95% CI of 
2.15 (1.53-3.04) (84). Approximately 7% of HNC are attributed to alcohol drinking alone, and 75% to 
alcohol drinking and cigarette smoking combined (83,84). 
 Recently, a series of meta-analyses on the association between alcohol consumption and 
risk of HNC have been published. Including 40 studies on the association between alcohol and 
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laryngeal cancer, the summary estimate was found to be RR (95% CI) = 1.90 (1.59, 2.28), with null 
associations among light drinkers and increased risk among heavy drinkers (99). For oral cavity and 
pharyngeal cancers, both light drinkers (1 drink or less per day) and heavy drinkers (4 or more drinks 
per day) had increased risk; summary RRs (95% CIs) for 45 studies were 1.21 (1.10, 1.33) and 5.24 
(4.36, 6.30), respectively (100). Neither meta-analysis appeared to consider the effects of alcohol on 
HNC risk among non-smokers, however. 
1.4.5 Human Papillomavirus   
 Human papillomavirus (HPV) up-regulates oncoproteins, namely E6 and E7, which disrupt 
p53 and pRb tumor suppression pathways (101). An estimated 20-25% of HNC are attributed to oral 
infection with HPV (101). Increases in HPV infection have been implicated in recent increases in 
oropharyngeal cancer incidence, especially as alcohol and tobacco consumption appear to remain 
stable or decline in the US (78,101). The IARC Monograph on HPV summarizes several case series 
which report the prevalence of HPV in HNC ranging from 0% to 100%.  A review of case-control 
studies showed mixed results, but most demonstrated elevated ORs for HNC, especially for 
oropharyngeal cancer, among HPV-positive individuals (102). With regard to survival, a meta-
analysis reported a decrease in the 5-year risk of dying among HNSCC cases who were HPV-positive 
compared to HPV-negative, with hazard ratios (HR) ranging from 0.20 to 0.75 (103).  
1.4.6 Diet and Body Mass Index 
 Nutrition and body mass index (BMI) have also been hypothesized as risk factors for HNC 
(78). Although studies on specific micro- and macronutrients and HNC are limited, carotene, vitamin 
C, vitamin A, calcium, flavonoids, and fiber have all been implicated as beneficial due to antioxidant 
and other properties (104). Most studies on diet and HNC have focused on fruit and vegetable 
intake (78). In a meta-analysis by Pavia et al. (105), 16 studies of oral cavity cancer resulted in 
summary ORs (95% CIs) of 0.51 (0.40, 0.65) for fruit consumption and 0.50 (0.38, 0.65) for vegetable 
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consumption. In a separate meta-analysis by Riboli (106), 12 studies on oral/pharyngeal cancer (9 
studies and 7 studies included for fruits and vegetables, respectively) and 8 studies on laryngeal 
cancer (5 studies and 7 studies included for fruits and vegetables), produced summary ORs (95% CIs) 
of 0.53 (0.37, 0.76) for fruits and oral/pharyngeal cancer, 0.84 (0.67, 1.07) for vegetables and 
oral/pharyngeal cancer, 0.73 (0.64, 0.84) for fruits and laryngeal cancer, and 0.93 (0.83, 1.02) for 
vegetables and laryngeal cancer. In addition to fruits and vegetables, other diets and foods have 
been associated with lower or higher risk of HNC (78,104).  
 With regard to BMI, a recent INHANCE study showed increased risk of HNC among low BMI 
individuals and decreased risk among high BMI individuals at reference (diagnosis for cases and 
enrollment for controls) (107). Specifically, the study reported adjusted ORs (95% CIs) of 2.13 (1.75, 
2.58) for BMI ≤18.5 kg/m, 0.52 (0.44, 0.60) for BMI >25-30 kg/m, and 0.43 (0.33, 0.57) for BMI ≥30 
kg/m (BMI >18.5-25 was used as the referent).  
1.4.7 Oral Health 
 Poor oral health is believed to contribute to HNC risk due to chronic bacterial infection (78). 
Studies investigating oral health and HNC risk have reported mixed results, but most suggest a 
modest increased risk associated with ‘poor’ oral health (63,78,108,109). Individual evaluations of 
two multicenter studies included in IHANCE found a positive association between poor general oral 
health and HNC in Central Europe [OR (95% CI) = 2.89 (1.74, 4.81)] and Latin America [OR (95% CI) = 
1.91 (1.49, 2.45)], where general oral health was scored by a trained dentist as good, average, or 
poor based on the presence of tartar, gingival bleeding, mucosal irritation, and decaying teeth (108). 
Tooth loss was also assessed and was not associated with HNC in Central Europe [OR (95% CI) =1.09 
(0.73, 1.62) for 6-15 teeth lost and 0.70 (0.44, 1.11) for greater than 15 teeth lost], but was 
associated with an increased risk in Latin America [OR (95% CI) =1.28 (0.99, 1.65) for 6-15 teeth lost 
and 1.31 (1.00, 1.72) for greater than 15 teeth lost](108). Self-reported indicators of oral health, 
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namely frequency of tooth brushing, were also assessed but no strong (i.e. significant) associations 
were found in either the Central European or Latin American populations (108).  
 In a recent CHANCE study, tooth loss and use of mouth wash were not strongly associated 
HNC; adjusted ORs (95% CIs) were 1.07 (0.81, 1.42) for 6-15 teeth lost, 1.21 (0.94, 1.56) for 16-28 
teeth lost, and 0.95 (0.78, 1.15) for mouthwash use (63).  In contrast, tooth mobility was associated 
with an increased risk of HNC [OR (95% CI) = 1.33 (1.07, 1.65)] and routine dental visits was 
associated with a decreased risk of HNC [OR (95% CI) = 0.68 (0.53, 0.87)] (63). 
1.4.8 Marijuana Use 
 Since marijuana contains combustion-related carcinogens similar to cigarettes, associations 
between marijuana use and HNC have been suggested (110). However, results of several case-
control studies have been mixed. While one study reported elevated risk (111) and another study 
reported decreased risk among ever marijuana smokers (112), the majority of studies report near 
null ORs (110,113-117). The INHANCE pooled analysis of 5 case-control studies on marijuana use 
reported a summary adjusted OR (95% CI) of 0.88 (0.67, 1.16) for ever use (110).  
1.5 HEAD AND NECK CANCER: SURVIVAL SPECIFIC FACTORS 
1.5.1 Stage 
 Cancer stage is a measure of tumor progression or metastasis (59,60). SEER classifies stage 
into four general categories: localized (confined to primary site), regional (spread to lymohnodes), 
distant (cancer has metastasized), and unknown (unstagged) (59,60). Approximately half of oral 
cavity and pharyngeal cancers are diagnosed at a regional stage (59). An additional one-third of oral 
cavity and pharyngeal cancers are diagnosed at a localized stage, while 15% at a distant stage (59). 
For laryngeal cancers, the bulk of tumors are diagnosed at a localized stage (57%) (60). 
Approximately 20% of laryngeal cancers are diagnosed at a regional stage and another 20% at a 
distant stage (60). For oral cavity, pharyngeal, and laryngeal cancers, the 5-year relative survival 
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ranges from approximately 80% for localized tumors to around 33% for distant cancers based on the 
SEER estimates from 2001-2007 (59,60). 
  Survival based on TNM staging display similar survival distributions.  TNM staging, as 
instituted by the American Joint Committee on Cancer (AJCC) and utilized by the American Cancer 
Society (ACS), classifies tumors based on the size of the tumor (T), the spread of the tumor (N), and 
metastasis to other locations (M) into 7 standard stages:  0 (in situ) I, II, III, IVA, IVB, and IVC (118).  
Based on this system, five- year survival rates range from 70-80% for stage 1 to 30-40% for stage IV 
among oral cavity cancers and from 60-90% for stage 1 to 35-45% for stage IV among laryngeal 
cancers (119). Survival among oropharyngeal and hypopharyngeal cancers is somewhat lower and 
more consistent across TNM stages (119).  
1.5.2 Grade 
 Tumor grade is used to classify cancer cells with respect to appearance (also known as 
histologic grade or differentiation) and progression as measured by nucleus size and shape and cell 
division (also known as nuclear grade) (120). SEER classifies grade into 4 general categories: well-
differentiated (low grade, G1), moderately differentiated (intermediate grade, G2), poorly 
differentiated (high grade, G3), and undifferentiated (high grade, G4) (120).  Among oral cavity 
cancers, approximately 18% of tumors are grade 1, 43% grade 2, 21% stage 3 or 4, and 18% are of 
unknown stage at diagnosis (121). Among oropharyngeal and hypopharyngeal cancers, 
approximately 6% of tumors are grade 1, 39% grade 2, 40% stage 3 or 4, and 15% are of unknown 
stage (121). In general, survival improves with increasing level of differentiation (decreasing grade 
number) for HNC (120,121). Among cancer sites in the oral cavity, 5-year survival ranges from 63-
70% for grade 1 to 40-48% for grade 3 or 4 (121). For cancer of the pharynx, 5-year survival ranged 
from 50% (oropharynx) to 26% (hypopharynx) for grade 1 and 55% (oropharynx) to 29% 
(hypopharynx) for grade 3 and 4 (121). 
17 
 
1.5.3 Treatment 
 Treatment for HNC usually involves one or more of the following medical procedures: 
surgery, radiation therapy, or chemotherapy (122). Choice of treatment is determined based on a 
variety of factors such as tumor location, tumor size, and tumor stage, as well as the patients’ age, 
health, and preference (122). Historically, HNC was treated by surgery, radiation therapy, or both, 
with patients with stage 3 and 4 tumors received higher doses of radiation (65,72). Chemotherapy 
was reserved for treating recurrent tumors (65,72). However, in the 1990’s a series of clinical trials 
demonstrated improved survival among advanced primary HNC by adding chemotherapy to existing 
treatment regimens (72). Radiation and chemotherapy can be administered using an induction 
(chemotherapy before surgery or radiation), concurrent (chemotherapy and radiotherapy at the 
same time), or adjuvant (chemotherapy after surgery or radiation) approach (72). Patients with 
stage 1 and 2 tumors are still typically treated with surgery and/or radiation therapy (possibly 
chemotherapy), but the majority of advanced tumors (stage 3 and 4), especially those that have 
metastasized to be inoperable, are now treated with concurrent or induction chemotherapy (65,72). 
It should also be noted that given the potential for voice loss with surgery, laryngeal and 
hypopharyngeal cancers are usually treated with radiotherapy and/or chemotherapy; though 
advances in surgical techniques which preserve the voice are making surgery more feasible (65,72). 
1.6 NUCLEOTIDE EXCISION REPAIR  
1.6.1 DNA Damage and Repair 
 DNA damage includes base substitutions, strand breaks, and bulky adducts which bind to 
DNA (123). DNA damage is caused by a host of endogenous and exogenous factors (123). 
Endogenous causes include spontaneous alterations and oxidative damage by reactive oxygen 
species (123). Exogenous causes include externally induced damage catalyzed by physical and 
chemical agents such as ionizing radiation, UV radiation, and tobacco-related nitrosamines 
18 
 
(123,124). To resolve DNA damage, endogenous systems detect and repair alterations (123). 
Specifically, DNA repair comprises several biologic processes or pathways which include direct 
reversal, mismatch repair (MMR), nucleotide excision repair (NER), base excision repair (BER), 
homologous recombination, and non-homologous end joining (125,126).  
Direct reversal repairs methylation damage and unlike other DNA repair pathways it is a 
single step process that does not involve excision of bases (123,125). Mismatch repair (MMR) 
corrects single base insertions and deletions (125). MMR plays a crucial role in a number of cancers 
including colorectal cancer, skin cancer, and lymphomas (125). Nucleotide excision repair (NER) 
removes bulky adducts (around 30 nucleotides) and base excision repair (BER) removes smaller 
adducts (typically 1-13 nucleotides) (123-125).  Homologous recombination and non-homologous 
end joining genes are responsible for repairing double strand breaks in the DNA in conjunction with 
cell cycle genes (125). Non-homologous end joining repairs 90% of double strand breaks in 
mammals (125).  
 This dissertation focused on the function of genes in the NER pathway. In addition to a 
number of studies linking SNPs in NER genes directly to HNC (as will be detailed in later sections), 
genes within the NER pathway were chosen as the focus of this dissertation for two reasons. First, 
NER is the pathway primarily responsible for removing bulky DNA adducts produced from tobacco 
smoke (3,126). Second, NER genes also repair bulky DNA adducts produced from ionizing radiation 
and platinum containing agents such as several chemotherapies used in treating HNC (6). Therefore, 
NER has been shown to have the potential to impact both HNC incidence and survival. 
1.6.2 DNA Adducts 
 DNA adducts are defined by La et al. (127) as “a covalent interaction between an 
electrophile and a nucleophilic site in DNA.” A number of carcinogenic compounds can act as 
electrophiles and form such complexes with DNA. Chemicals contained in tobacco smoke, such as 
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benzo[a]pyrene, have been shown to form bulky DNA adducts (3,4).  In addition, radiotherapy and 
platinum-based chemotherapy have been associated with DNA adduct formation (6,7,48).  If left 
unrepaired, DNA adducts can contribute to cancer initiation and progression (127). 
1.6.3 Nucleotide Excision Repair Mechanism 
 Nucleotide excision repair involves four general phases: recognition, pre-incision, incision, 
polymerization and ligation (also known as repair synthesis) (123,124,128). Table 5 and figure 1 
(adapted from Friedberg 2001 (124)) provide an overview of the proteins involved in each phase of 
NER. During the recognition phase, XPC, HHRAD23A, and HHRAD23B proteins (encoded by XPC, 
RADA, and RADB genes, respectively) bind with a DNA adduct, followed by XPA (encoded by the XPA 
gene) and the RPA complex which begin to distort the damaged nucleotide region, marking it for 
incision (123,124,128) (figure1, panel b). The transition from the recognition phase to the incision 
phase continues with the binding of the TFIIH complex (123,124,128) (figure 1, panel c). This 
complex is composed of several subunits, including proteins ERCC3 (XPB), ERCC2 (XPD), CDK7, and 
CCNH which are encoded by genes of the same name, and has the primary function to unwind the 
DNA strands surrounding the damaged nucleotides (123,124,128). Following the denaturing of the 
double helix, incisions on either side of the damaged site, known as a dual incision, occur via ERCC1 
and ERCC4 (XPF) at the 5’ end and ERCC5 (XPG) at the 3’ end (proteins encoded by genes of the 
same name) (123,124,128) (figure1, panel d).  Once the DNA adduct (approximately 27-30 
nucleotides) is removed, the gap is filled with functional nucleotides which are mobilized by DNA 
polymerase, in connection with RPA, RFC, and PCNA  (123,124,128) (figure1, panel e). Finally, the 
functional nucleotides are covalently bound by DNA ligase which is encoded by LIG1 (123,124,128) 
(figure1, panel e). DDB2 (XPE) also contributes to NER, but its exact function remains to be 
elucidated (124). ERCC6 and ERCC8 encode proteins of the same name, also known as CSB and CSA, 
which function in transcription-coupled NER (123,124). While the general steps of transcription-
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coupled NER have been outlined, the exact mechanisms of transcription-coupled NER, namely 
during the recognition phase, is not known as well as the NER mechanisms previously discussed 
(123,124). 
1.6.4 Health Consequences of Variants in Nucleotide Excision Repair Genes 
 Germline mutations in NER genes can result in a number of diseases and conditions 
including Xeroderma pigmentosum (XP), Cockayne syndrome (CS), Cerebo-oculo-facio-skeletoal 
syndrome, and UV-sensitive syndrome (123). Most of these conditions are neurological and/or skin-
related and arise when mutations in NER genes prevent repair of nucleotides damaged by UV-
radiation (123). In addition, mutations in NER genes have been linked to a number of cancers, 
including skin cancer, lung cancer, bladder cancer and head and neck cancer (3). As described in 
detail in the Nature Reviews Cancer article titled How Nucleotide Excision Repair Protects Against 
Cancer by Friedberg (124), SNPs in NER genes can contribute to carcinogenesis if left unrepaired. 
Although Friedman’s article is in specific reference to skin cancer (124), the principle holds for HNC; 
when SNPs render NER genes inoperative, DNA damage persists and HNC can arise.  
 In the context of HNC incidence, SNPs in NER genes may influence the efficiency of excision 
of bulky DNA adducts caused by tobacco smoking (3,4). Therefore, the odds of HNC may vary based 
on the population distribution of variants in NER genes, especially among smokers. With regard to 
survival, radiotherapy and chemotherapy target damaged DNA sites to produce bulky DNA adducts, 
among other alterations, in order to initiate apoptosis of cancerous cells (6,7). Therefore, functional 
NER genes can actually counteract this effect by repairing damage and reducing the impact of 
treatment (6).  As noted in a New England Journal of Medicine article by Gazdar (6), “it has been 
known for about a decade that nucleotide excision repair is involved in the resistance of several 
types of tumors to certain drugs, including platinum compounds.” While some HNC studies support 
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the hypothesis of improved survival associated with polymorphisms in NER genes, some studies 
suggest no association or a counter effect with respect to mortality (7,47-55). 
 The following sections summarize previous epidemiologic studies on the effects of SNPs in 
NER genes, as well as interactions between NER genes and tobacco, on HNC incidence. Previous 
epidemiologic studies on the associations between SNPs in NER genes, as well as interactions 
between NER genes and treatment, and HNC mortality will also be discussed.  
1.7 SINGLE NUCLEOTIDE POLYMORPHISMS IN NUCLEOTIDE EXCISION REPAIR GENES, CIGARETTE 
SMOKING, AND HNC INCIDENCE 
 
1.7.1 ERCC3 (XPB) 
 XPB, previously known as ERCC3, is one of many components in the TFIIH subunit which is 
responsible for unwinding the double helix surrounding the DNA adduct (123). The gene which 
encodes this protein is located at 2q21 (129,130). Only one study has reported on the association 
between variants in XPB and HNC incidence (table 7) (31). Michiels et al. (31) investigated the role of 
rs423358 among former and current smokers in France. Age, tobacco, and alcohol adjusted ORs 
(95% CIs) of 0.37 (0.15, 0.90) and 0.62 (0.39, 0.97) for AA and AC, respectively, compared to CC were 
reported (31).  
1.7.2 XPC 
 XPC acts first in the NER pathway to bind the DNA adduct in a complex (123). The XPC gene 
is located at 3p25 (129,130). Three SNPs in XPC have been considered for HNC incidence:  PAT, 
rs2228001, and rs2228000 (table 7). The PAT SNP, an insertion/deletion polymorphism, has been 
associated with increased odds of HNC in two studies, but not in a third (24,35,40). Contrasting the 
++ versus - - genotypes, Kietthubthew et al. (24) reported an adjusted OR (95% CI) of 1.60 (0.55, 
2.36) for oral cancer among a Thai population, and the more powered study by Shen et al. (35) (287 
HNC cases and 311 controls) reported an OR (95% CI) of 1.85 (1.12, 3.05) for HNC among a 
predominantly Caucasian population in Texas. In contrast, a study conducted in a Japanese 
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population by Sugimura et al. (40) reported an OR (95% CI) of 0.83 (0.51, 1.34) for PAT and oral 
cancer using a dominant genetic model. A meta-analysis by Flores-Obando et al. of these three 
studies (131), plus a South Korean study which focused on expression of XPC but reported frequency 
of PAT (42), resulted in crude ORs (95% CIs) of 1.09 (0.86-1.37) for +- versus ++, 1.39 (0.99-1.97) for -
- versus ++, and 1.14 (0.92-1.43) for +- and -- versus ++. These results therefore suggest elevated risk 
may be associated with the absence of the PAT SNP. Another meta-analysis which considered the 
studies on XPC and oral cancer separate from the studies on HNC found similar results (132).  
 Three studies have investigated the association between rs2228001, which is a Lys939Gln 
substitution, and HNC incidence (4,5,24). The largest case-control study (829 HNC cases and 854 
controls) in the US reported a near null association, with an adjusted OR (95% CI) of 1.08 (0.81, 1.43) 
under a recessive model (Gln/Gln vs. Lys/Gln + Lys/Lys) (5). A dominant model of this SNP (Gln/Gln + 
Lys/Gln vs. Lys/Lys) was also explored in a large study (248 laryngeal cases and 647 controls) in 
Germany, and also resulted in near null results; OR (95% CI) = 0.98 (0.68, 1.40) (4). A Thai study on 
oral cancer reported an OR (95% CI) of 1.35 (0.50, 3.92) for CC versus AA genotypes, but as 
evidenced by the wide confidence interval for the estimated effect estimate, this study was much 
smaller (106 oral cancer cases and 164 controls) (24). A meta-analysis of these three studies by 
Flores-Obando (2010) (131) suggested modest increased risk from rs2228001 with crude ORs (95% 
CIs) of 0.94 (0.80-1.12) for Lys/Gln versus Lys/Lys, 1.17 (0.92-1.49) for Gln/Gln versus Lys/Lys, and 
0.99 (0.85-1.16) for Lys/Gln and Gln/Gln versus Lys/Lys. The large US-based study by An et al. (5) 
also reported an elevated association for the genotype associated with Val/Val of rs2228000. Even 
after adjustment for age, gender, tobacco, and alcohol, the OR (95% CI) was 1.65 (1.16, 2.36) (5).  
 For the PAT SNP in XPC, Shen et al. (35) investigated the joint role of tobacco, but found no 
substantial differences between smoking groups (table 8). Across never smokers, former smokers, 
and current smokers, the OR (95% CI) associated with the risk genotype appeared similarly elevated; 
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ORs (95% CIs) were 1.87 (0.72, 4.86), 1.83 (0.85, 3.94), and 1.69 (0.66, 4.35), respectively (35). A 
Japanese study by Sugimura et al. (40) also reported on the interaction between XPC-PAT and 
tobacco finding the OR (95% CI) for HNC to be 0.48 (0.13, 1.87).  
1.7.3 XPA 
 XPA is located at 9q22.3 (129,130). The XPA protein, along with the RPA complex, acts early 
in the NER pathway to bind DNA and proteins in a pre-incision complex (123). One SNP in XPA has 
been studied extensively in relation to HNC incidence; a nucleotide substitution of A23G (rs1800975) 
(table 7). Across five studies mixed results have been observed, with a dominant model suggesting 
some elevated risk (OR = 1.20; 95% CI = 0.86, 1.70 for AG + AA versus GG) (4), a recessive model also 
suggesting an effect (OR = 2.04; 95% CI =1.18, 3.55 for AG + GG versus AA) (40) and other recessive 
and general models suggesting no or weak associations (5,9,18). A recent meta-analysis of these five 
studies found a summary crude ORs (95% CIs) of 1.15 (0.96, 1.36) for GG vs. AA (general model) and 
1.12 (0.95-1.32) for AG + GG vs. AA (dominant model)(131).  
 One of the studies which considered the SNP rs1800975 reported on the interaction with 
tobacco, concluding a synergistic effect of the SNP and cigarette smoking (9). Specifically, this 
Taiwanese study (154 cases and 105 controls) reported ORs with wide confidence intervals of 3.52 
(1.26, 9.84) for nonsmokers with the risk genotype and 47.7 (15.48, 147.01) for smokers with the 
risk genotype compared to nonsmokers with the reference genotype (table 8) (9). Another study 
which considered this SNP found an interaction OR (95% CI) of 0.48 (0.11, 2.16) for smokers with the 
risk genotype AG or GG in a Japanese population (122 cases and 241 controls) (40).  
1.7.4 RAD23B 
 RAD23B, along with XPC and RAD23A, binds the distorted DNA adduct in a pre-incision 
complex (123). The RAD23B gene is located at 9q31.2 (129,130). One study has investigated the 
association between one SNP in RAD23B and HNC (table 7) (4). Abbasi et al. (4), a case-control study 
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of 248 laryngeal cancer cases and 647 controls in Germany, reported a borderline elevated OR (95% 
CI) of 1.30 (0.92, 1.90) for rs1805239 (Ala/Val + Val/Val versus Ala/Ala) after adjusting for age, 
gender, education, tobacco, and alcohol. Unfortunately, this study did not consider joint effects of 
this SNP with tobacco.  
1.7.5 ERCC6 
 ERCC6 operates in transcription-coupled NER (123). The gene which encodes this protein is 
located at 10q11.23 (129,130). Five different SNPs in ERCC6 have been investigated in the context of 
HNC incidence (table 7) (4,13). Abbasi et al. (4) reported on two SNPs, finding a protective effect of 
an arginine substitution of proline in a dominant model of rs4253211 (OR = 0.52; 95% CI = 0.34, 
0.85) and no apparent effect for an arginine substitution of glycine in a similar model of rs2228527 
(OR=0.87; 95% CI = 0.61, 1.20) on laryngeal cancer among 248 cases and 647 controls in Germany. 
Chiu et al. (13) investigated 3 additional SNPs among 292 oral cancer cases and 290 controls in 
Taiwan using unadjusted logistic regression. Elevated odds were found in a dominant model of 
rs2228528 (OR = 1.43, 95% CI = 1.02, 2.01 for GA + AA vs. GG) (13). For the other two SNPs, 
rs2228526 and rs228529, no strong associations were noted (13).   
 Abbasi et al. (4) and Chiu et al. (13) both examined the joint effects of selected SNPs and 
tobacco on HNC incidence (table 8). For rs4253211, the ORs (95% CIs) were similar between light (≤ 
20 packyears) and heavy (>20 packyears) smokers; 0.52 (0.18, 1.50) and 0.56 (0.34, 0.93), 
respectively (4). For rs2228528, the OR (95% CI) among ever smokers was 0.99 (0.64, 1.55) using 
never smokers as the referent (13).  
1.7.6 ERCC5 (XPG) 
 XPG, previously named ERCC5, encodes a 3’ incision nuclease which functions with XPF to 
remove DNA adduct complexes (123). The XPG gene is located at 13q33 (129,130). The most 
commonly studied SNP in XPG in relation to HNC is rs17655. Seven studies have considered this 
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Asp1104His substitution (table 7) (4,5,15,28,40,41,45). The study with the most power (1059 cases 
and 1066 controls) was conducted in Texas and reported a null association for rs17655 and HNC 
(OR=0.99, 95% CI=0.83, 1.19) using a dominant genetic model (CG + GG vs. CC) (28). Another large 
study from Texas (829 HNC cases and 854 controls) found an adjusted OR (95% CI) for rs17655 and 
HNC of 0.80 (0.51, 1.28) based on a recessive model (Asp/Asp versus His/Asp + His/His) (5).  
Likewise, a study in Los Angeles by Cui (2005) (15) used a recessive model (Asp/Asp vs. His/Asp + 
His/His) and found a similar adjusted OR (95% CI) of 0.67 (0.42, 1.10). Stratifying by race, this study 
was also the only study on polymorphisms in NER genes and HNC to date to report the effects in 
African Americans only, finding an OR (95% CI) of 0.51 (0.15, 1.80) among 119 African Americans 
(15).  A study conducted among 397 cases and 900 controls in China reported an OR (95% CI) of 0.97 
(0.82, 1.15) using an additive model (CC vs. CG vs. GG) (45). Finally, two other studies reported on 
rs17655, with one using a dominant genetic model (His/Asp + His/His versus Asp/Asp) in a German 
population (4) and the other contrasting the heterozygote genotype with the wild-type genotype 
(Asp/His versus Asp/Asp) in a Chinese population (41). Both studies reported elevated ORs (95% CIs) 
of 1.30 (0.93, 1.90) [OR = 0.77 if referent group assigned to be His/Asp + His/His as in other studies] 
and 1.88 (1.05, 3.40), respectively (4,41).  
 The largest study, conducted by Ma et al. (28), also reported on associations between 11 
other ERCC4 (XPF) SNPs and HNC risk. Of these SNPs, only 1 appeared to be associated with HNC risk 
(28). Specifically, rs4150351 was associated with reduced HNC risk using a dominant model (AC+CC 
vs AA, OR=0.81, 95% CI=0.67,0.98) (28). Both Ma et al. (28)and Abbasi et al. (4) investigated the SNP 
rs1047768, finding adjusted ORs (95% CIs) of 1.00 (0.84, 1.21) and 1.20 (0.80, 1.70), respectively, for 
the genotypes CT and TT versus CC which results in no amino acid change. Finally, a study by Zavras 
et al. (46) found an association between another SNP, rs751402, and HNC using the general model; 
OR (95% CI) were 1.71 (1.04, 2.79) for CT vs TT and 2.2 (0.93, 4.75) for TT vs CC. 
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 The most comprehensive exploration of interaction between XPG and tobacco HNC was 
conducted by Cui et al. (15) (table 8). Using never smokers with the referent genotype for rs17655 
(Asp/Asp) as the referent, the adjusted ORs (95% CIs) were 3.60 (1.20, 11.00) for never smokers with 
the risk genotype, 2.20 (0.51, 9.60) for individuals who smoked 1-20 packyears with the referent 
genotype, and 3.20 (1.10, 9.50) for individuals who smoked 1-20 packyears with the risk genotype 
(15).  Although the risk genotype resulted in larger magnitude ORs in both nonsmokers and smokers, 
interaction between this SNP and smoking did not appear to be additive.  Abbasi et al. (4) also 
considered joint effects by stratifying the adjusted ORs (95% CIs) for rs1047768 by cigarette 
smoking, finding that the odds among heavy smokers (>20 packyears, OR = 1.40, 95% CI = 0.97, 2.20) 
appeared larger than among light smokers (≤20 packyears, OR = 0.85, 95% CI = 0.43, 1.70). In 
addition, Ma et al. (28) stratified the adjusted ORs (95% CIs) for rs4150351 by cigarette smoking and 
found similar odds among never (OR = 0.84, 0.63, 1.34) and ever (OR=0.79, 95% CI=0.62, 1.00) 
cigarette smokers.  
1.7.7 ERCC4 (XPF) 
 ERCC4, also commonly known as XPF, is located at 16p13.12 (129,130). The XPF protein acts 
along with XPG as an incision nuclease on the 5’ end of the DNA adduct (123). Five studies have 
explored the relationship between XPF and HNC (table 7) (4,11,40,44). XPF SNP rs1800067 is marked 
by an amino acid substitution of Arg415Gln (4,11,40,44). Canova et al. (11), the largest study to date 
with 1511 cases of HNC and esophageal cancer and 1457 controls from the ARCAGE study, 
considered a general model of this SNP, reporting an adjusted OR (95% CI) of 1.13 (0.46, 2.78) for 
individuals homozygote for the risk allele (A) compared to individuals homozygote for the reference 
allele (G). Yu et al. (44), which considered a recessive model (AA vs. GG + AG), reported an OR (95% 
CI) of 1.40 (0.51, 3.85) after adjustment for age, gender, tobacco, and alcohol.  In comparison, 
Abbasi et al. (4), which considered a dominant model (Arg/Gln + Gln/Gln) vs Arg/Arg), reported a 
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borderline elevated OR (95% CI) of 1.40 (0.89, 2.20) after adjustment for age, gender, education, 
tobacco, and alcohol. Canova et al. (11) also reported on SNP rs1799801, finding a near null OR (95% 
CI) of 1.06 (0.80, 1.41) for CC versus TT and Yu et al. (44) also reported on SNPs rs2776466, 
rs1799798, and rs3136038 finding near null OR 95% CIs based on recessive models. In addition, 
Sugimura et al. (40) explored a nucleotide replacement of A for T at position 2063 on XPF in a small 
Japanese case-control study (122 oral cancer cases and 241 controls), resulting in an OR (95% CI) of 
0.84 (0.53, 1.32) for a dominant model. 
 Yu et al. (44) assessed the effects of rs2276466 and rs3136038 within strata of nonsmokers 
and smokers, finding both SNPs were associated with reduced HNC risk among nonsmokers 
(OR=0.57, 95% CI=0.33, 1.00 and OR=0.55, 95% CI=0.34, 0.88, respectively) but not smokers (OR= 
0.78, 95% CI=0.52, 1.17 and OR=0.96, 95% CI=0.66, 1.39, respectively] (table 8). For a 5’ UTR SNP on 
ERCC4 (XPF), Sugimura et al. (40) reported an interaction OR (95% CI) of 0.60 (0.17, 2.12) for 
smokers with a risk genotype (TA or AA).  Krupa et al. (26), which used a dominant genetic model 
(Arg/Gln + Gln/Gln) vs Arg/Arg) in a study population of 253 laryngeal cancer cases and 253 controls 
in Poland, found similar near null odds associated with the risk genotype of rs1800067 among 4 
smoking levels. The ORs (p-values) were 1.13 (p=0.69) among never smokers, 1.07 (p=0.80) among 
ever smokers, 1.06 (p=0.85) among moderate smokers, and 0.98 (p=0.95) among heavy smokers 
(26).  
1.7.8 ERCC2 (XPD) 
 ERCC2, also commonly known as XPD, is located at 19q13.3 and encodes a protein which 
functions as a component of the TFIIH subunit to denature the double helix in preparation for 
incision (123,129,130). With respect to HNC incidence, XPD is the most studied NER gene. In 
particular, three SNPs, rs13181, rs17991793, and rs238406, have been studied extensively (table 7).  
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 rs13181 is known as a nucleotide substitution as A35931C and as an amino acid substitution 
as Lys751Gln (4,5,8-10,14,16,17,19-22,24,25,29,30,32-34,36,37,45,133). Over 20 case-control 
studies have studied the impact of rs13181 on HNC (4,5,8-10,14,16,17,19-22,24,25,29,30,32-
34,36,37,45,133). Chuang et al. (14) investigated the effect of rs13181 on HNC risk in the INHANCE 
study, the largest study to date to explore this association, finding a null association based on a 
general model (OR=0.97, 95% CI=0.87, 1.07 for Lys/Gln vs. Lys/Lys and OR=1.03, 95% CI=0.88, 1.21 
for Gln/Gln vs. Lys/Lys). An et al. (5), the study with the next largest sample size (829 HNC cases and 
854 controls), reported an OR (95% CI) of 1.06 (0.79, 1.43) for a recessive model (Gln/Gln vs. Lys/Gln 
+ Lys/Lys). Another study from Texas which considered a recessive model (CC vs. AA + AC) noted an 
even stronger positive association with an OR (95% CI) of 1.55 (0.96, 2.52) (37). Seven studies with 
similar sample sizes (250 to 550 cases) used a dominant model ((Lys/Gln + Gln/Gln vs. Lys/Lys or AC 
+ CC vs. AA) and reported OR (95% CIs) ranging from 0.83 (0.41, 1.69) to 1.5 (1.3, 2.0) 
(4,8,10,19,20,25,32). Eight other studies considered general genetic models, with two overlapping 
analyses suggesting protective effects (17), one study suggesting harmful effects (33), and the 
majority showing no association with HNC for Gln/Gln compared to Lys/Lys (or CC compared to AA) 
(22,24,29,30,34,36).The odds ratios (95% CIs) for homozygous variant versus homozygous referent 
allele from general models ranged from 0.51 (0.27, 0.95) to 2.72 (1.07, 6.91)(9,21,21,24,29,36) 
(17,22,24,29,30,33,34,36). Besides the INHANCE study (14), the next most powered study for a 
general model (310 oral cancer cases and 389 controls from India) reported an age, sex, and tobacco 
adjusted effect estimate of 1.0 (0.9, 2.3) for Gln/Gln versus Lys/Lys and 1.0 (0.9, 2.3) for Gln/Lys 
versus Lys/Lys (29). A meta-analysis of rs13181 and HNC incidence, which included the majority of 
studies listed in table 7, found summary crude ORs (95% CIs) of 1.01 (0.91-1.12) for AC versus AA 
and 0.96 (0.82, 1.11) for CC versus AA suggesting no association between the variant allele and HNC 
incidence (131). 
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 rs17991793 results from a nucleotide substitution of G23591A and an amino acid 
substitution of Asp312Asn (4,5,8,10,17,19,21,22,29,30,38). Eleven different case controls studies 
have investigated rs17991793 and HNC incidence (4,5,8,10,17,19,21,22,29,30,38). The study with 
the most power was An et al. (5) which used a recessive model (Asn/Asn vs. Asp/Asn + Asp/Asp). 
This study reported a borderline elevated OR (95% CI) of 1.15 (0.85, 1.57) (5). Four studies used a 
dominant genetic model (Asp/Asn + Asn/Asn vs. Asp/Asp or GA + AA vs. GG). The two studies with 
the largest number of cases (approximately 275 to 300 cases) were both conducted in the US (Texas 
and Pennsylvania) and reported nearly identical elevated adjusted odds (OR= 1.3; 95% CI = 1.0, 1.8 
and OR=1.28; 95% CI = 0.93, 1.76, respectively) (10,39), while the other two studies reported near 
null results (OR =0.97; 95% CI=0.68, 1.40 and OR=0.86; 95% CI=0.57, 1.30, respectively) (4,19). It is 
important to note that the Pennsylvania study included both HNC and lung cancer cases (10). Four 
studies considered general genetic models, but none of the studies reported any significant findings 
(17,22,29,30). A meta-analysis of rs17991793 and HNC incidence, which included the majority of 
studies listed in table 7, found a summary crude ORs (95% CIs) of 1.14 (1.01, 1.29) for GA versus AA  
(general model) and 1.11 (0.99, 1.25) for GA and AA versus GG (dominant model) suggesting a 
weakly increased risk with the variant allele (131). 
 The nucleotide substitution C22541A results in no amino acid substitution (Arg156Arg) and 
is known as rs238406 (4,16,19,24,29,34,37). Seven studies, one using a recessive model ) AA vs. CA + 
CC) (37), three using a dominant model (AA + CA vs. CC) (4,16,19), and three using a general genetic 
model (24,29,34), have explored the role of rs238406 on HNC. All of these studies, except one (16), 
found near null results. A meta-analysis of rs17991793 and HNC incidence, which included the 
majority of studies listed in table 7, found a summary crude OR (95% CI) of 0.84 (0.68, 1.04) for AA 
versus CC supporting the hypothesis of no association (131).  
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 Nine studies reported joint effects for rs13181 and tobacco smoking (table 8) (8-
10,16,22,30,33,36,37). The study with the largest population (655 cases and 805 controls) reported 
an adjusted additive OR (95% CI) for rs13181 among never tobacco users as 0.55 (0.28, 1.08), among 
exclusive users of chewing tobacco as 0.76 (0.59, 0.97), among exclusive smokers as 0.78 (0.59, 
1.03), and among individuals with mixed tobacco habits as 0.78 (0.59, 1.03) (8).  A study by Buch et 
al. (10)conducted among 273 cases and 269 controls in the US found that compared to nonsmokers 
with the reference genotype, the adjusted ORs (95% CIs) were 1.26 (0.73, 2.18) among nonsmokers 
with the risk genotype, 0.79 (0.45, 1.36) among smokers with the referent genotype, and 3.99 (2.30, 
6.92) among smokers with the risk genotype suggesting a possible additive effect. Likewise, a 
smaller study in Taiwan by Bau et al. (9) concluded a synergistic effect of rs13181and cigarette 
smoking. However, this conclusion was based on imprecise ORs (95% CIs) of 28.48 (13.93, 58.23) for 
nonsmokers with the risk genotype and 26.33 (7.87, 88.04) for smokers with the risk genotype 
compared to nonsmokers with the reference genotype (9). In addition, a study conducted in India by 
Ramachandran et al. (33) noted a stronger association between the variant of allele of rs13181 and 
HNC among ever smokers (OR=3.37, 95% CI=1.51, 7.51) than among never smokers (OR=1.48, 95% 
CI = 0.80, 2.74). Other studies which stratified by the effect of rs13181 by smoking status did not 
note substantial differences in effect across smoking groups (22,30,36,37).  
 For rs1799793, the study by Anantharaman et al. (8) was again the largest and reported 
adjusted additive OR (95% CI) for this SNP among never tobacco users as 1.50 (0.69, 3.12), among 
exclusive users of chewing tobacco as 0.92 (0.0.69, 1.22), among exclusive smokers as 0.89 (0.37, 
2.13), and among individuals with mixed tobacco habits as 1.15 (0.83, 1.58). Among never or former 
smokers, Mautllo et al. (30) reported an OR (95% CI) of 0.34 (0.09, 1.24) for AA vs. GG genotypes 
using data from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. 
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Among light and heavy smokers, Ji et al. (22) reported ORs (95% CIs) for GA vs. AA of 2.4 (0.78, 7.35) 
and 0.94 (0.47, 7.35), respectively. 
 Two other studies considered the joint effects between rs238406 and tobacco. Using a 
recessive genetic model (AA vs. CA +CC), Sturgis et al. (37) reported ORs (95% CIs) of 1.15 (0.57, 
2.32) among never smokers, 0.72 (0.41, 1.58) among former smokers, and 1.48 (0.64, 2.44) among 
current smokers suggesting little modification by cigarette smoking. In a separate study of only 
current smokers, or at least controls who smoked, Gajecka et al. (16) reported an OR (95% CI) of 
0.81 (0.49, 1.31).  
1.7.9 ERCC1 
 ERCC1 encodes a 5' incision nuclease subunit and is located at 19q13.32 (123,129,130). 
Several SNPs within this gene have been considered in the etiology of HNC (table 7). The most 
studied SNP is an adenine replacement of cysteine at 8092 (rs3212986) (4,5,38,40,43). Five studies 
have investigated the effects of this SNP on HNC incidence, with three resulting in comparable near 
null ORs for various dominant (CA + AA vs. CC) and recessive models (AA vs. CA + CC and CC vs. CA 
+AA) (4,5,38), one reporting little difference in the frequency of genotypes between cases and 
controls (43), and one suggesting increased risk (i.e. an elevated OR) in a Japanese population using 
a recessive model  (AA vs. CC + CA) (40). In 2010, Flores-Obando et al. (131) meta-analyzed the four 
studies which investigated rs3212986 in ERCC1. The summary ORs (95% CIs) were 1.07 (0.80-1.43) 
for A/A versus C/C (general model) and 1.00 (0.87-1.14) for C/A + A/A versus C/C (dominant model) 
(131).   
 A study by Jones et al. (23), conducted among 175 cases and 790 controls in Florida, studied 
four additional SNPs in ERCC1: rs1319052, rs3212948, rs3212955, rs735482. No strong associations 
between these SNPs,  nor haplotypes of these SNPS, and HNC incidence were found, though some 
excess risk may exist for rs3212955 (OR = 1.36; 95% CI = 0.67, 2.75 for GG versus AA) (23). Estimates 
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were adjusted for demographic factors (age, sex, and race), but not behavioral factors (tobacco and 
alcohol). Other SNPs which have been studied by Abbasi et al. (4), Canova et al. (11), and Matullo et 
al. (30) in relation to HNC incidence are summarized in table 7 and include rs3212961, rs11615, and 
rs3177700. 
 Evidence regarding the joint effects of ERCC1 SNPs and tobacco on HNC is more limited, but 
seems to suggest interactions may exist (table 8). For rs3212986, Sugimura et al. (40) reported a 
highly elevated, but imprecise, interaction OR (95% CI) for smokers with the risk genotype (AA) as 
8.49 (1.22, 59.31). Among a study population of only never and former smokers from the EPIC study, 
the OR (95% CI) was 1.79 (0.80, 4.01) for rs3177700 and HNC incidence (30). In a study by Sturgis et 
al. (38) at MD Anderson in Texas, the adjusted OR (95% CI) for risk genotypes in both ERCC1 and XPD 
among nonsmokers was 1.24 (0.61, 2.51) and among smokers was 1.46 (0.95, 2.25). Given the low 
sample sizes of these studies, especially when restricted or stratified by smoking groups, further 
replication in larger studies is needed.   
1.7.10 LIG1 
 LIG1 operates in the final step of NER and BER by encoding DNA ligase which binds function 
DNA strands after excision of DNA adducts (123). LIG1 is located at 19q13.2-q13.3 (129,130). Two 
studies have considered the effect of multiple SNPs in LIG1 on HNC incidence (table 7) (27,31). Lee 
et al. (27), a large study conducted among 489 oral, pharyngeal, laryngeal, and esophageal cancer 
cases and 948 controls in Los Angeles, considered four SNPs: rs20581, rs20580, rs20579, and 
rs439132. rs20581 demonstrated the strongest, positive association with HNC; age, sex, education, 
ethnicity, and tobacco adjusted ORs (95% CIs) were 1.20 (0.85, 1.80) for CT versus TT and 1.5 (1.0, 
2.3) for CC versus TT(27). ORs (95% CIs) for rs20580, rs20579, and rs439132 also suggested possible 
positive associations with HNC. For example, the adjusted ORs (95% CIs) for rs20579 were 1.30 
(1.00, 1.80) for CT versus CC and 2.00 (0.69, 5.80) for TT versus CC (27). Lee et al. (27) also estimated 
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haplotype effects across these 4 LIG1 SNPs. With regard to interaction with tobacco, modification 
appeared strongest for rs20581 (table 8). The adjusted ORs (95% CIs) for the risk genotype 
compared to the referent genotype were 0.83 (0.42, 1.60) among never smokers (0 packyears), 2.30 
(0.95, 5.40) among individuals who smoked 0.1 to 20 packyears, and 2.20 (1.00, 4.70) among 
individuals who smoked more than 20 packyears (27). The effect of rs20580 also appeared to be 
stronger in smokers compared to nonsmokers (27). There was less evidence for differences in ORs 
across smoking groups for rs20579 and rs439132, but strata were sparse for these analyses (27). 
 Michiels et al. (31) identified 251 cases and 172 controls among a cohort of smokers in 
France. This study investigated 10 LIG1 SNPs, of which 9 were found to have a positive relationship 
with HNC (31). The strongest associations were observed for rs13436/rs3182008 (OR = 1.94; 95% CI 
1.06, 2.75, GG vs. CC); rs153023 (OR = 2.13; 95% CI = 1.13, 2.90, TT vs. CC); rs156640 (OR = 1.94; 
95% CI=1.06, 3.56, CC vs. GG); and rs274892 (OR = 2.05; 95% CI = 1.12, 3.78, AA vs. CC) (31).  
1.7.11 ERCC8, CDK7, CCNH, DDB2 (XPE), RAD23A 
 There is no previous literature regarding the associations between ERCC8, DDB2, RAD23A, 
CDK7, and CCNH and HNC. Therefore, this dissertation was the first study to consider the effects of 
SNPs in these 5 NER genes on HNC. ERCC8, located at 15q2.1, encodes a protein which functions 
with ERCC6 in Cockayne syndrome and transcription coupled NER (123,129,130). CDK7 and CCNH 
are subunits of the TFIIH complex and assist in the unwinding of DNA surround DNA adducts prior to 
incision (123). Both CDK7 and CCNH genes are located at 5q12.1 and 5q13.3-q14, respectively 
(129,130). DDB2, also known as XPE, is located at 11p12-p11 and functions in NER, but its 
mechanism is not well understood (123,129,130).  RAD23A, located at 19p13.2, encodes a protein 
which functions with XPC and RAD23B to bind the distorted DNA adduct as a complex (123,129,130).  
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1.7.12 Nucleotide Excision Repair Genes and Oral Premalignant Lesions Incidence 
 In addition to the studies on NER genes and HNC listed in table 7, a study by Wang et al. 
(2007) (134) considered the effects of polymorphisms in NER genes on oral premalignant lesions 
(OPL; leukoplakia and erythroplakia) among 144 OPL cases and 288 controls. In addition to 
considering SNPs in the core NER genes, namely XPA, XPC, ERCC2 (XPD), ERCC4 (XPF), and ERCC5 
(XPG), this study estimated the effects of SNPs in ERCC6, RAD23B and CCNH (134). Among the core 
NER genes, the strongest association was found between a SNP in XPA (rs1800975) and OPL; OR 
(95% CI) was 1.97 (1.27, 3.06) under a recessive genetic model (134). Elevated risk was also noted 
for SNPs in XPD (rs13181 and rs1799793) under a dominant model (134). Among SNPs in the less 
studied NER genes, ERCC6, RAD23B and CCNH, there was little evidence for an association with OPL, 
except for a suggested protective effect among RAD23B (rs1805239); OR (95% CI) was 0.67 (0.41, 
1.07) under a dominant model (134). When stratified by smoking, the joint effects of smoking with 
rs1800975 in XPA appeared have an above additive or synergistic effect on OPL incidence, while 
rs1805239 in RAD23B and rs13181 in XPD appeared to have below additive or antagonistic effect 
(134). In addition, studies by Majumder et al. (29), Ramachandran et al. (33), and Anantharaman et 
al. (8) reported mixed results on the association between polymorphisms in ERCC2 (XPD) and 
leukoplakia, with studies reporting null results for rs13181, rs1799793, and rs238406 (8,29,33), 
except one study reporting a highly elevated OR for rs13181 (OR = 4.2, 95% CI = 1.2, 15.0 for 
Gln/Gln/ vs. Lys/Lys) (29). 
1.7.13 Summary of NER Genes, Tobacco, and HNC Incidence 
 Approximately 40 previous studies have collectively investigated the role of 10 NER genes 
and nearly 60 associated SNPs (4,5,8-46). The most studied SNPs and genes were rs13181 
(Lys751Gln), rs1799793 (Asp312Asn), and rs238406 (Arg156Arg) in XPD (ERCC1) and rs3212986 in 
ERCC1. Studies on the effects of rs13181 and rs1799793 reported mixed results (4,5,9,10,16,17,19-
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21,24,29,30,32-34,36-38), while studies on rs238406 and rs3212986 reported mostly null 
associations with HNC (4,5,16,19,24,29,34,37,38,40,43). Other commonly studied genes included 
ERCC6 and LIG1. SNPs in ERCC6 seemed to be associated with reduced risk of HNC (4,13), while SNPs 
in LIG1 seemed to be associated with increased risk (27,31). Joint effects of SNPs and cigarette 
smoking were reported in approximately 20 studies. Again the most studied SNP was rs13181 
(Lys751Gln) in XPD. Two studies on the effect of rs13181 on HNC reported stronger positive 
associations among smokers with risk genotype (9,10), while two studies observed similar effects 
across smokers and non-smokers (36,37). Results for joint effects between cigarette smoking and 
other SNPs in NER genes were mixed for other studies, but some suggested stronger effects in 
smokers compared to non-smokers for most SNPs (4,8-10,13,15,16,22,24,26-28,30,31,33,35-
38,40,44). 
1.8 SINGLE NUCLEOTIDE POLYMORPHISMS IN NUCLEOTIDE EXCISION REPAIR GENES, TREATMENT, 
AND HEAD AND NECK CANCER MORTALITY 
 
1.8.1 XPA and XPC 
 Evidence linking SNPs in XPA and XPC to HNC survival are limited (table 10). Only two studies 
have considered SNPs in XPA and XPC (47,48). Azad et al. (47) found no association between 
rs1800975, a 5’ UTR SNP on XPA, and overall survival (OS HR=0.96, 95% CI=0.78, 1.18) nor disease 
free survival (DFS HR=1.10, 95% CI 0.88, 1.36) among 531 HNC cases from Canada treated with 
radiation therapy based on an additive genetic model (A>G). Likewise, Carles et al. (48) found no 
difference in progression free survival (p=0.23) nor overall survival (p=0.64) across genotypes (TT, 
CT, CC) using the log-rank test among 107 HNC and 1 esophageal cancer patients receiving 
radiotherapy in Spain. Carles et al. (48) also noted no difference in progression free survival (p=0.74) 
nor overall survival (p=0.96) across genotypes of for rs2228001 in XPC (CC, CA, AA). 
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1.8.2 ERCC5 (XPG) 
 The studies by Azad et al. (47) and Carles et al. (48) also studied two SNPs in ERCC5 (XPG) 
(table 10).  Azad et al. (47) found near null associations between rs17655 (G>C, OS HR=0.89, 95% 
CI=0.70, 1.13 and DFS HR=0.85, 95% CI=0.66, 1.09) and rs1047768 (T>C, OS HR=1.03, 95% CI=0.85, 
1.25 and DFS HR=1.06, 95% CI=0.86, 1.30) and survival using an additive model. Carles et al. (48) also 
found little difference in progression free or overall survival was reported across genotypes (AA, AG, 
and GG) for rs17655. In contrast, Carles et al. (48) did find significant differences in progression free 
(p=0.049) and overall (p=0.0066) survival for rs1047768, with individuals with the genotype TC and 
CC experiencing better survival compared to individuals with TT. 
1.8.3 ERCC4 (XPF) 
 In addition to the study by Azad et al. (47) which reported near null HRs for rs1799801 and 
survival using an additive model (T>C,  OS HR = 1.02, 95% CI= 0.83, 1.27 and DFS HR= 0.96, 95% CI= 
0.77,1.21), a study by Vaezi et al. (55) considered the impact of 9 SNPs in ERCC4 (XPF), as well as 
expression of XPF, on 1 year progression free survival following initiation of treatment (table 10). 
The study included 80 HNC cases in Pennsylvania, of whom 70 received X-ray therapy and platinum-
based chemotherapy and 10 received only radiotherapy (55). Forty-two of the 72 patients also 
received surgery (55). Although all SNPs were found to have elevated HRs for the variant allele 
versus the common allele, only four SNPs demonstrated borderline significance using a recessive or 
additive model (55). The age, gender, stage, site, and treatment adjusted HRs (p-values) for these 
four SNPs were 1.94 (p=0.065) for rs1799799 (T>C), 2.00 (p=0.053) for rs3136155 (C>T), 1.94 
(p=0.065) for rs3136166 (T>G), and 1.95 (p=0.065) for rs3136202 (G>A) (55).  
1.8.4 ERCC2 (XPD) 
 ERCC2 (XPD) is another commonly studied NER gene in relation to HNC mortality (table 10). 
Six studies have investigated the role of rs13181 on HNC mortality (7,47,48,50,53,54). In addition, 
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three studies have considered rs1799793 (47,53,54). Zhong et al. (7) provides the most 
comprehensive analysis of rs13181 with 485 HNC from Pennsylvania, and is the only study to stratify 
any relationship between NER genes and HNC survival by different treatment types. Among 275 
patients receiving radiotherapy and 210 not receiving radiotherapy, the effect of rs13181 varied by 
treatment regime (7). Among cases with stage 3 and 4 tumors, the genotype AA (wild-type 
genotype) was associated with poorer overall survival among those treated with radiation (HR = 
1.66, 95% CI = 1.15, 2.40, Kaplan Meier p-value < 0.01), but better survival among those not 
receiving radiation (HR = 0.26, 95% CI = 0.11, 0.62, Kaplan Meier p-value <0.01) (7). Distinct 
differences in disease free survival and progression free survival were also noted (7).  Among cases 
with stage 1 and 2 tumors who did not receive radiation, overall, disease free, and progression free 
survival did not vary across genotypes (p=0.78, 0.98, 0.79, respectively) (7). Carles et al. (48) also 
considered the impact of rs13181 on survival among HNC cases treated with radiotherapy, but 
found no differences in progression free or overall survival across genotypes (Kaplan Meier p-value = 
0.78 and 0.87, respectively). In contrast, Azad et al. (47)and Mahimakr et al. (53) found that rs13181 
was associated with improved disease/relapse free survival (HR=0.80, 95% CI=0.64, 1.00 and 
HR=0.52, 95% CI=0.20, 0.91 respectively) using an additive (A>C) and dominant model (Lys/Gln + 
Gln/Gln vs. Lys/Lys)respectively. Likewise, these studies reported improved disease/relapse free 
survival associated with rs1799793 (G>A, HR=0.89, 95% CI=0.72, 1.11 in Azad et al. study and 
Asp/Asn + Asn/Asn vs. Asp/Asp, HR=0.43, 95% CI=0.22, 0.84 for Mahimakr et al. study) (47,53). 
Among those treated with chemotherapy, Quintela-Fandino et al. (54) found significantly improved 
overall survival among individuals with the common allele (p=0.0012) for both rs13181 and 
rs1799793. In contrast, Gal et al. (50) found no association between rs13181 and survival outcomes 
using a dominant model (Lys/Gln + Gln/Gln vs. Lys/Lys).  
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1.8.5 ERCC1 
 ERCC1 is one of the most commonly studied NER genes in relation to HNC mortality (table 
10). In particular, three SNPs have been investigated: rs735482, rs3212986, and rs11615. rs735482 
is marked by a Thr substitution of Lys resulting from a cysteine replacement of adenine (47,48,51). 
Three studies have explored the association between this SNP and HNC survival (47,48,51). The 
largest study conducted by Azad et al. (47) found that rs735482 was not associated with overall 
survival (HR=0.92, 95% CI=0.68, 1.24), but was associated with disease free survival (HR=0.78, 95% 
CI=0.44, 0.95) using an additive model (A>C) among a population receiving radiation therapy.  The 
study by Carles et al. (48), also among patients receiving radiation treatment, reported significant 
differences in progression free survival (p=0.0005) and overall survival (p=0.0089) were found across 
all three genotypes, with individuals homozygous for the risk allele (Thr259Thr) experiencing much 
worse survival than individuals with Lys259Lys or Lys259Thr (48). Grau et al. (51) also noted 
increased, although nonsignificant, risk associated with the variant allele of this SNP. Specifically, 
this study found unadjusted ORs (95% CIs) of 1.54 (0.71, 3.32) for AC versus AA and 1.57 (0.63, 3.91) 
for CC versus AA (51).  Two studies reported on the association between rs3212986 and survival. 
Azad et al.  (47) reported HRs (95% CIs) for this SNP and overall and disease free survival as 0.85 
(0.67, 1.09) and 0.96 (0.75, 1.23), respectively, using an additive model (C>A) among HNC patients 
treated with radiation.  In addition, Quintela-Fandino reported a Kaplan Meier p-value of 0.8 for 
comparing the common and polymorphic allele of this SNP among HNC patients receiving 
chemotherapy (54). Finally, two low powered studies considered rs11615 (cysteine substitution of 
tyrosine), with one study concluding that there was no association among 59 HNC patients receiving 
surgery and chemotherapy in Brazil (49) and the other suggesting poorer survival associated with 
the variant genotype (OS HR =3.4, 95% CI=0.9, 12.0 for CC + CT vs. TT) (52). 
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1.8.6 ERCC3 (XPB), ERCC8, CDK7, CCNH, RAD23B, ERCC6, DDB2 (XPE), RAD23A, LIG1 
 To date, no studies have considered the impact of SNPs in ERCC3 (XPB), ERCC8, CDK7, CCNH, 
RAD23B, ERCC6, DDB2 (XPE), RAD23A, and LIG1 and HNC survival. Therefore, this dissertation was 
the first to assess the associations between these genes and overall and disease-specific survival in a 
large, racially diverse population of HNC cases.  
1.8.7 Summary of NER Genes, Treatment, and HNC Mortality 
 Approximately 10 studies investigated the role of variants in NER genes and treatment on 
HNC survival (7,47-55). Five studies considered populations of patients who received radiation (with 
or without surgery or chemotherapy) (7,47,48,50,53), while the other five studies considered 
patients receiving chemotherapy (2 studies induction chemotherapy, 1 study concurrent 
chemotherapy, 1 study adjuvant chemotherapy, and 1 study with various combinations of 
chemotherapy and radiation) (49,51,52,54,55). Only 1 study compared 2 separate treatment 
regimens: radiation versus no radiation (7). Most studies (N=8) considered overall survival as an 
endpoint (7,47-52,54). In addition,  3 studies reported disease-specific survival (50,52,53)and 7 
studies progression/relapse/recurrence/disease free survival (7,47,48,51-53,55). These studies 
collectively investigated a total of 6 NER genes and nearly 20 associated SNPs (7,47-55). The most 
studied SNP was rs13181 (Lys751Gln) in XPD (47,48,50,53,54). For this SNP, 2 studies among 
patients receiving radiation showed no difference in OS, PFS, of DS across genotypes (48,50). In 
contrast, 2 other studies suggested the variant genotype using an additive and dominant model, 
respectively, may be associated with improved survival (47,53). Another study found the common 
allele was associated with worse survival among a radiation treatment group but better survival 
among a no treatment group (7). Other studied NER genes with regard to treatment and HNC 
survival were XPF (ERCC4) and ERCC1 (47-49,51,54,55). For ERCC4, most SNPs displayed worse 
survival associated with the variant allele (55). For ERCC1, evidence for rs735482 was mixed 
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(47,48,51), and no difference in OS or PFS was noted across genotypes for rs3212986 and rs11615 
(49,54). 
1.9 SUMMARY OF LITERATURE REVIEW 
 Head and neck cancers, principally squamous cell carcinomas, comprise tumors of the oral 
cavity, pharynx, and larynx (65,66,70). Numerous demographic and behavioral factors are associated 
with HNC incidence, with 75% of cancers attributed to cigarette smoking and alcohol drinking (84). 
With regard to mortality, several clinical factors, including treatment, as well as demographic and 
behavioral factors are associated with survival. Historically, HNC were treated with surgery and/or 
radiotherapy, but over the last few decades individuals treated with chemotherapy in addition to 
surgery and radiotherapy have demonstrated improved survival (72). 
 Tobacco contains a number of chemicals, including nitrosamines and benzenes, known to 
produce bulky DNA adducts (2,3). Nucleotide excision repair is the primary pathway responsible for 
removing such adducts (3,4). Single nucleotide polymorphisms in NER genes, however, can alter this 
pathway, allowing DNA damage to persist and initiation of carcinogenesis (3,124). Studies regarding 
the individual effects of polymorphisms in NER genes, as well as joint effects with cigarette smoking, 
on HNC risk have reported mixed results (tables 7 and 8) (4,5,8-46). 
 Radiotherapy and platinum-based chemotherapies also produce bulky DNA adducts (6,7,48). 
However, since these DNA adducts can function to initiate apoptosis in cancer cells, SNPs in NER 
genes may actually confer a survival advantage (6). Studies regarding the individual effects of 
polymorphisms in NER genes, as well as joint effects with treatment, on HNC risk have reported 
mixed results, but some support this hypothesis (table 10) (7,47-55). 
 As discussed in detail in the methods chapter, this dissertation builds upon the existing 
literature by 1) including one of the largest study population to date (1,227 cases and 1,325 
controls); 2) estimating effects among African Americans (305 cases and 251 controls); 3) evaluating 
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more NER genes, including more SNPs, than previous studies (84 SNPs in 15 NER genes); and 4) 
formally assessing gene-environment interactions, namely the joint effects of polymorphisms in NER 
genes and cigarette smoking with respect to HNC incidence and polymorphisms in NER genes and 
treatment with respect to HNC mortality, which few studies have done. 
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Table 1. Head and Neck Cancer Incidence in the United States from SEER, 2004-2008 (59,60) 
 Oral Cavity and Pharyngeal Cancer 
Cases (per 100,000 persons) 
Laryngeal Cancer Cases (per 
Deaths persons) 
Race/Ethnicity Male Female Male Female 
All Races 15.7  6.2  6.0  1.3  
White 16.1  6.2  6.0  1.3  
Black 15.6  5.6  9.8  1.9  
 
 
Table 2. Head and Neck Cancer Mortality in the United States from SEER, 2004-2008 (59,60) 
 Oral Cavity and Pharyngeal Cancer 
Deaths (per 100,000 persons) 
Laryngeal Cancer Deaths (per 
100,000 persons) 
Race/Ethnicity Male Female Male Female 
All Races 3.9  1.4  2.2  0.5  
White 3.7  1.4  2.0  0.4  
Black 6.3  1.5  4.6  0.7  
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Table 3. Oral and Pharyngeal Cancer Survival in the United States from SEER 9, 1988-2007 (61) 
 Ages <65 (% dead) Ages 65+ (% dead) 
Survival (years since diagnosis) All Races White Black All Races White  Black 
0 100.0 100.0 100.0 100.0 100.0 100.0 
1 87.2 88.8 74.30 77.7 78.7 64.7 
2 76.2 78.7 56.9 65.9 67.1 50.3 
3 70.1 73.0 48.4 59.8 61.2 42.2 
4 66.2 69.2 44.0 55.6 57.1 37.8 
5 63.4 66.6 40.7 52.5 54.0 34.3 
6 61.3 64.6 37.5 49.5 51.1 31.5 
7 59.3 62.7 35.6 46.8 48.3 29.5 
8 57.5 60.9 33.9 44.2 45.6 27.7 
9 55.8 59.1 32.3 41.8 43.1 26.3 
10 53.9 57.2 30.8 40.0 41.1 25.6 
 
 
Table 4. Laryngeal Cancer Survival in the United States from SEER 9, 1988-2007 (62) 
 Ages <65 (% dead) Ages 65+ (% dead) 
Survival (years since diagnosis) All Races White Black All Races White  Black 
0 100.0 100.0 100.0 100.0 100.0 100.0 
1 89.5 90.8 83.0 85.0 85.7 79.4 
2 79.1 81.4 68.4 75.5 76.4 68.3 
3 73.2 75.9 60.6 69.8 70.7 61.6 
4 69.0 71.9 55.7 65.7 66.6 57.8 
5 65.9 68.8 52.7 62.1 63.2 51.9 
6 62.7 65.7 49.1 59.1 60.4 46.2 
7 60.3 63.3 46.7 56.1 57.2 44.0 
8 57.7 60.7 44.0 53.2 54.6 39.2 
9 55.6 58.5 42.3 49.8 51.4 35.5 
10 53.4 56.2 40.3 47.3 48.7 34.6 
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Table 5. Nucleotide Excision Repair Genes Locations (HapMap (129)) and Function (Friedberg et al., 
2006 (123)) 
Gene 
Chromosome and Position 
(HapMap) Protein Function (Friedberg, 2006) 
ERCC3 (XPB) 2 127,731,336 to 127,768,222 Subunit of transcription factor II H (TFIIH) 
which unwinds double helix 
XPC 3 14,161,651 to 14,195,143 Binds to DNA adduct 
ERCC8 5 60,205,415 to 60,276,648 Transcription-coupled NER 
CDK7 5 68,566,471 to 68,609,004 Subunit of transcription factor II H (TFIIH) 
which unwinds double helix 
CCNH 5 86,725,839 to 86,744,592 Subunit of transcription factor II H (TFIIH) 
which unwinds double helix 
XPA 9 99,477,013 to 99,499,460 Binds to DNA adduct 
RAD23B 9 109,085,365 to 109,134,290 Binds to DNA adduct 
ERCC6 10 50,336,715 to 50,417,078 Transcription-coupled NER 
DDB2 (XPE) 11 47,193,089 to 47,217,339  
ERCC5 (XPG) 13 102,296,175 to 102,326,346 3' incision nuclease (dual incision to remove 
adduct) 
ERCC4 (XPF) 16 13,921,524 to 13,949,704 5' incision nuclease (dual incision to remove 
adduct) 
RAD23A 19 12,917,654 to 12,925,455 Binds to DNA adduct 
ERCC2 (XPD) 19 50,546,686 to 50,565,669 Subunit of transcription factor II H (TFIIH) 
which unwinds double helix 
ERCC1 19 50,604,712 to 50,619,017 5' incision nuclease (dual incision to remove 
adduct) 
LIG1 19 53,310,515 to 53,365,372 DNA ligase 
 
 
  
 
Table 6. Characteristics of case-control studies on the association between polymorphisms in nucleotide excision repair genes                                
and head and neck cancer incidence (4,5,8-46)  
Author Year Country
Recruitment of Cases / 
Controls Matching HN Site(s) Genes Genetic Model Adjustment Variables
Interaction 
with Smoking
Abbasi 2009 Germany 248 / 647 age and gender larynx dominant X
(general also available)
An 2007 US (TX) 829 / 854 age and gender oral, pharynx, larynx recessive
(general also available)
Anantharaman 2012 India 655/    802 hospital / hospital age, sex, tobacco oral ERCC2 additive age, sex, education X
Bau 2007 Taiwan 154 / 105 hospital / hospital age oral ERCC2 (XPD), XPA dominant X
(general also available)
Buch 2005 US (PA) 273 / 269 hospital / hospital ERCC2 (XPD) dominant age, smoking X
(general also available)
Canova 2009 Europe 1511 / 1457 ERCC1, ERCC4 (XPF) general
Chiu 2008 Taiwan 292 / 290 hospital / hospital age, sex oral ERCC6 dominant X
(general also available)
Chuang 2011 International 
(CHANCE)
5,915/ 10,644 hospital and population/ 
hospital and population
age, sex, race, 
location
oral, pharynx, larynx ERCC2 general age, sex, country, race
Cui 2005 US (CA) 443 / 912 age, sex ERCC5 (XPG) recessive X
(general also available)
Gajecka 2005 Poland 293 / 322 larynx ERCC2 (XPD) recessive X
(general also available)
Gugatschka 2011 Austria 169 / 463 oral, pharynx, larynx ERCC2 (XPD) general
Gugatschka 2011 Austria 294 / 463 oral, pharynx, larynx ERCC2 (XPD) general
replication 
Hall 2007 811 / 1083 XPA general
Harth 2008 Germany 312 / 300 hospital / clinic oral, pharynx, larynx ERCC2 (XPD) dominant
(general also available)
Huang 2005 555 / 792 age, sex oral, pharynx, larynx ERCC2 (XPD) dominant
(general also available)
Jelonek 2010 Poland 105 / 507 age, sex oral, pharynx, larynx ERCC2 (XPD), XPA general (Χ2 p-value)
Ji 2010 South Korea 290/ 358 hospital / hospital oral, pharynx, larynx ERCC2 (XPD) general age, sex X
Jones 2011 US (FL) 175 / 790 oral, pharynx, larynx ERCC1 general age, sex, smoking
Kietthubthew 2006 Thailand 106 / 164 hospital / community age, sex, smoking, 
alcohol
oral ERCC2 (XPD), XPC general age, sex, smoking, alcohol, 
betel quid chewing
X
Kostrzewska-
Poczekaj 
2013 Poland 295 160 population / population age oral, larynx, other ERCC2 (XPD) dominant                                                            
(general also available)
crude
X (1-3 or 4-6 risk 
genotypes by 
smoking)
X (2 genotypes by 
smoking)
N Cases / 
Controls
population / population ERCC1, ERCC2 (XPD), 
ERCC4 (XPF),ERCC5 (XPG), 
ERCC6, XPA, XPC,  RAD23B
age, gender, education, 
smoking, alcohol
ERCC1, ERCC2 (XPD), 
ERCC5 (XPG), XPA, XPC
age, sex, smoking, alcohol, 
country
age, sex, smoking, alcohol, 
center
age, sex, ethnicity, 
education, smoking, 
alcohol
Central & 
Eastern 
Europe 
larynx, tongue, oral, 
lung
hospital / blood donors 
at cancer institute
hospital / hospital 
(population / population 
for Puerto Rico)
US (WA & 
NC) & 
Puerto Rico
hospitals and clinics / 
hospitals and clinics
hospital / another study
hospital / hospital and 
population
sex, age, center, 
ethnicity, referal/ 
residence area
oral, pharynx, larynx, 
esophagus
age, gender, smoking, 
alcohol
age, sex, country, smoking, 
alcohol
age (simple and 
quadratic), sex
hospital / community 
(cancer sreening 
program)
population / 
neighborhood
hospital / another study
hospital /visitors
oral, pharynx, larynx, 
esophagus
hospital / smokers from 
blood bank
age, sex, referal/ 
residence area
oral, pharynx, larynx, 
esophagus
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Table 6 cont. Characteristics of case-control studies on the association between polymorphisms in nucleotide excision repair genes                    
and head and neck cancer incidence 
Author Year Country
Recruitment of Cases / 
Controls Matching HN Site(s) Genes Genetic Model Adjustment Variables
Interaction 
with Smoking
Krupa 2011 Poland 253 / 253 hospital / hospital age, sex larynx ERCC4 (XPF) dominant age, sex X (only)
Lee 2008 US (CA) 489 / 948 hospital / neighborhood age, sex, 
neighborhood
oral, pharynx, larynx, 
esophagus
LIG1 general age, sex, education, 
ethnicity, smoking
X
Ma 2012 US (TX) 1059/ 1066 hospital / hospital age, sex oral, pharynx, larynx ERCC5 (XPG) dominant                                                            
(general also available)
age, sex, smoking, alcohol X
Majumder 2007 India 310 / 389 oral ERCC2 (XPD) general age, sex, tobacco
Matullo 2006 Western 
Europe 
(Epic)
88 / 1094 nested case-control 
(population); never or 
former smokers only
oral, pharynx, larynx ERCC1, ERCC2 (XPD) general X
Michiels 2007 France 251 / 172 nested case-control 
(hospital); regular 
smokers only
age, sex , hospital oral, pharynx, larynx ERCC3 (XPB), LIG1 general age, smoking, alcohol X
Mitra 2009 India 285 / 400 ethnicity oral, pharynx, larynx ERCC2 (XPD) dominant
(general also available)
Ramachandran 2005 India 110 / 110 hospital / relatives and 
visitors 
oral ERCC2 (XPD) general X
Rydzanicz 2005 Poland 182 / 143 ERCC2 (XPD) general
Shen 2001 US (TX) 287 / 311 hospital / MCO oral, pharynx, larynx XPC general X
Sliwinski 2010 Poland 265 / 280 hospital / hospital oral, pharynx, larynx ERCC2 (XPD) general X
Sturgis 2002 US (TX) 180 / 400 hospital / MCO oral, pharynx, larynx ERCC2 (XPD) dominant (Χ2 p-value)
(general also available)
Sturgis 2002 US (TX) 313 / 313 hospital / MCO oral, pharynx, larynx ERCC1, ERCC2 (XPD) X
Sturgis 2000 US (TX) 189 / 496 hospital / MCO oral, pharynx, larynx ERCC2 (XPD) recessive X
(general also available)
Sugimura 2005 Japan 122 / 241 hospital / hospital oral XPA, XPC and XPF dominant X
XPG and ERCC1 recessive 
(general also available)
Wen 2006 China 175 / 525 larynx, hypopharynx ERCC5 (XPG) dominant
Yang 2005 73 / 85 hospital / hospital oral, pharynx, larynx XPC general (Χ2 p-value) age, sex, smoking, alcohol
Yang 2006 67 / 73 hospital / hospital oral, pharynx, larynx ERCC1 general (Χ2 p-value) age, sex, smoking, alcohol
Yu 2012 US (TX) 1040 / 1046 hospital / hospital age, sex oral, pharynx, larynx ERCC4 (XPF) recessive                                
(general also available)
age, sex, smoking, alcohol X
Yuan 2012 China hospital / hospital oral, pharynx, larynx ERCC2 (XPD), ERCC5 (XPG) additive age, sex, smoking, alcohol
Zavras
2012 Taiwan 239 /  336 hospital / population race
oral
ERCC5 (XPG) general
age, smoking, alcohol, and 
areca nut 
397 / 900
hospital / smokers from 
blood bank
tonsil, tongue, 
hypopharynx and 
paranasal sinus
age, sex, smoking, 
alcohol
age, sex, smoking, 
betel quid 
chewing, alcohol
age, sex, smoking, 
alcohol
South Korea
South Korea
age, sex, smoking, alcohol
age, sex, smoking, alcohol
age,sex, smoking, alcohol
age, sex, smoking, alcohol
N Cases / 
Controls
ERCC1 recessive                
ERCC2 (XPD) dominant 
hospital / hospital 
(dental patients)
hospital / blood donors 
in province
age, sex, smoking, 
alcohol
ERCC1, ERCC4 (XPF), 
ERCC5 (XPG), XPA, XPC
age, sex, 
ethnicity, smoking
age, smoking, tobacco 
chewing, pan masala
age, sex, smoking, betel 
quid chewing, alcohol
 
4
6
 
 47 
 
Table 7. Effect estimates among case-control studies on the association between polymorphisms in 
nucleotide excision repair genes and head and neck cancer incidence (4,5,8-46)  
Gene SNP variant Study OR (95% CI) Genetic Contrast (risk vs ref)
ERCC3 (XPB) rs4233583 Michiels 2007 (smokers) 0.37 (0.15, 0.90) AA vs CC
XPC rs2228001 Abbasi 2009 0.98 (0.68, 1.40) (Lys/Gln + Gln/Gln) vs Lys/Lys
An 2007 1.08 (0.81, 1.43) Gln/Gln vs (Lys/Gln + Lys/Lys)
Kietthubthew 2006 1.35 (0.50, 3.92) CC vs AA
rs2228000 An 2007 1.65 (1.16, 2.36) Val/Val vs (Ala/Val + Ala/Ala)
PAT Kietthubthew 2006 1.60 (0.55, 4.66) ++ vs --
Shen 2001 1.85 (1.12, 3.05) ++ vs --
Sugimura 2005 0.83 (0.51, 1.34) (-+ '+' ++) vs --
Yang 2005 p=0.96 Χ2 for freq in cases vs controls
ERCC8 none
CDK7 none
CCNH none
XPA rs1800975 Abbasi 2009 1.20 (0.86, 1.70) (AG + AA) vs GG
Bau 2007 1.17 (0.66, 2.05) (AG + GG) vs AA
Sugimura 2005 2.04 (1.18, 3.55) (AG + GG) vs AA
An 2007 0.87 (0.65, 1.16) AA vs (AG + GG)
Hall 2007 0.74 (0.53, 1.03) AA vs GG
unspecfied Jelonek 2010 p=0.1881 Χ2 for freq of AA in cases vs controls
RAD23B rs1805239 Abbasi 2009 1.30 (0.92, 1.90) (Ala/Val + Val/Val) vs Ala/Ala
ERCC6 rs4253211 Abbasi 2009 0.53 (0.34, 0.85) (Arg/Pro + Pro/Pro) vs Arg/Arg
rs2228527 Abbasi 2009 0.87 (0.61, 1.20) (Arg/Gly + Gly/ Gly) vs Arg/Arg
rs2228526 Chiu 2008 0.82 (0.50, 1.34) (AG + GG) vs AA
rs2228528 Chiu 2008 1.43 (1.02, 2.01) (GA + AA) vs GG
rs2228529 Chiu 2008 0.79 (0.49, 1.26) (AG + GG) vs AA
DDB2 (XPE) none
ERCC5 (XPG) rs2094258 Ma 2012 0.99 (0.82, 1.20) (CT + TT) vs CC
rs2296147 Ma 2012 1.06 (0.87, 1.28) (CT + CC) vs TT
rs4771436 Ma 2012 1.01 (0.85, 1.20) (GT + TT) vs GG
rs1047768 Abbasi 2009 1.20 (0.80, 1.70) (CT + TT) vs CC
Ma 2012 1.00 (0.84, 1.21) (CT + TT) vs CC
rs2227869 Ma 2012 0.73 (0.52, 1.01) (CC+CG) vs GG
rs4150351 Ma 2012 0.81 (0.67, 0.98) (AC + CC) vs AA
rs4150355 Ma 2012 1.10 (0.92, 1.31) (CT + TT) vs CC
rs4150383 Ma 2012 1.02 (0.85, 1.24) (AG + GG) vs AA
rs4150386 Ma 2012 0.97 (0.79, 1.20) (AC + CC) vs AA
rs17655 Abbasi 2009 1.30 (0.93, 1.90) (His/Asp + His/His) vs Asp/Asp
Wen 2006 1.88 (1.05, 3.40) Asp/His vs Asp/Asp
An 2007 0.80 (0.51, 1.28) Asp/Asp vs (His/Asp + His/His)
Cui 2005 0.67 (0.42, 1.10) Asp/Asp vs (His/Asp + His/His)
Ma 2012 0.99 (0.83, 1.19) (CG + GG) vs CC
Sugimura 2005 0.79 (0.44, 1.42) GG vs (CC + CG) 
Yuan 2012 0.97 (0.82, 1.15) CC vs CG vs GG
rs873601 Ma 2012 1.04 (0.87, 1.24) (AG + GG) vs AA
rs4150393 Ma 2012 0.93 (0.76, 1.15) (AG + GG) vs AA
rs751402 Zavras 2012 2.20 (0.93-4.57) TT vs CC
ERCC4 (XPF) rs2276466 Yu 2012 0.69 (0.50, 0.96) GG vs (CC + CG) 
rs1800067 Abbasi 2009 1.40 (0.89, 2.20) (Arg/Gln + Gln/Gln) vs Arg/Arg
Yu 2012 1.40 (0.51, 3.85) AA vs (GG + AG)
Canova 2009 1.13 (0.46, 2.78) AA vs GG
rs1799801 Canova 2009 1.06 (0.80, 1.41) CC vs TT
rs1799798 Yu 2012 0.90 (0.33, 2.52) AA vs (GG + AG)
rs3136038 Yu 2012 0.76 (0.58, 1.01) TT vs (CC+ CT)
5' UTR, T2063A Sugimura 2005 0.84 (0.53, 1.32) (TA + AA) vs TT
RAD23A none  
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Table 7 cont. Effect estimates among case-control studies on the association between 
polymorphisms in nucleotide excision repair genes and head and neck cancer incidence  
Gene SNP variant Study OR (95% CI) Genetic Contrast (risk vs ref)
ERCC2 (XPD) rs13181 Abbasi 2009 0.89 (0.63, 1.30) (Lys/Gln + Gln/Gln) vs Lys/Lys
Buch 2005 1.5 (1.3, 2.0) (Lys/Gln + Gln/Gln) vs Lys/Lys
Huang 2005 1.04 (0.81, 1.34) (Lys/Gln + Gln/Gln) vs Lys/Lys
Bau 2007 0.83 (0.41, 1.69) (Lys/Gln + Gln/Gln) vs Lys/Lys
Harth 2008 0.86 (0.58, 1.28) (AC + CC) vs AA
Kostrzewska-Poczekaj 2013 0.74 (0.42, 1.29) (AC + CC) vs AA, young adults
Kostrzewska-Poczekaj 2013 1.05 (0.62, 1.79) (AC + CC) vs AA, older adults
Mitra 2009 1.33 (0.75, 2.35) (AC + CC) vs AA
Anantharaman 2012 0.75 (0.63-0.89) Gln/Gln vs Lys/Gln vs Lys/Lys
An 2007 1.06 (0.79, 1.43) Gln/Gln vs (Lys/Gln + Lys/Lys)
Gajecka 2005 (controls smokers) 1.13 (0.74, 1.72) CC vs (AC+ AA)
Sturgis 2000 1.55 (0.96, 2.52) CC vs (AA + AC)
Chuang 2011 1.03 (0.88, 1.21) Gln/Gln vs Lys/Lys
Gugatschka 2011 0.51 (0.27, 0.95) Gln/Gln vs Lys/Lys
Gugatschka 2011 rep 0.54 (0.32, 0.92) Gln/Gln vs Lys/Lys
Majumder 2007 1.0 (0.9, 2.3) Gln/Gln vs Lys/Lys
Ramachandran 2005 2.72 (1.07, 6.91) Gln/Gln vs Lys/Lys
Sliwinski 2010 0.84 (0.42, 1.67) Gln/Gln vs Lys/Lys
Ji 2010 2.68 (0.71, 10.10) CC vs AA
Kietthubthew 2006 2.04 (0.19, 21.66) CC vs AA
Rydzanicz 2005 0.93 (0.49, 1.78) CC vs AA
Matullo 2006 (nonsmokers) 0.62 (0.25, 1.53) CC vs AA
Jelonek 2010 p=0.3802 Χ2 for freq of CC in cases vs. controls
Yuan 2012 1.00 (0.73, 1.36) GG vs TG vs TT
rs1799793 Abbasi 2009 0.97 (0.68, 1.40) (Asp/Asn + Asn/Asn) vs. Asp/Asp
Buch 2005 1.3 (1.0, 1.8) (Asp/Asn + Asn/Asn) vs. Asp/Asp
Harth 2008 0.86 (0.57, 1.30) (GA + AA) vs GG
Sturgis 2002 1.28 (0.93, 1.76) (GA + AA) vs GG
Anantharaman 2012 1.05 (0.86, 1.27) Asn/Asn vs Asp/Asn vs Asp/Asp
An 2007 1.15 (0.85, 1.57) Asn/Asn vs (Asp/Asn + Asp/Asp)
Gugatschka 2011 0.70 (0.38, 1.28) Asn/Asn vs Asp/Asp
Gugatschka 2011 rep 0.73 (0.44, 1.21) Asn/Asn vs Asp/Asp
Majumder 2007 1.0 (0.9, 1.0) Asn/Asn vs Asp/Asp
Ji 2010 1.94 (0.92, 4.08) GA vs GG
Matullo 2006 (nonsmokers) 0.34 (0.09–1.24) AA vs GG
Jelonek 2010 p=0.3209 Χ2 for freq of AA in cases vs. controls
rs1799792 Sturgis 2002 p=0.682 Χ2 for freq of CT + TT in cases vs. controls
rs1799791 Sturgis 2002 p=0.832 Χ2 for freq of CG + GG in cases vs. controls
rs238406 Abbasi 2009 0.98 (0.68, 2.40) (CA + AA) vs CC
Harth 2008 0.98 (0.66, 1.47) (CA + AA) vs CC
Gajecka 2005 (controls smokers) 0.81 (0.49, 1.31) AA vs (CA + CC)
Sturgis 2000 0.92 (0.98, 1.32) AA vs (CA + CC)
Majumder 2007 1.0 (0.9, 1.0) AA vs CC
Kietthubthew 2006 0.85 (0.30, 2.37) AA vs CC
Rydzanicz 2005 0.96 (0.48, 0.90) AA vs CC
ERCC1 rs735482 Jones 2011 0.32 (0.04, 2.49) CC vs AA
rs3212986 Abbasi 2009 0.90 (0.64, 1.30) (CA + AA) vs CC
An 2007 0.89 (0.59, 1.35) AA vs (CA+CC)
Strugis 2002 1.15 (0.84, 1.59) CC vs (AA + AC)
Sugimura 2005 1.95 (0.93, 4.09) AA vs (CC + CA)
Yang 2006 p=0.82 Χ2 for freq in cases vs controls
rs3212961 Abbasi 2009 0.77 (0.51, 1.20) (CA + AA) vs CC
Canova 2009 0.45 (0.23, 0.90) CC vs AA
rs3212955 Jones 2011 1.36 (0.67, 2.75) GG vs AA
rs11615 Abbasi 2009 0.83 (0.58, 1.20) (TC + CC) vs TT
rs3212948 Jones 2011 0.82 (0.46, 1.45) GG vs CC
Canova 2009 1.02 (0.79, 1.31) GG vs CC
rs1319052 Jones 2011 0.90 (0.51, 1.59) AA vs GG
rs3177700 Mautllo  2006 (nonsmokers) 1.79 (0.80, 4.01) CC vs TT
rs11615, rs3177700 Canova 2009 1.02 (0.80, 1.30)  
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Table 7 cont. Effect estimates among case-control studies on the association between 
polymorphisms in nucleotide excision repair genes and head and neck cancer incidence 
Gene SNP variant Study OR (95% CI) Genetic Contrast (risk vs ref)
LIG1 rs13436, rs3182008 Michiels 2007 (smokers) 1.94 (1.06, 2.75) GG vs CC
rs153023 Michiels 2007 (smokers) 2.13 (1.13, 2.90) TT vs CC
rs156640 Michiels 2007 (smokers) 1.94 (1.06, 3.56) CC vs GG
rs156641 Michiels 2007 (smokers) 1.75 (0.92, 3.31) TT vs CC
rs2241721 Michiels 2007 (smokers) 1.69 (0.89, 3.21) CC vs TT
rs274892 Michiels 2007 (smokers) 2.05 (1.12, 3.78) AA vs CC
rs3730912 Michiels 2007 (smokers) 0.86 (0.53, 1.40) GT vs GG
rs20581 Lee 2007 1.50 (1.00, 2.30) CC vs TT
rs20580 Lee 2007 1.20 (0.83, 1.70) AA vs CC
rs20579 Lee 2007 2.00 (0.69, 2.30) TT vs CC
rs439132 Lee 2007 5.90 (1.10, 31.00) GG vs AA
rs288882 Michiels 2007 (smokers) 1.83 (0.96, 3.50) AA vs GG
rs228883 Michiels 2007 (smokers) 1.78 (0.94, 3.40) GG vs TT  
 
  
Table 8. Effect estimates by cigarette smoking among case-control studies on the association between polymorphisms in                              
nucleotide excision repair genes and head and neck cancer incidence (4,8-10,13,15,16,22,24,26-28,30,31,33,35-38,40,44) 
Gene SNP variant Study Definition OR (95% CI) Definition OR (95% CI)
ERCC3 (XPB) rs4233583 Michiels 2007 regular smokers (5 
cigarettes/day for 5+ years)
0.37 (0.15, 0.90) AA vs CC
XPC PAT Shen 2001 never smoker 1.87 (0.72, 4.86) former smoker 1.83 (0.85, 3.94) ++ vs --
current smoker 1.69 (0.66, 4.35)
Sugimura 2005 smoker, risk genotype 0.48 (0.13, 1.87) (-+ '+' ++) vs --
ERCC8 none
CDK7 none
CCNH none
XPA rs1800975 Bau 2007 nonsmoker, ref genotype 1.00 (ref) smoker, ref genotype -- (AG + GG) vs AA
nonsmoker, risk genotype 3.52 (1.26, 9.84) smoker, risk genotype 47.7 (15.48, 147.01)
Sugimura 2005 smoker, risk genotype 0.48 (0.11, 2.16) (AG + GG) vs AA
RAD23B rs1805239 Abbasi 2009 light smoker (≤20 packyears) 0.95 (0.47, 1.90) heavy smoker (>20 packyears) 1.60 (1.10, 2.50) (Ala/Val + Val/Val) vs Ala/Ala
ERCC6 rs4253211 Abbasi 2009 light smoker (≤20 packyears) 0.52 (0.18, 1.50) heavy smoker (>20 packyears) 0.56 (0.34, 0.93) (Arg/Pro + Pro/Pro) vs Arg/Arg
rs2228528 Chiu 2007 never smoker 0.99 (0.64, 1.55) ever smoker 2.36 (1.36, 4.10) (GA + AA) vs GG
DDB2 (XPE) none
ERCC5 (XPG) rs1047768 Abbasi 2009 light smoker (≤20 packyears) 0.85 (0.43, 1.70) heavy smoker (>20 packyears) 1.40 (0.97, 2.20) (His/Asp + His/His) vs Asp/Asp
rs17655 Cui 2005 never smoker, ref genotype 1.00 (ref) 1-20 packyears, ref genotype 2.20 (0.51, 9.60) (His/Asp + His/His) vs Asp/Asp
never smoker, risk genotype 3.60 (1.20, 11.0) 1-20 packyears, risk genotype 3.20 (1.10, 9.50)
>20 packyears, ref genotype 3.80 (1.00, 1.40)
>20 packyears, risk genotype 8.00 (2.70, 24.0)
Sugimura 2005 smoker, risk genotype 0.33 (0.06, 1.74) GG vs (CC + CG) 
rs4150351 Ma 2012 never smoker 0.84 (0.63, 1.34) ever smoker 0.79 (0.62, 1.00) (AC + CC) vs AA
ERCC4 (XPF) rs2276466 Yu 2012 nonsmoker 0.57 (0.33, 1.00) smoker 0.78 (0.52, 1.17) GG vs (CC + CG) 
 rs1800067 Krupa 2011 never smoker 1.13 (p=0.69) ever smoker 1.07 (p=0.80) (Arg/Gln + Gln/Gln) vs Arg/Arg
moderate smoking 1.06 (p=0.85)
heavy smoking 0.98 (p=0.95)
rs3136038 Yu 2012 nonsmoker 0.55 (0.34, 0.88) smoker 0.96 (0.66, 1.39) TT vs (CC + CT)
5' UTR, T2063A Sugimura 2005 smoker, risk genotype 0.60 (0.17, 2.12) (TA + AA) vs TT
RAD23A none
ERCC2 (XPD) rs13181 Anantharaman 2012 no tobacco habit 0.55 (0.28, 1.08) exlusive chewer 0.76 (0.59, 0.97) Gln/Gln vs Lys/Gln vs Lys/Lys
exlusive smoker 0.69 (0.33, 1.43)
mixed habits 0.78 (0.59, 1.03)
Bau 2007 nonsmoker, ref genotype 1.00 (ref) smoker, ref genotype -- (AG + GG) vs AA
nonsmoker, risk genotype 28.48 (13.93, 58.23) smoker, risk genotype 26.33 (7.87, 88.04)
Buch 2005 nonsmoker, ref genotype 1.00 (ref) smoker, ref genotype 0.79 (0.45, 1.36) (Lys/Gln + Gln/Gln) vs Lys/Lys
nonsmoker, risk genotype 1.26 (0.73, 2.18) smoker, risk genotype 3.99 (2.30, 6.92)
Gajecka 2005 control current smoker 1.13 (0.74, 1.72) CC vs (AC+ AA)
Ji 2010 nonsmoker 7.2 (0.39, 34.22) light smoker 1.27 (0.40, 4.08) AC vs AA
heavy smoker 0.73 (0.39, 1.36)
Mautllo  2006 never or former smoker 0.62 (0.25, 1.53) CC vs AA
Ramachandran 2005 never smoker 1.48 (0.80, 2.74) ever smoker 3.37 (1.51, 7.51) (Lys/Gln + Gln/Gln) vs Lys/Lys
Sliwinski 2010 nonsmoker 1.07 (0.36, 3.21) smoker 0.72 (0.29, 1.76) Gln/Gln vs Lys/Lys
Sturgis 2000 never smoker 1.44 (0.54, 3.81) former smoker 1.40 (0.65, 3.00) CC vs (AA + AC)
current smoker 1.83 (0.79, 4.27)
Genetic Contrast (risk vs ref)
Nonsmokers Smokers
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Table 8 cont. Effect estimates by cigarette smoking among case-control studies on the association between polymorphisms in nucleotide 
excision repair genes and head and neck cancer incidence 
Gene SNP variant Study Definition OR (95% CI) Definition OR (95% CI)
ERCC2 (XPD) rs1799793 Mautllo  2006 never or former smoker 0.34 (0.09, 1.24) AA vs GG
Anantharaman 2012 no tobacco habit 1.50 (0.69, 3.12) exlusive chewer 0.92 (0.69, 1.22) Asn/Asn vs Asp/Asn vs Asp/Asp
exlusive smoker 0.89 (0.37, 2.13)
mixed habits 1.15 (0.83, 1.58)
Ji 2010 light smoker 2.4 (0.78, 7.35)
heavy smoker 0.94 (0.47, 7.35) GA vs AA
rs238406  Sturgis 2000 never smoker 1.15 (0.57, 2.32) former smoker 0.72 (0.41, 1.58) AA vs (CA + CC)
current smoker 1.04 (0.54, 2.01)
Gajecka 2005 control current smoker 0.81 (0.49, 1.31) AA vs (CA + CC)
exon 6 Kietthubthew nonsmoker and nondrinker 4.10 (1.20, 14.0) smoker and drinker 1.48 (0.64, 3.44) AA vs CC
ERCC1 and ERCC2 (XPD) rs3212986/rs1799793 Sturgis 2002 nonsmoker 1.24 (0.61, 2.51) smoker 1.46 (0.95, 2.25) CC vs (AA + AC) and (GA + AA) vs GG
ERCC1 rs3212986 Sugimura 2005 smoker, risk genotype 8.49 (1.22, 59.31) AA vs (CC + CA)
rs3177700 Mautllo  2006 never or former smoker 1.79 (0.80, 4.01) CC vs TT
LIG1 rs13436/rs3182008 Michiels 2007 regular smokers (ie 5 
cigarettes/day for 5+ years)
1.94 (1.06, 2.75) GG vs CC
rs153023 Michiels 2007 regular smokers 2.13 (1.13, 2.90) TT vs CC
rs156640 Michiels 2007 regular smokers 1.94 (1.06, 3.56) CC vs GG
rs156641 Michiels 2007 regular smokers 1.75 (0.92, 3.31) TT vs CC
rs2241721 Michiels 2007 regular smokers 1.69 (0.89, 3.21) CC vs TT
rs274892 Michiels 2007 regular smokers 2.05 (1.12, 3.78) AA vs CC
rs3730912 Michiels 2007 regular smokers 0.86 (0.53, 1.40) TT vs GG
rs20581 Lee 2007 0 packyears 0.83 (0.42, 1.60) >0 to 20 packyears 2.30 (0.95, 5.40) CC vs TT
>20 packyears 2.20 (1.00, 4.70)
rs20580 Lee 2007 0 packyears 0.86 (0.47, 1.60) >0 to 20 packyears 1.50 (0.74, 3.20) AA vs CC
>20 packyears 1.60 (0.84, 3.10)
rs20579 Lee 2007 0 packyears 1.50 (0.91, 2.30) >0 to 20 packyears 1.20 (0.21, 6.90) TT vs CC
(heterozygote presented) >20 packyears 0.95 (0.18, 5.00)
rs439132 Lee 2007 0 packyears 2.70 (0.16, 45.0) >0 to 20 packyears 3.30 (0.18, 60.0) GG vs AA
>20 packyears 2.00 (0.74, 5.70)
(heterozygote presented)
rs288882 Michiels 2007 regular smokers 1.83 (0.96, 3.50) AA vs GG
rs228883 Michiels 2007 regular smokers 1.78 (0.94, 3.40) GG vs TT
Nonsmokers Smokers
Genetic Contrast (risk vs ref)
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Table 9. Characteristics of case-only studies on the association between polymorphisms in nucleotide excision repair genes and head and neck 
cancer mortality (7,47-55) 
Author Year Country N Cases HN Site(s) Treatment Genes Genetic Model
Kaplan 
Meier 
Curve
Cox 
Proptional 
Model
Cox Proportinoal Model 
Adjustment Variables
Azad 2012 Canada 531 oral, pharybx, larynx radiation ERCC1, ERCC4, 
ERCC5, XPA, 
ERCC2
additive                                            
(general also available)
X age, smoking, alcohol, BMI, 
comorbidity, performance 
status, tumor site, stage
Carles 2006 Spain 108 general
(dominant also available for 
time to progression)
De Castro 2011 Brazil 59 oral, pharynx, larynx ERCC1 general X multivariate model
X X
X X
Gal 2005 US (WA) 328 oral radiation or surgery XPD dominant
(general also available)
Grau 2009 Spain 47 oral, pharynx, larynx induction chemotherapy (paclitaxel) ERCC1 general X unadjusted
Hao 2012 Canada 55 oral, pharynx, larynx concurrent chemotherapy (cisplatin) ERCC1 dominant X unadjusted
Mahimkar 2012 India 458 oral surgery and radiation XPD dominant                                                          
(general also available)
X age, sex, tobacco, grade, 
stage
2006 Spain 103 oral, pharynx, larynx induction chemotherapy ERCC1, XPD general
CDDP + radiotherapy (N=26), CDDP + 
fluoropyrimidine (N=31), CDDP + 
fluoropyrimidine + taxane (N=42), and cisplatin + 
cetuximab (N=4)
Vaezi 2011 US (PA) 80 oral, pharynx, larynx radiation and chemotherapy (platinum-based) 
(N=70), radiation only (N=10), 
XPF X
primary chemotherapy or radiation (N=38), or 
surgery + chemotherapy + radiotherapy (N=42)
Zhong 2011 US (PA) 485 oral, pharynx, larynx radiation (with/without chemotherapy) N=275 XPD dominant (inverted)
no treatment N=210
Quintela-
Fandino
age, smoking, alcohol, 
tumor site
age, sex, tumor stage, 
tumor site, treatment
age, sex, tumor site, stage, 
treatment, CCND1 G870A 
genotype
X X
X
X
additive or recessive? 
(homozygous variant versus 
referent allele)
ajuvant chemotherapy (cisplatin) 
radiationoral, pharynx, larynx, 
nasopharynx
ERCC1, XPA, 
XPC, XPD, XPG
X
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Table 10. Effect estimates of case-only studies on the association between polymorphisms in nucleotide excision repair genes                              
and head and neck cancer mortality (7,47-55) 
Gene SNP variant Study Treatment Outcome
Cox Proportional HR 
(95% CI)
Kaplan Meier  
Curve p-value Genetic Contrast
ERCC3 (XPB) none
XPC rs2228001 Carles 2006 radiation progression free survival 0.74 general (C>A)
overall survival 0.96
ERCC8 none
CDK7 none
CCNH none
XPA rs1800975 Azad 2012 radiation overall survival 0.96 (0.78, 1.18) additive (A>G)
disease free survival 1.10 (0.88, 1.36)
Carles 2006 radiation progression free survival 0.23 general (T>C)
overall survival 0.64
RAD23B none
ERCC6 none
DDB2 none
ERCC5 (XPG) rs1047768 Azad 2012 radiation overall survival 1.03 (0.85, 1.25) additive (T>C)
disease free survival 1.06 (0.86, 1.30)
Carles 2006 radiation progression free survival 0.049 general (T>C)
overall survival 0.0066
rs17655 Azad 2012 radiation overall survival 0.89 (0.70, 1.13) additive (G>C)
disease free survival 0.85 (0.66, 1.09)
Carles 2006 radiation progression free survival 0.22 general (G>C)
overall survival 0.44
ERCC4 (XPF) rs3136105 Vaezi 2011 X-ray therapy, chemotherapy, surgery 1-year progression free survival 1.41 (p=0.415) T>C
rs3136146 Vaezi 2011 X-ray therapy, chemotherapy, surgery 1-year progression free survival 1.69 (p=0.191) G>A
rs3136152 Vaezi 2011 X-ray therapy, chemotherapy, surgery 1-year progression free survival 2.30 (p=0.240) G>A
rs3136155 Vaezi 2011 X-ray therapy, chemotherapy, surgery 1-year progression free survival 2.00 (p=0.053) C>T
rs3136166 Vaezi 2011 X-ray therapy, chemotherapy, surgery 1-year progression free survival 1.94 (p=0.065) T>G
rs3136189 Vaezi 2011 X-ray therapy, chemotherapy, surgery 1-year progression free survival 1.44 (p=0.285) T>C
rs3136202 Vaezi 2011 X-ray therapy, chemotherapy, surgery 1-year progression free survival 1.95 (p=0.065) G>A
rs1799799 Vaezi 2011 X-ray therapy, chemotherapy, surgery 1-year progression free survival 1.94 (p=0.065) T>C
rs1799801 Azad 2012 radiation overall survival 1.02 (0.83, 1.27) additive (T>C)
disease free survival 0.96 (0.77, 1.21)
Vaezi 2011 X-ray therapy, chemotherapy, surgery 1-year progression free survival 1.46 (p=0.265) T>C
RAD23A none
ERCC2 (XPD) rs13181 Azad 2012 radiation overall survival 0.86 (0.71, 1.06) additive (A>C)
disease free survival 0.80 (0.64, 1.00)
Carles 2006 radiation progression free survival 0.78 general (A>C)
overall survival 0.87
Gal 2005 radiation or surgery overall survival 1.06 (0.74, 1.51) (Lys/Gln + Gln/Gln) vs Lys/Lys
disease-specific survival 0.80 (0.41, 1.56)
Mahimkar 2012 sugery and radiation disease-specific survival 0.72 (0.41, 1.24) (Lys/Gln + Gln/Gln) vs Lys/Lys
relapse free survival 0.52 (0.20, 0.91)
Quintela-Fandino 2006 induction chemotherapy overall survival 0.0012 common vs polymorphic allele  
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Table 10 cont. Effect estimates of case-only studies on the association between polymorphisms in nucleotide excision repair genes and head and 
neck cancer mortality 
Gene SNP variant Study Treatment Outcome
Cox Proportional HR 
(95% CI)
Kaplan Meier  
Curve p-value Genetic Contrast
ERCC2 (XPD) rs13181 cont Zhong 2011 stage 3-4, radiation overall survival 1.66 (1.15,2.40) <0.01 AA vs (AC + CC)
disease free survival 0.02
progression free survival 0.03
stage 3-4, no radiation overall survival 0.26 (0.11,0.62) <0.01
disease free survival 0.05
progression free survival 0.02
stage I-II, no radiation overall survival 0.78
disease free survival 0.98
progression free survival 0.79
rs1799793 Azad 2012 radiation overall survival 0.89 (0.73, 1.10) additive (G>A)
disease free survival 0.89 (0.72, 1.11)
Mahimkar 2012 sugery and radiation disease-specific survival 0.51 (0.28, 0.92) (Asp/Asn + Asn/Asn) vs Asp/Asp
relapse free survival 0.43 (0.22, 0.84)
Quintela-Fandino 2006 induction chemotherapy overall survival 0.0012 common vs polymorphic allele
ERCC1 rs735482 Azad 2012 radiation overall survival 0.92 (0.68, 1.24) additive (A>C)
disease free survival 0.78 (0.44, 0.95)
Carles 2006 radiation progression free survival 0.0005 general (A>C)
overall survival 0.0089
Grau 2009 induction chemotherapy overall survival 1.54 (0.71, 3.32) AC vs AA
overall survival 1.57 (0.63, 3.91) CC vs AA
progression free survival
rs3212986 Azad 2012 radiation overall survival 0.85 (0.67, 1.09) additive (C>A)
disease free survival 0.96 (0.75, 1.23)
Quintela-Fandino 2006 induction chemotherapy overall survival 0.80 common vs polymorphic allele
rs11615 Hao 2012 concurrent chemotherapy overall survival 3.4 (0.9, 12.0) CC + CT vs TT
disease-specific survival 6.8 (0.8, 54.8)
recurrence 3.6 (0.8 ,16.6)
De Castro 2011 adjuvant  chemotherapy 5-year overall survival p=0.808 general (C>T)
LIG1 none
"No statistically significant differences in time to 
progression….between wild-type and SNP patients"
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Figure 1. Overview of Nucleotide Excision Repair Pathway (adapted from Friedberg (124); other 
sources consulted include: (123,128)) 
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CHAPTER 2 
METHODS 
2.1 STUDY POPULATION  
2.1.1 Carolina Head and Neck Cancer Epidemiology (CHANCE) Study  
  The Carolina Head and Neck Cancer Epidemiology (CHANCE) study is a population-based 
case-control study of 2,785 individuals (1,389 cases and 1,396 controls) from 46 of 100 counties in 
North Carolina (57,63,64).  To be eligible, cases and controls were between 20 to 80 years of age at 
diagnosis (57,63,64). Cases were identified from the North Carolina Central Cancer Registry between 
January 1, 2002 and February 28, 2006 (57,63,64). To ensure quick recruitment of cases, rapid case 
ascertainment was employed (57,63,64). Cancers were classified according to ICD-03 codes; cancers 
of the oral cavity (C02.0-C02.3; C03.0-C03.1; C03.9-C04.1; C04.8-C05.0; C06.0-C06.2; C06.8-C06.9), 
oropharynx (C01.9; C02.4; C05.1-C05.2; C09.0-C09.1; C09.8-C10.4; C10.8-C10.9), hypopharynx 
(C12.9-C13.2; C13.8-C13.9); larynx (C32.0-C32.3; C32.9), and oral cavity/pharynx not otherwise 
specified (C02.8-C02.9; C05.8-05.9; C14.0; C14.2; C14.8) were included in the study, while cancers of 
the salivary glands (C07.9, C08.0 to C08.9), nasopharynx (C11 .0 to C11.9), nasal cavity (C30.0), and 
nasal sinuses (C31.0 to C31 .9) were excluded (57,63,64). With regard to histology, only invasive 
squamous cell carcinomas (basaloid, keratinizing, large and small cell nonkeratinizing, spindle cell, 
microinvasive, verrucous,  not otherwise specified, and epithelial neoplasms not otherwise 
specified) were included, while benign and in situ carcinomas, including papillary carcinomas and 
adenoid squamous cell carcinomas, were excluded (82,135). Medical records and tumor samples for 
cases were reviewed by the CHANCE study pathologist, Dr. William K. Funkhouser to verify
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 diagnoses (82,135). Controls, defined as never being diagnosed with HNC, were randomly sampled 
from the Department of Motor Vehicle records and were frequency matched to cases based on 
strata of age (20-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-80 years of age), race (white, African 
American, other race), and sex (male, female) (57,63,64).   
2.1.2 Recruitment Methods  
  Physicians of HNC cases who were eligible for CHANCE were provided with information 
regarding the study and a request for permission for investigators to contact the patient(s) under 
their care (82,135). If physicians did not refuse or did not respond, eligible cases were then 
approached about participation via mail (82,135). Likewise, eligible controls were initially contacted 
via mail (82,135). Mailed materials explained the purpose of the study, study components 
(administration of interview and collection of biologic samples), and compensation ($50) (82,135). 
Following mailings, trained nurses followed-up with individuals by phone to inquire about their 
willingness to participate, verify eligibility, and schedule an interview (82,135). Consenting 
participants were then given in-person interviews by a trained nurse (57,63,64). In circumstances 
where the selected case was deceased at the time of interview, the interview was administered to a 
proxy who was usually a close relative, which is considered a reliable substitute for some items 
(82,135,136). Interviews consisted of questions on demographic (age, gender, race, education level, 
etc.) and behavioral (tobacco use, alcohol use, diet, oral health, etc.), as well as collection of biologic 
specimens (57,63,64). Details of the CHANCE questionnaire and collection of biologic samples will 
discussed in the exposure and covariate assessment sections. 
2.1.3 Study Population 
  A total of 2,135 cases of HNC were identified within the study time and location (figure 2) 
(82,135). Of these, physicians refused permission for investigators to contact 39 (1.8%) cases, 269 
(12.6%) cases were determined to be ineligible (e.g., outside the age range), 50 (2.3%) cases were 
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unlocatable, and 77 (3.6%) cases were deceased and had no proxy (82,135). Of the remaining 1700 
eligible cases, 311 (18.3%) refused to participate in the study (82,135). In-person and proxy 
interviews were completed by 1337 (78.6%) and 52 (3.1%) individuals, respectively (82,135). 
Therefore, the response for cases was approximately 81.7% (1389 completed interviews / 1700 
eligible cases).  
  A total of 4,049 controls were sampled to match cases within the study time and location 
(figure 3) (82,135). Of these, 780 (19.3%) controls were not contacted, 234 (5.8%) controls were 
determined to be ineligible (e.g., outside the age range), 655 (16.2%) controls were unlocatable, and 
109 (2.7%) controls were deceased and had no proxy (82,135). Of the remaining 2271 eligible 
controls, 875 (38.5%) refused to participate in the study (82,135). In-person and proxy interviews 
were completed by 1379 (60.7%) and 17 (0.7%) individuals, respectively (82,135). Therefore, the 
response for controls was approximately 61.5% (1396 completed interviews / 2271 eligible 
controls).  
  Of the 1,389 cases and 1,379 controls who completed interviews, 1329 (95.7%) cases and 
1376 controls (99.8%) provided blood and/or buccal cell samples (82,135). Of these, 1313 (98.8%) 
cases and 1368 (99.4%) controls had sufficient quantity and quality of DNA for genotyping (82,135). 
DNA samples from 1274 (97.0%) cases and 1343 (98.2%) controls were successfully genotyped 
(82,135). 
  To address the dissertation aims only cases and controls with successfully genotyped DNA 
were included. Individuals who self-reported race as white or African American were included; other 
races and minorities (26 cases and 18 controls) were not considered in this dissertation due to 
sparse data. In addition, lip cancers (21 cases) were excluded.  The study population therefore 
comprised 1,227 cases and 1,325 controls. Table 11 summarizes the distribution of demographic 
characteristics for cases and controls in the overall CHANCE study and those eligible for this 
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dissertation. No material differences between the overall and dissertation study populations were 
noted.  
2.2 EXPOSURE ASSESSMENT: GENETIC FACTORS 
2.2.1 Biologic Specimen Collection  
 At the time of interview, trained nurses collected three 10 ml blood samples from 
participants (82,135). As described in the CHANCE Protocol and Dr. Anne Hakenewerth’s dissertation 
(82,135): 
 [One] tube was used for plasma and collection of mononuclear cells for subsequent DNA 
 extraction… [, one] tube was used for plasma, buffy coat and packed red blood cell 
 separation (the buffy coat was stored frozen for subsequent DNA extraction)…[, and one] 
 tube was used to collect serum that was stored for potential use in future assays (82,135).  
 
If individuals refused to provide a blood sample, they were asked to provide buccal cell samples 
instead (82,135). Buccal cell samples were collected using 1.5 ounces of mouthwash or saline for 30 
seconds and repeating (82,135). All blood and buccal samples were packed on ice and returned to 
the lab within 12 hours for processing (82,135). DNA extraction was usually completed within 12-72 
hours of sample receipt (82,135). Among cases, 1217 provided blood samples and 112 provided 
buccal cell samples. Among controls, 1280 provided blood samples and 96 provided buccal samples 
(82,135). As described in the CHANCE Protocol and Dr. Anne Hakenewerth’s dissertation (82,135): 
DNA was extracted from [fresh blood samples or buccal cell pellets] frozen at -80°C using a 
modified salt procedure with Puregene chemistries. DNA samples were quantified in multi-
spectral optical density spectrophotometers. The 260/280 ratio was used to assess sample 
quality. Ratios of >1.7 for DNA extracted from blood or >1.6 for buccal rinse samples were 
considered to be quality samples. In addition, each DNA sample was subjected to 0.4% 
agarose gel electrophoresis to assess the size of the DNA. Greater than 96% of the blood 
samples’ genomic DNA was of high quality as demonstrated by a single large band of DNA 
with a size greater than 25kb. DNA from [some] buccal samples was of insufficient quantity 
for genotyping. DNA was aliquotted into multiple vials which were stored at -80°C for long-
term storage (82,135). 
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2.2.2 Genotyping Methods  
 Genotyping was conducted at the University of North Carolina at Chapel Hill, Mammalian 
Genotyping Core Facility (64). Illumina GoldenGate assay with Sentrix Array Matrix and 96-well 
standard microtiter plates were used to genotype 1,536 different SNPs from CHANCE, including the 
129 SNPs proposed in this dissertation (82,135). In addition to the large number of SNPs processed 
simultaneously, the Illumina GoldenGate technology is a commonly used due to the relatively small 
amount of DNA required for the assay (approximately 160 pg of DNA for each SNP) and efficiency of 
the process (3 days) (137). As described in the manufacturer’s online materials, the Illumina 
GoldenGate assay comprises nine general steps: 1) activation of DNA; 2) addition of DNA to 
oligonucleotides followed by hybridization, 3) extension, ligation, and clean-up, 4) universal PCR 
cycles, 5) binding PCR product, elution of dye-labeled strand, preparation for hybridization; 6) 
hybridization to the Sentrix Array Matrix; 7) washing and drying of array matrix; 8)imaging of array 
matrix; 9) auto-calling genotypes and generating report (137). 
 To improve the integrity of genotyping results, several laboratory and analytic quality 
control measures were implemented. First, laboratory technicians were blinded to which samples 
were from cases and which were from controls (82,135). Second, samples from cases and controls, 
as well as DNA controls, were included on each plate (82,135). Third, 109 samples were randomly 
selected for duplicated or blinded genotyping (82,135). Among the repeated or blinded SNPs, five 
out 145,568 pairs (0.003%) were discrepant (82). Only one SNP for one participant included in this 
dissertation was discrepant, and only that single SNP was dropped for that single individual (138). 
Fourth, genetic data were checked for illogical values (82,135). For example, inconsistencies 
between self-reported and genetically determined sex were checked using an algorithm in SAS 
(Cary, NC), and six samples were found to be inconsistent (138). Gender discrepancies were resolved 
for five of these samples, but not for one sample which was excluded from analyses (138). Finally, 
 61 
 
commonalities among samples which failed genotyping were explored (e.g, plate location or DNA 
volume and concentration) and resolved by re-testing, or in circumstances where re-testing failed 
set to missing (82,135). 
2.2.3 Single Nucleotide Polymorphisms Selection  
 The majority of the 129 SNPs for NER genes were chosen based on two previous studies: the 
MD Anderson Head and Neck Cancer Study and the Carolina Breast Cancer Study (CBCS). In addition, 
a few SNPs were chosen by the CHANCE PI, Dr. Andrew Olshan. Tables 12 and 13 summarize the 
selection methods for each SNP.  
2.2.3.1 MD Anderson Head and Neck Cancer Study 
Dr. Qingyi Wei and colleagues at MD Anderson Hospital in Dallas, Texas conducted a case-
control study on HNC (28,44,139). As part of this study, investigators considered the effects of 8 NER 
genes: ERCC3 (XPB), XPC, XPA, DDB2 (XPE), ERCC5 (XPG), ERCC4 (XPF), ERCC2 (XPD), and ERCC1 
(28,44,139). To select tag SNPs for these genes, investigators queried the NIEHS-EGP (140) and 
HapMap (129) databases using a selection criteria of r2 ≥ 0.80, minor allele frequency (MAF) ≥ 0.05, 
1-2Kb flanking region (139). The NIEHS-EGP database is based on a heterogeneous population which 
includes whites, African Americans, and Asians (140). However, since the MD Anderson study 
contained over 80% Caucasians, only the CEU (Utah residents with ancestry from northern and 
western Europe) population was ultimately considered (139). From this database, 67 tag SNPs were 
selected to capture the variation in NER genes among whites (139). Using the CEU population in 
HapMap, an additional 58 tag SNPs (63 including flanking regions) were identified (139). Taking into 
account duplicates between the databases, 85 tag SNPs were chosen to represent the variation in 
the 8 NER genes: 6 SNPs in ERCC1, 9 SNPs in XPA, 8 SNPs in XPB, 15 SNPs in XPC, 13 SNPs in XPD, 7 
SNPs in XPF, 13 SNPS in XPG, and 14 SNPS in DDB2 (139). The majority of these SNPs were targeted 
for genotyping in CHANCE as summarized in table 12. Some tag SNPs chosen by Wei were not 
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included in CHANCE: rs229881 in ERCC1; rs238405, rs1799793, rs1799788 in ERCC2; rs1047768, 
rs2094258 in ERCC5, rs3176633 in XPA, rs1124303, rs2470353, rs1126547, rs2470352 in XPC; 
rs2276466 in XPF; rs3758667, rs10742797, rs11039138 in DDB2. 
2.2.3.2 Carolina Breast Cancer Study (CBCS) 
 Dr. Robert Millikan and colleagues at UNC-Chapel Hill conducted a case-control study on 
breast cancer (141). As part of this study, investigators considered the effects of 13 NER genes: XPC, 
ERCC8, CDK7, CCNH, XPA, RAD23B, ERCC6, ERCC5 (XPG), XPF (ERCC4), RAD23A, ERCC2 (XPD), ERCC1, 
and LIG1 (142). Candidate SNPs for these genes were selected based on previous studies and/or 
potential function, such as amino acid changes, 3'UTR, and 5'UTR (table 12) (142).  
2.2.3.3 Carolina Head and Neck Cancer Epidemiology Study 
 In addition to SNPs identified from the MD Anderson HNC and CBCS studies, Dr. Andrew 
Olshan and colleagues at UNC-Chapel Hill selected several additional candidate SNPs included in 
CHANCE based on previous studies and/or potential functions (135).  Two additional SNPs were 
included for ERCC1, 3 for ERCC5 (XPG), and 4 for LIG1 (table 12).  
2.2.3.4 Variation Captured by CHANCE SNPs 
Since a mixture of tag and candidate SNPs are included in this dissertation, the variation 
within each gene captured by SNPs in CHANCE was calculated as the percentage of SNPs on each 
gene which were in linkage disequilibrium (LD; i.e. correlated) with SNPs in CHANCE. A “complete” 
list of SNPs for each gene was identified using HapMap for the CEU and YRI (Yoruba in Ibadan, 
Nigeria) populations separately (129).  Using Tagger in Haploview, SNPs with a MAF above 0.05 and 
an r2≥0.8 were considered for tagging (143). Using the force include and exclude options, only SNPs 
which were genotyped in CHANCE were ultimately chosen as tag SNPs.  The proportion of HapMap 
SNPs with a MAF above 0.05 which were tagged by CHANCE SNPs are summarized in table 12 by 
gene and ancestral population. Variation captured by CHANCE SNPs varied by gene. The most 
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complete coverage was achieved for ERCC1; 76% and 53% among the CEU and YRI populations, 
respectively. While comparable coverage was achieved for several other genes, some genes had 
relatively low proportions of SNPs captured in CHANCE. Therefore, haplotype estimation was not 
considered in this dissertation.  
2.2.3.5 SNP Exclusion Criteria 
Of the 129 NER SNPs, variants with weak signal intensity or indistinguishable genotype 
clusters (14 SNPs) or a MAF less than 0.05 (30 SNPs among whites and 36 SNPs among African 
Americans) were excluded (table 13). Nearly all excluded SNPs were candidate SNPs selected based 
on previous literature (i.e. only 5 tag SNPs were excluded for failing genotyping and only 1 tag SNP 
among whites was excluded for having a MAF < 0.05). Therefore, the analysis included 84 SNPs in 15 
NER genes among whites and 79 SNPs in 14 NER genes among African Americans. A summary of 
inclusion and exclusion criteria for each SNP is provided in table 13. 
2.2.4 Assessment of Hardy-Weinberg Equilibrium 
 As outlined in the US National Institutes of Health online glossary, Hardy-Weinberg 
equilibrium (HWE) is based on the principle that genotype frequencies are expected to be constant 
across generations  of a population given that the population is 1) sufficiently large, 2) randomly 
mating, 3) devoid of selection, migration, and mutation (144). If p represents the frequency of one 
allele in a population and q the frequency of the other allele, as is commonly notated, then one 
would expect the frequency of genotypes to be described by the following equation: p2 + 2pq + q2 = 
1 (145,146). To assess HWE for each SNP in this dissertation, the predicted frequency of genotypes 
in the controls was calculated using the preceding equation (145). The predicted frequencies were 
then compared to the frequency of genotypes observed in the study population using a Pearson’s 
chi-square test (145). It is important to note that HWE was assessed only in controls as they 
represent the target population. Further, assessment of HWE was conducted separately among 
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African Americans and whites. Frequencies for 7 SNPs in white controls and 7 SNPs in African 
American controls were inconsistent with Hardy-Weinberg equilibrium (p<0.05); however, since 
genotype scatter plots showed reasonable clustering none of these SNPs were excluded from 
analyses (147). 
2.2.5 Genetic Model  
 Previous studies on the association between polymorphisms in NER genes and HNC risk and 
survival have utilized a variety of genetic models (tables 6) (4,5,8-46). Although no single model has 
emerged as the standard, the general model appeared to be the most frequently used and was 
therefore originally considered in this dissertation.  The general (or codominant) model considers 
three exposure categories to estimate two ORs: the odds of HNC for heterozygous individuals and 
the odds of HNC for individuals homozygous for the variant allele compared to individuals 
homozygous for the referent allele (146). It was further intended to assess the additive effects of 
each copy of the variant allele (146). However, a large portion of SNPs had fewer than 5 cases or 
controls homozygous for the variant allele (~7% among whites and ~33% among African Americans).  
Therefore, SNPs were ultimately defined using a dominant genetic model, as it was more commonly 
used in the literature than the recessive model. For the dominant model, the effect of having any 
copy of the variant allele was assessed. In other words, heterozygous individuals and individuals 
homozygous for the variant allele were combined and compared to individuals homozygous for the 
referent allele to produce a single OR (146). The referent allele for both whites and African 
Americans was assigned to be the major (i.e. more frequent) allele based on controls from the 
overall study population (which was concurrent with the race-specific major allele for 98% of SNPs in 
whites and 92% of SNP in African Americans). 
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2.3 EXPOSURE ASSESSMENT: ENVIRONMENTAL AND BEHAVIORAL FACTORS 
2.3.1 Cigarette Smoking  
 To ascertain self-reported information on cigarette smoking, the CHANCE interview 
asked several questions on duration and frequency of use. Self-reported cigarette-smoking is 
generally considered a valid and accurate measure of actual cigarette smoking. A systematic 
review of studies which compared self-reported cigarette smoking with measured cotinine 
levels found that the majority of studies reported measurements that differed by less than 10%; 
specifically, the median difference between reported and measured cigarette smoking was 
−4.8% for studies based on saliva measurements, −6.2% for studies based on serum, blood, or 
plasma measurements, and −9.4% for studies based on urine measurements (148). Questions 
used in CHANCE to ascertain cigarette smoking were based on questionnaires from previous 
studies of HNC and other cancers (82,135). Exact questions from the CHANCE questionnaire are 
provided in table 14. Ever cigarette users were defined as smoking at least 100 cigarettes or 5 
packs during one’s lifetime (149). Frequency was measured in number of cigarettes smoked per 
day (149). Duration of use was measured in years from initiation to cessation (149). For analysis, 
frequency, and duration of cigarette smoking were categorized based on previous CHANCE 
publications (57) and quantity of observations in each strata.  
 In addition to active cigarette smoking, information on environmental tobacco smoke 
(ETS) was also ascertained during interviews. Such information included ever/never and 
duration (years) of exposure in the home or at a workplace, separately (135). For analysis, 
duration of ETS exposure was categorized similar to active cigarette smoking.  
2.3.2 Treatment 
 First-course treatment information was abstracted from patients’ medical records which 
were obtained from health care providers if patients provided informed consent at the time of the 
 66 
 
interview (medical records were obtained for all cases in this dissertation) (82,135). Information 
included whether the patient received surgery, radiation therapy, and chemotherapy, including 
types of chemotherapy drugs. Chemotherapy drugs included: carboplatin, paraplatin, cisplatin, 5 FU, 
taxol, taxotere, docetaxel, paclitaxel, ifosfamide, and other. Information on concurrent treatment 
and duration of treatment, including start and stop dates, was also abstracted, but were not 
considered complete (138).  Since treatment dates were most frequently missing due to a missing 
value in the day field (138), individuals having month and year recorded but no day were assigned a 
day of ‘15’ based on the approximate midpoint of the month (138). However, even after this 
correction was applied, a sizeable portion of individuals were still missing treatment dates (138). In 
particular, chemotherapy end dates (e.g., month and/or year) were missing for approximately a 
quarter of patients treated with chemotherapy (138).  Therefore, combinations of treatment were 
generated from dichotomous variables for surgery, radiation, chemotherapy regardless of timing.  
 Specifically, treatment was categorized into six mutually exclusive levels: surgery only; 
radiation only; surgery and radiation; radiation and chemotherapy; surgery, radiation, and 
chemotherapy; and other (no treatment, chemotherapy only, or surgery and chemotherapy without 
radiation). Surgery only was used as the referent category because few individuals received no 
treatment (9 cases, 0.7%). Because even fewer individuals received chemotherapy only or 
chemotherapy with surgery without radiation (4 cases, 0.3%), these individuals were combined with 
individuals receiving no treatment into a single category labeled “other treatment.”  In a separate 
model, treatment was also defined as ever receiving platinum-based chemotherapy drugs 
(carboplatin, paraplatin, or cisplatin, N=464) versus never receiving platinum-based chemotherapy 
drugs (i.e. never receiving chemotherapy, N=754, or only receiving non-platinum based 
chemotherapy drugs, including 5 FU, taxol, taxotere, docetaxel, paclitaxel, or ifosfamide, N=9). 
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2.4 OUTCOME ASSESSMENT 
2.4.1 Incidence  
 As previously discussed, incident cases with invasive cancers of the oral cavity, pharynx, and 
larynx were identified from the North Carolina Central Cancer Registry between January 1, 2002 and 
February 28, 2006 using rapid identification techniques (57,63,64). Medical records and tumor 
samples for cases were reviewed by the CHANCE study pathologist, William K. Funkhouser (UNC-
Chapel Hill) to verify diagnoses (82,135). Controls were identified through the North Carolina 
Department of Motor Vehicles records and trained nurses verified with the controls during the 
interview that he/she had never been diagnosed with HNC (57,63,64) 
2.4.2 Mortality 
 To assess survival, CHANCE was recently linked to the National Death Index (NDI) based on 
name, social security number, and date of birth to identify deaths through 2009, including date of 
death, location of death, and cause of death. Recent research indicates that linkage to the NDI with 
proper information (e.g., social security number, name, and birth date) accurately identifies up to 
95% of deceased individuals (150). Analyses primarily considered overall survival (i.e. risk of dying 
from any cause), but also considered disease-specific survival (i.e. risk of dying from HNC). Disease-
specific deaths were defined as those having HNC listed as the primary or secondary cause of death. 
While misclassification of cause of death may occur in the NDI, it is estimated to be below 7% for all 
causes of death and below 3% for cancer related deaths (151). 
2.5 COVARIATE ASSESSMENT 
2.5.1 Interview Variables 
2.5.1.1 Demographics 
 Demographics were self-reported and included: sex (male, female); age (continuous 
based on date of birth); and race (white, African American, American Indian, Alaskan Native, 
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Asian/Pacific Islander); education (less than high school, some college, college or more) 
(57,63,64). Controls were matched to cases based on age, sex, and race (57,63,64). Age was 
matched and analyzed within categorizes (20-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-80 years 
of age) (57). For race, only white and African American cases were considered in this analysis 
due to low frequencies of other minorities in CHANCE. For analysis, education was collapsed into 
three levels (less than a high school education, a high school education, or a college education). 
2.5.1.2 Alcohol Drinking 
 Alcohol use was self-reported and assessed separately for beer, wine, and hard liquor 
(57,64). Ever beer drinkers were defined as drinking at least 50 beers or two cases during one’s 
lifetime, ever wine drinkers as drinking wine 20 or more times in one’s lifetime, and ever hard 
liquor drinkers as drinking hard liquor 20 or more times in one’s lifetime (57,64). Frequency of 
each alcohol product was measured in ounces per day and duration of each alcohol product was 
measured in years from initiation to cessation (57,64). For consideration as a covariate in 
models, total frequency of alcohol drinking frequency summed across type of alcohol (i.e. ml 
ethanol per week) was used.  
2.5.1.3 Other Tobacco Use 
 Use of tobacco products were self-reported and assessed separately for cigars, pipes, 
chewing tobacco, and snuff (57).  Ever use for each tobacco product was defined as engaging in the 
behavior 20 or more times during one’s lifetime (57). Frequency of each tobacco product was 
measured in number of cigars smoked, pipe fulls smoked, times tobacco chewed or times snuff used 
per day, respectively (57). Duration of use for each product was measured in years from initiation to 
cessation. For adjustment, a single dichotomous variable for ever using any tobacco product other 
than cigarettes was assessed. 
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2.5.1.4 Family History of Cancer 
 Information on cancer diagnoses among family members (mother, father, siblings, 
children, and spouse) was self-reported by participants (135,152).  This information was 
condensed into a single variable capturing the total number of first-degree blood relatives with 
a cancer diagnosis (135,152). Given the limited number of CHANCE participants with a family 
member who was diagnosed with HNC, a dichotomous variable (yes/no) which enumerates any 
cancer diagnoses among first degree relatives was considered in models (135,152).  
2.5.1.5 Oral Health 
 Behaviors related to oral health were self-reported and included oral medical conditions 
(leukoplakia, erythroplakia, ulcers, and sores), dental exams, cavities and tooth loss, brushing 
and flossing, and mouthwash (63). Based on a previous analysis of oral health variables in 
CHANCE, which showed no association between tooth loss nor mouthwash use and HNC but 
strong associations between routine dental visits and tooth mobility and HNC, frequency of 
dental exams (categorized) was considered as a covariate in models (63).  
2.5.2 Tumor Characteristics 
 Information on stage, grade and location of tumors were abstracted from cases’ medical 
records (135,153). Stage was classified according to TNM measures where T characterizes the size of 
the tumor, N the spread of the tumor, and M metastasis to other locations (118).  These three 
measures were then collapsed into a single categorized variable, which was included in models, with 
4 stages:   I, II, III, and IV (note: stage 0 indicates in situ cancers and were therefore not be included 
in this study) (118). Information on grade was found to be incomplete for many cases and was 
therefore not considered (135,138). For primary site, HNC was classified according to ICD-03 codes 
into five categories as has been done in previous studies: oral cavity (N=172; C02.0-C02.3;C03.0-
C03.1;C03.9-C04.1;C04.8-C05.0;C06.0-C06.2; C06.8-C06.9), oropharynx (N=333; C01.9; C02.4; C05.1-
 70 
 
C05.2; C09.0-C09.1; C09.8-C10.4; C10.8-C10.9), hypopharynx (N=55; C12.9-C13.2;C13.8-C13.9); 
larynx (N= 443; C32.0-C32.3;C32.9), and not otherwise specified (N=224; C02.8-C02.9;C05.8-
C05.9;C14.0;C14.2;C14.8) (57,64).  
2.5.3 Ancestral Informative Markers (AIMs) 
 Ancestral informative markers (AIMS) are SNPs which display ancestry-speciﬁc genotype 
frequencies that allow for the estimation of an individual’s admixture (154-156). In recent years, 
AIMS have become widely accepted as a cost-effective way to control for ancestry (154,155). 
Several validation studies have shown the efficiency of AIMS in predicting and controlling for 
admixture in logistic regression (154-156). For example, these studies demonstrate that 
approximately 100 to 200 AIMS accurately estimate the proportion of European ancestry in 
African American populations, yet suggest that as few as 30 AIMs can sufficiently estimate 
admixture (154-156). 
 Since CHANCE is comprised primarily of African Americans and whites, 157 AIMS (table 
15) were selected to estimate the proportions of African and European ancestry of each 
participant (64,157). A total of 12 AIMS failed genotyping procedures and were therefore 
excluded (table 15) (138). The AIMS were selected and the proportions of African and European 
ancestry calculated by Dr. Jill Barnholtz-Sloan at Case-Western Reserve University using an 
algorithm based on differences in allele frequencies between HapMap populations and Fisher’s 
information criterion (FIC) (82,157,158). Since only two ancestral populations were considered, 
the proportions of European and African ancestry for each individual sum to one and analyses 
need only include one or the other ancestral variables as a covariate. In this dissertation, 
analyses were adjusted for proportion African ancestry.  In addition, since self-reported race is 
important when considering the distribution of socially related exposures and confounders, 
population stratification (i.e. stratification by self-reported race) was also employed. 
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2.5.4 Assessment of Confounding and Effect Measure Modification  
 Since this dissertation included 84 different SNPs (i.e., different exposures), it would 
have been logistically difficult to use empirical methods, such as change in estimate approaches 
or likelihood ratio tests (159), to determine adjustment sets because one covariate may 
significantly contribute to the model for one SNP but not another. Therefore, a priori covariate 
selection was based primarily on directed acyclic graphs (figures 4-7) (160). In addition, the 
following covariate selection criteria were considered. First, variables used in matching cases 
and controls, namely age and sex, were included because failure to account for matching 
variables in models can bias results (159). Although self-reported race was also a matching 
variable, it was not included in the final model because it is highly correlated with ancestry. 
Rather, models were stratified by self-reported race and adjusted for ancestry. Second, variables 
were examined for completeness. Since a large proportion of cases and controls are missing 
certain diet variables, these variables were not included in models (82,135,153). Third, strength 
of associations based on previous literature were considered. Since marijuana smoking is weakly 
associated with HNC in previous studies it was not included in models (110).  
 Because genetic exposures were based on germline DNA, which would not reflect the 
influences of behavioral factors such as smoking and drinking, SNP-HNC risk were only adjusted 
for matching factors (sex and age, including pairwise interactions) and ancestry (continuous 
percent African ancestry) based on the DAG (figure 4). Cigarette smoking-HNC and ETS-HNC 
models were adjusted for matching factors (sex and age, including pairwise interactions), 
education (categorical indicator for less than a high school education, a high school education, 
or a college education), and frequency of alcohol use (categorical indicator for never drinking 
alcohol and quartiles of lifetime alcohol consumption in ml/day) (figure 5). ETS ORs were 
additionally adjusted for duration of cigarette smoking (continuous years), as well as stratified 
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by ever/never cigarette smoking. Models were not adjusted for use of other tobacco products 
(cigars, pipes, chewing tobacco, and snuff), family history of cancer, and oral health variables 
because estimates did not change substantially when these variables were included in models. 
SNP-cigarette smoking joint effects models were adjusted for age, sex, education, frequency of 
alcohol use, and ancestry since both behavioral and genetic exposures were being modeled. 
 For HNC survival, SNP models were again adjusted for matching factors (sex and age, 
including pairwise interactions) and ancestry (continuous percent African ancestry) based on the 
DAG (figure 6). Behavioral factors, namely cigarette smoking and alcohol drinking, are not 
believed to impact germline SNPs. SNP models were not adjusted for tumor characteristics, such 
as stage, because they were determined to be causal intermediates (e.g., SNPs may impact 
stage, but stage would not impact SNPs). However, SNP-HNC survival models stratified by stage 
and tumor location were considered. All treatment models were adjusted for sex, age (5 year 
categories), race, stage (categorical stage I, II, III, IV), anatomic subsite (oral cavity, oropharynx, 
hypopharynx, larynx, HNC NOS), education (less than a high school education, a high school 
education, or a college education), duration of cigarette smoking (years), and frequency of 
alcohol use (categorical indicator for lifetime alcohol consumption in ml/day) (figure 7). 
Likewise, SNP-treatment joint effects models were adjusted for sex, age, stage, anatomic site, 
education, cigarette smoking, alcohol drinking, and ancestry.  
2.6 STATISTICAL ANALYSIS 
2.6.1 Aim 1: Incidence Models 
 Unconditional logistic regression was used to estimate odds ratios (OR) and 95% 
confidence intervals (CI) for SNP and cigarette smoking and HNC risk. As previously described, 
SNPs were defined using a dominant genetic model and cigarette smoking were considered as 
ever, frequency and duration. Models of ETS exposure (ever, duration) were also considered as 
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a supplemental analysis. All models were adjusted for confounders as determined by the DAG 
and other criteria as described in the covariate assessment section. In addition, since allele 
frequencies, cigarette consumption and HNC incidence differs by race in the US, models were 
stratified by self-reported race (white and African American) (56,59,60,129). 
 Logistic regression is considered the standard for analyzing case-control data as it allows 
the estimation of risk for a binary outcome while controlling for possible confounders (160). 
Traditionally conditional logistic regression is used for matched case-control and sparse strata 
data (159). However, when sample size is large compared to the number of matching strata, 
such as in CHANCE, unconditional logistic regression provides accurate estimates (159). As 
discussed previously, though, matching variables should still be included as covariates in 
unconditional logistic regression to avoid bias (159). Therefore, unconditional logistic regression 
including matching covariates (represented as indicator variables for the cross-products of the 
matching factors) was utilized in this dissertation to estimate odds of HNC incidence.  
 Odds ratios for the joint effects of SNPs in NER genes and cigarette smoking were also 
estimated using unconditional logistic regression. Interaction between SNPs in NER genes and 
cigarette smoking were assessed on the additive scale using the interaction contrast ratio (ICR), also 
known as the relative excess risk due to interaction (RERI), as follows: OR11 - OR01 - OR10 + OR00, 
where OR11 is the odds ratio among smokers with the variant genotype, OR01 is among smokers 
with the referent genotype, OR10 is among never smokers with the variant genotype, and OR00 is 
among never smokers with the referent genotype (which equals 1.0 as it is the referent) (160,161). 
An ICR of zero indicates no interaction beyond what is expected on the additive scale (160,161). An 
ICR above zero should be interpreted as a superadditive (or synergistic) effect, while an ICR below 
zero as a less than subadditive (or antagonistic) effect (160,161). A 95% CI for the ICR was also 
calculated using the Hosmer and Lemeshow method (161). Although interaction may also be 
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assessed on the multiplicative scale, the additive scale was used to enhance power as suggested by 
Weinberg (162). Joint effects were primarily assessed among whites, because low cell counts 
precluded precise estimation among African Americans. Estimation of joint effects among African 
Americans was performed for exploratory purposes only. Analyses for aim 1 were completed using 
the statistical software package SAS (Cary, NC) (163). 
2.6.2 Aim 1: Multiple Testing  
 Multiple testing, also referred to as multiple comparisons, is a concern when conventional 
statistical significance testing methods are applied to studies which investigate multiple exposure-
disease associations (e.g., exploring associations between 84 SNPs and HNC risk) because this may 
amplify the number of false positive results (160,164-166). As described by Rothman in Modern 
Epidemiology, in a study of 10 exposures and 10 disease outcomes (i.e. 100 associations) one would 
expect  5 confidence intervals (5%) to not contain the null value by chance alone using the 
conventional 0.05 alpha level (160). To account for this, this dissertation employed the conservative 
Bonferroni approach which is widely used. In addition, an innovative hierarchical approach which 
incorporates dependence of associations (i.e. correlation of SNPs) was also used. For reasons 
described below, preference was given to results from hierarchical modeling. 
2.6.2.1 Bonferroni Method 
Bonferroni is the most commonly used method to account for multiple testing. It is 
employed by dividing the chosen alpha level, customarily 0.05, by the number of associations being 
tested (160). For this dissertation, the Bonferroni corrected alpha level was set at 0.0006 based on 
the conventional 0.05 alpha level divided by 84 tests (i.e. one for each SNP) among whites and 79 
tests among African Americans. The major advantage of the Bonferroni correction is its accessibility, 
both in terms of ease and uptake (166). The major disadvantages of Bonferroni is that it ignores 
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correlation of tests, which occurs among SNPs, and produces overly conservative confidence 
intervals for individual estimates which may fail to highlight true associations (160,164-166).  
2.6.2.2 Hierarchical Regression 
 Hierarchical regression incorporates multiple levels or stages of data into a single model 
(164,165,167,168).  For this reason, it is also commonly referred to as multilevel regression. One 
level of data is often defined by individual observations, while a higher level represents natural 
aggregates or clusters of observations (164,165,167,168).  In the context of genetics, SNPs on the 
same gene are more likely to be inherited (e.g., if in linkage disequilibrium) and share function than 
SNPs on different genes (166). Likewise, genes within the same pathway are related with regard to 
function (164,165,168). Therefore models which incorporate this clustering of data within a 
hierarchical structure provide more accurate and plausible estimates (164). Since this dissertation is 
concerned with only one pathway, NER, hierarchical logistic regression was used to model the 
effects of individual SNPs while incorporating a SNP-gene matrix to account for clustering of SNP 
data by gene. The model is described as follows (164,165,167): 
Level 1: ln (pi / 1-pi) = α + Xijβj + Wiγ 
where pi represents the probability of case status in the sample, Xij contains indicators of SNPs, and 
Wi represents important covariates or potential confounders (164,165). 
Level 2: βj = Zjπ + δj 
where βj represents the coefficients for the effects of the SNPs, Zj  represents the matrix linking SNPs 
with their associated genes, and δj represents independent errors which are normally distributed 
with a mean of zero and a variance of τ2 (164,165). 
 To create the SNP-gene matrix (i.e. Zj) required for this model, SNPs are assigned a ‘one’ for 
the gene on which they are located and a ‘zero’ for all other genes (164,165). Since SNPs are located 
on only one gene, each SNP (i.e. each row) only contained one ‘one.’ However, since genes contain 
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many SNPs, each gene (i.e. each column) may contain several ‘ones.’ See table 16 for an example of 
part of this matrix. To avoid over-parameterization by modeling one large SNP-gene matrix (ie 
including all 84 SNPs across 15 genes) in a single model, 15 models, one for each gene, were 
employed to shrink estimates for SNPs on the same gene towards a common gene effect. Since SNPs 
on the same gene were included in the same model, one SNP from pairs of extremely correlated 
SNPs was excluded (rho>0.98; 11 SNPs in whites and 5 SNPs in African Americans). 
Using first level and second level (i.e. SNP-gene matrix; Zj) data, hierarchal modeling 
addresses non-independence of tests. In addition, hierarchical regression allows shrinking the error 
term towards a prior through controlling its variance (τ2) (164,165,167). In other words, using a 
Bayesian approach, the posterior distribution of the error becomes the average of the prior 
distribution and the maximum likelihood distribution (167). Therefore, stronger priors for the 
variance (i.e. smaller values of τ2) will invoke a greater influence on the posterior estimate of the 
error (167). In this dissertation, a semi-Bayesian approach was used to set τ2 to 0.05 as this 
corresponded with the most plausible range of expected ORs for the association between SNPs in 
NER genes and HNC based on previous literature (i.e. 0.6 to 1.6) (165).  
Cigarette-SNP joint effects were modeled using three disjoint indicator variables for 1) 
individuals who smoked but did not have the variant genotype, 2) individuals who did not smoke but 
had the variant genotype, and 3) individuals who smoked and had the variant genotype (165). As 
described in Hung et al. (165), hierarchical models included a 3x2 gene-environment matrix to 
account for clustering of the disjoint indicator variables by single SNP and cigarette effects (see table 
17 for an example). Models with a larger gene-environment matrix to account for all SNPs on the 
same gene were explored, but found to be over-parameterized. A τ2 of 0.35 was used for joint effect 
models since this corresponded to expected ORs between approximately 0.3 and 3.0 for each 
 77 
 
indicator variable (165). The GLIMMIX procedure in SAS (Cary, NC) was used for all hierarchical 
models (163,164,169). 
 Use of hierarchical modeling is becoming more common in the epidemiologic literature. 
Witte, Carmichael, and colleagues have championed its use in exploring the effect of nutritional 
exposures on neural tube defects and breast cancer (164,170). Likewise, Hung and colleagues has 
published several studies using hierarchical modeling to estimate the effect of genetic exposures on 
bladder cancer and lung cancer (165,168). Of particular interest, a recent paper by Hung et al. (2007) 
utilized hierarchical regression via the GLIMMIX macro to estimate the effects of various DNA repair 
genes (which were defined by one or two SNPs in the gene) on lung cancer incidence in a large case-
control study (168). In this analysis, first level data were based on genes and second level data on a 
gene-pathway matrix (168). Comparing hierarchical and conventional logistic regression models, 
Hung et al. (168) found 5 genes associated with lung cancer using conventional logistic regression 
with a single gene in each regression, 4 genes associated with lung cancer using conventional logistic 
regression with all genes in a single regression, and 3  genes associated with lung cancer using 
hierarchical logistic regression (whether using empirical or semi-Bayes, with or without a covariate 
for sequence conservation of the variants) based on a 0.05 alpha level. As concluded by Hung et al in 
this study, compared to the conventional models, the hierarchical models improved the precision of 
estimates (i.e. narrower intervals), mitigated false positives by shrinking estimates toward a prior 
mean, and allowed for pathway estimation (168). Therefore, it is believed that hierarchical modeling 
was a valuable tool to account for multiple comparisons and more accurately estimate SNP effects 
on HNC incidence in this dissertation.  
2.6.3 Aim 2: Survival Models  
 Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% CIs 
for SNP and cigarette smoking and HNC risk. As previously described, SNPs were defined using a 
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dominant genetic model and treatment was defined as combinations of dichotomous variables 
for surgery, radiation, and chemotherapy (irrespective of timing). Models of platinum-based 
chemotherapy (yes/no) were also considered. All models were adjusted for confounders as 
determined by the DAG and other criteria as described in the covariate assessment section. In 
addition, since allele frequencies and survival rates differ by race in the US, models were 
stratified by self-reported race (white and African American) (59-61,129).  
 Joint effects of SNPs and treatment (combinations of surgery, chemotherapy, and surgery) 
were also estimated using Cox proportional hazard models. In addition, joint effects of SNPs and 
platinum-based chemotherapy (yes/no) were assessed in a separate model. Like aim 1, interactions 
were assessed on the additive scale, only calculating the RERI using HRs instead of ORs, and 
considered primarily among whites because low cell counts precluded reliable precise estimation 
among African Americans.  
  Cox proportional hazards modeling have been frequently used in previous literature on 
SNPs in NER genes, treatment, and HNC survival (table 9) (7,47-55). Although other survival 
models are available and can be useful in analyzing survival data, these parametric models often 
have stringent assumptions regarding the distribution and function of the hazard rate (171,172). 
As examples, consider the following accelerated failure time models: under the exponential 
distribution it is assumed that the hazard rates are constant, under the Weibull distribution it is 
assumed that the hazard rates smoothly increase or decrease, and under the log-normal, 
generalized gamma, and log-logistic distributions, proportional hazards modeling cannot be 
utilized (171,172). In contrast, Cox proportional hazards models are semi-parametric in that no 
assumptions about the distribution of the baseline hazard is required, but it is assumed that the 
hazard is expressed as a function of covariates (171,172). Further, Cox proportional models fit 
non-constant hazards (171). However, it is assumed that the hazard functions for each group 
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(e.g., the hazard function for each genotype) are proportional (171). This assumption was 
checked by examining adjusted log negative log plots by treatment/genotype and assessing the 
significance of including an interaction term for treatment/genotype and time in models 
(171,172). Evidence of non-proportional hazards (i.e. log plots indicated a violation of the 
proportional hazards assumption and interaction terms with time were significant, p<0.05) was 
noted for 4 SNPs in whites (rs3731068, rs744154, rs3136085, rs3136172) and 3 SNPs in African 
Americans (rs4150360, rs2020955, rs13181). However, because p-values for the AFT models 
were similar to those obtained from Cox models (i.e. the same set of significant SNP-HNC 
survival associations resulted from both approaches), results from the Cox models without an 
interaction term between SNPs and time are presented for simplicity. 
 Absolute differences in HNC survival by genotype and treatment were also assessed via 
Kaplan-Meier plots (171). Kaplan-Meier curves were constructed by graphing time on the x-axis and 
the cumulative survival on the y-axis (171). In this dissertation, time was measured in days and 
cumulative survival was calculated as the percent of cases alive at each time point (171). Log rank 
tests were used to assess differences in survival (171). 
 For overall survival models, follow-up started at date of diagnosis for all cases and 
ended at date of death for individuals who died or censoring on December 31, 2009 for 
individuals who were still alive. For HNC disease-specific survival models, follow-up started at 
date of diagnosis for all cases and ended at date of death for individuals who died of HNC or 
censoring at date of death for individuals who died from other causes or December 31, 2009 for 
individuals who were still alive.  
 For survival analyses, a Bonferroni corrected 0.0006 alpha level of significance (based on a 
0.05 alpha divided by 84 SNPs among whites and 79 SNPs among African Americans) was used to 
account for multiple comparisons. The GLIMMIX procedure for hierarchical modeling is not designed 
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for survival analyses on a continuous time scale so hierarchal models were not considered for aim 2 
(173). Analyses for aim 2 were completed using the statistical software SAS (Cary, NC) (163). 
2.7 POWER 
2.7.1 Aim 1: Incidence Models 
2.7.1.1 Power Calculations 
 To calculate the power in CHANCE to detect associations between SNPs in NER genes and 
HNC incidence, as well as the joint effects of SNPs and cigarette smoking, I used the National Cancer 
Institute’s Power program (174,175). For these calculations alpha was set at 0.05 and the incidence 
of HNC in the general population was assumed to be 0.0001 based on NCI and ACS estimates 
(1,59,60). The overall sample size was 2552 with a case-control ratio of 1.08 (1,325 controls to 1,227 
cases) for reasons summarized in figures 2 and 3. For race-specific power calculations, the overall 
sample sizes and case-control ratios were 1996 and 1.16 for whites and 556 and 0.82 for African 
Americans.  The prevalence of exposure (i.e. frequency of the risk genotype) was varied between 
0.10 and 0.50 based on the minor allele frequencies for SNPs in NER genes as determined by 
HapMap (table 12) (129).  The effect estimate (i.e. OR) was also varied between 1.05 and 2.00 based 
on previous literature which indicated weakly to moderately elevated risks (or conversely weakly to 
moderately reduced risks with ORs between 0.50 to 0.95) (4,5,8-46). For joint effects, the 
prevalence and effect estimate (i.e. OR) for cigarette smoking among the overall study population 
was set at 0.62 and 2.13, respectively, based on a preliminary analysis by Stingone et al. prior to 
publication (57,176). For race-specific  joint effect power calculations, preliminary estimates of 
prevalence and ORs for cigarette smoking were  0.61 and 1.83, respectively, for whites and  0.62 and 
4.00 (which is a dampened estimate of the preliminary OR of  13.5 for African Americans in 
CHANCE), respectively, for African Americans  (57,176).  Joint effects were considered on the 
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additive scale as suggested by Weinberg (162) and gamma (excess OR for interaction) was set at the 
default value of 2.0 (174,175).  
2.7.1.2 Power Results 
  Figure 8a displays the resulting trends in power to detect associations between SNPs 
and HNC incidence. If the frequency of the risk genotype is 10%, then CHANCE achieves 80% 
power to detect an OR of approximately 1.40 or higher. If the frequency of the risk genotype is 
50%, then CHANCE achieves 80% power to detect an OR of approximately 1.20 or higher. 
Figures 8b,c display the power to detect various ORs for SNPs among whites and African 
Americans separately. Among whites, CHANCE achieves 80% power to detect an OR of 
approximately 1.50 or higher if the frequency of the risk genotype is 10% and an OR of 
approximately 1.30 or higher if the frequency is 50%. Among African Americans, the study has 
80% power to detect an OR of approximately 1.65 or higher if the frequency is 50%.  
 Figures 9a shows the power to detect joint effects of SNPs and cigarette smoking on 
HNC incidence on the additive scale among the overall study population. If the frequency of the 
risk genotype is 20% and the OR for the risk genotype is approximately 1.45 or higher, then 
CHANCE achieves approximately 80% power to detect an excess OR for interaction of 2.0. If the 
frequency of the risk genotype is 50% and OR for the risk genotype is approximately 1.25 or 
higher, then CHANCE achieves approximately 80% power to detect an excess OR for interaction 
of 2.0. Figure 9b,c show the power to detect joint effects on the additive scale among whites 
and African Americans separately. For whites, CHANCE achieves 80% power when the 
prevalence of the risk genotype is at minimum 0.30 and the OR for the risk genotype is at 
minimum 1.75. For African Americans, CHANCE achieves only 62.4% power under the same 
conditions. 
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 CHANCE is one of the largest case-control studies to date to estimate the effects of SNPs 
in NER genes, including joint effects with cigarette smoking, on HNC risk. Based on the power 
calculations and results just described, it is believed that this dissertation has sufficient power to 
achieve aim 1. Although power is lower among African Americans, CHANCE will only be the 
second study to date to provide an African American specific estimate for the effects of SNPs in 
NER genes on HNC incidence, and will include more African Americans than the previous study. 
Therefore race-specific analyses are warranted for main effect analyses. For analysis of gene 
environment interactions, CHANCE has sufficient power in the overall study populations, but 
questionable power in the race-stratified populations. Therefore, analyses of joint effects 
stratified by race were primarily considered in whites, and for exploratory purposes only in 
African Americans. 
2.7.2 Aim 2: Survival Models 
2.7.2.1 Power Calculations 
 To calculate the power of log rank tests to detect statistically significant differences in 
HNC survival by genotype and treatment status (i.e. significant hazard ratios), the Lakatos 
normal approximation methods in SAS 9.2 (Cary, NC) were used (163,177). For these calculations 
alpha was specified as 0.05. The overall sample size was 1,227 cases, including 922 white cases 
and 305 African American cases. Since follow-up begins at the date of diagnosis for cases, 
accrual time was set to zero. Survival estimates were based on National Cancer Institute (NCI) 
Surveillance and Epidemiology and End Results (SEER) survival rates from 1988-2007 for cancers 
of the oral cavity and pharynx (table 3) respectively (61,62). Overall 3- and 5-year survival rates 
were approximately 65% and 58%, respectively (61,62). Among whites, 3- and 5-year survival 
rates were approximately 67% and 60% , respectively, and among African Americans 3- and 5- 
year survival rates were approximately 45% and 38%, respectively (61,62). For disease-specific 
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survival rates, it was assumed that survival rates would be slightly higher than overall survival 
rates; 75% for 3-year 70% for 5-year survival. For all analyses, loss to follow-up was assumed to 
be 5% based on research indicating that the NDI accurately identifies up to 95% of deceased 
individuals (150). The prevalence of exposure (i.e. frequency of the risk genotype) was varied 
between 0.10 and 0.50 based on the minor allele frequencies for SNPs in NER genes as 
determined by HapMap (table 12) (129).  The effect estimate (i.e. HR) was also varied between 
1.05 and 2.00 based on previous literature which indicated weakly to moderately elevated 
hazards (or conversely weakly to moderately reduced hazards with HRs between 0.50 and 0.95) 
(table 10) (7,47-55). To estimate the power to detect joint effects of NER genes and treatment 
on HNC, power calculations for overall survival were stratified by treatment type. Therefore, all 
parameters (i.e. accrual time, survival rates, and loss to follow-up) remained the same, while 
only sample size varied. In CHANCE, 690 cases received surgery, 945 cases received radiation, 
and 473 cases received chemotherapy. 
2.7.2.2 Power Results 
  Figure 10a,b display the resulting trends in power to detect overall HRs for SNPs and 
HNC survival during various follow-up periods in CHANCE. For all cases, CHANCE achieves 
approximately 80% power to detect a HR of approximately 1.55 or greater for a risk genotype 
prevalence of 0.10 and 1.25 or greater for  a risk genotype prevalence of 0.50 during 3-year and 
5-year follow-up. For disease-specific survival (data not shown), CHANCE achieves 80% power to 
detect a HR of 1.70 for a risk genotype prevalence of 0.10 and 1.35 for a risk genotype 
prevalence of 0.50 during 3-year and 5-year follow-up. Figure10c,d display the achieved power 
to detect HRs for polymorphisms in NER genes and HNSCC survival among whites and African 
Americans separately. For white cases, CHANCE achieves 80% power to detect a HR of 1.70 for a 
risk genotype prevalence of 0.10 and 1.35 for a risk genotype prevalence of 0.50 during 3-year 
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and 5-year follow-up (only 3-year shown). For African American cases, CHANCE achieves 80% 
power to detect a HR of approximately 2.10 for a risk genotype prevalence of 0.10 and 1.50 for a 
risk genotype prevalence of 0.50 during 3-year and 5-year follow-up (only 3-year shown). 
 Figure 11 displays the power achieved in each treatment group in CHANCE. Among 
cases who underwent surgery, CHANCE achieves  80% power to detect a HR of approximately 
1.85 or greater for a risk genotype prevalence of 0.10 and 1.45 or greater for  a risk genotype 
prevalence of 0.50 during 3-year and 5-year follow-up. Among cases who received radiation 
treatment, CHANCE achieves  80% power to detect a HR of approximately 1.65 or greater for a 
risk genotype prevalence of 0.10 and 1.35 or greater for  a risk genotype prevalence of 0.50 
during 3-year and 5-year follow-up. Among cases who received chemotherapy, CHANCE 
achieves  80% power to detect a HR of approximately 2.10 or greater for a risk genotype 
prevalence of 0.10 and 1.55 or greater for  a risk genotype prevalence of 0.50 during 3-year and 
5-year follow-up. 
 CHANCE is the largest study to date to estimate the effects of SNPs in NER genes, 
including joint effects with treatment, on HNC survival. As demonstrated in figure 10 this 
dissertation has adequate power to detect an association over a range of HRs among all cases, 
as well as among white and African American cases separately (aim 2). Although power to 
detect associations is lower among African Americans and among cases treated with 
chemotherapy, it still appears sufficient. Further, this analysis is the first to estimate HRs for 
SNPs in NER genes and HNC survival among African Americans only. Power to detect joint 
effects of NER genes and treatment stratified by race were not conducted, but are believed to 
have questionable power. Therefore, analyses of joint effects stratified by race were primarily 
considered in whites, and for exploratory purposes only in African Americans. 
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2.8 SUMMARY OF METHODS 
2.8.1 Limitations 
 As with any research, some analyses and interpretations proposed in this disstertion 
were limited. First,  it should be noted that not all genes in the NER pathway were included in 
this dissertation. Although some accessory NER genes which code for protein subunits of the 
TFIIH complex were not included, namely GTF2H1, GTF2H2, GTF2H3, GTF2H4, GTF2H5 (TTDA), 
and MNAT1 (MAT1), several SNPs in all of the core NER genes were analyzed  (123). Second, a 
combination of candidate and tag SNPs were selected for this dissertation. Candidate SNPs 
include polymorphisms which have been reported in previous studies or have presumed 
functional impact. Tag SNPs were based on a previous HNC case-control study conducted at MD 
Anderson which utlized only the CEU population in NIEHS-EGP and HapMap databases 
(129,139,140). Therefore, the amount of variation captured across some genes was limited, 
especially among African Americans. The percentage of SNPs on each gene which were in LD 
with SNPs in CHANCE is reported in table 12. As a result of low coverage across some genes and 
ancestral populations, haplotype estimation was not conducted in this dissertation.  
 With regard to treatment information, information on yes/no receiving surgery, 
radiation therapy, and chemotherapy are considered complete for this dissertation. Information 
on start and stop dates for treatments were more frequently missing and therefore not 
considered. With regard to potential covariates, several studies have shown strong associations 
between human pappilomavirus (HPV) and HNC incidence and survival (78,103). However, HPV 
status of cases and controls in CHANCE has not yet been assayed and was therefore not 
considered as a covariate in analyses for this dissertation. Also with regard to covariates, 
survival analyses were adjusted for behaviors (e.g. cigarette smoking) prior to diagnosies rather 
than post-diagnsosis. Although post-diagnosis behaviors among cases in CHANCE were collected 
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through a follow-up study, such information was often incomplete (135,153). Further, despite 
our large sample size, exploration of gene-environment interactions among African Americans 
was limited. Some HNC tumor site-specific estimates were also limited by sparse numbers. 
Finally, I did not have access to information on tumor recurrent disease and were therefore 
unable to consider disease-free or relapse-free survival.  
2.8.2 Strengths 
 This dissertation offers several advantages to previous studies. Strengths include a large, 
racially diverse population-based study; assessment of numerous SNPs across core NER genes; 
correction for multiple comparisons and correlated exposures using traditional and hierarchical 
approaches; and consideration of interactions with genetic and environmental (e.g., behavioral 
and treatment) factors.  
 This dissertation has the third largest study population to date (1,227 cases and 1,325 
controls). However, the two larger studies included esophageal cancer cases and considered 
only 5 polymorphisms in ERCC1 and ERCC4 among an all Caucasian study population (11,14). 
With 305 African American cases and 251 African American controls, this dissertation 
encompasses a racially diverse population. No previous studies have estimated effects of 
polymorphisms in NER genes on HNC survival among African Americans, and only one smaller 
study (N=119 African Americans) has reported effects with regard to HNC and esophageal 
cancer incidence (15).  As demonstrated in the statistical power section, this study has adequate 
power to detect main effect associations in the overall and race-stratified populations.  
 In addition to being one of the largest study, this dissertation considered 84 SNPs in 15 
NER genes which, despite shortcomings to completely tag variation, was the most 
comprehensive evaluation of NER genes and HNC incidence and survival to date. Further, to my 
knowledge, this was the first study on NER genes and HNC incidence to use both Bonferroni 
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corrections and hierarchical regression methods to account not only for multiple testing, but 
correlated exposures. Most previous studies have not corrected for multiple or correlated 
comparisons when testing associations between various polymorphisms in NER genes and HNC 
outcomes. Of those that have, one study utilized the Bonferroni method (4), two studies 
employed the false discovery rate (31,55), and four used an assortment of other methods, 
mainly the false positive report probability (18,23,24,30). One other study used a full Bayesian 
approach to weight variables based on known function (i.e. higher weights for variables with 
stronger associations with HNC) (19); however, this approach does not appear to utilize a matrix 
of SNP-gene relationships. Therefore, it is believed that the approach used in this dissertation 
will improve the accuracy of estimates and better inform conclusions regarding the effect of 
polymorphisms in NER genes, including joint effects with tobacco and treatment, on HNC 
incidence and survival.  
 Finally, given the prior knowledge linking tobacco, ionizing radiation, and platinum-
containing chemotherapies to the formation of bulky DNA adducts, estimation of interactions 
between polymorphisms in NER genes and tobacco and treatment is an imperative contribution 
of this dissertation. Characterizing such gene-environment interactions clarifies the etiology of 
HNC and can identify avenues for more tailored and effective interventions. 
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Table 11. Characteristics of the Overall CHANCE Study Population and Participants with Genotype 
Data Included in Dissertation 
Characterisitc Cases N % Controls N % Cases N %
Controls 
N %
Total 1289 1361 1227 1325
Sex
Male 984 76.3 945 69.4 938 76.4 924 69.7
Female 305 23.7 416 30.6 289 23.6 401 30.3
Race/Ethnicity
White 959 74.4 1100 80.8 922 75.1 1074 81.1
African American 330 25.6 261 19.2 305 24.9 251 18.9
Age
20-49 253 19.6 156 11.5 239 19.5 151 11.4
50-54 200 15.5 160 11.8 189 15.4 156 11.8
55-59 216 16.8 206 15.1 207 16.9 199 15.0
60-64 217 16.8 205 15.1 205 16.7 202 15.2
65-69 174 13.5 241 17.7 168 13.7 237 17.9
70-74 141 10.9 227 16.7 135 11.0 216 16.3
75-80 88 6.8 166 12.2 84 6.8 164 12.4
Education
 High school or less 798 61.9 540 39.7 754 61.5 520 39.2
Some college 307 23.8 406 29.8 294 24.0 395 29.8
College or more 184 14.3 415 30.5 179 14.6 410 30.9
Overall CHANCE Study Population* Dissertation Study Population**
*The overall CHANCE study population represents interviewed participants (N=1389 cases and 1396 controls)without 
proxy interviews (N=52 cases and 17 controls), individuals of other race (N=26 cases and  18 controls), or lip cancer (N=21 
cases), or gender discrepancies (N=1 case)
**The dissertation study population represents participants with successfully genotyped samples (N=1274 cases and 
1343 controls) without individuals of other race (N=26 cases and  18 controls) or lip cancer (N=21 cases)  
  
Table 12. Single nucleotide polymorphisms in nucleotide excision repair genes included in the Carolina Head and Neck Cancer Study  
(4,5,9,18,28,40,129,178-198) 
Gene SNP
Major 
Allele
Minor 
Allele CEU YRI ASW Investigator (Study) Reason for Selection Articles for Candidate SNPs
ERCC3 (XPB) rs4150496 2 127,745,973 C T 0.336 0.163 0.307 Wei (MD Anderson HNC) Tag X 60% (23/38) X 26% (13/49)
rs4150459 2 127,753,948 C T 0.062 0.218 0.158 Wei (MD Anderson HNC) Tag X X
rs1011019 2 127,754,030 G A 0.270 0.272 0.237 Wei (MD Anderson HNC) Tag X X
rs4150434 2 127,758,570 C T 0.300 0.087 -- Wei (MD Anderson HNC) Tag X X
rs4150416 2 127,763,018 T G 0.283 0.542 -- Wei (MD Anderson HNC) Tag
rs4150407 2 127,766,101 T C 0.429 0.432 0.491 Wei (MD Anderson HNC) Tag X X
rs4150403       2 127,766,538 C T 0.120 0.000 0.009 Wei (MD Anderson HNC) Tag X
rs4150402 2 127,766,604 C T 0.270 0.272 0.237 Wei (MD Anderson HNC) Tag X X
XPC rs2228001 3 14,162,450 T G 0.407 0.276 0.316
Wei (MD Anderson HNC), 
Millikan (CBCS)
Tag X 72% (32/44) X 24% (14/58)
rs2279017† 3 14,165,238 G T 0.403 0.306 0.333 Millikan (CBCS) Joshi, 2009 X X
rs3731143 3 14,172,547 A G 0.071 0.000 0.009 Wei (MD Anderson HNC) Tag X
rs2228000 3 14,174,889 G A 0.288 0.031 0.175
Wei (MD Anderson HNC), 
Millikan (CBCS)
Tag X X
rs3731124 3 14,176,404 T G 0.203 0.097 0.061
Wei (MD Anderson HNC), 
Millikan (CBCS)
Tag X X
rs13099160 3 14,177,803 A G 0.062 0.000 -- Wei (MD Anderson HNC) Tag X
rs35629274 3 14,181,357 -- -- -- -- -- Millikan (CBCS) Function, F287C
rs3731093 3 14,185,043 A G 0.080 0.065 0.061 Wei (MD Anderson HNC) Tag X X
rs3731089 3 14,185,666 G A 0.085 0.067 -- Wei (MD Anderson HNC) Tag
rs2733537 3 14,186,105 A G 0.367 0.105 0.246 Wei (MD Anderson HNC) Tag X X
rs3731068 3 14,188,760 G T 0.164 0.000 0.018 Wei (MD Anderson HNC) Tag X
rs2607755 3 14,189,037 T C 0.492 0.358 -- Wei (MD Anderson HNC) Tag X X
rs3731062 3 14,189,528 G A 0.022 0.000 0.018 Millikan (CBCS) Function, L48F
rs1902658 3 14,190,161 A G 0.417 0.467 -- Wei (MD Anderson HNC) Tag
rs3731055 3 14,195,443 C T 0.004 0.003 -- Millikan (CBCS) Candidate Bai, 2007
ERCC8 rs4647153 5 60,205,962 A G 0.000 0.016 0.016 Millikan (CBCS) Function, 3'UTR 18% (12/65) X 19% (12/61)
rs3117 5 60,206,094 A G 0.447 0.315 0.315 Millikan (CBCS) Function, 3'UTR X X
rs158922† 5 60,276,743 C T 0.392 0.305 -- Millikan (CBCS) Function, upstream
CDK7 rs2972388 5 68,567,009 A G 0.392 0.175 -- Millikan (CBCS) Candidate Jeon, 2010 0%(0/13) 0%(0/14)
rs34584424 5 68,604,614 C T -- -- -- Millikan (CBCS) Function, T28 M
CCNH rs2266690† 5 86,731,030 A G 0.195 0.048 -- Millikan (CBCS) Function, V270A X 55% (10/18) X 14% (4/27)
rs2266691 5 86,739,661 T C 0.000 0.095 0.088 Millikan (CBCS) Function, K138R X
rs2266692 5 86,744,396 C A 0.013 0.105 0.105 Millikan (CBCS) Function, 5' UTR X X
rs1807895 5 86,744,593 A C 0.008 0.000 -- Millikan (CBCS)
Fucntional change, 
upstream
X
*Pecentage of total SNPs (as identified by HapMap) tagged by CHANCE SNPs (as indicated by X)
†SNPs which failed genotyping (i.e. weak signal intensity or in distinguishable genotype clusters)
CHANCE Carolina Head and Neck Cancer Epidemiology Study; CBCS Carolina Breast Cancer Study; HNC head and neck cancer; SNP single nucleotide polymorphism; CEU Utah residents with ancestry from northern and western Europe; YRI Yoruba in 
Ibadan, Nigeria; ASW African ancestry in Southwest United States
Selection Method
Chromosome and 
Position
Minor Allele Frequency (MAF) Variation Captured by CHANCE SNPs*
CEU YRI
 
 
8
9
 
  
Table 12 cont. Single nucleotide polymorphisms in nucleotide excision repair genes included in the Carolina Head and Neck Cancer Study  
Gene SNP
Major 
Allele
Minor 
Allele CEU YRI ASW Investigator (Study) Reason for Selection Reason for Selection
XPA rs3176757 9 99,476,879 G A 0.252 0.109 0.167 Wei (MD Anderson HNC) Tag X 55% (10/18) X 18% (11/59)
rs3176753 9 99,477,264 A G 0.004 0.160 0.149 Millikan (CBCS) Function, 3'UTR X
rs3176750 9 99,477,610 G C 0.000 0.041 0.018 Millikan (CBCS) Function L252V X
rs3176748 9 99,478,165 T C 0.354 0.032 -- Wei (MD Anderson HNC) Tag X X
rs2808667    9 99,482,627 C T 0.081 0.007 -- Wei (MD Anderson HNC) Tag X
rs2805835 9 99,484,772 C G 0.100 0.008 -- Wei (MD Anderson HNC) Tag X X
rs3176689 9 99,487,617 T A 0.092 0.000 -- Wei (MD Anderson HNC) Tag X
rs3176683 9 99,488,438 A G 0.106 0.000 0.018 Wei (MD Anderson HNC) Tag X
rs2808668† 9 99,492,256 T C 0.423 0.325 -- Wei (MD Anderson HNC) Tag X X
rs3176658     9 99,493,684 G A 0.115 0.143 -- Wei (MD Anderson HNC) Tag X X
rs1800975 9 99,499,399 C T 0.381 0.245 0.259 Millikan (CBCS) Function, upstream
Abassi, 2009; An, 2007; Hall, 2007; Bau, 
2007; Sugimara, 2005; Han, 2010; Qian, 
2011; Pan, 2009; Joshi, 2009; Hung, 2008; 
Wu, 2008; Lin, 2008; Wu, 2006
X X
RAD23B rs1805330 9 109,124,082 C T 0.098 0.197 0.149 Millikan (CBCS) Funcation, splice X 10% (9/82) X 10% (11/101)
rs1805329 9 109,124,149 C T 0.154 0.000 -- Millikan (CBCS)  Function, Ala249Val
McKean, 2009; Pan, 2009; Wu, 2008; Lin, 
2008; Change, 2008; Zhang, 2008; Mechanic, 
2006;  Hill, 2006; Wu, 2006
X
ERCC6 rs4253230 10 50,337,027 G A 0.000 0.099 0.035 Millikan (CBCS) Function, !1441I X 34% (34/99) X 27% (38/136)
rs2228529 10 50,337,111 T C 0.204 0.122 0.096 Millikan (CBCS) Function Q1413R Han, 2009 X X
rs2229761 10 50,339,465 C G 0.000 0.024 -- Millikan (CBCS) Function, V1308L X
rs2228527 10 50,348,375 T C 0.204 0.153 0.114 Millikan (CBCS) Function Arg1213Gly Abassi, 2009; Mechanic, 2006 X X
rs2228526† 10 50,348,723 T C 0.204 0.136 0.107 Millikan (CBCS) Function, M1097V
Rajaraman, 2008; Ma, 2009; Pan, 2009; Wu, 
2008; Lin, 2008; Wu, 2006; Han, 2009
X X
rs4253132 10 50,371,162 A G 0.133 0.329 0.316 Millikan (CBCS) Function, splice X X
rs4253072 10 50,394,022 T C 0.016 0.038 0.009 Millikan (CBCS) Function, R382K X
rs4253047† 10 50,402,145 C T 0.027 0.000 -- Millikan (CBCS) Function, 5' UTR X X
rs2228528 10 50,402,286 C T 0.161 0.177 0.211 Millikan (CBCS) Function, G399D X X
DDB2 (XPE) rs2029298 11 47,191,294 T C 0.327 0.378 0.535 Wei (MD Anderson HNC) Tag 70% (17/24) 36% (12/33)
rs4647709 11 47,193,935 C T 0.085 0.000 0.080 Wei (MD Anderson HNC) Tag X
rs2291120 11 47,194,256 T C 0.128 0.003 0.018 Wei (MD Anderson HNC) Tag X
rs1685404 11 47,200,241 G C 0.323 0.221 -- Wei (MD Anderson HNC) Tag X X
rs2957873 11 47,205,870 A G 0.181 0.510 0.386 Wei (MD Anderson HNC) Tag X X
rs326224 11 47,212,174 G A 0.083 0.525 -- Wei (MD Anderson HNC) Tag
rs2306353 11 47,213,284 C T 0.092 -- -- Wei (MD Anderson HNC) Tag X
rs326222 11 47,216,244 C T 0.301 0.646 0.623 Wei (MD Anderson HNC) Tag X
rs901746 11 47,216,895 A G 0.301 0.605 0.588 Wei (MD Anderson HNC) Tag X X
rs11988† 11 47,217,836 G A 0.372 0.054 0.158 Wei (MD Anderson HNC) Tag X X
*Pecentage of total SNPs (as identified by HapMap) tagged by CHANCE SNPs (as indicated by X)
†SNPs which failed genotyping (i.e. weak signal intensity or in distinguishable genotype clusters)
Minor Allele Frequency (MAF) Selection Method Variation Captured by CHANCE SNPs*
Chromosome and 
Position CEU YRI
CHANCE Carolina Head and Neck Cancer Epidemiology Study; CBCS Carolina Breast Cancer Study; HNC head and neck cancer; SNP single nucleotide polymorphism; CEU Utah residents with ancestry from northern and western Europe; YRI Yoruba in 
Ibadan, Nigeria; ASW African ancestry in Southwest United States
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Table 12 cont. Single nucleotide polymorphisms in nucleotide excision repair genes included in the Carolina Head and Neck Cancer Study  
Gene SNP
Major 
Allele
Minor 
Allele CEU YRI ASW Investigator (Study) Reason for Selection Reason for Selection
ERCC5 (XPG) rs2296147 13 102,296,376 T C 0.442 0.156 0.254
Wei (MD Anderson HNC), 
Millikan (CBCS)
Tag X 70% (40/57) X 31% (33/104)
rs2296148 13 102,296,546 C T 0.046 -- -- Millikan (CBCS) Hussain, 2009 X
rs4771436 13 102,300,021 T G 0.214 0.249 0.158 Wei (MD Anderson HNC) Tag X X
rs1047768 13 102,302,518 C T 0.425 0.274 0.333 Olshan (CHANCE) Candidate Abassi, 2009; Hussain, 2009; Kiyohara, 2007 X X
rs2020915 13 102,302,651 G A 0.000 0.323 -- Millikan (CBCS) Function, splice X
rs4987063† 13 102,304,691 G A 0 0.067 -- Millikan (CBCS) Function, V148I
rs4150313 13 102,311,952 A G 0.000 0.122 0.116 Millikan (CBCS) Function, Q259R X
rs2227869 13 102,313,086 G C 0.053 0.044 0.035
Wei (MD Anderson HNC), 
Millikan (CBCS)
Tag X X
rs3818356 13 102,317,471 C T 0.225 0.142 -- Wei (MD Anderson HNC) Tag
rs4150351 13 102,320,968 A C 0.177 0.000 0.009 Wei (MD Anderson HNC) Tag X
rs4150355 13 102,321,313 C T 0.345 0.139 0.196 Wei (MD Anderson HNC) Tag X X
rs4150360 13 102,322,763 T C 0.478 0.789 0.254 Millikan (CBCS) Function, L968F Chang, 2006 X
rs4150383 13 102,325,231 G A 0.168 0.087 0.061 Wei (MD Anderson HNC) Tag X X
rs4150386 13 102,325,529 A C 0.123 0.000 -- Wei (MD Anderson HNC) Tag X
rs17655 13 102,326,003 G C 0.277 0.460 --
Wei (MD Anderson HNC), 
Millikan (CBCS)
Tag X X
rs873601      13 102,326,338 A G 0.308 0.714 0.357 Wei (MD Anderson HNC) Tag X X
rs4150393 13 102,326,659 A G 0.102 0.016 -- Wei (MD Anderson HNC) Tag X X
rs876430 13 102,327,285 G A 0.310 0.687 0.377 Wei (MD Anderson HNC) Tag X X
rs1051677 13 216,778,493 T C 0.106 0.163 0.105 Olshan (CHANCE) Candidate
rs1051685 13 216778621, A G 0.111 0.364 0.333 Olshan (CHANCE) Candidate Hayden, 2007; Cibeira, 2011; Wu, 2006
ERCC4 (XPF) rs3136038 16 13,920,880 C T 0.296 0.418 0.482 Wei (MD Anderson HNC) Tag X 51% (28/54) X 34% (24/70)
rs1799798 16 13,921,779 G A 0.083 0 -- Wei (MD Anderson HNC) Tag
rs744154 16 13,922,582 G C 0.227 0.095 -- Millikan (CBCS) Candidate Osorio, 2009; Gaudet, 2009; Milne, 2006 X X
rs3136085 16 13,927,082 G C 0.246 0.297 -- Wei (MD Anderson HNC) Tag
rs3136091 16 13,927,883 C G 0.000 0.075 0.044 Millikan (CBCS) Function, intron X
rs254942 16 13,933,508 A G 0.035 0.000 -- Millikan (CBCS) Function, splice X
rs3136130 16 13,934,452 G T 0.258 0.443 -- Wei (MD Anderson HNC) Tag X X
rs1799802 16 13,935,582 C T 0.018 0.000 0.018 Millikan (CBCS) Candidate X
rs1800067 16 13,936,534 G A 0.049 0.000 0.018
Wei (MD Anderson HNC), 
Millikan (CBCS)
Tag X
rs3136172 16 13,940,377 A G 0.250 0.108 -- Wei (MD Anderson HNC) Tag
rs1799800† 16 13,946,053 G A 0.230 0.088 0.132 Wei (MD Anderson HNC) Tag X X
rs2020955 16 13,946,160 T C 0.000 0.272 0.196 Millikan (CBCS) Function, Ser662Pro X
rs4986933 16 13,949,533 C A 0.004 0.007 -- Millikan (CBCS) Function, A863D X X
RAD23A rs2974752 19 12,917,557 A G 0.379 0.490 0.544 Millikan (CBCS) Function, upstream X 60% (3/5) X 50% (2/4)
rs11558955 19 12,920,147 A G -- -- -- Millikan (CBCS) Function, T131A
rs4987202 19 12,920,626 C T 0.008 0.000 -- Millikan (CBCS) Function, T200M X
*Pecentage of total SNPs (as identified by HapMap) tagged by CHANCE SNPs (as indicated by X)
†SNPs which failed genotyping (i.e. weak signal intensity or in distinguishable genotype clusters)
Minor Allele Frequency (MAF) Selection Method Variation Captured by CHANCE SNPs*
Chromosome and 
Position CEU YRI
CHANCE Carolina Head and Neck Cancer Epidemiology Study; CBCS Carolina Breast Cancer Study; HNC head and neck cancer; SNP single nucleotide polymorphism; CEU Utah residents with ancestry from northern and western Europe; YRI Yoruba in 
Ibadan, Nigeria; ASW African ancestry in Southwest United States
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Table 12 cont. Single nucleotide polymorphisms in nucleotide excision repair genes included in the Carolina Head and Neck Cancer Study  
Gene SNP
Major 
Allele
Minor 
Allele CEU YRI ASW Investigator (Study) Reason for Selection Reason for Selection
ERCC2 (XPD) rs13181 19 50,546,759 T G 0.332 0.177 0.263
Wei (MD Anderson HNC), 
Millikan (CBCS)
Tag X 55% (16/29) X 43% (14/32)
rs238418 19 50,547,102 C A 0.339 0.025 -- Wei (MD Anderson HNC) Tag
rs1799787 19 50,547,984 G A 0.270 0.071 0.096 Wei (MD Anderson HNC) Tag X X
rs3916874 19 50,548,766 C G 0.329 0.000 0.061 Wei (MD Anderson HNC) Tag X
rs238416 19 50,548,889 C T 0.350 0.027 0.088 Wei (MD Anderson HNC) Tag X X
rs238414† 19 50,549,660 C T 0.325 0.728 -- Wei (MD Anderson HNC) Tag
rs50872 19 50,554,289 G A 0.305 0.139 0.842 Wei (MD Anderson HNC) Tag X X
rs50871 19 50,554,355 C A 0.465 0.973 0.886 Wei (MD Anderson HNC) Tag X X
rs238407 19 50,560,318 A T 0.500 0.016 -- Wei (MD Anderson HNC) Tag X X
rs3810366 19 50,565,782 G C 0.425 0.976 -- Wei (MD Anderson HNC) Tag X X
ERCC1 rs735482 19 50,603,842 A C 0.133 0.259 0.289 Olshan (CHANCE) Candidate Jones, 2011; Cibeira, 2011; Ricceri, 2010 X 76% (10/13) X 53% (7/13)
rs762562† 19 50,604,183 A G 0.133 0.257 0.300 Wei (MD Anderson HNC) Tag X X
rs2336219 19 50,604,246 G A 0.133 0.248 0.281 Wei (MD Anderson HNC) Tag X X
rs3212986† 19 50,604,576 C A 0.232 0.330 0.298 Olshan (CHANCE) Candidate
Abassi, 2009; An, 2007; Sturgis, 2002; 
Sugimara, 2005; etc.
X X
rs3212964 19 50,612,636 C T 0.129 0.178 0.231 Wei (MD Anderson HNC) Tag X X
rs3212955 19 50,615,336 T C 0.238 0.294 -- Wei (MD Anderson HNC) Tag X
rs3212948 19 50,616,202 G C 0.325 0.976 -- Wei (MD Anderson HNC) Tag X
rs3212935 19 50,618,615 T C -- 0.394 0.325 Millikan (CBCS) Function, intron X
rs3212930 19 50,619,450 T C 0.208 0.051 -- Millikan (CBCS) Candidate
LIG1 rs13436† 19 53,312,848 G C 0.388 0.520 -- Millikan (CBCS) Function, splice Michiels, 2007 37% (27/72) 20% (20/97)
rs3729512† 19 53,314,187 G A 0.117 0.288 -- Olshan (CHANCE) Candidate
rs3731003 19 53,323,070 G A 0.000 0.027 0.018 Millikan (CBCS) Function, T614I X
rs156641 19 53,323,220 C T 0.381 0.058 -- Olshan (CHANCE) Candidate Chang,2008; Michiels, 2007 X X
rs3730980 19 53,330,834 T C 0.000 0.040 -- Millikan (CBCS) Function, M480V X
rs3730933 19 53,339,009 T C 0.000 0.041 0.009 Millikan (CBCS) Function, N267S X
rs20580 19 53,346,365 G T 0.487 0.566 0.554 Olshan (CHANCE) Candidate Liu, 2009; Lee, 2007 X X
rs4987070 19 53,356,469 T C 0.000 0.000 -- Millikan (CBCS) Function, D72G
rs20579 19 53,360,642 G A 0.119 0.323 -- Millikan (CBCS) Function, 5' UTR Liu, 2009; Chang, 2008; Lee, 2007 X X
rs439132 19 53,360,726 T C 0.004 0.364 -- Olshan (CHANCE) Candidate Chang,2008; Lee, 2007 X
*Pecentage of total SNPs (as identified by HapMap) tagged by CHANCE SNPs (as indicated by X)
†SNPs which failed genotyping (i.e. weak signal intensity or in distinguishable genotype clusters)
Minor Allele Frequency (MAF) Selection Method Variation Captured by CHANCE SNPs*
Chromosome and 
Position CEU YRI
CHANCE Carolina Head and Neck Cancer Epidemiology Study; CBCS Carolina Breast Cancer Study; HNC head and neck cancer; SNP single nucleotide polymorphism; CEU Utah residents with ancestry from northern and western Europe; YRI Yoruba in 
Ibadan, Nigeria; ASW African ancestry in Southwest United States
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Table 13. Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes 
Inclusion and Exclusion Criteria, Carolina Head and Neck Cancer Epidemiology (CHANCE) Study 
Gene SNP
Major 
Allele
Minor 
Allele
Selection Method
Failed 
Genotyping
Whites
African 
Americans
Whites
African 
Americans
ERCC3 (XPB) rs4150496 G A Tag
rs4150459 G A Tag X
rs1011019 C T Tag
rs4150434 G A Tag
rs4150416 T G Tag
rs4150407 A G Tag
rs4150403 G A Tag X
rs4150402 G A Tag
XPC rs2228001 A C Literature/Function
rs3731143 T C Tag X
rs2228000 C T Function
rs3731124 A C Literature/Function
rs13099160 A G Tag X
rs35629274 A C Literature /Function X X
rs3731093 T C Tag
rs3731089 G A Tag
rs2733537 A G Tag X
rs3731068 C A Tag X
rs2607755 T C Tag
rs3731062 C T Literature/Function X X
rs1902658 G A Tag X
rs3731055 G A Literature/Function X X
rs2279017 -- -- Literature/Function X
ERCC8 rs4647153 T C Literature/Function X X
rs3117 T C Literature/Function
rs58922 -- -- Literature/Function X
CDK7 rs2972388 A G Literature/Function X
rs34584424 C T Literature/Function X X
CCNH rs2266691 A G Literature/Function X
rs2266692 G T Literature/Function X
rs1807895 T -- Literature/Function X X
rs2266690 -- -- Literature/Function X
XPA rs3176757 C T Tag
rs3176753 T C Literature/Function X
rs3176750 C G Literature/Function X X
rs3176748 A G Tag
rs2808667    C T Tag X
rs2805835 G C Tag X
rs3176689 A T Tag X
rs3176683 T C Tag X
rs3176658     C T Tag X
rs1800975 G A Literature/Function
rs2808668 -- -- Tag X
MAF < 0.05 HWE P-value < 0.05
MAF Minor Allele Frequency, HWE Hardy-Weinberg Equilibrium  
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Table 13 cont. Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes 
Inclusion and Exclusion Criteria, Carolina Head and Neck Cancer Epidemiology (CHANCE) Study 
Gene SNP
Major 
Allele
Minor 
Allele
Selection Method
Failed 
Genotyping
Whites
African 
Americans
Whites
African 
Americans
RAD23B rs1805330 C T Literature/Function
rs1805329 C T Literature/Function X
ERCC6 rs4253230 C -- Literature/Function X X
rs2228529 A G Literature/Function
rs2229761 G C Literature/Function X X
rs2228527 A G Literature/Function
rs4253132 T C Literature/Function X
rs4253072 A G Literature/Function X X
rs2228528 G A Literature/Function
rs4253047 -- -- Literature/Function X
rs2228526 -- -- Literature/Function X
DDB2 (XPE) rs2029298 A G Tag
rs4647709 C T Tag X
rs2291120 T C Tag X
rs1685404 G C Tag
rs2957873 A G Tag
rs326224 G A Tag
rs2306353 G A Tag
rs326222 C T Tag
rs901746 A G Tag
rs11988 -- -- Tag X
ERCC5 (XPG) rs2296147 T C Tag
rs2296148 C T Literature/Function X X
rs4771436 T G Tag
rs1047768 C T Literature/Function
rs2020915 G A Literature/Function X
rs4150313 A -- Literature/Function X X
rs2227869 G C Tag X X
rs3818356 C T Tag
rs4150351 A C Tag X
rs4150355 C T Tag
rs4150360 T C Literature/Function X
rs4150383 G A Tag
rs4150386 A C Tag X
rs17655 C G Tag
rs873601      A G Tag
rs4150393 A G Tag X
rs876430 C T Tag
rs1051677 T C Literature/Function
rs1051685 A G Literature/Function
rs4987063 -- -- Literature/Function X
MAF < 0.05 HWE P-value < 0.05
MAF Minor Allele Frequency, HWE Hardy-Weinberg Equilibrium  
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Table 13 cont. Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes 
Inclusion and Exclusion Criteria, Carolina Head and Neck Cancer Epidemiology (CHANCE) Study 
Gene SNP
Major 
Allele
Minor 
Allele
Selection Method
Failed 
Genotyping
Whites
African 
Americans
Whites
African 
Americans
ERCC4 (XPF) rs3136038 C T Tag X
rs1799798 G A Tag X
rs744154 C G Literature/Function
rs3136085 G C Tag
rs3136091 C G Literature/Function X
rs254942 T C Literature/Function X X
rs3136130 G T Tag
rs1799802 C T Literature/Function X X
rs1800067 G A Literature/Function X
rs3136172 A G Tag
rs2020955 T C Literature/Function X X
rs4986933 C A Literature/Function X X
rs1799800 -- -- Tag X
RAD23A rs2974752 A G Literature/Function X
rs11558955 A G Literature/Function X
rs4987202 C T Literature/Function X X
ERCC2 (XPD) rs13181 T G Tag
rs238418 C A Tag
rs1799787 C T Tag
rs3916874 G C Tag
rs238416 G A Tag
rs50872 C T Tag
rs50871 T G Tag
rs238407 A T Tag
rs3810366 C G Tag
rs238414 -- -- Tag X
ERCC1 rs735482 A C Literature/Function
rs2336219 G A Tag
rs3212964 G A Tag
rs3212955 A G Tag
rs3212948 C G Tag
rs3212935 A G Literature/Function X X
rs3212930 T C Literature/Function
rs3212986 -- -- Literature/Function X
rs762562 -- -- Tag X
LIG1 rs3731003 C T Literature/Function X X
rs156641 G A Literature/Function X
rs3730980 A G Literature/Function X X
rs3730933 A G Literature/Function X X
rs20580 C A Literature/Function
rs4987070 A -- Literature/Function X X
rs20579 C T Literature/Function
rs439132 A G Literature/Function X X X
rs13436 -- -- Literature/Function X
rs3729512 -- -- Literature/Function X
MAF Minor Allele Frequency, HWE Hardy-Weinberg Equilibrium
MAF < 0.05 HWE P-value < 0.05
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Table 14. Questions Related to Cigarette Smoking from the CHANCE Questionnaire (149) 
Variable  Question 
Ever Cigarette Smoking Have you smoked 100 cigarettes or 5 packs in your entire life? 
Current Cigarette Smoking Do you still smoke cigarettes? 
Duration of Cigarette 
Smoking 
At what age did you start smoking cigarettes? 
At What age did you stop? 
For how many years did you not smoke cigarettes during this 
period? 
Frequency of Cigarette 
Smoking 
How many cigarettes did you usually smoke?...per day, week, 
month, year? 
Types of Cigarettes 
Smoked 
Did you usually smoke?...filtered, non-filtered, both filtered and 
non-filtered, menthol, non-menthol, both menthol and non-
menthol? 
 
 
Table 15. Ancestral Informative Markers used in CHANCE  
rs12094678 rs11264110 rs10908312* rs7161* rs6666101 rs7512316 rs4659762 rs12129648 rs798443 rs12612040 rs1508061 rs7575147* 
rs3755446 rs10195705 rs1257010 rs4149436 rs17049450 rs17261772 rs1117382 rs1372115 rs12692701 rs1982235 rs7424137 rs12997060 
rs10202705 rs3791896 rs11901793 rs155409* rs1303629 rs13318432 rs2660769 rs1462309 rs6414248 rs1256197 rs13080353* rs6765491 
rs9849733 rs833282 rs4859147 rs6820509 rs2687427 rs9306906 rs4619931 rs12640848 rs7689609 rs10028057* rs6535244 rs385194 
rs1372894 rs316598 rs13169284 rs16891982 rs10056388 rs13173738 rs10041728 rs33957 rs1917028 rs1380014 rs13178470 rs6556352 
rs857440 rs2451563 rs10806263 rs6937164 rs4896780* rs10952147 rs7810554 rs7788641 rs17520733 rs10254729 rs10255169 rs344454 
rs4602918 rs4143633 rs1870571 rs12676654 rs13261248 rs9297712 rs7021690 rs10124991 rs1415723 rs3861709 rs10962612* rs1885167*
rs2777804 rs1412521 rs870272 rs2488465 rs1335826 rs9416972 rs1733731 rs2184033 rs4529792 rs503677 rs9416026 rs11000419 
rs1911999 rs1125217* rs7107482 rs11607932 rs7111814 rs11223503 rs2416791 rs1490728 rs10842753 rs7134682 rs328744 rs3759171 
rs2596793 rs645510 rs9525462 rs9543532 rs4885162 rs9530646 rs6491743 rs1477921 rs222674 rs2246695 rs710052 rs12900552 
rs1470608 rs12900262 rs4489979 rs7086 rs4923940 rs12594483 rs567357 rs735480 rs1426654* rs17269594 rs6494466 rs9806307 
rs4506877 rs4350528 rs9923864 rs7187359 rs12926237 rs11150219 rs7189172 rs1862819 rs4792105 rs12945601 rs1043809 rs2593595 
rs4793237 rs228768 rs11652805 rs4789070 rs897351 rs8113143 rs1991818 rs1011643 rs2426515 rs6023376 rs4811651* rs2075902 
rs4823460 
*SNPs which failed genotyping (i.e. weak signal intensity or in distinguishable genotype clusters)
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Table 16. Example of SNP-gene matrix (Zj ) using select single nucleotide polymorphisms and genes 
included in the Carolina Head and Neck Cancer Study 
 ERCC3 XPC ERCC8 CDK7 CCNH XPA RAD23B … 
rs41509496 1 0 0 0 0 0 0 0 
Rs4150459 1 0 0 0 0 0 0 0 
…         
rs2228001 0 1 0 0 0 0 0 0 
rs2279017 0 1 0 0 0 0 0 0 
…         
rs4647153 0 0 1 0 0 0 0 0 
rs3117 0 0 1 0 0 0 0 0 
 
 
Table 17. Example of SNP-environment matrix  
 SNP Cigarette Smoking 
Never cigarette smoking, variant genotype 1 0 
Ever cigarette smoking, referent genotype 0 1 
Ever cigarette smoking, variant genotype 1 1 
Referent: Never cigarette smoking, referent genotype (i.e. SNP=0, Cigarette Smoking=0) 
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Figure 2. Flowchart of CHANCE Cases Included in Dissertation (adapted from Hakenewerth 
dissertation (82,135)) 
 
 
 99 
 
Figure 3. Flowchart of CHANCE Controls Included in Dissertation (adapted from Hakenewerth 
dissertation (82,135)) 
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 Figure 4. Direct Acyclic Graph for Nucleotide Excision Repair Genes (SNPs) and Head and Neck 
Cancer Incidence 
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Figure 5. Direct Acyclic Graph for Cigarette Smoking and Head and Neck Cancer Incidence 
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Figure 6. Direct Acyclic Graph for Nucleotide Excision Repair Genes (SNPs) and Head and Neck 
Cancer Mortality 
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Figure 7. Direct Acyclic Graph for Treatment and Head and Neck Cancer Mortality 
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Figure 8. Power to detect main effects of single nucleotide polymorphisms in nucleotide excision 
repair genes on head and neck cancer incidence, CHANCE 
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Figure 9. Power to detect joint effects of single nucleotide polymorphisms in nucleotide excision 
repair genes and cigarette smoking on head and neck cancer incidence, CHANCE 
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Figure 10. Power to detect main effects of single nucleotide polymorphisms in nucleotide excision 
repair genes on head and neck cancer mortality, CHANCE 
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Figure 10 cont. Power to detect main effects of single nucleotide polymorphisms in nucleotide 
excision repair genes on head and neck cancer mortality, CHANCE 
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Figure 11. Power to detect joint effects of single nucleotide polymorphisms in nucleotide excision 
repair genes and treatment on head and neck cancer mortality, CHANCE  
  
 
Chapter 3 
Single Nucleotide Polymorphisms in Nucleotide Excision Repair Genes, Cigarette Smoking, and the 
Risk of Head and Neck Cancer 
 
3.1 OVERVIEW 
 Cigarette smoking is strongly associated with increased risk of head and neck cancer (HNC). 
Carcinogens in cigarette smoke are known to cause bulky DNA adducts. Nucleotide excision repair 
(NER) genes encode enzymes that remove adducts and may be independent risk factors for HNC, as 
well as modifiers of the association between smoking and HNC.  Using population-based case-
control data from the Carolina Head and Neck Cancer Epidemiology (CHANCE) study (1,227 cases, 
1,325 controls), race-stratified (white, African American) conventional and hierarchical logistic 
regression models were utilized to estimate odds ratios (OR) with 95% intervals (I) for the 
independent and joint effects of cigarette smoking and 84 single nucleotide polymorphisms (SNPs) 
from 15 NER genes on HNC risk. The odds of HNC were elevated among ever cigarette smokers 
(OR=1.97, 95% I=1.54, 2.53 among whites and OR=7.75, 95% I=3.57, 16.83 among African 
Americans), and showed a dose-response gradient with smoking duration and frequency 
(ptrend<0.0001). Among whites, rs4150403 on ERCC3 was associated with increased HNC odds 
(AA+AG vs. GG, OR=1.28, 95% I=1.01, 1.61). Among African Americans, rs4253132 on ERCC6 was 
associated with decreased HNC odds (CC+CT vs. TT, OR=0.62, 95% I=0.45, 0.86). Interactions 
between cigarette smoking and 3 SNPs (rs4253132 on ERCC6, rs2291120 on DDB2, and rs744154 on 
ERCC4) suggested possible departures from additivity among whites.  We conducted one of the 
largest and most comprehensive evaluations of NER variants, identifying only a few SNPs from
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 biologically plausible candidate genes associated with HNC and possibly interacting with cigarette 
smoking.  
3.2 BACKGROUND 
 Head and neck cancer (HNC) includes tumors, principally squamous cell carcinomas, of the 
oral cavity, pharynx, and larynx (199). In the United States, an estimated 52,140 incident HNC cases 
and 11,460 associated deaths occurred in 2011 (1). Cigarette smoking is considered a major risk 
factor for HNC incidence with case-control studies consistently reporting elevated odds ratios (ORs) 
for ever smoking, as well as dose-response gradients with smoking duration and frequency (2). 
Among non-alcohol drinking HNC cases, 25% of cases are attributed to cigarette smoking (83). 
 Cigarette smoke contains numerous chemical carcinogens, such as benzo-a-pyrene, that are 
known to cause a host of DNA damage, including bulky DNA adducts (2,3,124,126).  Nucleotide 
excision repair (NER) enzymes are principally responsible for removing bulky DNA adducts, and are 
therefore hypothesized to be independent risk factors for HNC, as well as important modifiers of the 
association between cigarette smoking and HNC (3,124,126). Several previous studies have 
considered associations between variants in NER genes and HNC risk, but studies vary with regard to 
which specific single nucleotide polymorphisms (SNPs) were investigated and often present 
inconsistent evidence for analysis of the same SNP (4,5,8-46,131-133). In general, most previous 
studies have evaluated only a few SNPs on a single NER gene among a few hundred HNC cases 
(4,5,8-46). Few studies have examined the association of NER SNPs and HNC among African-
Americans (15), a group shown to have a stronger association for smoking and HNC (57). Studies of 
the joint effects of cigarette smoking and variants in NER genes on HNC risk also present varying 
results, though some studies indicate stronger associations among smokers with polymorphisms in 
NER genes (4,8-10,13,15,16,22,24,26-28,30,31,33,35-38,40,44).  However, many of these studies 
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were limited by sparse numbers of NER SNPs investigated and small sample sizes (4,8-
10,13,15,16,22,24,26-28,30,31,33,35-38,40,44). 
 To comprehensively assess associations between cigarette smoking, NER genes, and HNC 
risk, we used data from the Carolina Head and Neck Cancer Epidemiology (CHANCE) study to 
estimate main and joint effects of cigarette smoking and 84 SNPs across 15 NER genes on HNC risk 
among a racially diverse population including whites (922 cases and 1074 controls) and African 
Americans (305 cases and 251 controls). 
3.3 METHODS 
3.3.1 Study Population 
 The CHANCE study is a population-based case-control study of 2,785 individuals (1,389 cases 
and 1,396 controls) from 46 of 100 counties in North Carolina (57,63,64).  Eligible participants were 
between 20 to 80 years of age (57,63,64). Cases were identified from the North Carolina Central 
Cancer Registry between January 1, 2002 and February 28, 2006 using rapid case ascertainment 
(57,63,64). Tumors were classified according to ICD-03 codes; cancers of the oral cavity (C02.0-
C02.3; C03.0-C03.1; C03.9-C04.1; C04.8-C05.0; C06.0-C06.2; C06.8-C06.9), oropharynx (C01.9; C02.4; 
C05.1-C05.2; C09.0-C09.1; C09.8-C10.4; C10.8-C10.9), hypopharynx (C12.9-C13.2; C13.8-C13.9); 
larynx (C32.0-C32.3; C32.9), and oral cavity/pharynx not otherwise specified (C02.8-C02.9; C05.8-
05.9; C14.0; C14.2; C14.8) were included in the study, while cancers of the salivary glands (C07.9, 
C08.0 to C08.9), nasopharynx (C11 .0 to C11.9), nasal cavity (C30.0), and nasal sinuses (C31.0 to C31 
.9) were excluded (57,63,64,200). Controls were randomly sampled from the Department of Motor 
Vehicle records and were frequency matched to cases based on strata of age (20-49, 50-54, 55-59, 
60-64, 65-69, 70-74, 75-80 years of age), race (white, African American, other race), and sex (male, 
female) (57,63,64). 
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  For this analysis we excluded cases and controls who did not provide biologic samples for 
DNA extraction or whose biologic samples were insufficient for genotyping [115 (8.3%) cases and 53 
(3.8%) controls]. We further excluded individuals because of sparse data for self-reported race other 
than white or African American [26 (1.9%) cases and 18 (1.3%) controls] and excluded cases with lip 
cancers because of etiologic differences from our other HNC sites [21 (1.3%) cases].  Our final 
sample included 1,227 HNC cases and 1,325 controls. 
3.3.2 Cigarette Smoking 
 Self-reported demographic and behavioral information was ascertained through nurse-
administered questionnaires (57,63,64). Information on cigarette smoking included ever/never, 
frequency (cigarettes/day) and duration (years). Information on environmental tobacco smoke (ETS) 
included ever/never and duration (years) of exposure in the home and at work.  
3.3.3 SNP Selection and Genotyping 
Blood (~90%) or buccal cell (~10%) samples were collected from cases and controls at the 
time of interview for DNA extraction (64).  An Illumina GoldenGate assay with Sentrix Array Matrix 
and 96-well standard microtiter platform was used to genotype 1,536 SNPs, including 129 SNPs in 15 
NER genes (64,137). Seventy-one tag SNPs in NER genes were selected based on a case-control 
study of HNC at MD Anderson, which queried NIEHS-EGP and HapMap databases using selection 
criteria of r2≥0.80, a minor allele frequency (MAF)≥0.05, 1-2kb flanking regions, and the CEU 
population (Utah residents with ancestry from northern and western Europe) (Table 13) 
(129,139,140). The other 58 SNPs in NER genes were selected based on several criteria including 
association in other cancer studies and/or potential function (Table 13). We excluded SNPs in NER 
genes for which genotyping resulted in weak signal intensity or indistinguishable genotype clusters 
(14 SNPs), as well as SNPs with a minor allele frequency less than 0.05 (31 SNPs among whites and 
36 SNPs among African Americans) (Table 13). Most excluded SNPs had been selected based on 
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previous literature and/or function (Table 13). Among the remaining SNPs, genotype frequencies for 
7 SNPs in whites and 7 SNP in African Americans were not consistent with Hardy-Weinberg 
equilibrium (p<0.05) (Table 13); however, because genotyping scatter plots showed reasonable 
genotype clustering, these SNPs were not excluded from analyses but interpreted with caution 
(147). Our final analysis included 84 SNPs in 15 NER genes among whites and 79 SNPs in 14 NER 
genes among African Americans.  
3.3.4 Statistical Analysis 
3.3.4.1 Cigarette Smoking-HNC Associations.  
 Unconditional logistic regression models were used to estimate OR with 95% intervals (I) 
for the main effects of cigarette smoking and ETS on HNC risk. Adjusted cigarette smoking and 
ETS models included matching factors (categorical age, sex, race), education (categorical less 
than high school education, high school education, or college education), and frequency of 
alcohol use (categorical for never drinking alcohol and quartiles of lifetime alcohol consumption 
in ml/day). ETS ORs were additionally adjusted for duration of cigarette smoking (continuous 
years), as well as stratified by ever/never cigarette smoking. Cigarette smoking and ETS models 
were considered in the overall study population and stratified by race (white and African 
American). 
3.3.4.2 SNPs-HNC Associations 
 For SNPs, race-stratified hierarchical unconditional logistic regression was used to estimate 
OR and 95% I for the main effects of SNPs on HNC risk by including a SNP-gene matrix to account for 
clustering of SNP data by gene. Since the conventional logistic regression approach of modeling one 
SNP at a time with p-values corrected for multiple comparisons using the Bonferroni method is 
overly conservative because it assumes tests are independent, which is generally not the case with 
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correlated exposures, we selected a hierarchical approach (164,165,167). Results from the 
conventional approach are provided in supplemental tables. 
 We used a two-stage hierarchical model:  
Level 1: ln (pi / 1-pi) = α + Xijβj + Wiγ 
where pi represents the probability of case status in the sample, Xij contains indicators of SNPs, and 
Wi represents important covariates or potential confounders (164,165,167). 
Level 2: βj = Zjπ + δj 
where βj represents the coefficients for the effects of the SNPs, Zj  represents the matrix linking SNPs 
with their associated genes, and δj represents independent errors which are normally distributed 
with a mean of zero and a variance of τ2 (164,165,167). To avoid over-parameterization by modeling 
one large SNP-gene matrix (i.e. including all 84 SNPs across 15 genes) in a single model, 15 models, 
one for each gene, were employed to shrink estimates for SNPs on the same gene towards a 
common gene effect (i.e. the Z matrix was a single column representing a single gene, with rows of 
1’s for each SNP). Since SNPs on the same gene were included in the same model, we excluded 
some SNPs due to collinearity (estimated correlation rho>0.98; 11 SNPs in whites and 5 SNPs in 
African Americans). A semi-Bayes approach was used to set τ2 to 0.05, as this corresponded with the 
most plausible range of expected ORs for the association between SNPs in NER genes and HNC 
based on previous literature (i.e. 0.6 to 1.6) (165).   Sensitivity analyses with τ2=0.01, τ2=0.10 and τ2 
=1.0 evaluated robustness of this choice. 
 SNPs were defined using a dominant genetic model given the large portion of SNPs with few 
cases and controls homozygous for the variant allele (~7% among whites and ~33% among African 
Americans).  The referent allele for both whites and African Americans was assigned to be the major 
allele based on controls from the overall study population (which was concurrent with the race-
specific major allele for 98% of SNPs in whites and 92% of SNPs in African Americans). Because 
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genetic exposures were based on germline DNA, which would not reflect the influences of 
behavioral factors such as smoking and drinking, SNP models were adjusted for matching factors 
(sex and age, including pairwise interactions) and ancestry (continuous percent African ancestry), as 
informed by our directed acyclic graph (DAG) analysis (160). Based on previous studies of cancer 
among whites and African Americans in North Carolina, 157 ancestral informative markers (AIMS) 
were selected based on differences in allele frequencies between European and African HapMap 
populations and then used to estimate the proportion of African ancestry in each participant based 
on Fisher’s information criterion (FIC) (64,157,201). Finally, site-specific models were considered to 
estimate the association between SNPs and tumors of the oral cavity, pharynx (oropharynx and 
hypopharynx), larynx, and not otherwise specified (NOS) separately. 
3.3.4.3 Joint Effects 
 Odds ratios and 95% Is for the joint effects of ever cigarette smoking and SNPs in NER genes 
were estimated using conventional and hierarchical logistic regression.  Joint effects were modeled 
using three disjoint indicator variables for 1) individuals who smoked but did not have the variant 
genotype, 2) individuals who did not smoke but had the variant genotype, and 3) individuals who 
smoked and had the variant genotype (165). As described in Hung et al., hierarchical models 
included a 3x2 gene-environment matrix to account for clustering of the disjoint indicator variables 
by SNP and cigarette effects (i.e. the Z matrix had two columns, one representing SNP effects and 
one representing smoking effects, and three rows, each representing the disjoint indicator variables, 
with 1’s and 0’s entered according to concordance of rows and columns) (165). A τ2 of 0.35 was used 
since this corresponded to expected ORs between 0.3 and 3.0 for each indicator variable (165). 
Sensitivity analyses with τ2=0.05 evaluated robustness of this choice.  Joint effects models were 
stratified by self-reported race. Only joint effect estimates among whites are presented because 
small cell counts among African Americans prohibited reliable estimation for most SNP-cigarette 
 116 
 
effects.  Joint effects models were adjusted for matching factors (sex and age, including pairwise 
interactions), education, frequency of alcohol use, and ancestry since both behavioral and genetic 
exposures were being modeled.  Interactions between SNPs in NER genes and cigarette smoking 
were assessed on the additive scale using the relative excess risk due to interaction (RERI), also 
known as the interaction contrast ratio (ICR), with 95% CIs calculated using the Hosmer and 
Lemeshow method (161).  Statistical analyses were performed using SAS 9.3 (Cary, NC) (163). 
3.4 RESULTS 
3.4.1 Characteristics of Study Population 
 The study population included 922 cases and 1074 controls who self-reported race as white 
and 305 cases and 251 controls who self-reported African American (table 18). The majority of cases 
(76.4%) and controls (69.7%) were male. Approximately one-third of cases (33.6%) and controls 
(30.2%) were between the ages of 55 and 65. Controls were more highly educated than cases with 
60.7% of controls attending college compared to 38.6% of cases. 
3.4.2 Cigarette Smoking-HNC Associations 
 In the overall study population, the adjusted OR was elevated for ever compared to never 
cigarette smokers (2.28, 95% I=1.81, 2.88; table 19). Stratified by race, the adjusted OR for ever 
cigarette smoking was 1.97 (1.54, 2.53) among whites and 7.75 (3.57, 16.83) among African 
Americans. Further, the risk of HNC increased with increasing frequency and duration of cigarette 
smoking (ptrend<0.0001). In contrast, we did not observe strong associations between ETS and HNC 
(supplementary table 1S, Appendix A); the adjusted OR (95% I) for ever compared to never ETS 
exposure was 0.87 (0.63, 1.19) among whites and 0.91 (0.45, 1.82) among African Americans. 
Stratified by active cigarette smoking, ETS ORs were not elevated among never cigarette smokers 
(0.84, 95% I=0.54, 1.33) nor ever cigarette smokers (0.92, 95% I=0.62, 1.37). Duration of ETS 
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exposure at work or home was also not associated with HNC risk (supplementary table 1S, Appendix 
A).  
3.4.3 SNPs-HNC Associations 
 Among whites, most ORs were close to the null value for associations between SNPs and 
HNC (table 20).  The SNP rs4150403 on the excision repair cross-complementing 3 (ERCC3) gene,  
also known as xeroderma pigmentosum B (XPB), however, was statistically significantly associated 
with elevated HNC risk (AA + AG vs. GG, OR=1.28, 95% I=1.01, 1.61). In addition, another SNP on 
ERCC3 (XPB), rs4150496, suggested a possible reduced HNC risk among whites (AA + AG vs GG, 
OR=0.80, 95% I=0.62, 1.02). When we considered associations between these SNPs and each tumor 
site separately, associations between rs4150403 and oral cavity cancer resulted in the largest 
magnitude OR (1.32, 95% I=1.01, 1.71; supplementary table 2S, Appendix A). For rs4150496, 
associations with oral cavity and orpharyngeal cancers resulted in the smallest magnitude ORs 
(OR=0.79, 95% I=0.60, 1.04 and OR= 0.77, 95% I=0.56, 1.06, respectively). 
Among African Americans, one SNP on ERCC6, rs4253132, was significantly associated with 
reduced HNC risk (CC + CT vs. TT, OR=0.62, 95% I=0.45, 0.86; table 21). Due to low cell counts, we 
were unable to assess the association between this SNP and all tumor sites among African 
Americans. We did find, however, that rs4253132 was significantly associated with reduced risk of 
laryngeal cancer (OR=0.65, 95% I=0.44, 0.97; supplementary table 3S, Appendix A). 
 No other significant SNP-HNC associations were detected, including none of the extensively 
studied associations between SNPs in ERCC2 (also known as XPD), ERCC1, or ligase 1 (LIG1) and HNC 
risk. In particular, we did not find an association between rs13181 on ERCC2 (XPD) and HNC among 
whites (GG + TG vs. TT, OR=1.05, 95% I=0.76, 1.45; table 20) nor among African Americans (OR=1.01, 
95% I=0.75, 1.37; table 21). In sensitivity analyses, results from tables 20 and 21 were robust to 
further adjustment for cigarette smoking and alcohol drinking and variation of τ2 (i.e. results were 
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similar when adjusting for cigarette smoking and alcohol drinking or when τ2=0.01, 0.10 and 1.0 
rather than 0.05, though the OR for rs4150403 among whites was non-significantly elevated when 
adjusting for cigarette smoking and alcohol drinking or when τ2=0.01, data not shown). Compared to 
the hierarchical model, ORs (95% Is) for the conventional model were similar though less stable, 
with a few additional SNP-HNC associations implicated at 0.05 alpha level but none at a Bonferroni 
corrected significance level of 0.0006 (supplementary tables 4S and 5S, Appendix A). 
3.4.4 Joint Effects  
 Using the conventional method (table 22), interactions between cigarette smoking and 3 
SNPs suggested possible departures from the null on the additive scale at an uncorrected 0.05 alpha 
level among whites. Specifically, the interaction between cigarette smoking and rs4253132 on 
ERCC6 (RERI=0.70, 95% I=0.14, 1.26) as well as rs2291120 on DDB2 (RERI=0.68, 95% I=0.11, 1.26) 
appeared to be more than additive, while the interaction between cigarette smoking and rs744154 
on ERCC4 (RERI=-1.02, 95% I=-2.02, -0.02) appeared to be less than additive. However, RERI 
estimates were generally imprecise and none were significant at a Bonferroni corrected significance 
level (table 22). It should also be noted that genotype frequencies for rs4253132 on ERCC6 among 
whites appeared inconsistent with HWE at a 0.05 alpha level, although the genotype clustering plot 
appeared reasonable, and should therefore be interpreted with some caution. ORs (95% Is) for joint 
effects from the hierarchical model (table 23) were similar to estimates from the conventional 
method. RERI point estimates were also similar between the two methods, but I was unable to 
obtain the covariance matrix using hierarchical regression and therefore could not estimate 95% 
intervals for RERI estimates using that method. Among African Americans, no significant interactions 
were noted; however, estimates were unreliable due to relatively low cell counts and are therefore 
not presented (Appendix B). For the joint effects of SNPs and ETS, a few possible interactions were 
noted among whites (supplementary table 6S, Appendix A). 
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3.5 DISCUSSION 
 Consistent with extensive literature, we found a positive association between cigarette 
smoking and HNC risk (2). In particular, we found noticeably larger ORs among African Americans 
compared to whites. A detailed analysis of smoking-HNC associations by race using CHANCE data 
has been previously published (57). Briefly, elevated HNC ORs among African American cigarette 
smokers were noted even when accounting for frequency and duration of smoking, cigarette 
product preferences (e.g., mentholated vs. non-mentholated), and tumor site (57). Racial 
differences in carcinogen metabolism and smoking cessation patterns may be contributing factors 
(57). 
Our study identified associations between two tag SNPs in the same NER gene and HNC 
among whites. Specifically, we detected elevated HNC risk associated with rs4150403 and possibly 
reduced HNC risk associated with rs4150496. These SNPs are in intron 3 and 11, respectively, of 
ERCC3 (XPB) which is a component of the transcription factor II H (TFIIH) subunit which unwinds the 
double helix surrounding a DNA adduct (123,124,202). In the epidemiologic literature neither of 
these SNPs has previously been evaluated with respect to HNC risk. Only one previous study has 
examined the effects of any variant in ERCC3 (XPB). This study by Michiels et al., conducted among a 
European population of smokers, found reduced HNC risk associated with rs4233583 (AA vs. CC, 
OR=0.37, 95% CI=0.15, 0.90), which is correlated with rs4150496 (r2=0.96, CEU population) (31,203).   
An association between rs4253132 and reduced HNC risk was detected among African 
Americans in our study. This candidate SNP occurs in intron 9 of ERCC6 which operates in NER of 
transcriptionally active DNA (123,124,202). Two previous studies have collectively reported on 
associations between 5 SNPs in ERCC6 and HNC risk; however, neither study evaluated rs4253132 
nor considered an African American population (4,13). A study by Abbasi et al. in a European 
population reported reduced HNC risk associated with rs4253211 (Arg/Pro + Pro/Pro vs. Arg/Arg, OR 
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= 0.53, 95% CI=0.34, 0.85) and no association with rs2228527 (Arg/Gly + Gly/Gly vs. Arg/Arg, 
OR=0.87, 95% CI=0.61, 1.20) (4). Another study by Chiu et al. conducted in an Asian population 
found elevated HNC risk associated with rs2228528 (GA + AA vs. GG, OR=1.43, 95% CI=1.02, 1.34) 
and no association with rs2228526 (AG + GG vs AA, OR= 0.82, 95% CI= 0.61, 1.20) and rs2228529 
(AG + GG vs. AA, OR =0.79, 95% CI=0.49, 1.26) (13). Our study also evaluated rs2228527, rs2228528, 
and rs2228529 finding near null associations among whites and African Americans (ORs~0.9). SNPs 
rs2228526, rs2228527, and rs2228529 are correlated (r2=1.0, CEU population), but not rs4253132, 
rs4253211, or rs2228528 (203).  
 Among all previous studies of NER variants and HNC, SNPs in ERCC2 (XPD) have been the 
most commonly investigated, in particular rs13181 which results in an amino acid change of 
Lys751Gln. ERCC2 (XPD) is located on chromosome 19 and encodes a protein component of the 
TFIIH subunit which denatures the double helix of DNA in preparation for excision of bulky DNA 
adducts (123,124). Over 20 previous case-control studies have studied rs13181 and HNC risk, with 
the majority finding null associations (4,5,8-10,14,16,17,19-22,24,25,29,30,32-34,36,37,45,133). The 
largest study, based on data from the International Head and Neck Cancer Epidemiology (INHANCE) 
consortium, found no association between rs13181 and HNC risk (OR= 0.97, 95% CI=0.86, 1.09 for 
Lys/Gln vs. Lys/Lys and OR= 1.03, 95% CI=0.88, 1.21 for Gln/Gln vs. Lys/Lys) (14). Likewise, we did 
not find strong evidence for an association between rs13181 and HNC risk among whites or African 
Americans.  Further, several previous studies have found inconsistent associations for rs13181 
within strata of cigarette smoking (8-10,16,30,33,36,37). Of particular interest, Buch et al. estimated 
joint effects using an approach similar to our method, reporting ORs (95% CIs) of 1.26 (0.73, 2.18) 
for nonsmokers with the risk genotype, 0.79 (0.45, 1.36) for smokers with the referent genotype, 
and 3.99 (2.30, 6.92) for smokers with the risk genotype (25). In our study, we did not find an 
additive effect for smoking and rs13181. 
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 Interactions between cigarette smoking and 3 SNPs, rs4253132 (candidate SNP, intron 9 of 
ERCC6), rs2291120 (tag SNP, intron 1 of DDB2), and rs744154 on (candidate SNP, intron 1 of ERCC4), 
were suggestive of possible super- or sub-additive effects among whites in our study (203). Using 
the conventional method, RERIs for these SNPs were significant at an uncorrected 0.05 alpha level, 
but not at a Bonferroni corrected level. Using hierarchical regression, RERI point estimates were 
similar to those obtained from the conventional method. Although no previous studies considered 
interactions between cigarette smoking and rs4253132, rs2291120, or rs744154, four studies did 
investigate the effects of other SNPs, though not in LD with implicated SNPs in our study, in ERCC6 
and ERCC4 within strata of cigarette smoking (4,13,26,44,203). Studies of rs4253211 on ERCC6, 
rs1800067 on ERCC4, and rs2276466 on ERCC4 reported similar SNP-HNC associations across strata 
of cigarette smokers (4,26,44), while a study of rs2228528 on ERCC6 found the SNP was associated 
with elevated HNC risk among ever smokers (GA + AA vs. GG, OR=2.36, 95% CI=1.36, 4.10), but not 
among never smokers  (OR=0.99, 95% CI=0.64, 1.55) (13) and a study of rs3136038 on ERCC4 found 
the SNP was associated with reduced HNC risk among nonsmokers (TT vs. CC + CT, OR=0.55, 95% 
CI=0.34, 0.88), but not smokers (OR=0.96, 95% CI=0.66, 1.39) (44). 
 Differences in joint effect results between the present and past studies likely stem from 
differences in analytic approaches. Namely, most previous studies examined the effects of SNPs on 
HNC stratified by cigarette smoking but did not consider the ORs for singly and doubly exposed 
individuals (i.e. individuals who had the variant allele or smoked cigarettes or both) which would 
have allowed testing the interaction on the additive scale by calculating a RERI (4,8,13,24,26-
28,30,31,33,35,37,38,44). Although previous studies may have found an effect for having both the 
variant genotype of a SNP and smoking cigarettes, it is likely that RERIs may have been insignificant 
if calculated given the smaller sample size of previous studies. Additional studies which assess 
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interactions on the additive scale among large study populations are needed to follow-up our 
suggestive findings.  
 The present study builds upon the existing literature by 1) including one of the largest study 
populations to date, 2) estimating race-stratified effects, and 3) evaluating more NER genes, 
including more SNPs, than any single previous study. Besides two studies which evaluated a limited 
number of SNPs in NER genes (11,14), this study was the largest to evaluate the independent and 
joint effects of cigarette smoking and SNPs in NER genes with respect to HNC. Most previous studies 
included a hundred to a thousand cases and controls (4,5,8-46). Further, our study included more 
African Americans than any previous study. Only one previous study, which included 119 African 
Americans, has considered effects for HNC and esophageal cancer incidence (15).  Consideration of 
race-specific estimates is an important contribution of this study since HNC incidence, including 
patterns of risk factors such as cigarette smoking, varies by race, and linkage disequilibrium among 
SNPs varies by ancestry (56,59,60,129). Despite our large sample size, exploration of gene-
environment interactions among African Americans was limited. HNC tumor site-specific estimates 
were also limited by sparse numbers. 
In addition to including more individuals than previous studies, our analysis also examined 
more SNPs in NER genes than any previous study. Previous studies have collectively examined 
approximately 60 SNPs in 10 NER genes and HNC risk (4,5,8-46). Our study alone included 84 SNPs 
across 15 NER genes.  Although our study included the largest array of SNPs in NER genes to date, it 
should be noted that selection of SNPs was based on a variety of approaches which limited the 
variation captured across some genes, especially among African Americans. Specifically, tagging 
SNPs were not selected for all genes and SNPs were selected based on only the CEU population.  For 
this reason, we did not consider haplotypes.   
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 Although we did not confirm some previously reported associations, we found new 
associations between SNPs in NER genes and HNC risk. Among whites, rs4150403 on ERCC3 (XPB) 
was associated with increased HNC risk. Among African Americans, rs4253132 on ERCC6 was 
associated with decreased HNC risk. Three suggestive cigarette smoking- SNP interactions were 
identified. Although our study was one of the largest to date, studies with even larger sample sizes 
are needed to confirm these results, especially to estimate gene-environment interactions more 
precisely. Further studies focusing on African American and other diverse populations are 
recommended.
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Table 18. Demographic Characteristics of Study Population, 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study 
Characteristic 
Controls 
N 
% 
Cases 
N 
% 
Total 1325   1227   
Sex         
Male 924 69.7 938 76.4 
Female 401 30.3 289 23.6 
Race/Ethnicity         
White 1074 81.1 922 75.1 
African American 251 18.9 305 24.9 
Age         
20-49 151 11.4 239 19.5 
50-54 156 11.8 189 15.4 
55-59 199 15.0 207 16.9 
60-64 202 15.2 205 16.7 
65-69 237 17.9 168 13.7 
70-74 216 16.3 135 11.0 
75-80 164 12.4 84 6.8 
Education         
 High school or less 520 39.2 754 61.5 
Some college 395 29.8 294 24.0 
College or more 410 30.9 179 14.6 
Tumor Site         
Oral cavity     172 14.0 
Oropharynx     333 27.1 
Hypophaynx     55 4.5 
NOS     224 18.3 
Larynx     443 36.1 
 
  
Table 19. Odds Ratios for Cigarette Smoking and Head and Neck Cancer in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study 
  Overall Whites African Americans 
Active Cigarette Smoking Controls Cases OR (95% I)
a
 Controls Cases OR (95% I)
a
 Controls Cases OR (95% I)
a
 
Never  508 163   409 150   99 13   
Ever 817 1064 2.28 (1.81, 2.88) 665 772 1.97 (1.54, 2.53) 152 292 7.75 (3.57, 16.83) 
Missing 0 0   0 0   0 0   
Duration (years)                   
Never Smokers 508 163   409 150   99 13   
1-19 280 110 0.98 (0.72, 1.35) 228 92 0.88 (0.63, 1.23) 52 18 2.54 (0.94, 6.87) 
20-39 320 465 2.34 (1.79, 3.07) 256 305 1.95 (1.46, 2.62) 64 160 7.62 (3.38, 17.21) 
40+ 214 485 5.30 (3.94, 7.13) 178 373 4.75 (3.45, 6.53) 36 112 16.28 (6.52, 40.62) 
Missing 3 4   3 2   0 2   
ptrend
b
     <0.0001     <0.0001     <0.0001 
Frequency (cigarettes/day)                   
Never Smokers 508 163   409 150   99 13   
1-19 322 211 1.39 (1.05, 1.85) 230 115 1.14 (0.83, 1.57) 92 96 4.78 (2.12, 10.82) 
20+ 495 850 2.99 (2.33, 3.84) 435 654 2.56 (1.96, 3.33) 60 196 13.16 (5.73, 30.23) 
Missing 0 3   0 3   0 0   
ptrend     <0.0001     <0.0001     <0.0001 
OR odds ratio, I interval estimates 
a
Odds ratios adjusted for matching factors (age, sex, and race, including pairwise interactions), education, and alcohol drinking. 122 individuals missing 
alcohol drinking, and therefore dropped from models. 
b
P-value for linear trend obtained from modeling the continuous forms of the frequency, duration, and cumulative variables 
1
2
5
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Table 20. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) 
Genes and Head and Neck Cancer Using Hierarchical Logistic Regression for SNPs by Gene, the Carolina 
Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
  Coded Allele Cases/Controls   
Gene SNP 
Referent (A) / 
Variant (B)  
AA AB + BB OR (95% I)
a
 
p-
value
b
 
ERCC3 (XPB) rs4150496 G A 401 392 520 682 0.80 (0.62, 1.02) 0.08 
  rs1011019 C T 462 548 460 526 0.94 (0.72, 1.24) 0.68 
  rs4150434 G A 548 670 374 404 1.00 (0.81, 1.24) 0.97 
  rs4150416 T G 410 481 509 593 0.89 (0.68, 1.17) 0.4 
  rs4150407 A G 318 311 604 763 0.94 (0.72, 1.23) 0.65 
  rs4150403 G A 736 904 186 170 1.28 (1.01, 1.61) 0.04 
XPC rs2228001 A C 337 375 584 699 0.90 (0.72, 1.12) 0.35 
  rs3731143 T C 818 957 104 117 1.05 (0.81, 1.36) 0.72 
  rs2228000 C T 524 598 396 475 0.93 (0.70, 1.25) 0.64 
  rs3731124 A C 521 599 401 475 0.88 (0.68, 1.15) 0.35 
  rs13099160 A G 814 962 108 112 1.03 (0.75, 1.40) 0.87 
  rs3731089 G A 778 919 144 155 1.03 (0.75, 1.40) 0.86 
  rs2733537 A G 416 480 506 594 0.95 (0.72, 1.25) 0.69 
  rs3731068 C A 624 732 298 342 1.05 (0.83, 1.33) 0.70 
  rs2607755 T C 242 284 680 790 1.04 (0.82, 1.32) 0.75 
ERCC8 rs3117 T C 337 397 585 677 1.02 (0.84, 1.22) 0.87 
CDK7 rs2972388 A G 266 335 656 739 1.12 (0.92, 1.36) 0.25 
XPA rs3176757 C T 609 710 313 364 0.98 (0.75, 1.29) 0.90 
  rs3176748 A G 440 510 482 564 0.89 (0.71, 1.12) 0.32 
  rs2808667     C T 814 950 106 124 1.11 (0.84, 1.47) 0.46 
  rs2805835 G C 727 848 195 226 0.96 (0.76, 1.22) 0.75 
  rs3176689 A T 622 728 300 346 0.92 (0.74, 1.15) 0.48 
  rs3176683 T C 818 944 104 130 0.88 (0.68, 1.16) 0.37 
  rs3176658      C T 699 792 223 282 0.81 (0.62, 1.07) 0.14 
  rs1800975 G A 420 473 465 563 0.99 (0.76, 1.29) 0.93 
RAD23B rs1805330 C T 764 870 158 204 0.94 (0.75, 1.18) 0.60 
  rs1805329  C T 590 711 332 363 1.10 (0.92, 1.33) 0.30 
ERCC6 rs2228529 A G 597 661 313 396 0.87 (0.72, 1.05) 0.15 
  rs4253132 T C 723 829 199 245 0.90 (0.73, 1.12) 0.36 
  rs2228528 G A 637 746 284 328 0.96 (0.79, 1.17) 0.71 
DDB2 (XPE) rs2029298 A G 425 478 497 596 1.02 (0.82, 1.27) 0.85 
  rs4647709 C T 766 902 156 172 1.01 (0.79, 1.30) 0.93 
  rs2291120 T C 685 812 237 262 1.00 (0.81, 1.22) 0.97 
OR odds ratio, I interval estimates 
a
Odds ratios adjusted for matching factors (age and sex including pairwise interactions) and percent 
African ancestry 
b
Significant associations using a dominant genetic model (p<0.05) highlighted in gray 
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Table 20 cont. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair 
(NER) Genes and Head and Neck Cancer Using Hierarchical Logistic Regression for SNPs by Gene, the 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
  Coded Allele Cases/Controls   
Gene SNP 
Referent (A) 
/ Variant (B)  
AA AB + BB OR (95% I)
a
 p-value
b
 
 DDB2 (XPE) rs1685404  G C 418 502 504 572 1.01 (0.83, 1.22) 0.95 
  rs2957873 A G 643 711 279 363 1.00 (0.75, 1.33) 0.99 
  rs326224 G A 683 761 239 313 1.08 (0.79, 1.46) 0.64 
  rs2306353 G A 696 762 226 312 0.81 (0.59, 1.13) 0.21 
  rs326222 C T 484 526 438 548 0.96 (0.76, 1.21) 0.70 
ERCC5 (XPG) rs2296147 T C 280 303 637 765 0.96 (0.76, 1.21) 0.73 
  rs4771436  T G 563 659 359 415 0.95 (0.71, 1.26) 0.71 
  rs1047768 C T 319 377 603 696 1.01 (0.77, 1.34) 0.93 
  rs4150351 A C 595 692 327 382 0.86 (0.67, 1.11) 0.24 
  rs4150355 C T 402 428 520 646 0.85 (0.67, 1.09) 0.21 
  rs4150360 T C 275 316 647 758 0.89 (0.66, 1.19) 0.43 
  rs4150383 G A 630 749 292 325 1.09 (0.84, 1.41) 0.52 
  rs4150386 A C 724 836 198 237 1.01 (0.81, 1.25) 0.96 
  rs17655 C G 555 658 367 416 1.05 (0.79, 1.40) 0.74 
  rs873601       A G 464 539 458 535 0.97 (0.74, 1.25) 0.80 
  rs4150393 A G 702 844 220 230 1.16 (0.89, 1.52) 0.26 
  rs1051677 T C 735 858 186 216 1.02 (0.83, 1.25) 0.87 
  rs1051685 A G 736 832 185 242 0.91 (0.74, 1.11) 0.34 
ERCC4 (XPF) rs3136038 C T 402 490 520 584 1.00 (0.78, 1.28) 1.00 
  rs1799798 G A 757 901 165 173 1.16 (0.93, 1.44) 0.20 
  rs744154 C G 480 582 442 492 0.97 (0.70, 1.33) 0.83 
  rs1800067 G A 778 920 144 154 1.06 (0.83, 1.34) 0.64 
  rs3136172 A G 458 566 464 508 1.15 (0.84, 1.55) 0.38 
RAD23A rs2974752 A G 333 424 561 617 1.16 (0.96, 1.40) 0.11 
ERCC2 (XPD) rs13181 T G 381 437 534 633 1.05 (0.76, 1.45) 0.79 
  rs238418 C A 382 426 540 648 0.91 (0.66, 1.26) 0.58 
  rs1799787 C T 472 545 450 529 1.06 (0.82, 1.35) 0.67 
  rs3916874 G C 477 545 445 529 1.01 (0.83, 1.25) 0.9 
  rs238416 G A 369 468 552 604 1.10 (0.88, 1.38) 0.39 
  rs50872 C T 531 584 389 488 0.91 (0.76, 1.08) 0.27 
  rs50871 T G 242 258 680 815 0.91 (0.75, 1.11) 0.36 
  rs238407 A T 263 338 658 736 1.05 (0.82, 1.35) 0.71 
  rs3810366 C G 178 232 743 842 1.08 (0.84, 1.40) 0.54 
ERCC1 rs735482 A C 688 797 234 277 0.92 (0.74, 1.14) 0.44 
  rs3212955 A G 528 607 394 466 0.93 (0.71, 1.23) 0.63 
  rs3212948 C G 382 458 540 616 1.17 (0.91, 1.50) 0.22 
  rs3212930 T C 576 657 346 417 0.92 (0.73, 1.17) 0.50 
LIG1 rs156641 G A 370 440 552 634 1.02 (0.81, 1.29) 0.86 
  rs20580 C A 237 293 685 781 1.02 (0.79, 1.31) 0.87 
  rs20579 C T 691 826 231 248 1.09 (0.87, 1.35) 0.45 
OR odds ratio, I interval estimates 
a
Odds ratios adjusted for matching factors (age and sex including pairwise interactions) and percent 
African ancestry 
b
Significant associations using a dominant genetic model (p<0.05) highlighted in gray 
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Table 21. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) 
Genes and Head and Neck Cancer Using Hierarchical Logistic Regression for SNPs by Gene, the Carolina 
Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans  
  Coded Allele Cases/Controls   
Gene SNP 
Referent (A) / 
Variant (B)  AA AB + BB OR (95% I)
a
 p-value
b
 
ERCC3 (XPB) rs4150496 G A 178 136 125 115 0.85 (0.61, 1.20) 0.35 
  rs4150459 G A 190 164 115 87 1.04 (0.74, 1.48) 0.81 
  rs1011019 C T 183 143 122 108 0.85 (0.60, 1.20) 0.35 
  rs4150434 G A 232 186 73 65 0.94 (0.65, 1.36) 0.73 
  rs4150416 T G 85 76 219 175 1.04 (0.74, 1.47) 0.81 
  rs4150407 A G 84 68 221 183 0.95 (0.68, 1.35) 0.79 
XPC rs2228001 A C 180 134 125 117 0.88 (0.63, 1.23) 0.46 
  rs2228000 C T 251 205 54 46 0.99 (0.69, 1.43) 0.95 
  rs3731124 A C 252 212 53 39 0.97 (0.68, 1.37) 0.84 
  rs3731089 G A 263 208 42 43 0.91 (0.62, 1.34) 0.64 
  rs2733537 A G 212 164 93 87 0.91 (0.66, 1.28) 0.60 
  rs2607755 T C 111 109 194 142 1.15 (0.85, 1.56) 0.37 
  rs1902658 G A 53 51 252 200 1.02 (0.71, 1.45) 0.93 
ERCC8 rs3117 T C 126 94 179 157 0.82 (0.57, 1.17) 0.27 
CDK7 rs2972388 A G 160 132 145 119 1.05 (0.74, 1.49) 0.78 
CCNH rs2266691 A G 257 221 48 30 1.35 (0.88, 2.09) 0.17 
  rs2266692 G T 237 202 68 48 1.26 (0.85, 1.87) 0.25 
XPA rs3176757 C T 236 193 69 58 1.00 (0.69, 1.44) 0.99 
  rs3176753 T C 225 184 80 67 1.00 (0.69, 1.44) 0.86 
  rs3176748 A G 250 208 55 43 1.05 (0.72, 1.51) 0.81 
  rs3176658      C T 260 210 45 41 0.99 (0.67, 1.45) 0.95 
  rs1800975 G A 187 141 106 93 0.92 (0.66, 1.28) 0.62 
RAD23B rs1805330 C T 183 160 122 91 1.16 (0.81, 1.67) 0.43 
ERCC6 rs2228529 A G 234 189 69 60 0.85 (0.58, 1.22) 0.37 
  rs2228527  A G 218 175 87 76 0.91 (0.65, 1.29) 0.61 
  rs4253132 T C 191 125 114 126 0.62 (0.45, 0.86) 0.005 
  rs2228528 G A 212 182 92 69 0.92 (0.65, 1.30) 0.62 
DDB2 (XPE) rs2029298 A G 90 88 215 163 1.16 (0.86, 1.56) 0.33 
  rs1685404  G C 164 140 141 111 1.10 (0.82, 1.48) 0.51 
  rs2957873 A G 90 82 214 169 1.07 (0.75, 1.53) 0.71 
  rs326224 G A 80 63 225 188 0.87 (0.62, 1.24) 0.45 
  rs2306353 G A 106 97 199 154 1.14 (0.80, 1.61) 0.47 
  rs326222 C T 54 50 251 201 1.09 (0.75, 1.59) 0.64 
  rs901746 A G 65 58 240 193 0.97 (0.68, 1.40) 0.89 
ERCC5 (XPG) rs2296147 T C 193 148 111 102 0.90 (0.65, 1.23) 0.51 
  rs2296148 C T 228 190 76 61 1.04 (0.74, 1.45) 0.83 
  rs4771436  T G 204 172 101 79 0.95 (0.68, 1.33) 0.78 
  rs1047768 C T 116 115 189 136 1.12 (0.81, 1.54) 0.49 
  rs2020915 G A 205 144 100 107 0.80 (0.58, 1.10) 0.16 
  rs4150355 C T 218 175 87 76 1.02 (0.72, 1.44) 0.92 
  rs4150360 T C 19 17 286 232 0.95 (0.64, 1.42) 0.80 
  rs4150383 G A 242 200 63 51 0.95 (0.67, 1.35) 0.78 
OR odds ratio, I interval estimates 
a
Odds ratios adjusted for matching factors (age and sex including pairwise interactions) and percent 
African ancestry 
b
Significant associations using a dominant genetic model (p<0.05) highlighted in gray 
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Table 21 cont. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair 
(NER) Genes and Head and Neck Cancer Using Hierarchical Logistic Regression for SNPs by Gene, the 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
  Coded Allele Cases/Controls   
Gene SNP 
Referent (A) / 
Variant (B)  AA AB + BB OR (95% I)
a
 p-value
b
 
 ERCC5 XPG) rs17655 C G 90 70 215 181 0.98 (0.70, 1.37) 0.91 
  rs873601       A G 30 30 275 221 1.13 (0.77, 1.67) 0.52 
  rs1051677 T C 232 184 73 67 0.89 (0.65, 1.23) 0.48 
  rs1051685 A G 138 117 167 133 0.99 (0.73, 1.33) 0.93 
ERCC4 (XPF) rs3136038 C T 92 84 213 167 1.12 (0.82, 1.54) 0.46 
  rs744154 C G 221 174 84 77 0.97 (0.68, 1.40) 0.88 
  rs3136085 G C 173 146 132 105 1.08 (0.78, 1.49) 0.65 
  rs3136091 C G 255 199 50 52 0.86 (0.59, 1.24) 0.41 
  rs3136130 G T 75 65 230 186 0.99 (0.71, 1.37) 0.93 
  rs3136172 A G 216 171 89 80 1.01 (0.70, 1.44) 0.97 
  rs2020955  T C 193 165 112 86 1.03 (0.75, 1.42) 0.86 
RAD23A rs2974752 A G 77 62 216 170 1.06 (0.75, 1.50) 0.73 
  rs11558955 A G 256 214 49 37 1.13 (0.76, 1.68) 0.54 
ERCC2 (XPD) rs13181 T G 173 140 131 109 1.01 (0.75, 1.37) 0.93 
  rs238418 C A 8 11 296 240 1.09 (0.70, 1.69) 0.72 
  rs1799787 C T 235 192 70 59 0.98 (0.71, 1.37) 0.92 
  rs3916874 G C 268 226 37 25 1.09 (0.74, 1.59) 0.67 
  rs238416 G A 243 208 61 41 1.15 (0.80, 1.64) 0.45 
  rs50872 C T 223 158 82 93 0.78 (0.58, 1.05) 0.10 
  rs50871 T G 229 195 76 56 1.10 (0.80, 1.52) 0.57 
  rs238407 A T 226 190 79 61 0.99 (0.69, 1.42) 0.97 
  rs3810366 C G 212 180 93 71 1.06 (0.75, 1.49) 0.74 
ERCC1 rs735482 A C 156 122 149 129 0.96 (0.71, 1.30) 0.79 
  rs3212964 G A 207 142 96 107 0.78 (0.57, 1.07) 0.13 
  rs3212955 A G 159 142 146 109 1.09 (0.80, 1.50) 0.58 
  rs3212948 C G 9 6 296 245 0.94 (0.60, 1.48) 0.79 
  rs3212935 A G 143 125 162 125 1.10 (0.81, 1.50) 0.54 
  rs3212930 T C 250 205 55 46 0.94 (0.66, 1.34) 0.74 
LIG1 rs156641 G A 234 192 71 59 1.02 (0.72, 1.45) 0.91 
  rs20580 C A 62 57 242 194 1.09 (0.77, 1.54) 0.62 
  rs20579 C T 150 128 155 123 0.99 (0.72, 1.36) 0.96 
  rs439132 A G 172 136 133 115 0.93 (0.67, 1.30) 0.68 
OR odds ratio, I interval estimates 
a
Odds ratios adjusted for matching factors (age and sex including pairwise interactions) and percent 
African ancestry 
b
Significant associations using a dominant genetic model (p<0.05) highlighted in gray 
 
 
  
Table 22. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on Head and 
Neck Cancer Risk Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Cases/Controls OR (95% I)a   
Gene SNP 
Referent (A) 
/ Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 
 Cigarette=1, 
SNP=0 
 Cigarette=0, 
SNP=1 
 Cigarette=1, 
SNP=1 RERI (95% CI) 
ERCC3 
(XPB) rs4150496 G A 70 154 79 255 331 238 441 427 1.83 (1.27, 2.64) 0.66 (0.44, 0.98) 1.40 (0.99, 1.98) -0.08 (-0.63, 0.46) 
  rs1011019 C T 66 201 84 208 396 347 376 318 2.18 (1.54, 3.08) 1.26 (0.85, 1.87) 2.28 (1.61, 3.23) -0.16 (-0.86, 0.54) 
  rs4150434 G A 89 264 61 145 459 406 313 259 2.13 (1.56, 2.89) 1.20 (0.80, 1.80) 2.09 (1.51, 2.90) -0.24 (-0.94, 0.45) 
  rs4150416 T G 56 176 93 233 354 305 416 360 2.27 (1.57, 3.30) 1.27 (0.84, 1.90) 2.27 (1.57, 3.27) -0.27 (-1.01, 0.46) 
  rs4150407 A G 55 129 95 280 263 182 509 483 2.00 (1.33, 3.00) 0.77 (0.51, 1.16) 1.53 (1.05, 2.21) -0.24 (-0.90, 0.41) 
  rs4150403 G A 118 338 32 71 618 566 154 99 1.95 (1.49, 2.56) 1.26 (0.77, 2.06) 2.60 (1.80, 3.74) 0.39 (-0.57, 1.34) 
  rs4150402 G A 66 201 84 208 396 347 376 317 2.19 (1.55, 3.09) 1.26 (0.85, 1.87) 2.29 (1.62, 3.26) -0.15 (-0.85, 0.55) 
XPC rs2228001 A C 56 135 94 274 281 240 490 425 1.91 (1.29, 2.83) 0.86 (0.57, 1.29) 1.70 (1.17, 2.48) -0.06 (-0.66, 0.54) 
  rs3731143 T C 135 361 15 48 683 596 89 69 1.88 (1.45, 2.44) 0.90 (0.48, 1.70) 2.51 (1.66, 3.82) 0.73 (-0.33, 1.80) 
  rs2228000 C T 91 222 59 187 433 376 337 288 1.74 (1.27, 2.39) 0.77 (0.51, 1.14) 1.78 (1.28, 2.47) 0.27 (-0.23, 0.78) 
  rs3731124 A C 81 228 69 181 440 371 332 294 2.11 (1.53, 2.90) 1.10 (0.74, 1.64) 1.98 (1.42, 2.76) -0.23 (-0.89, 0.43) 
  rs13099160 A G 127 366 23 43 687 596 85 69 2.07 (1.59, 2.69) 1.60 (0.90, 2.83) 2.24 (1.47, 3.43) -0.43 (-1.65, 0.80) 
  rs3731093 T C 120 350 27 56 656 569 111 90 2.10 (1.60, 2.75) 1.52 (0.89, 2.58) 2.47 (1.68, 3.64) -0.15 (-1.26, 0.96) 
  rs3731089 G A 121 350 29 59 657 569 115 96 2.07 (1.58, 2.71) 1.53 (0.92, 2.57) 2.35 (1.61, 3.44) -0.25 (-1.32, 0.82) 
  rs2733537 A G 70 175 80 234 346 305 426 360 1.75 (1.23, 2.50) 0.88 (0.59, 1.31) 1.91 (1.35, 2.70) 0.28 (-0.25, 0.81) 
  rs3731068 C A 99 275 51 134 525 457 247 208 1.97 (1.47, 2.65) 1.03 (0.68, 1.56) 2.01 (1.44, 2.79) 0.01 (-0.65, 0.66) 
  rs2607755 T C 39 110 111 299 203 174 569 491 2.12 (1.35, 3.34) 1.11 (0.71, 1.73) 2.12 (1.39, 3.22) -0.11 (-0.86, 0.63) 
  rs1902658 G A 37 107 113 302 198 173 573 492 2.10 (1.32, 3.33) 1.12 (0.71, 1.76) 2.15 (1.40, 3.29) -0.07 (-0.81, 0.67) 
ERCC8 rs3117 T C 60 144 90 265 277 253 495 412 1.70 (1.16, 2.49) 0.81 (0.54, 1.22) 1.75 (1.22, 2.51) 0.23 (-0.28, 0.75) 
CDK7 rs2972388 A G 42 122 108 287 224 213 548 452 1.81 (1.17, 2.79) 1.06 (0.69, 1.63) 2.16 (1.45, 3.23) 0.29 (-0.31, 0.89) 
XPA rs3176757 C T 98 268 52 141 511 442 261 223 1.94 (1.44, 2.62) 1.03 (0.68, 1.56) 2.08 (1.50, 2.89) 0.11 (-0.53, 0.75) 
  rs3176748 A G 74 185 76 224 366 325 406 340 1.76 (1.25, 2.48) 0.84 (0.57, 1.25) 1.82 (1.30, 2.57) 0.22 (-0.30, 0.74) 
  rs2808667     C T 133 352 17 57 681 598 89 67 1.86 (1.43, 2.42) 0.87 (0.47, 1.60) 2.44 (1.61, 3.71) 0.71 (-0.31, 1.73) 
  rs2805835 G C 119 328 31 81 608 520 164 145 2.03 (1.54, 2.68) 1.12 (0.69, 1.82) 1.95 (1.38, 2.76) -0.20 (-0.98, 0.58) 
  rs3176689 A T 94 279 56 130 528 449 244 216 2.15 (1.60, 2.90) 1.14 (0.76, 1.72) 1.88 (1.34, 2.63) -0.41 (-1.12, 0.29) 
  rs3176683 T C 134 353 16 56 684 591 88 74 1.88 (1.45, 2.45) 0.76 (0.41, 1.40) 2.05 (1.35, 3.10) 0.41 (-0.46, 1.28) 
  rs3176658      C T 114 297 36 112 585 495 187 170 1.91 (1.44, 2.52) 0.85 (0.54, 1.35) 1.86 (1.32, 2.60) 0.10 (-0.54, 0.73) 
  rs1800975 G A 72 180 75 215 348 293 390 348 1.83 (1.29, 2.60) 0.90 (0.61, 1.35) 1.86 (1.32, 2.63) 0.13 (-0.43, 0.69) 
RAD23B rs1805330 C T 125 321 25 88 639 549 133 116 1.85 (1.41, 2.43) 0.68 (0.41, 1.13) 1.68 (1.16, 2.43) 0.15 (-0.49, 0.79) 
  rs1805329  C T 101 277 49 132 489 434 283 231 2.01 (1.50, 2.70) 1.13 (0.74, 1.72) 2.12 (1.53, 2.93) -0.02 (-0.70, 0.66) 
ERCC6 rs2228529 A G 96 258 52 146 501 403 261 250 2.13 (1.57, 2.89) 1.08 (0.71, 1.63) 1.85 (1.33, 2.56) -0.37 (-1.05, 0.32) 
  rs2228527  A G 97 260 53 149 501 405 271 260 2.13 (1.57, 2.87) 1.07 (0.71, 1.61) 1.84 (1.33, 2.55) -0.35 (-1.03, 0.32) 
  rs4253132 T C 126 303 24 106 597 526 175 139 1.65 (1.26, 2.18) 0.50 (0.30, 0.84) 1.86 (1.32, 2.62) 0.70 (0.14, 1.26) 
  rs2228528 G A 104 287 46 122 533 459 238 206 2.01 (1.50, 2.68) 1.05 (0.69, 1.62) 1.97 (1.42, 2.74) -0.09 (-0.76, 0.58) 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry. 122 individuals missing alcohol drinking, and 
therefore dropped from models. 
bSignificant associations using a dominant genetic model (p<0.05) highlighted in gray. No associations significant at Bonferroni corrected level (p<0.0006). 
Interval estimates presented not corrected for multiple comparisons. 
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Table 22 cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on Head 
and Neck Cancer Risk Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Cases/Controls OR (95% I)a   
Gene SNP 
Referent (A) 
/ Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 
 Cigarette=1, 
SNP=0 
 Cigarette=0, 
SNP=1 
 Cigarette=1, 
SNP=1 RERI (95% CI) 
DDB2 
(XPE) rs2029298 A G 69 195 81 214 356 283 416 382 2.39 (1.69, 3.38) 1.22 (0.82, 1.81) 2.03 (1.44, 2.86) -0.58 (-1.34, 0.18) 
  rs4647709 C T 123 342 27 67 643 560 129 105 2.01 (1.53, 2.63) 1.17 (0.70, 1.96) 2.12 (1.46, 3.07) -0.06 (-0.94, 0.82) 
  rs2291120 T C 123 296 27 113 562 516 210 149 1.68 (1.28, 2.22) 0.59 (0.36, 0.96) 1.95 (1.39, 2.74) 0.68 (0.11, 1.26) 
  rs1685404  G C 72 180 78 229 346 322 426 343 1.66 (1.17, 2.35) 0.88 (0.59, 1.30) 2.01 (1.43, 2.83) 0.47 (-0.03, 0.98) 
  rs2957873 A G 101 275 49 134 542 436 230 229 2.22 (1.65, 2.98) 1.16 (0.76, 1.75) 1.77 (1.28, 2.46) -0.60 (-1.33, 0.13) 
  rs326224 G A 105 288 45 121 578 473 194 192 2.14 (1.61, 2.86) 1.18 (0.77, 1.80) 1.87 (1.33, 2.62) -0.45 (-1.19, 0.29) 
  rs2306353 G A 109 292 41 117 587 470 185 195 2.18 (1.64, 2.90) 1.12 (0.72, 1.74) 1.66 (1.19, 2.33) -0.64 (-1.38, 0.10) 
  rs326222 C T 76 209 74 200 408 317 364 348 2.39 (1.71, 3.34) 1.17 (0.79, 1.73) 1.88 (1.34, 2.63) -0.68 (-1.43, 0.08) 
  rs901746 A G 76 210 74 199 409 318 363 347 2.41 (1.73, 3.37) 1.19 (0.80, 1.77) 1.89 (1.35, 2.65) -0.71 (-1.48, 0.05) 
ERCC5 
(XPG) rs2296147 T C 41 114 109 291 239 189 528 474 2.14 (1.38, 3.33) 1.00 (0.64, 1.55) 1.88 (1.24, 2.83) -0.27 (-1.01, 0.48) 
  rs4771436  T G 97 259 53 150 466 400 306 265 1.98 (1.46, 2.68) 0.98 (0.65, 1.48) 1.92 (1.39, 2.65) -0.05 (-0.66, 0.57) 
  rs1047768 C T 57 142 93 267 262 235 510 429 1.71 (1.16, 2.52) 0.84 (0.56, 1.26) 1.79 (1.24, 2.59) 0.25 (-0.28, 0.78) 
  rs3818356 C T 97 259 53 149 466 400 304 264 1.97 (1.46, 2.67) 0.99 (0.66, 1.5) 1.91 (1.38, 2.64) -0.06 (-0.67, 0.56) 
  rs4150351 A C 97 258 53 151 498 434 274 231 1.92 (1.42, 2.60) 0.94 (0.63, 1.42) 1.94 (1.40, 2.69) 0.07 (-0.53, 0.68) 
  rs4150355 C T 57 159 93 250 345 269 427 396 2.28 (1.57, 3.32) 1.06 (0.70, 1.58) 1.87 (1.29, 2.69) -0.47 (-1.20, 0.26) 
  rs4150360 T C 50 119 100 290 225 197 547 468 1.70 (1.12, 2.58) 0.81 (0.53, 1.24) 1.71 (1.16, 2.51) 0.19 (-0.36, 0.74) 
  rs4150383 G A 106 296 44 113 524 453 248 212 2.02 (1.51, 2.70) 1.08 (0.70, 1.67) 2.00 (1.44, 2.78) -0.10 (-0.78, 0.58) 
  rs4150386 A C 113 317 37 92 611 519 161 145 2.03 (1.53, 2.68) 1.03 (0.65, 1.63) 1.84 (1.29, 2.61) -0.22 (-0.95, 0.51) 
  rs17655 C G 89 238 61 171 466 420 306 245 1.78 (1.30, 2.42) 0.88 (0.59, 1.32) 2.04 (1.46, 2.84) 0.38 (-0.18, 0.94) 
  rs873601       A G 73 190 77 219 391 349 381 316 1.72 (1.22, 2.41) 0.82 (0.55, 1.21) 1.83 (1.30, 2.58) 0.30 (-0.21, 0.80) 
  rs4150393 A G 114 317 36 92 588 527 184 138 1.94 (1.47, 2.57) 1.14 (0.72, 1.81) 2.35 (1.67, 3.32) 0.27 (-0.53, 1.06) 
  rs876430 C T 73 190 77 219 392 350 380 315 1.72 (1.22, 2.41) 0.82 (0.55, 1.21) 1.83 (1.30, 2.58) 0.30 (-0.21, 0.80) 
  rs1051677 T C 126 331 23 78 609 527 163 138 1.88 (1.43, 2.46) 0.80 (0.47, 1.36) 2.01 (1.42, 2.85) 0.34 (-0.36, 1.03) 
  rs1051685 A G 117 323 33 86 619 509 152 156 2.10 (1.59, 2.76) 1.12 (0.70, 1.80) 1.67 (1.17, 2.38) -0.55 (-1.31, 0.22) 
ERCC4 
(XPF) rs3136038 C T 51 195 99 214 351 295 421 370 2.88 (1.97, 4.21) 1.77 (1.17, 2.66) 2.67 (1.84, 3.87) -0.97 (-1.99, 0.04) 
  rs1799798 G A 126 331 24 78 631 570 141 95 1.82 (1.39, 2.39) 0.80 (0.47, 1.34) 2.32 (1.59, 3.40) 0.70 (-0.11, 1.52) 
  rs744154 C G 59 224 91 185 421 358 351 307 2.81 (1.98, 3.99) 1.85 (1.24, 2.76) 2.63 (1.84, 3.77) -1.02 (-2.02, -0.02) 
  rs3136085 G C 59 220 91 189 416 356 356 309 2.75 (1.93, 3.92) 1.80 (1.21, 2.69) 2.63 (1.84, 3.77) -0.92 (-1.89, 0.05) 
  rs3136130 G T 51 193 99 216 349 292 423 373 2.85 (1.95, 4.16) 1.73 (1.15, 2.61) 2.65 (1.83, 3.83) -0.93 (-1.93, 0.06) 
  rs1800067 G A 125 355 25 54 653 565 119 100 2.03 (1.55, 2.64) 1.26 (0.73, 2.17) 2.11 (1.45, 3.07) -0.18 (-1.13, 0.77) 
  rs3136172 A G 59 216 91 193 399 350 373 315 2.63 (1.85, 3.76) 1.71 (1.14, 2.55) 2.63 (1.84, 3.76) -0.71 (-1.63, 0.20) 
RAD23A rs2974752 A G 56 180 92 216 277 244 469 401 2.38 (1.63, 3.46) 1.43 (0.95, 2.16) 2.41 (1.68, 3.44) -0.40 (-1.22, 0.42) 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry. 122 individuals missing alcohol drinking, and 
therefore dropped from models. 
bSignificant associations using a dominant genetic model (p<0.05) highlighted in gray. No associations significant at Bonferroni corrected level (p<0.0006). 
Interval estimates presented not corrected for multiple comparisons. 
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Table 22 cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on Head 
and Neck Cancer Risk Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Cases/Controls OR (95% I)a   
Gene SNP 
Referent (A) 
/ Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 
 Cigarette=1, 
SNP=0 
 Cigarette=0, 
SNP=1 
 Cigarette=1, 
SNP=1 RERI (95% CI) 
ERCC2 
(XPD) rs13181 T G 55 155 95 252 326 282 439 381 2.08 (1.42, 3.05) 1.06 (0.71, 1.60) 1.97 (1.36, 2.85) -0.18 (-0.84, 0.49) 
  rs238418 C A 54 155 96 254 328 271 444 394 2.21 (1.50, 3.24) 1.10 (0.73, 1.65) 2.01 (1.38, 2.91) -0.30 (-1.00, 0.41) 
  rs1799787 C T 68 203 82 206 404 342 368 323 2.19 (1.56, 3.09) 1.17 (0.79, 1.74) 2.08 (1.47, 2.94) -0.29 (-0.98, 0.40) 
  rs3916874 G C 81 201 69 208 396 344 376 321 1.69 (1.21, 2.35) 0.75 (0.50, 1.11) 1.72 (1.23, 2.40) 0.28 (-0.20, 0.77) 
  rs238416 G A 62 193 88 216 307 275 464 388 2.17 (1.51, 3.12) 1.34 (0.90, 1.99) 2.40 (1.69, 3.41) -0.11 (-0.83, 0.61) 
  rs50872 C T 80 221 70 187 451 363 319 301 2.15 (1.55, 2.97) 1.06 (0.71, 1.57) 1.85 (1.32, 2.59) -0.36 (-1.02, 0.31) 
  rs50871 T G 43 89 107 320 199 169 573 495 1.37 (0.86, 2.16) 0.66 (0.42, 1.03) 1.47 (0.96, 2.23) 0.44 (-0.01, 0.89) 
  rs238407 A T 43 136 107 273 220 202 551 463 2.36 (1.54, 3.62) 1.40 (0.91, 2.16) 2.53 (1.71, 3.76) -0.23 (-1.05, 0.59) 
  rs3810366 C G 32 95 118 314 146 137 625 528 2.29 (1.38, 3.77) 1.29 (0.80, 2.09) 2.42 (1.54, 3.80) -0.16 (-1.03, 0.72) 
ERCC1 rs735482 A C 117 302 33 107 571 495 201 170 1.87 (1.41, 2.47) 0.81 (0.51, 1.30) 1.90 (1.36, 2.65) 0.22 (-0.40, 0.84) 
  rs2336219 G A 117 302 33 107 571 495 201 170 1.87 (1.41, 2.47) 0.81 (0.51, 1.30) 1.90 (1.36, 2.65) 0.22 (-0.40, 0.84) 
  rs3212964 G A 118 302 32 107 574 492 198 173 1.86 (1.41, 2.46) 0.78 (0.49, 1.24) 1.84 (1.32, 2.56) 0.20 (-0.40, 0.80) 
  rs3212955 A G 82 229 68 180 446 378 326 286 2.08 (1.51, 2.86) 1.10 (0.74, 1.63) 2.02 (1.45, 2.81) -0.16 (-0.81, 0.49) 
  rs3212948 C G 60 171 90 238 322 287 450 378 2.01 (1.39, 2.90) 1.10 (0.74, 1.64) 2.14 (1.50, 3.05) 0.03 (-0.60, 0.66) 
  rs3212930 T C 92 248 58 161 484 409 288 256 1.95 (1.43, 2.65) 0.99 (0.66, 1.48) 1.98 (1.43, 2.75) 0.04 (-0.57, 0.65) 
LIG1 rs156641 G A 56 166 94 243 314 274 458 391 2.14 (1.46, 3.13) 1.22 (0.81, 1.82) 2.27 (1.58, 3.27) -0.09 (-0.77, 0.60) 
  rs20580 C A 30 109 120 300 207 184 565 481 2.52 (1.55, 4.12) 1.54 (0.95, 2.48) 2.83 (1.79, 4.47) -0.23 (-1.15, 0.69) 
  rs20579 C T 105 305 45 104 586 521 186 144 2.06 (1.55, 2.73) 1.34 (0.87, 2.08) 2.43 (1.71, 3.45) 0.03 (-0.81, 0.87) 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry. 122 individuals missing alcohol drinking, and 
therefore dropped from models. 
bSignificant associations using a dominant genetic model (p<0.05) highlighted in gray. No associations significant at Bonferroni corrected level (p<0.0006). 
Interval estimates presented not corrected for multiple comparisons. 
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Table 23. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on 
Head and Neck Cancer Risk Using Hierarchical Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Cases/Controls OR (95% I)a  
Gene SNP 
Referent (A) 
/ Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 
 Cigarette=1, 
SNP=0 
 Cigarette=0, 
SNP=1 
 Cigarette=1, 
SNP=1 RERI 
ERCC3 
(XPB) rs4150496 G A 70 154 79 255 331 238 441 427 1.84 (1.28, 2.64) 0.66 (0.45, 0.98) 1.41 (1.00, 1.99) -0.09 
  rs1011019 C T 66 201 84 208 396 347 376 318 2.17 (1.54, 3.05) 1.25 (0.85, 1.85) 2.27 (1.60, 3.22) -0.15 
  rs4150434 G A 89 264 61 145 459 406 313 259 2.12 (1.56, 2.87) 1.19 (0.80, 1.77) 2.09 (1.50, 2.90) -0.23 
  rs4150416 T G 56 176 93 233 354 305 416 360 2.26 (1.57, 3.26) 1.25 (0.84, 1.87) 2.26 (1.57, 3.25) -0.26 
  rs4150407 A G 55 129 95 280 263 182 509 483 2.00 (1.34, 2.98) 0.77 (0.51, 1.15) 1.53 (1.05, 2.21) -0.24 
  rs4150403 G A 118 338 32 71 618 566 154 99 1.96 (1.49, 2.56) 1.26 (0.78, 2.04) 2.60 (1.80, 3.74) 0.38 
  rs4150402 G A 66 201 84 208 396 347 376 317 2.18 (1.54, 3.06) 1.25 (0.85, 1.85) 2.29 (1.61, 3.24) -0.14 
XPC rs2228001 A C 56 135 94 274 281 240 490 425 1.91 (1.30, 2.82) 0.86 (0.57, 1.28) 1.70 (1.17, 2.48) -0.06 
  rs3731143 T C 135 361 15 48 683 596 89 69 1.89 (1.46, 2.45) 0.93 (0.51, 1.70) 2.50 (1.65, 3.78) 0.67 
  rs2228000 C T 91 222 59 187 433 376 337 288 1.75 (1.28, 2.39) 0.77 (0.52, 1.15) 1.78 (1.29, 2.48) 0.26 
  rs3731124 A C 81 228 69 181 440 371 332 294 2.10 (1.53, 2.88) 1.10 (0.74, 1.62) 1.98 (1.42, 2.75) -0.22 
  rs13099160 A G 127 366 23 43 687 596 85 69 2.06 (1.59, 2.68) 1.56 (0.90, 2.70) 2.26 (1.48, 3.45) -0.36 
  rs3731093 T C 120 350 27 56 656 569 111 90 2.09 (1.60, 2.74) 1.50 (0.89, 2.50) 2.48 (1.68, 3.65) -0.11 
  rs3731089 G A 121 350 29 59 657 569 115 96 2.06 (1.58, 2.69) 1.51 (0.91, 2.49) 2.36 (1.61, 3.45) -0.21 
  rs2733537 A G 70 175 80 234 346 305 426 360 1.76 (1.24, 2.50) 0.89 (0.60, 1.31) 1.92 (1.36, 2.71) 0.26 
  rs3731068 C A 99 275 51 134 525 457 247 208 1.97 (1.48, 2.64) 1.02 (0.68, 1.54) 2.01 (1.44, 2.79) 0.01 
  rs2607755 T C 39 110 111 299 203 174 569 491 2.11 (1.36, 3.29) 1.10 (0.71, 1.71) 2.11 (1.40, 3.19) -0.10 
  rs1902658 G A 37 107 113 302 198 173 573 492 2.09 (1.33, 3.29) 1.11 (0.71, 1.74) 2.14 (1.40, 3.27) -0.06 
ERCC8 rs3117 T C 60 144 90 265 277 253 495 412 1.71 (1.18, 2.50) 0.82 (0.55, 1.22) 1.76 (1.23, 2.52) 0.22 
CDK7 rs2972388 A G 42 122 108 287 224 213 548 452 1.82 (1.19, 2.78) 1.06 (0.70, 1.63) 2.17 (1.46, 3.23) 0.29 
XPA rs3176757 C T 98 268 52 141 511 442 261 223 1.94 (1.44, 2.61) 1.03 (0.69, 1.55) 2.09 (1.50, 2.89) 0.11 
  rs3176748 A G 74 185 76 224 366 325 406 340 1.77 (1.26, 2.49) 0.85 (0.57, 1.25) 1.83 (1.30, 2.57) 0.21 
  rs2808667     C T 133 352 17 57 681 598 89 67 1.87 (1.44, 2.43) 0.90 (0.50, 1.61) 2.42 (1.60, 3.68) 0.65 
  rs2805835 G C 119 328 31 81 608 520 164 145 2.03 (1.54, 2.67) 1.11 (0.69, 1.78) 1.95 (1.38, 2.76) -0.19 
  rs3176689 A T 94 279 56 130 528 449 244 216 2.14 (1.59, 2.88) 1.13 (0.75, 1.69) 1.87 (1.34, 2.62) -0.39 
  rs3176683 T C 134 353 16 56 684 591 88 74 1.89 (1.46, 2.45) 0.78 (0.43, 1.40) 2.04 (1.35, 3.08) 0.37 
  rs3176658      C T 114 297 36 112 585 495 187 170 1.91 (1.45, 2.52) 0.86 (0.55, 1.34) 1.86 (1.32, 2.60) 0.09 
  rs1800975 G A 72 180 75 215 348 293 390 348 1.84 (1.30, 2.60) 0.91 (0.61, 1.34) 1.87 (1.32, 2.63) 0.12 
RAD23B rs1805330 C T 125 321 25 88 639 549 133 116 1.86 (1.42, 2.43) 0.69 (0.42, 1.14) 1.68 (1.16, 2.43) 0.13 
  rs1805329  C T 101 277 49 132 489 434 283 231 2.01 (1.50, 2.69) 1.13 (0.75, 1.70) 2.12 (1.53, 2.93) -0.02 
ERCC6 rs2228529 A G 96 258 52 146 501 403 261 250 2.12 (1.57, 2.87) 1.07 (0.71, 1.61) 1.84 (1.33, 2.56) -0.35 
  rs2228527  A G 97 260 53 149 501 405 271 260 2.12 (1.57, 2.86) 1.06 (0.71, 1.58) 1.84 (1.33, 2.54) -0.34 
  rs4253132 T C 126 303 24 106 597 526 175 139 1.67 (1.27, 2.20) 0.53 (0.32, 0.86) 1.86 (1.32, 2.62) 0.65 
  rs2228528 G A 104 287 46 122 533 459 238 206 2.01 (1.51, 2.68) 1.05 (0.69, 1.60) 1.97 (1.42, 2.74) -0.08 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry. 122 individuals missing alcohol drinking, 
and therefore dropped from models. 
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Table 23 cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking 
on Head and Neck Cancer Risk Using Hierarchical Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Cases/Controls OR (95% I)a  
Gene SNP 
Referent (A) 
/ Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 
 Cigarette=1, 
SNP=0 
 Cigarette=0, 
SNP=1 
 Cigarette=1, 
SNP=1 RERI 
DDB2 
(XPE) rs2029298 A G 69 195 81 214 356 283 416 382 2.37 (1.68, 3.34) 1.20 (0.82, 1.77) 2.02 (1.44, 2.84) -0.55 
  rs4647709 C T 123 342 27 67 643 560 129 105 2.00 (1.53, 2.62) 1.16 (0.71, 1.92) 2.12 (1.46, 3.07) -0.05 
  rs2291120 T C 123 296 27 113 562 516 210 149 1.70 (1.29, 2.24) 0.61 (0.38, 0.98) 1.95 (1.39, 2.74) 0.64 
  rs1685404  G C 72 180 78 229 346 322 426 343 1.67 (1.19, 2.36) 0.89 (0.60, 1.31) 2.02 (1.43, 2.84) 0.46 
  rs2957873 A G 101 275 49 134 542 436 230 229 2.20 (1.64, 2.95) 1.14 (0.76, 1.71) 1.77 (1.27, 2.46) -0.57 
  rs326224 G A 105 288 45 121 578 473 194 192 2.13 (1.60, 2.84) 1.16 (0.76, 1.77) 1.87 (1.33, 2.62) -0.43 
  rs2306353 G A 109 292 41 117 587 470 185 195 2.17 (1.64, 2.87) 1.10 (0.72, 1.69) 1.66 (1.19, 2.33) -0.61 
  rs326222 C T 76 209 74 200 408 317 364 348 2.37 (1.70, 3.29) 1.15 (0.78, 1.70) 1.87 (1.34, 2.62) -0.65 
  rs901746 A G 76 210 74 199 409 318 363 347 2.39 (1.72, 3.32) 1.17 (0.80, 1.73) 1.88 (1.35, 2.63) -0.68 
ERCC5 
(XPG) rs2296147 T C 41 114 109 291 239 189 528 474 2.13 (1.38, 3.28) 0.99 (0.65, 1.53) 1.87 (1.24, 2.81) -0.26 
  rs4771436  T G 97 259 53 150 466 400 306 265 1.98 (1.47, 2.68) 0.98 (0.66, 1.47) 1.92 (1.39, 2.65) -0.05 
  rs1047768 C T 57 142 93 267 262 235 510 429 1.72 (1.17, 2.52) 0.85 (0.57, 1.26) 1.80 (1.25, 2.60) 0.24 
  rs3818356 C T 97 259 53 149 466 400 304 264 1.97 (1.46, 2.66) 0.99 (0.66, 1.48) 1.91 (1.38, 2.64) -0.06 
  rs4150351 A C 97 258 53 151 498 434 274 231 1.92 (1.43, 2.59) 0.95 (0.63, 1.42) 1.94 (1.40, 2.69) 0.07 
  rs4150355 C T 57 159 93 250 345 269 427 396 2.26 (1.56, 3.27) 1.05 (0.70, 1.56) 1.86 (1.29, 2.67) -0.45 
  rs4150360 T C 50 119 100 290 225 197 547 468 1.71 (1.14, 2.59) 0.82 (0.54, 1.24) 1.71 (1.17, 2.52) 0.18 
  rs4150383 G A 106 296 44 113 524 453 248 212 2.02 (1.51, 2.69) 1.08 (0.70, 1.65) 2.00 (1.44, 2.78) -0.09 
  rs4150386 A C 113 317 37 92 611 519 161 145 2.02 (1.53, 2.67) 1.02 (0.65, 1.60) 1.84 (1.29, 2.61) -0.21 
  rs17655 C G 89 238 61 171 466 420 306 245 1.78 (1.31, 2.43) 0.89 (0.60, 1.32) 2.04 (1.46, 2.84) 0.36 
  rs873601       A G 73 190 77 219 391 349 381 316 1.73 (1.24, 2.42) 0.83 (0.56, 1.21) 1.84 (1.31, 2.58) 0.28 
  rs4150393 A G 114 317 36 92 588 527 184 138 1.94 (1.47, 2.56) 1.15 (0.73, 1.80) 2.35 (1.67, 3.32) 0.26 
  rs876430 C T 73 190 77 219 392 350 380 315 1.73 (1.24, 2.41) 0.83 (0.56, 1.21) 1.84 (1.31, 2.59) 0.29 
  rs1051677 T C 126 331 23 78 609 527 163 138 1.89 (1.44, 2.47) 0.81 (0.49, 1.36) 2.01 (1.42, 2.85) 0.31 
  rs1051685 A G 117 323 33 86 619 509 152 156 2.09 (1.59, 2.74) 1.10 (0.70, 1.75) 1.67 (1.18, 2.38) -0.52 
ERCC4 
(XPF) rs3136038 C T 51 195 99 214 351 295 421 370 2.82 (1.94, 4.10) 1.72 (1.16, 2.57) 2.64 (1.83, 3.81) -0.91 
  rs1799798 G A 126 331 24 78 631 570 141 95 1.83 (1.40, 2.40) 0.82 (0.50, 1.36) 2.32 (1.58, 3.39) 0.66 
  rs744154 C G 59 224 91 185 421 358 351 307 2.76 (1.95, 3.90) 1.80 (1.22, 2.66) 2.61 (1.82, 3.73) -0.95 
  rs3136085 G C 59 220 91 189 416 356 356 309 2.71 (1.91, 3.83) 1.76 (1.19, 2.60) 2.61 (1.82, 3.73) -0.86 
  rs3136130 G T 51 193 99 216 349 292 423 373 2.79 (1.92, 4.05) 1.69 (1.13, 2.52) 2.61 (1.81, 3.78) -0.87 
  rs1800067 G A 125 355 25 54 653 565 119 100 2.02 (1.55, 2.63) 1.24 (0.73, 2.11) 2.11 (1.45, 3.07) -0.15 
  rs3136172 A G 59 216 91 193 399 350 373 315 2.60 (1.83, 3.68) 1.67 (1.13, 2.48) 2.61 (1.82, 3.73) -0.66 
RAD23A rs2974752 A G 56 180 92 216 277 244 469 401 2.35 (1.62, 3.41) 1.42 (0.95, 2.11) 2.39 (1.67, 3.42) -0.37 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry. 122 individuals missing alcohol drinking, 
and therefore dropped from models. 
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Table 23 cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking 
on Head and Neck Cancer Risk Using Hierarchical Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Cases/Controls OR (95% I)a  
Gene SNP 
Referent (A) 
/ Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 
 Cigarette=1, 
SNP=0 
 Cigarette=0, 
SNP=1 
 Cigarette=1, 
SNP=1 RERI 
ERCC2 
(XPD) rs13181 T G 55 155 95 252 326 282 439 381 2.08 (1.43, 3.02) 1.06 (0.71, 1.58) 1.96 (1.36, 2.84) -0.17 
  rs238418 C A 54 155 96 254 328 271 444 394 2.19 (1.50, 3.20) 1.09 (0.73, 1.63) 2.00 (1.38, 2.89) -0.28 
  rs1799787 C T 68 203 82 206 404 342 368 323 2.18 (1.56, 3.06) 1.16 (0.79, 1.71) 2.07 (1.47, 2.93) -0.27 
  rs3916874 G C 81 201 69 208 396 344 376 321 1.70 (1.22, 2.36) 0.76 (0.51, 1.11) 1.73 (1.24, 2.41) 0.27 
  rs238416 G A 62 193 88 216 307 275 464 388 2.16 (1.51, 3.09) 1.33 (0.90, 1.96) 2.40 (1.69, 3.39) -0.09 
 rs50872 C T 80 221 70 187 451 363 319 301 2.14 (1.55, 2.95) 1.05 (0.71, 1.55) 1.85 (1.32, 2.58) -0.34 
  rs50871 T G 43 89 107 320 199 169 573 495 1.40 (0.89, 2.19) 0.67 (0.44, 1.05) 1.49 (0.98, 2.25) 0.41 
  rs238407 A T 43 136 107 273 220 202 551 463 2.33 (1.53, 3.55) 1.39 (0.91, 2.11) 2.51 (1.70, 3.72) -0.21 
  rs3810366 C G 32 95 118 314 146 137 625 528 2.26 (1.39, 3.68) 1.28 (0.81, 2.04) 2.41 (1.54, 3.75) -0.14 
ERCC1 rs735482 A C 117 302 33 107 571 495 201 170 1.87 (1.42, 2.47) 0.82 (0.52, 1.30) 1.90 (1.36, 2.65) 0.20 
  rs2336219 G A 117 302 33 107 571 495 201 170 1.87 (1.42, 2.47) 0.82 (0.52, 1.30) 1.90 (1.36, 2.65) 0.20 
  rs3212964 G A 118 302 32 107 574 492 198 173 1.87 (1.42, 2.46) 0.79 (0.50, 1.24) 1.84 (1.32, 2.56) 0.18 
  rs3212955 A G 82 229 68 180 446 378 326 286 2.08 (1.51, 2.85) 1.09 (0.74, 1.61) 2.02 (1.45, 2.81) -0.15 
  rs3212948 C G 60 171 90 238 322 287 450 378 2.01 (1.40, 2.88) 1.10 (0.74, 1.63) 2.14 (1.50, 3.05) 0.03 
  rs3212930 T C 92 248 58 161 484 409 288 256 1.95 (1.44, 2.64) 0.99 (0.67, 1.47) 1.98 (1.43, 2.75) 0.04 
LIG1 rs156641 G A 56 166 94 243 314 274 458 391 2.13 (1.47, 3.10) 1.21 (0.81, 1.80) 2.26 (1.57, 3.26) -0.08 
  rs20580 C A 30 109 120 300 207 184 565 481 2.48 (1.54, 4.00) 1.51 (0.95, 2.41) 2.80 (1.78, 4.38) -0.20 
  rs20579 C T 105 305 45 104 586 521 186 144 2.05 (1.55, 2.72) 1.34 (0.87, 2.05) 2.43 (1.71, 3.45) 0.04 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry. 122 individuals missing alcohol drinking, 
and therefore dropped from models. 
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CHAPTER 4 
SINGLE NUCLEOTIDE POLYMORPHISMS IN NUCLEOTIDE EXCISION REPAIR GENES, CANCER 
TREATMENT, AND HEAD AND NECK CANCER SURVIVAL 
 
4.1 OVERVIEW 
 Head and neck cancers (HNC) are commonly treated with radiation and platinum-based 
chemotherapies which produce bulky DNA adducts to eradicate cancerous cells. Because nucleotide 
excision repair (NER) enzymes remove adducts, variants in NER genes may be associated with 
survival among HNC cases both independently and jointly with treatment. Cox proportional hazards 
models were used to estimate race-stratified (white, African American) hazard ratios (HR) and 95% 
confidence intervals (CI) for overall (OS) and disease-specific (DS) survival based on treatment 
(combinations of surgery, radiation, and chemotherapy) and 84 single nucleotide polymorphisms 
(SNPs) in 15 NER genes among 1,227 HNC cases from the Carolina Head and Neck Cancer 
Epidemiology (CHANCE) study. None of the NER variants were associated with survival at a 
Bonferroni-corrected alpha of 0.0006. However, rs3136038 [OS HR=0.79 (0.65, 0.97), DS HR=0.69 
(0.51,0.93)] and rs3136130 [OS HR=0.78 (0.64,0.96), DS HR=0.68 (0.50,0.92)] of ERCC4 and rs50871 
[OS HR=0.80 (0.64, 1.00), DS HR=0.67 (0.48,0.92)] of ERCC2 among whites, and rs2607755 [OS 
HR=0.62 (0.45, 0.86), DS HR=0.51 (0.30, 0.86)] of XPC among African Americans were associated 
with survival at 0.05 alpha before correction. Three SNP-treatment joint effects showed possible 
departures from additivity for overall survival among whites. Our study, the largest and most 
comprehensive evaluation of SNPs in NER genes to date, identified mostly null associations between 
SNPs in NER genes and survival among HNC cases, though a few variants were suggestively
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associated with survival and potentially interacted additively with treatment. 
4.2 BACKGROUND 
An estimated 52,140 incident head and neck cancer (HNC) cases and 11,460 associated 
deaths occurred in the US during 2011 (1). HNC is a relatively fatal disease, with 5 year survival rates 
of 58.9% and 61.2% for white men and women, respectively, and  30.7% and 50.6% among African 
American men and women, respectively (61,62). HNC was historically treated with surgery and/or 
radiation therapy (65). However, following a series of clinical trials in the 1990s the majority of 
advanced tumors (stage 3 and 4) are increasingly treated with concurrent or induction radiation and 
chemotherapy (72). In addition to stage, other tumor characteristics (e.g., location and size) and the 
patients’ demographics (e.g., age) can influence treatment decisions and outcomes (122).  
Emerging literature suggests that genetic factors, namely, variants in nucleotide excision 
repair (NER) genes, may also impact treatment response and survival among HNC cases (7,47-
55,204).  In order to initiate cell death (apoptosis) of cancerous cells, radiation and platinum-based 
chemotherapy are known to cause bulky DNA adducts, among other types of DNA damage (6,7,48).  
Since NER is the pathway primarily responsible for removing DNA adducts, functional NER processes 
may lessen the efficacy of cancer treatment (6). This hypothesis has led some researchers to 
describe DNA repair, including NER, as a “double-edged sword” or “Janus-the two faced Roman god” 
since functional genes are thought to protect against cancer incidence, but may also mitigate the 
effectiveness of cancer treatments thus decreasing survival (6).  
Previous epidemiologic studies on the effects of single nucleotide polymorphisms (SNPs) in 
NER genes and treatment on HNC mortality have been inconsistent (7,47-55). For example, some 
studies conducted among patients receiving radiation reported null associations for rs13181 in 
excision repair cross-complementing 2 (ERCC2) and survival (48,50). Other studies showed evidence 
for significant differences in survival across genotypes of rs13181 (47,53,54), including a study which 
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found the wild-type genotype was associated with worse survival among individuals treated with 
radiation and better survival among those receiving no treatment (7). However, previous studies 
have been based on small sample sizes, predominantly European-descent populations, and a limited 
number of variants in NER genes (7,47-55). The present study, therefore, extends the literature by 
estimating main and joint effects of treatment and 84 SNPs across 15 NER genes on survival among 
a large, racially diverse population-based study of HNC cases. 
4.3 METHODS 
4.3.1 Study Population 
 The Carolina Head and Neck Cancer Epidemiology (CHANCE) study is a population-based 
case-control study of 2,785 individuals (1,389 cases and 1,396 controls) from 46 of 100 counties in 
North Carolina (57,63,64). For the present analysis, a case-only study design was employed to 
compare survival among cases by treatment and genotype. All cases were aged 20 to 80 years of age 
and were identified from the North Carolina Central Cancer Registry between January 1, 2002 and 
February 28, 2006 using rapid case ascertainment (57,63,64). Self-reported demographic and 
behavioral information, including age, sex, race, education, alcohol drinking, and cigarette smoking, 
was ascertained for each case through nurse-administered questionnaires (57,63,64). Biologic 
samples (~90% blood and ~10% buccal cells) were also collected from cases at the time of interview 
(64). Individuals who self-reported race other than white or African American were excluded due to 
sparse data (26 cases, 1.9%) and lip cancer cases (21 cases, 1.3%) were excluded for differences in 
etiology compared to the more common HNC sites studied. Cases who either did not provide blood 
or buccal cell samples or whose sample was insufficient for genotyping (115 cases, 8.3%) were also 
excluded. Therefore, our analysis included 1,227 HNC cases (922 white cases and 305 African 
American cases).   
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4.3.2 SNP Selection and Genotyping 
 Illumina GoldenGate assay with Sentrix Array Matrix and 96-well standard microtiter plates 
were used for genotyping (64,137). As described for aim 1, 129 SNPs in 15 NER genes included 71 
tag SNPs in 8 genes selected based on a case-control study of HNC at The University of Texas MD 
Anderson Cancer Center (r2 ≥ 0.80, a minor allele frequency (MAF) ≥ 0.05, 1 to 2 kb up- or down-
stream, CEU population) (129,139,140) and 58 SNPs in 12 genes selected based on other HNC 
studies and/or potential function (129,139,140) (table 13). Since tagging SNPs were selected for only 
8 genes among the CEU population, and other candidate SNPs were selected based on previous 
literature conducted primarily among European-descent populations, it should be noted that the 
amount of variation captured across some genes was limited, especially among African American. 
For this reason, haplotypes were not explored.  
 Of the 129 NER SNPs, variants with weak signal intensity or indistinguishable genotype 
clusters (14 SNPs) or a MAF less than 0.05 (30 SNPs among whites and 36 SNPs among African 
Americans) were excluded (table 13). Nearly all excluded SNPs were candidate SNPs selected based 
on previous literature (i.e. only 5 tag SNPs were excluded for failing genotyping and only 1 tag SNP 
among whites was excluded for having a MAF < 0.05) (table 13). As determined for aim 1, 
frequencies for 7 SNPs in white controls and 7 SNPs in African American controls were inconsistent 
with Hardy-Weinberg equilibrium (p<0.05); however, since genotype scatter plots showed 
reasonable clustering, none of these SNPs were excluded from analyses (147). Our analysis included 
84 SNPs in 15 NER genes among whites and 79 SNPs in 14 NER genes among African Americans.  
4.3.3 Treatment 
 First-course treatment information was abstracted from patients’ medical records. 
Information included whether the patient received surgery, radiation therapy, and chemotherapy, 
including types of chemotherapy drugs (82,135). Chemotherapy drugs included: carboplatin, 
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paraplatin, cisplatin, 5 FU, taxol, taxotere, docetaxel, paclitaxel, ifosfamide, and other.  Information 
on treatment start and end dates and whether radiation and chemotherapy were administered 
concurrently was not available for a large proportion of individuals (e.g., chemotherapy end dates 
were missing for approximately a quarter of patients treated with chemotherapy). Therefore, 
combinations of treatment were generated from dichotomous variables for surgery, radiation, 
chemotherapy regardless of timing. Finally, information on tumor histology and stage were 
abstracted from cases’ medical records (82,135). 
4.3.4 HNC Survival 
 CHANCE data were linked to the National Death Index (NDI) based on name, social security 
number, and date of birth to identify deaths through 2009, including date of death, location of 
death, and cause of death (205). Death records with HNC listed as the primary or secondary cause of 
death were considered disease-specific deaths. Individuals not present in the NDI were considered 
alive as of December 31, 2009. 
4.3.5 Statistical Analysis 
 Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% 
confidence intervals (CIs) for the independent effects of treatment, the independent effects of 
SNPs in NER genes, and the joint effects of treatment and SNPs on HNC survival among whites 
and African Americans separately. To evaluate the proportionality of hazards, we examined 
adjusted log negative log plots by treatment/genotype (171,172).  In addition, we assessed the 
significance of including an interaction term for treatment/genotype and time in models 
(171,172). If log negative log plots indicated a violation of the proportional hazards assumption 
and interaction terms with time were significant (p<0.05), accelerated failure time (AFT) models 
were fit to explore robustness of results.  This was the case for 4 SNPs in whites (rs3731068, 
rs744154, rs3136085, rs3136172) and 3 SNPs in African Americans (rs4150360, rs2020955, 
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rs13181). However, because p-values for the AFT models were similar to those obtained from 
Cox models (ie the same set of significant SNP-HNC survival associations resulted from both 
approaches), results from the Cox models without an interaction term between SNPs and time 
are presented for simplicity.  
 Absolute differences in HNC survival by genotype and treatment were also assessed via 
Kaplan-Meier plots, with cumulative survival calculated as the percent of cases alive at each 
time point, and log rank tests were used to assess differences in survival.  
 For overall survival models, follow-up started at date of diagnosis for all cases and 
ended at date of death for individuals who died or censoring on December 31, 2009 for 
individuals who were still alive. For HNC disease-specific survival models, follow-up started at 
date of diagnosis for all cases and ended at date of death for individuals who died of HNC or 
censoring at date of death for individuals who died from causes other than HNC or December 
31, 2009 for individuals who were still alive.  
4.3.5.1 Treatment-Survival Associations  
 Treatment was modeled as a categorical variable with six mutually exclusive levels: 
surgery only; radiation only; surgery and radiation; radiation and chemotherapy; surgery, 
radiation, and chemotherapy; and other (no treatment, chemotherapy only, or surgery and 
chemotherapy without radiation). Surgery only was used as the referent category because few 
individuals received no treatment (9 cases, 0.7%). Because even fewer individuals received 
chemotherapy only or chemotherapy with surgery without radiation (4 cases, 0.3%), these 
individuals were combined with individuals receiving no treatment into a single category labeled 
“other treatment.”  In a separate model, we also considered ever receiving platinum-based 
chemotherapy drugs (carboplatin, paraplatin, or cisplatin, N=464) versus never receiving 
platinum-based chemotherapy drugs (i.e. never receiving chemotherapy, N=754, or only 
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receiving non-platinum based chemotherapy drugs, including 5 FU, taxol, taxotere, docetaxel, 
paclitaxel, or ifosfamide, N=9).  All treatment models were adjusted for sex, age (5 year 
categories), race, stage (American Joint Committee on Cancer, AJCC, stages I, II, III, IV) (118), 
tumor site (oral cavity, oropharynx, hypopharynx, larynx, HNC NOS), education (less than a high 
school education, a high school education, or a college education), duration of cigarette smoking 
(years), and frequency of alcohol use (categorical indicator for lifetime alcohol consumption in 
ml/day). 
4.3.5.2 SNPs-Survival Associations 
 In agreement with aim 1, SNPs were defined using a dominant genetic model and the 
referent allele for both whites and African Americans was assigned to be the major allele based 
on controls from the overall CHANCE study population. Models included a single SNP at a time, 
with p-values adjusted using the Bonferroni method (0.05/84 =0.0006 among whites and 
0.05/79=0.0006 among African Americans). SNP-survival associations with p-values below 0.05 
but not significant at a Bonferroni corrected alpha level were considered as “suggestive” 
associations. Because NER germline SNPs are unlikely to be associated with smoking and 
drinking, and therefore these behaviors would not be considered confounders based on our 
directed acyclic graph (DAG) (160), SNP models only included sex, age, and ancestry (percent 
African ancestry). As described in previous studies of cancer among whites and African 
Americans in North Carolina, 157 ancestral informative markers (AIMS) were used to estimate 
the proportion of African and European ancestry of each participant based on Fisher’s 
information criterion (FIC) (64,157,201).  
4.3.5.3 Joint Effects  
 Joint effects models included a single SNP at a time (defined using the dominant genetic 
model), treatment (disjoint indicator variables for six treatment categories), and interaction 
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terms between the SNP and treatments. Joint effects between SNPs and platinum-based 
chemotherapy (yes/no) were considered in a separate model. Since both treatment and genetic 
exposures were assessed, joint effects models were adjusted for sex, age, stage, anatomic site, 
education, cigarette smoking, alcohol drinking, and ancestry. Interactions between SNPs in NER 
genes and treatments were assessed on the additive scale using the relative excess risk for 
interaction (RERI), also known as the interaction contrast ratio (ICR). Specifically, RERIs were 
calculated as HR11 - HR01 - HR10 + HR00, where HR11 is the hazard ratio among individuals who 
received the specified treatment and had a variant genotype, HR01 is among individuals who 
received the specified treatment and had a referent genotype, HR10 is among individuals who 
received surgery only and had the variant genotype, and HR00 is among individuals who 
received surgery only and had the referent genotype (which equals 1.0 as it is the referent) 
(160,161). Confidence intervals for the ICR were calculated using the Hosmer and Lemeshow 
method (161).  Statistical analyses were performed using SAS 9.3 (Cary, NC) (163). 
4.4 RESULTS 
4.4.1 Characteristics of Study Population 
 Of the 1,227 HNC cases in CHANCE, 545 (44.4%) cases linked with the National Death Index 
through 2009 (table 24). The remaining 682 (55.6%) cases were assumed to be alive as of December 
31, 2009. The median and mean follow-up times were 919.7 days and 764.0 days, respectively, 
among individuals who died and 2138.4 days and 2087.0 days, respectively, among those who were 
alive. Among the 545 individuals who died, just under half (227 cases, 41.7%) had head and neck 
cancer listed as primary or secondary cause of death. Among these disease-specific deaths, the 
median and mean follow-up times were 729.7 days and 594.0 days, respectively. 
 Very modest variation by sex and age at diagnosis was observed when comparing cases who 
were living and dead after study follow-up (table 24). However, a noticeably higher proportion of 
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individuals who died were African American (29.7% vs. 21.0%) or had a high school education or less 
(71.9% vs. 53.1%) compared to living cases. With respect to tumor site, similar proportions had a 
diagnosis of laryngeal cancer (36.1%). In contrast, 23.5% of cases who died had oropharyngeal 
cancer compared to 30.1% of cases who were living. As expected (59,60), the distribution of tumor 
stage also varied by survival status, with living individuals tending to have lower tumor stage.  
4.4.2 Treatment-Survival Associations 
 Among whites, individuals who received radiation only tended to have worse overall survival 
(HR=1.59, 95% CI=1.08, 2.34) and disease-specific survival (HR=2.47, 95% CI=1.34, 4.56) compared to 
individuals who were treated with surgery alone (table 25). Individuals receiving no treatment or 
other treatment (i.e. chemotherapy only, chemotherapy and surgery, or no treatment) also 
appeared to have poorer overall and disease-specific survival, though estimates were imprecise.  In 
a separate model considering the effects of platinum-based chemotherapy on HNC survival, 
receiving platinum-based chemotherapy appeared to be associated with better overall survival 
(HR=0.71, 95% CI=0.52, 0.95 among whites and HR=0.77, 95% CI=0.48, 1.20 among African 
Americans) and disease-specific survival (HR=0.63, 95% CI=0.41, 0.97 among whites and HR=0.44, 
95% CI=0.19, 1.02 among African Americans) (table 25). 
4.4.3 SNPs-Survival Associations  
 Among whites, 4 SNPs were modestly associated with overall survival only and 3 SNPs were 
modestly associated with both overall and disease-specific survival at an uncorrected 0.05 alpha 
level (table 26). However, after correcting the alpha level using the Bonferroni method, no SNPs 
were statistically significantly associated with either survival outcome. Among the SNPs associated 
with overall and disease-specific survival at an uncorrected 0.05 alpha level, 2 tag SNPs were in 
linkage disequilibrium (LD) (r2=0.92, CEU population) on ERCC4, which is also known as xeroderma 
pigmentosum F (XPF) (203). Specifically, the variant genotypes of rs3136038 (TT and TC vs CC) and 
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rs3136130 (TT and GT vs GG) were suggestively associated with a similarly reduced hazards of 
overall death (HR=0.79, uncorrected 95% CI=0.65, 0.97 and HR=0.78, uncorrected 95% CI=0.64, 0.96, 
respectively) and disease-specific death (HR=0.69, uncorrected 95% CI=0.51, 0.93, and HR=0.68, 
uncorrected 95% CI=0.50, 0.92, respectively). In addition, the variant genotype of rs50871 (TT and 
TC vs CC), a tag SNP on ERCC2 which is also known as XPD, was associated with decreased hazards of 
overall death (HR=0.80, uncorrected 95% CI=0.64, 1.00) and disease-specific death (HR=0.67, 
uncorrected 95% CI=0.48, 0.92). Stratifying by tumor stage, associations for rs3136038 or rs3136130 
and survival were strongest among stage 4 cases and rs50871 among stage 3 cases (supplementary 
table 7S, Appendix C). Figure 12 shows the Kaplan-Meier plots for these SNPs and overall and 
disease-specific survival.  
 Among African Americans, 2 SNPs were associated with overall survival and 4 SNPs were 
associated disease-specific survival at a 0.05 alpha level, but again none of these SNPs were 
significantly associated with survival at a Bonferroni-corrected level (table 27). Only one SNP was 
associated with both overall and disease-specific survival at a 0.05 alpha level. Specifically, 
rs2607755 (CC and CT vs TT) on XPC was suggestively associated with reduced hazards of overall 
survival (HR=0.62, uncorrected 95% CI=0.45, 0.86) and disease-specific survival (HR=0.51, 
uncorrected 95% CI=0.30, 0.86). This association was strongest among cases with stage 4 tumors 
(supplementary table 7S, Appendix C). Figure 13 show the Kaplan-Meier plots for this SNP and 
overall and disease-specific survival.  
4.4.4 Joint Effects 
 At an uncorrected 0.05 alpha level, 3 SNPs appeared to interact super-additively with 
radiation, 6 SNPs appeared to interact super-additively with radiation and chemotherapy treatment, 
and 1 SNP appeared to interact sub-additively with surgery, radiation, and chemotherapy, with 
respect to overall survival among whites (supplementary table 8S, Appendix C).  Of these suggestive 
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interactions, 1 SNP-radiation and 2 SNP-radiation, chemotherapy interactions were significant at a 
Bonferroni corrected 0.0006 alpha level. Specifically, rs2972388 of CDK7 interacted super-additively 
with radiation only (RERI=1.07, uncorrected 95% CI=0.55, 1.60) and radiation and chemotherapy 
(RERI=0.72, uncorrected 95% CI=0.33, 1.10). In addition, rs2974752 of RAD23A interacted super-
additively with radiation and chemotherapy (RERI=0.80, uncorrected 95% CI=0.36, 1.24). However, 
genotype frequencies for both of these SNPs among white controls from aim 1 appeared 
inconsistent with HWE at a 0.05 alpha level, although the genotype clustering plots did appear 
reasonable. Therefore, some caution should be used in interpreting these interactions. When 
disease-specific survival was considered, no SNP-treatment interactions were significant at a 
Bonferroni-corrected level (data not shown).  Examining platinum-based chemotherapy separately, 
10 SNPs suggested additive interactions at an uncorrected alpha level with respect to overall survival 
among whites, but none were significant after correction for multiple comparisons (supplementary 
table 9S, Appendix C). Among African Americans, no SNP-treatment interactions appeared to be 
significant at a Bonferroni corrected alpha level; however, estimates were unreliable due to 
relatively low cell counts and are therefore not presented (data not shown, Appendix D). 
4.5 DISCUSSION 
 We detected mostly null associations between 84 SNPs in 15 NER genes and survival among 
white and African American HNC cases. Identifying null associations is important for following-up 
early positive associations, avoiding publication bias, and informing future meta-analyses (206). It 
should also be noted that we used the Bonferroni approach to account for multiple comparisons, 
which though widely used in genetic epidemiology, assumes independence of tests (164-166). Given 
the correlated nature of SNPs, including a number of SNPs in our study, using the Bonferroni 
correction may be overly conservative potentially resulting in false negatives (164-166). Therefore 
 147 
 
we also highlighted SNP-survival associations with the lowest p-values (i.e. p-values below 0.05) in 
this paper as suggestive associations warranting further investigation.  
Among white HNC cases, we found that the variant genotypes of 3 tag SNPs, rs3136038 
located near the 5’ end of ERCC4 (XPF), rs3136130 in intron 5 of ERCC4 (XPF), and rs50871 in intron 
11 of ERCC2 (XPD), were modestly associated with improved overall and disease-specific survival 
among white HNC cases (202,207). The ERCC4 enzyme acts in conjunction with XPG to remove DNA 
adducts by creating an incision at the 5’ end of a damage site, while ERCC2 operates as a component 
of the transcription factor II H (TFIIH) subunit which denatures the double helix in preparation for 
this incision (123,124). Among African American HNC cases, the variant genotype of tag SNP 
rs2607755 of XPC intron 2 (202,207) was also suggestively associated with improved overall and 
disease-specific survival. The XPC enzyme acts first in the NER pathway to recognize and bind to 
DNA adducts (123,124).  
Although no previous HNC studies examined rs3136038 or rs3136130 on ERCC4 (XPF), two 
studies assessed 9 other ERCC4 (XPF) SNPs (rs1799799, rs1799801, rs3136105, rs3136146, 
rs3136152, rs3136155, rs3136166, rs3136189, rs3136202), many of which were in LD with the SNPs 
in our study (based on CEU population) (47,55,203). While 5 of these SNPs were not associated with 
progression free survival among HNC cases, 4 SNPs appeared to be potentially associated with 
worse progression free survival (PFS HR=1.94, p-value=0.065 for rs1799799 T>C; PFS HR= 2.00, p-
value=0.053 for rs3136155 C>T; PFS HR=1.94, p-value=0.065 for rs3136166 T>G; PFS HR=1.44, p-
value=0.065 for rs3136202 G>A) contrary to our study (47,55). Among esophageal cancer cases, a 
study by Lee et al. did assess rs3136038 reporting better overall survival associated with the 
genotype TT, though HRs were not statistically significant (OS HR=1.55, 95% CI=0.84, 2.86 for CT vs. 
TT and OS HR=1.20, 95% CI=0.66, 2.20 for CC vs TT) similar to our study. Further, ERCC4 protein 
expression has been found to be up regulated in HNC cell lines, and displayed cisplatin resistance 
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(208). With respect to ERCC2 (XPD), no previous studies have considered the effects of rs50871 on 
HNC survival. Rather, rs13181 and rs1799793 (which are not in LD for CEU) are the most commonly 
studied SNPs in ERCC2, with the majority of studies reporting near null associations between these 
SNPs and survival among HNC cases (47,48,50,53,54,203). In our study, rs13181 was also not 
associated with survival. Finally, no previous studies have considered associations between 
rs2607755 of XPC and survival, nor have any studies considered association between any NER 
variants and survival among African American HNC cases. Only one previous study has investigated a 
single variant in XPC, rs2228001 (which is not in LD with rs2607755 for YRI but is for CEU), noting no 
association with overall survival among a cohort of Spanish HNC patients (log rank p-value=0.96 for 
C>A) (48,203). Likewise, we did not find an association between rs2228001 and overall or disease-
specific survival.  
 Since radiation and platinum-based chemotherapy are known to cause DNA damage 
repaired by NER genes (6,7,48), we also considered associations between SNPs and survival among 
HNC cases in the context of treatment. Accounting for multiple comparisons using the Bonferroni 
method, we found interactions between the candidate SNP rs2972388 of CDK7 and radiation only, 
as well as radiation and chemotherapy, were more than additive with respect to overall survival 
among whites. In addition, rs2974752 of RAD23A, also a candidate SNP, interacted super-additively 
with radiation and chemotherapy. However, these SNPs showed some inconsistent evidence for 
HWE. No previous studies have considered SNPs in RAD23A and CDK7 in relation to treatment and 
HNC survival. Only one previous study has compared NER SNP-survival associations across strata of 
different treatment regimens (7).  Specifically, a study by Zhong et al. analyzed the effect of rs13181 
in ERCC2 on survival among 275 HNC cases receiving radiotherapy and 210 cases not receiving 
radiotherapy (7).  Among cases with stage 3 and 4 tumors, the genotype for those homozygous for 
the wild-type allele (AA) was associated with poorer overall survival among those treated with 
 149 
 
radiation (OS HR= 1.66, 95% CI=1.15, 2.40 for AA vs. AC + CC), but better survival among those who 
did not receive radiation (OS HR=0.26, 95% CI=0.11, 0.62) (7). Among cases with stage 1 and 2 
tumors who did not receive radiation, however, rs13181 was not associated with survival (OS log 
rank p-value=0.78) (7).  
With a population-based study of 1,227 HNC cases, the present study included more than 
double the number of HNC cases of the next largest study (47). Study populations of previous 
publications were mostly hospital-based and ranged from 47 to 531 HNC cases (47,51). Further, the 
present study population included 922 white cases and 305 African Americans cases which allowed 
for estimation of race-specific HRs, which is an important new contribution of this study. Linkage 
disequilibrium is known to vary by ancestral populations and distinct differences in survival by race 
occur in the United States (e.g., five-year survival rates among African Americans are almost half 
those among whites) (61,62,129). Yet, prior to this study, no studies had considered association 
between NER variants and survival among African American HNC cases. Another contribution of our 
study was the broad evaluation of NER variants which includes a large number of SNPs that have not 
been previously evaluated with respect to survival among HNC cases. Previous studies have 
collectively examined approximately 18 SNPs in 6 NER genes and survival among HNC cases (7,47-
55). This study included 84 SNPs across 15 NER genes.   
Although our study included the largest study population and the largest number of SNPs in 
NER genes to date, a few limitations should be noted. First, information on treatment was 
abstracted from medical records. While information on whether patients received (yes/no) surgery, 
radiation, and chemotherapy (including chemotherapy drug) was available, information on duration 
of treatment (e.g., start and end dates) and timing of treatments combinations (e.g., induction, 
adjuvant, or concurrent chemotherapy) were not complete. Therefore, treatment was considered 
solely as the first-course combinations of dichotomous variables for surgery, radiation, and 
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chemotherapy. Second, tagging SNPs were not selected for all genes and SNPs were selected based 
on the CEU population. Therefore, the amount of variation captured across some genes was limited, 
especially among African Americans. Third, joint effect estimates for SNPs and treatment were 
generally imprecise among whites and not considered among African Americans due to small cell 
counts. Fourth, models were adjusted for cigarette smoking and alcohol intake information that was 
ascertained at baseline based on behaviors prior to diagnosis since information on behavioral risk 
factors following diagnosis was not uniformly available.  Further, we did not have information on 
human papillomavirus (HPV), which is a strong predictor of survival among cases with oropharyngeal 
tumors. Finally, we did not have access to information on recurrent tumors and were therefore 
unable to consider disease-free or relapse-free survival.  
 Most associations between NER variants and survival among HNC cases were null. However, 
three SNPs in whites (rs3136038 and rs3136130 of ERCC4 and rs50871 of ERCC2) and 1 SNP among 
African Americans (rs2607755 of XPC) were suggestively associated with both overall and disease-
specific survival. Therefore, it is recommended that future genetic epidemiology studies of HNC 
survival include these SNPs for replication. With respect to SNP-treatment joint effects and overall 
survival, two SNPs (rs2972388 of CDK7 and rs2974752 of RAD23A) appeared to possibly interact 
additively with treatment consisting of radiation and chemotherapy, and one SNP (rs2972388 of 
CDK7) with radiation alone among whites. While our study is the largest to date, it is only the second 
to consider the NER variant-treatment effects on HNC survival.  Therefore, additional studies with 
even larger sample sizes are needed to evaluate gene-environment interactions more precisely. 
Further studies focusing on African American and other diverse populations are recommended.
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Table 24. Demographic Characteristics of Head and Neck Cancer Cases, Carolina 
Head and Neck Cancer Epidemiology (CHANCE) Study 
  Alive Overall Deaths Disease-Specific Deaths 
Characteristic N % N % N % 
Total 682 55.6 545 44.4 227   
Sex             
Male 519 76.1 419 76.9 169 74.4 
Female 163 23.9 126 23.1 58 25.6 
Race/Ethnicity             
White 539 79.0 383 70.3 169 74.4 
African American 143 21.0 162 29.7 58 25.6 
Age at Diagnosis             
20-49 152 22.3 87 16.0 42 18.5 
50-54 110 16.1 79 14.5 30 13.2 
55-59 125 18.3 82 15.0 35 15.4 
60-64 118 17.3 87 16.0 37 16.3 
65-69 78 11.4 90 16.5 33 14.5 
70-74 64 9.4 71 13.0 27 11.9 
75-80 35 5.1 49 9.0 23 10.1 
Education             
 High school or less 362 53.1 392 71.9 157 69.2 
Some college 195 28.6 99 18.2 48 21.1 
College or more 125 18.3 54 9.9 22 9.7 
Tumor Site             
Oral cavity 81 11.9 91 16.7 38 16.7 
Oropharynx 205 30.1 128 23.5 54 23.8 
Hypophaynx 16 2.3 39 7.2 15 6.6 
NOS 134 19.6 90 16.5 42 18.5 
Larynx 246 36.1 197 36.1 78 34.4 
Stage             
I 195 28.6 84 15.4 17 7.5 
II 119 17.4 101 18.5 38 16.7 
III 118 17.3 93 17.1 40 17.6 
IV 250 36.7 267 49.0 132 58.1 
Surgery             
No 269 39.4 268 49.2 119 52.4 
Yes 413 60.6 277 50.8 108 47.6 
Radiation             
No 177 26.0 105 19.3 37 16.3 
Yes 505 74.0 440 80.7 190 83.7 
Chemotherapy             
No 428 62.8 326 59.8 130 57.3 
Yes 254 37.2 219 40.2 97 42.7 
Mean Follow-Up 
Time (Days) 2138.4   919.7   729.7   
Median Follow-Up 
Time (Days) 2087.0   764.0   594.0   
  
Table 25. Hazard Ratios for Cancer Treatment and Head and Neck Cancer Survival in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study 
  Whites   African Americans 
Cancer Treatment 
Overall 
Deaths 
HNC 
Deaths Alive 
Overall Survival                                     
HR (95% CI)a,b 
Disease-Specific 
Survival HR (95% CI) a,b 
  
Overall 
Deaths 
HNC 
Deaths Alive 
Overall Survival                                     
HR (95% CI)a,b 
Disease-Specific 
Survival HR (95% CI)a,b                  
Surgery only 68 21 144 1.00 (Referent) 1.00 (Referent) 
 
26 9 31 1.00 (Referent) 1.00 (Referent) 
Radiation only 77 36 83 1.59 (1.08, 2.34) 2.47 (1.34, 4.56) 
 
24 7 31 1.00 (0.52, 1.92) 0.89 (0.26, 3.05) 
Surgery and Radiation 85 35 106 1.19 (0.81, 1.73) 1.28 (0.69, 2.36) 
 
38 16 32 1.10 (0.63, 1.94) 1.13 (0.44, 2.86) 
Radiation and 
Chemotherapy 102 50 118 1.19 (0.78, 1.81) 1.48 (0.78, 2.81) 
 
55 19 36 1.00 (0.56, 1.80) 0.52 (0.19, 1.39) 
Surgery, Radiation, 
Chemotherapy 43 22 87 0.98 (0.61, 1.59) 1.26 (0.61, 2.58) 
 
16 5 12 0.77 (0.36, 1.64) 0.36 (0.09, 1.39) 
Other (No Treatment, N=9; 
Chemotherapy only, N=2; 
Chemotherapy and Surgery, N=2) 
8 5 1 9.38 (3.62, 24.29) 20.39 (6.44, 64.57) 3 2 1 2.02 (0.40, 10.27) 4.13 (0.36, 47.74) 
Platinum-Based 
Chemotherapy 
           Did not receive platinum-
based chemotherapy 239 98 336 1.00 (Referent) 1.00 (Referent) 
 
93 34 95 1.00 (Referent) 1.00 (Referent) 
Did receive platinum-
based chemotherapy 144 71 203 0.71 (0.52, 0.95) 0.63 (0.41, 0.97) 
 
69 24 48 0.77 (0.48, 1.22) 0.44 (0.19, 1.02) 
HR hazards ratio, CI confidence interval 
a) HR adjusted for matching factors (age, sex, including pairwise interactions), stage, anatomic site, education, cigarette smoking, alcohol drinking 
b) Platinum-based chemotherapy HR adjusted for matching factors (age, sex, including pairwise interactions), stage, anatomic site, education, cigarette smoking, alcohol drinking, surgery, radiation 
 
1
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Table 26. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Survival among Head and Neck 
Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    
Coded Allele Overall Deaths / Deaths from HNC / 
Alive Overall Survival Disease-Specific Survival 
Gene SNP 
Referent (A) 
/ 
Variant (B) AA AB + BB HR (95% CI)
a
 
p-
value HR (95% CI)
a
 
p-
value 
ERCC3 
(XPB) rs4150496 G A 168 67 233 215 102 305 0.94 (0.77, 1.15) 0.55 1.10 (0.81, 1.51) 0.53 
  rs1011019 C T 191 84 271 192 85 268 1.02 (0.83, 1.24) 0.88 1.03 (0.76, 1.39) 0.87 
  rs4150434 G A 230 110 318 153 59 221 0.99 (0.80, 1.21) 0.91 0.80 (0.58, 1.10) 0.18 
  rs4150416 T G 165 69 245 217 99 292 1.10 (0.90, 1.35) 0.34 1.20 (0.88, 1.64) 0.24 
  rs4150407 A G 131 47 187 252 122 352 0.99 (0.80, 1.23) 0.94 1.32 (0.94, 1.85) 0.11 
  rs4150403 G A 303 139 433 80 30 106 1.02 (0.79, 1.31) 0.88 0.81 (0.55, 1.21) 0.31 
  rs4150402 G A 191 84 271 192 85 268 1.02 (0.83, 1.24) 0.88 1.03 (0.76, 1.39) 0.87 
XPC rs2228001 A C 135 58 202 248 111 336 1.13 (0.92, 1.40) 0.24 1.16 (0.84, 1.60) 0.36 
  rs3731143 T C 333 147 485 50 22 54 1.18 (0.87, 1.59) 0.29 1.16 (0.73, 1.82) 0.53 
  rs2228000 C T 213 94 311 168 74 228 1.04 (0.85, 1.28) 0.68 1.04 (0.76, 1.41) 0.82 
  rs3731124 A C 215 94 306 168 75 233 1.02 (0.83, 1.26) 0.83 1.08 (0.79, 1.47) 0.63 
  rs13099160 A G 335 146 479 48 23 60 1.13 (0.83, 1.53) 0.44 1.17 (0.75, 1.82) 0.50 
  rs3731093 T C 321 141 455 59 26 79 1.03 (0.78, 1.36) 0.83 0.98 (0.64, 1.49) 0.91 
  rs3731089 G A 321 141 457 62 28 82 1.05 (0.80, 1.38) 0.74 1.02 (0.68, 1.53) 0.94 
  rs2733537 A G 167 73 249 216 96 290 1.07 (0.87, 1.31) 0.53 1.06 (0.78, 1.44) 0.71 
  rs3731068 C A 257 111 367 126 58 172 1.09 (0.88, 1.35) 0.45 1.16 (0.84, 1.60) 0.36 
  rs2607755 T C 100 46 142 283 123 397 0.99 (0.79, 1.25) 0.95 0.96 (0.68, 1.35) 0.80 
  rs1902658 G A 99 46 136 284 123 402 0.97 (0.77, 1.22) 0.78 0.92 (0.65, 1.29) 0.61 
ERCC8 rs3117 T C 126 51 211 257 118 328 1.22 (0.98, 1.51) 0.07 1.37 (0.99, 1.91) 0.06 
CDK7 rs2972388 A G 110 50 156 273 119 383 0.99 (0.79, 1.24) 0.94 0.95 (0.68, 1.33) 0.76 
XPA rs3176757 C T 256 114 353 127 55 186 0.96 (0.77, 1.19) 0.71 0.93 (0.67, 1.29) 0.68 
  rs3176753 T C 381 169 537 1 0 2 0.47 (0.06, 3.70) 0.47 
    rs2808667     C T 345 153 469 36 16 70 0.70 (0.50, 1.00) 0.05 0.74 (0.44, 1.25) 0.26 
  rs2805835 G C 301 133 426 82 36 113 1.00 (0.78, 1.28) 0.97 0.94 (0.65, 1.36) 0.74 
  rs3176689 A T 267 118 355 116 51 184 0.90 (0.72, 1.12) 0.34 0.91 (0.65, 1.26) 0.57 
  rs3176683 T C 342 152 476 41 17 63 0.85 (0.61, 1.18) 0.33 0.8 (0.48, 1.33) 0.40 
  rs3176658      C T 294 137 405 89 32 134 0.93 (0.73, 1.18) 0.55 0.72 (0.49, 1.07) 0.10 
  rs1800975 G A 184 87 236 185 77 280 0.88 (0.71, 1.08) 0.22 0.78 (0.57, 1.07) 0.12 
RAD23B rs1805330 C T 306 136 458 77 33 81 1.33 (1.04, 1.72) 0.03 1.28 (0.87, 1.88) 0.21 
  rs1805329  C T 257 113 333 126 56 206 0.81 (0.65, 1.00) 0.05 0.83 (0.6, 1.14) 0.25 
ERCC6 rs2228529 A G 252 108 345 127 59 186 0.94 (0.76, 1.17) 0.58 1.03 (0.75, 1.42) 0.86 
  rs2228527  A G 251 107 347 132 62 192 0.96 (0.78, 1.19) 0.70 1.06 (0.78, 1.46) 0.70 
  rs4253132 T C 294 132 429 89 37 110 1.08 (0.85, 1.37) 0.55 1.01 (0.69, 1.46) 0.98 
  rs2228528 G A 265 115 372 117 53 167 1.05 (0.84, 1.31) 0.67 1.09 (0.78, 1.51) 0.61 
DDB2 
(XPE) rs2029298 A G 170 68 255 213 101 284 1.05 (0.86, 1.29) 0.63 1.31 (0.96, 1.79) 0.09 
  rs4647709 C T 317 137 449 66 32 90 1.06 (0.81, 1.39) 0.68 1.21 (0.82, 1.79) 0.34 
  rs2291120 T C 283 126 402 100 43 137 1.11 (0.88, 1.39) 0.39 1.06 (0.75, 1.50) 0.73 
  rs1685404  G C 172 71 246 211 98 293 1.08 (0.88, 1.32) 0.48 1.20 (0.88, 1.64) 0.24 
  rs2957873 A G 257 109 386 126 60 153 1.11 (0.90, 1.38) 0.33 1.29 (0.94, 1.78) 0.11 
  rs326224 G A 279 119 404 104 50 135 1.05 (0.84, 1.32) 0.65 1.24 (0.89, 1.73) 0.20 
  rs2306353 G A 281 121 415 102 48 124 1.10 (0.87, 1.38) 0.43 1.25 (0.89, 1.75) 0.20 
  rs326222 C T 190 81 294 193 88 245 1.09 (0.89, 1.34) 0.39 1.21 (0.89, 1.64) 0.22 
  rs901746 A G 190 81 295 193 88 244 1.10 (0.90, 1.34) 0.37 1.22 (0.89, 1.65) 0.21 
ERCC5 
(XPG) rs2296147 T C 130 45 150 250 123 387 0.78 (0.62, 0.97) 0.02 1.11 (0.79, 1.58) 0.54 
  rs4771436  T G 227 99 336 156 70 203 1.09 (0.89, 1.35) 0.39 1.13 (0.83, 1.55) 0.43 
  rs1047768 C T 122 62 197 261 107 342 1.20 (0.97, 1.50) 0.10 0.96 (0.70, 1.32) 0.82 
  rs3818356 C T 227 99 336 155 69 202 1.09 (0.89, 1.34) 0.41 1.12 (0.82, 1.53) 0.46 
  rs4150351 A C 254 114 341 129 55 198 0.84 (0.68, 1.04) 0.12 0.81 (0.59, 1.13) 0.22 
  rs4150355 C T 177 66 225 206 103 314 0.86 (0.70, 1.05) 0.14 1.15 (0.84, 1.57) 0.37 
  rs4150360 T C 106 55 169 277 114 370 1.18 (0.94, 1.48) 0.15 0.93 (0.67, 1.29) 0.67 
  rs4150383 G A 255 112 375 128 57 164 1.11 (0.90, 1.38) 0.34 1.13 (0.82, 1.56) 0.47 
  rs4150386 A C 304 133 420 79 36 119 1.03 (0.80, 1.33) 0.81 1.05 (0.72, 1.53) 0.80 
  rs17655 C G 223 112 332 160 57 207 1.15 (0.94, 1.41) 0.18 0.81 (0.59, 1.11) 0.19 
  rs873601       A G 190 93 274 193 76 265 1.05 (0.86, 1.28) 0.65 0.84 (0.62, 1.14) 0.25 
  rs4150393 A G 296 132 406 87 37 133 0.89 (0.70, 1.13) 0.34 0.88 (0.61, 1.26) 0.48 
  rs876430 C T 191 94 274 192 75 265 1.04 (0.85, 1.27) 0.72 0.82 (0.6, 1.11) 0.19 
  rs1051677 T C 303 129 432 80 40 106 1.06 (0.83, 1.36) 0.63 1.28 (0.89, 1.82) 0.18 
  rs1051685 A G 302 141 434 81 28 104 1.04 (0.81, 1.34) 0.74 0.79 (0.52, 1.19) 0.26 
ERCC4 
(XPF) rs3136038 C T 184 86 218 199 83 321 0.79 (0.65, 0.97) 0.03 0.69 (0.51, 0.93) 0.02 
  rs1799798 G A 320 143 437 63 26 102 0.90 (0.69, 1.19) 0.47 0.83 (0.55, 1.27) 0.40 
HR hazards ratio, CI confidence interval 
a) HR for dominant genetic model (AB + BB vs AA). HRs adjusted for matching factors (age, sex, including pairwise interactions) and ancestry (% 
African ancestry) 
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/84=0.0006) 
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Table 26 cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Survival among Head and 
Neck Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    
Coded Allele Overall Deaths / Deaths from HNC / 
Alive Overall Survival Disease-Specific Survival 
Gene SNP 
Referent (A) 
/ 
Variant (B) AA AB + BB HR (95% CI)
a 
p-
value HR (95% CI)a 
p-
value 
 ERCC4 
(XPF) rs744154 C G 208 96 272 175 73 267 0.88 (0.72, 1.08) 0.21 0.77 (0.57, 1.05) 0.10 
  rs3136085 G C 205 96 270 178 73 269 0.88 (0.72, 1.08) 0.23 0.75 (0.55, 1.02) 0.06 
  rs3136130 G T 184 86 216 199 83 323 0.78 (0.64, 0.96) 0.02 0.68 (0.50, 0.92) 0.01 
  rs1800067 G A 322 144 456 61 25 83 0.99 (0.75, 1.31) 0.96 0.89 (0.58, 1.37) 0.61 
  rs3136172 A G 195 91 263 188 78 276 0.92 (0.75, 1.13) 0.43 0.79 (0.58, 1.08) 0.14 
RAD23A rs2974752 A G 135 58 198 235 106 326 1.04 (0.84, 1.29) 0.72 1.10 (0.80, 1.52) 0.57 
ERCC2 
(XPD) rs13181 T G 154 73 227 224 94 310 1.07 (0.87, 1.31) 0.53 0.94 (0.69, 1.28) 0.69 
  rs238418 C A 156 74 226 227 95 313 1.05 (0.86, 1.29) 0.63 0.92 (0.68, 1.25) 0.59 
  rs1799787 C T 196 87 276 187 82 263 1.02 (0.83, 1.25) 0.85 1.00 (0.74, 1.35) 0.99 
  rs3916874 G C 209 96 268 174 73 271 0.85 (0.69, 1.04) 0.12 0.75 (0.55, 1.02) 0.07 
  rs238416 G A 152 68 217 231 101 321 1.00 (0.81, 1.23) 1.00 0.99 (0.73, 1.35) 0.96 
  rs50872 C T 226 91 305 157 78 232 0.95 (0.77, 1.16) 0.59 1.16 (0.86, 1.58) 0.34 
  rs50871 T G 110 55 132 273 114 407 0.80 (0.64, 1.00) 0.05 0.67 (0.48, 0.92) 0.01 
  rs238407 A T 121 54 142 262 115 396 0.81 (0.65, 1.01) 0.06 0.83 (0.60, 1.15) 0.27 
  rs3810366 C G 79 31 99 304 138 439 0.89 (0.69, 1.15) 0.36 1.09 (0.74, 1.62) 0.66 
ERCC1 rs735482 A C 278 131 410 105 38 129 1.13 (0.90, 1.42) 0.28 0.86 (0.60, 1.23) 0.40 
  rs2336219 G A 278 131 410 105 38 129 1.13 (0.90, 1.42) 0.28 0.86 (0.60, 1.23) 0.40 
  rs3212964 G A 280 132 412 103 37 127 1.13 (0.90, 1.41) 0.31 0.84 (0.58, 1.21) 0.34 
  rs3212955 A G 209 94 319 174 75 220 1.15 (0.94, 1.41) 0.18 1.10 (0.81, 1.50) 0.54 
  rs3212948 C G 154 73 228 229 96 311 1.06 (0.86, 1.30) 0.58 0.93 (0.68, 1.26) 0.64 
  rs3212930 T C 241 108 335 142 61 204 0.95 (0.77, 1.18) 0.66 0.93 (0.68, 1.27) 0.64 
LIG1 rs156641 G A 151 74 219 232 95 320 1.02 (0.83, 1.26) 0.84 0.86 (0.63, 1.17) 0.33 
  rs20580 C A 97 46 140 286 123 399 1.03 (0.82, 1.30) 0.78 0.94 (0.66, 1.32) 0.70 
  rs20579 C T 294 127 397 89 42 142 0.90 (0.71, 1.15) 0.41 1.01 (0.71, 1.44) 0.94 
HR hazards ratio, CI confidence interval 
a) HR for dominant genetic model (AB + BB vs AA). HRs adjusted for matching factors (age, sex, including pairwise interactions) and ancestry (% 
African ancestry) 
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/84=0.0006) 
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Table 27. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Survival among Head and Neck 
Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    
Coded Allele Overall Deaths / Deaths from HNC / 
Alive 
Overall Survival Disease-Specific Survival 
Gene SNP 
Referent (A) 
/ 
Variant (B) AA AB + BB HR (95% CI)
a 
p-
value HR (95% CI)a 
p-
value 
ERCC3 
(XPB) rs4150496 G A 95 30 83 66 28 59 0.98 (0.71, 1.36) 0.93 1.40 (0.82, 2.38) 0.22 
  rs4150459 G A 101 35 89 61 23 54 1.08 (0.78, 1.50) 0.65 1.14 (0.66, 1.98) 0.63 
  rs1011019 C T 94 34 89 68 24 54 1.06 (0.77, 1.47) 0.72 1.08 (0.62, 1.86) 0.78 
  rs4150434 G A 126 46 106 36 12 37 0.84 (0.57, 1.24) 0.38 0.79 (0.41, 1.55) 0.50 
  rs4150416 T G 39 13 46 122 44 97 1.32 (0.91, 1.90) 0.14 1.47 (0.78, 2.80) 0.23 
  rs4150407 A G 43 13 41 119 45 102 1.13 (0.79, 1.62) 0.49 1.35 (0.72, 2.53) 0.35 
  rs4150402 G A 94 34 89 68 24 54 1.06 (0.77, 1.47) 0.72 1.08 (0.62, 1.86) 0.78 
XPC rs2228001 A C 91 32 89 71 26 54 1.18 (0.85, 1.63) 0.32 1.36 (0.79, 2.32) 0.26 
  rs2228000 C T 137 50 114 25 8 29 0.77 (0.49, 1.21) 0.26 0.65 (0.30, 1.42) 0.28 
  rs3731124 A C 136 49 116 26 9 27 0.91 (0.60, 1.40) 0.67 0.75 (0.37, 1.53) 0.43 
  rs3731093 T C 140 54 123 19 3 19 0.86 (0.51, 1.45) 0.57 0.44 (0.14, 1.43) 0.17 
  rs3731089 G A 140 54 123 22 4 20 0.91 (0.56, 1.48) 0.70 0.52 (0.19, 1.47) 0.22 
  rs2733537 A G 115 46 97 47 12 46 0.86 (0.60, 1.23) 0.40 0.59 (0.30, 1.13) 0.11 
  rs2607755 T C 70 27 41 92 31 102 0.62 (0.45, 0.86) 0.004 0.51 (0.30, 0.86) 0.01 
  rs1902658 G A 30 10 23 132 48 120 0.94 (0.62, 1.43) 0.78 0.87 (0.43, 1.76) 0.71 
ERCC8 rs3117 T C 72 21 54 90 37 89 0.81 (0.59, 1.12) 0.20 1.15 (0.66, 1.99) 0.62 
CDK7 rs2972388 A G 77 30 83 85 28 60 1.36 (0.98, 1.87) 0.06 1.04 (0.61, 1.77) 0.88 
CCNH rs2266691 A G 140 52 117 22 6 26 0.83 (0.53, 1.32) 0.44 0.54 (0.23, 1.28) 0.16 
  rs2266692 G T 133 46 104 29 12 39 0.68 (0.45, 1.03) 0.07 0.80 (0.41, 1.53) 0.49 
XPA rs3176757 C T 126 42 110 36 16 33 1.00 (0.68, 1.46) 0.98 1.42 (0.78, 2.59) 0.25 
  rs3176753 T C 123 40 102 39 18 41 0.89 (0.62, 1.29) 0.54 1.17 (0.66, 2.08) 0.58 
  rs3176748 A G 132 53 118 30 5 25 1.03 (0.68, 1.56) 0.88 0.40 (0.16, 1.02) 0.05 
  rs3176658      C T 141 51 119 21 7 24 0.89 (0.55, 1.44) 0.64 0.88 (0.38, 2.00) 0.76 
  rs1800975 G A 100 32 87 55 54 51 1.05 (0.74, 1.47) 0.80 1.44 (0.82, 2.55) 0.21 
RAD23B rs1805330 C T 93 32 90 69 26 53 1.05 (0.76, 1.47) 0.76 1.15 (0.67, 1.99) 0.61 
ERCC6 rs2228529 A G 123 48 111 39 10 30 1.17 (0.81, 1.69) 0.41 0.74 (0.37, 1.49) 0.40 
  rs2228527  A G 115 44 103 47 14 40 1.04 (0.74, 1.48) 0.82 0.81 (0.44, 1.50) 0.51 
  rs4253132 T C 97 35 94 65 23 49 1.13 (0.82, 1.56) 0.46 1.17 (0.69, 1.99) 0.57 
  rs2228528 G A 107 40 105 54 18 38 1.46 (1.04, 2.04) 0.03 1.22 (0.69, 2.14) 0.50 
DDB2 
(XPE) rs2029298 A G 43 16 47 119 42 96 1.23 (0.86, 1.76) 0.26 1.27 (0.71, 2.30) 0.42 
  rs1685404  G C 86 31 78 76 27 65 1.07 (0.77, 1.47) 0.70 0.97 (0.56, 1.66) 0.90 
  rs2957873 A G 49 20 41 112 38 102 0.95 (0.67, 1.35) 0.78 0.79 (0.46, 1.38) 0.41 
  rs326224 G A 43 14 37 119 44 106 1.12 (0.78, 1.60) 0.54 1.21 (0.66, 2.21) 0.55 
  rs2306353 G A 60 21 46 102 37 97 0.88 (0.64, 1.22) 0.45 0.93 (0.54, 1.59) 0.78 
  rs326222 C T 26 12 28 136 46 115 1.17 (0.76, 1.80) 0.47 0.88 (0.46, 1.68) 0.70 
  rs901746 A G 35 15 30 127 43 113 0.96 (0.66, 1.41) 0.85 0.79 (0.43, 1.44) 0.44 
ERCC5 
(XPG) rs2296147 T C 101 32 92 60 25 51 1.07 (0.77, 1.48) 0.70 1.42 (0.84, 2.42) 0.19 
  rs2296148 C T 122 45 106 39 13 37 0.96 (0.66, 1.39) 0.81 0.93 (0.49, 1.75) 0.82 
  rs4771436  T G 110 35 94 52 23 49 0.90 (0.64, 1.26) 0.54 1.24 (0.73, 2.12) 0.43 
  rs1047768 C T 66 21 50 96 37 93 0.87 (0.63, 1.20) 0.39 1.06 (0.61, 1.84) 0.83 
  rs2020915 G A 103 42 102 59 16 41 1.22 (0.88, 1.70) 0.24 0.82 (0.45, 1.49) 0.52 
  rs3818356 C T 110 35 96 52 23 47 0.93 (0.66, 1.31) 0.68 1.27 (0.75, 2.18) 0.37 
  rs4150355 C T 119 39 99 43 19 44 0.92 (0.64, 1.34) 0.68 1.16 (0.65, 2.05) 0.62 
  rs4150360 T C 11 5 8 151 53 135 0.79 (0.42, 1.50) 0.48 0.65 (0.25, 1.70) 0.38 
  rs4150383 G A 131 42 111 31 16 32 0.88 (0.59, 1.31) 0.53 1.34 (0.75, 2.39) 0.33 
  rs17655 C G 44 19 46 118 39 97 1.09 (0.76, 1.56) 0.65 0.84 (0.47, 1.50) 0.56 
  rs873601       A G 14 8 16 148 50 127 1.16 (0.66, 2.02) 0.61 0.76 (0.35, 1.62) 0.47 
  rs876430 C T 15 8 17 147 50 126 1.17 (0.68, 2.00) 0.58 0.84 (0.39, 1.79) 0.65 
  rs1051677 T C 116 43 116 46 15 27 1.31 (0.92, 1.86) 0.14 1.15 (0.63, 2.11) 0.64 
  rs1051685 A G 77 30 61 85 28 82 0.84 (0.62, 1.15) 0.29 0.72 (0.43, 1.20) 0.20 
ERCC4 
(XPF) rs3136038 C T 43 17 49 119 41 94 1.26 (0.88, 1.81) 0.20 1.13 (0.64, 2.01) 0.67 
  rs744154 C G 114 40 107 48 18 36 1.16 (0.82, 1.64) 0.42 1.27 (0.72, 2.26) 0.41 
  rs3136085 G C 92 34 81 70 24 62 1.06 (0.76, 1.46) 0.75 1.01 (0.59, 1.75) 0.96 
  rs3136091 C G 131 45 124 31 13 19 1.27 (0.84, 1.90) 0.25 1.55 (0.82, 2.94) 0.18 
  rs3136130 G T 39 16 36 123 42 107 1.04 (0.72, 1.51) 0.84 0.90 (0.50, 1.63) 0.74 
  rs3136172 A G 112 39 104 50 19 39 1.12 (0.80, 1.59) 0.51 1.24 (0.70, 2.19) 0.46 
  rs2020955  T C 101 37 92 61 21 51 1.11 (0.80, 1.55) 0.53 1.05 (0.60, 1.82) 0.86 
RAD23A rs2974752 A G 39 12 38 116 42 100 1.11 (0.77, 1.62) 0.57 1.29 (0.67, 2.48) 0.45 
  rs11558955 A G 135 47 121 27 11 22 0.99 (0.65, 1.51) 0.97 1.14 (0.58, 2.22) 0.71 
HR hazards ratio, CI confidence interval 
a) HR for dominant genetic model (AB + BB vs AA). HRs adjusted for matching factors (age, sex, including pairwise interactions) and ancestry (% 
African ancestry) 
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006) 
 156 
 
Table 27 cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Survival among Head and 
Neck Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    
Coded Allele Overall Deaths / Deaths from HNC / 
Alive 
Overall Survival Disease-Specific Survival 
Gene SNP 
Referent (A) 
/ 
Variant (B) AA AB + BB HR (95% CI)
a 
p-
value HR (95% CI)a 
p-
value 
ERCC2 
(XPD) rs13181 T G 86 31 87 76 27 55 1.24 (0.90, 1.70) 0.19 1.18 (0.70, 2.00) 0.54 
  rs238418 C A 5 4 3 157 54 139 0.87 (0.34, 2.27) 0.78 0.27 (0.09, 0.82) 0.02 
  rs1799787 C T 120 40 115 42 18 28 1.36 (0.95, 1.95) 0.09 1.65 (0.93, 2.91) 0.09 
  rs3916874 G C 142 53 126 20 5 17 0.94 (0.58, 1.54) 0.82 0.59 (0.23, 1.52) 0.27 
  rs238416 G A 129 44 114 32 14 29 1.04 (0.70, 1.55) 0.83 1.33 (0.72, 2.45) 0.36 
  rs50872 C T 116 42 107 46 16 36 1.08 (0.76, 1.54) 0.66 0.98 (0.54, 1.76) 0.94 
  rs50871 T G 120 36 109 42 22 34 1.07 (0.74, 1.54) 0.73 1.93 (1.11, 3.35) 0.02 
  rs238407 A T 114 39 112 48 19 31 1.22 (0.86, 1.72) 0.27 1.36 (0.77, 2.38) 0.29 
  rs3810366 C G 108 39 104 54 19 39 1.13 (0.81, 1.59) 0.47 1.04 (0.59, 1.83) 0.89 
ERCC1 rs735482 A C 83 31 73 79 27 70 0.94 (0.69, 1.29) 0.72 0.86 (0.51, 1.46) 0.58 
  rs2336219 G A 84 31 73 78 27 70 0.93 (0.67, 1.27) 0.63 0.87 (0.51, 1.47) 0.59 
  rs3212964 G A 111 43 96 49 15 47 0.98 (0.69, 1.38) 0.89 0.76 (0.41, 1.39) 0.37 
  rs3212955 A G 82 31 77 80 27 66 0.92 (0.67, 1.27) 0.62 0.92 (0.54, 1.55) 0.75 
  rs3212948 C G 5 3 4 157 55 139 0.64 (0.24, 1.73) 0.38 0.36 (0.09, 1.37) 0.13 
  rs3212935 A G 81 32 62 81 26 81 0.84 (0.61, 1.16) 0.28 0.65 (0.38, 1.10) 0.11 
  rs3212930 T C 131 44 119 31 14 24 1.09 (0.73, 1.62) 0.68 1.43 (0.77, 2.64) 0.26 
LIG1 rs156641 G A 129 43 105 33 15 38 0.76 (0.51, 1.14) 0.19 1.13 (0.61, 2.09) 0.70 
  rs20580 C A 33 8 29 129 50 113 1.00 (0.68, 1.48) 0.99 1.62 (0.76, 3.45) 0.21 
  rs20579 C T 83 26 67 79 32 76 0.91 (0.66, 1.26) 0.58 1.32 (0.77, 2.25) 0.31 
  rs439132 A G 88 27 84 74 31 59 1.10 (0.79, 1.52) 0.57 1.48 (0.86, 2.55) 0.15 
HR hazards ratio, CI confidence interval 
a) HR for dominant genetic model (AB + BB vs AA). HRs adjusted for matching factors (age, sex, including pairwise interactions) and ancestry (% 
African ancestry) 
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006) 
  
Figure 12. Kaplan-Meier Plots for Overall (OS) and Disease-Specific (DS) Survival by Genotype (solid line=0, dash line=1), CHANCE, Whites. Panel 
A, rs3136038 OS, Log-Rank p-value =0.02. Panel B, rs3136130 OS, Log-Rank p-value=0.01. Panel C, rs50871 OS, Log-Rank p-value=0.15. Panel D, 
rs3136038 DS, Log-Rank p-value=0.02. Panel E, rs3136130, DS, Log-Rank p-value=0.02. Panel F, rs50871 DS, Log-Rank p-value=0.04 
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Figure 13. Kaplan-Meier Plots for Overall (OS) and Disease-Specific (DS) Survival by Genotype (solid 
line=0, dash line=1), CHANCE, African Americans. Panel A, rs2607755 OS, Log-Rank p-value=0.004. 
Panel B, rs2607755 DS, Log-Rank p-value=0.04. 
 
 
(b) Disease-Specific Survival by rs2607755 
  
CHAPTER 5 
SUMMARY AND CONCLUSIONS 
5.1 SUMMARY OF SPECIFIC AIMS 
 Nucleotide excision repair (NER) genes play an essential role in repairing DNA damage.  
Specifically, NER is the primary pathway for removing bulky DNA adducts (~30 damaged nucleotides) 
(123-125). Exogenous causes of bulky DNA adducts include a number of tobacco associated 
carcinogens, such as nitrosamines and benzopyrenes, as well as various cancer treatments, namely, 
radiotherapy and platinum-based chemotherapy (3,4,6,7,48). Researchers have described NER 
genes as a “double-edged sword” or “Janus, the two-faced Roman god” with respect to cancer 
progression (6). Specifically, functional NER genes are thought to protect against cancer incidence by 
repairing detrimental damage caused by carcinogens in cigarette smoke, among other sources (6). In 
contrast, radiation and platinum-based chemotherapy intentionally produce bulky DNA adducts in 
order to initiate cell death (apoptosis) of cancerous cells (6). Therefore, functional NER genes may 
lead to poorer survival by mitigating the effectiveness of cancer treatments (6). To test both aspects 
of this hypothesis with respect to head and neck cancer (HNC), the following research aims were 
explored in this dissertation. First, I assessed the individual and joint effects of polymorphisms in 
NER genes (15 genes, 84 SNPs) and smoking status (ever, frequency, and duration) on HNC risk. 
Second, I assessed the individual and joint effects of the same NER variants (15 genes, 84 SNPs) and 
treatment (combinations of chemotherapy, radiation therapy, and surgery) on risk of mortality 
among HNC cases. 
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5.2 SUMMARY OF RESULTS BY SPECIFIC AIM 
5.2.1 Aim 1 
 Odds ratios for most variants in NER genes and HNC were close to the null value. Using the 
conventional analysis approach, 5 SNPs among whites and 4 SNPs among African Americans were 
associated with HNC at 0.05 alpha level, but none were associated at a Bonferroni corrected alpha 
level. Using hierarchical modelling to shrink estimates on the same gene towards each other, 1 SNP 
among whites and 1 SNP among African Americans remained associated with HNC. Among whites, 
rs4150403 on ERCC3 (XPB) was associated with increased HNC odds. Further, rs4150496 also on 
ERCC3 (XPB) suggestively associated with reduced HNC odds. Among African Americans, rs4253132 
on ERCC6 was associated with decreased HNC odds. Interactions between cigarette smoking and 
rs4253132 on ERCC6, rs2291120 on DDB2, and rs744154 on ERCC4 suggested possible additive 
effects among whites. While interactions were significant at an uncorrected 0.05 alpha level, RERI 
estimates were generally imprecise and none were significant at a Bonferroni corrected alpha level. 
Further, HWE was questionable for rs4253132 of ERCC6 among whites. Compared to the 
conventional method, ORs (95% CIs) and RERI point estimates for joint effects from the hierarchical 
model were similar. 
5.2.2 Aim 2  
Hazard ratios for variants in NER genes and HNC were close to the null value. No SNPs were 
significantly associated with overall or disease-specific survival at a Bonferroni corrected alpha level 
of 0.0006.  However, 3 SNPs among whites and 1 SNP among African Americans were suggestively 
associated with both outcomes at an uncorrected 0.05 alpha level.  Among whites, the variant 
genotypes of rs3136038 and rs3136130, which are in linkage disequilibrium (LD) on ERCC4 (XPF), 
and rs50871 on ERCC2 were modestly associated with better overall and disease-specific survival. 
Among African Americans, rs2607755 on XPC was modestly associated with better survival. Hazard 
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ratios for SNP-survival associations were of largest magnitude among individuals with stage 3 or 4 
tumors. Interactions between rs2972388 of CDK7 and radiation only, as well as radiation and 
chemotherapy, and rs2974752 of RAD23A and radiation and chemotherapy suggested possible 
additive effects among whites. While interactions were significant at a Bonferroni corrected 0.0006 
alpha level, HWE was questionable for both rs2972388 and rs2974752.  
5.3 SUMMARY OF RESULTS ACROSS SPECIFIC AIMS 
5.3.1 Racial Differences 
HNC incidence and patterns of risk factors such as cigarette smoking vary by race in United 
States (56,58). HNC survival also varies by race, with five-year survival rates among African 
Americans half those among whites (61,62). Further, genotype frequencies and linkage 
disequilibrium (LD) structure is known to vary by ancestral populations (129,203). Therefore, 
consideration of race-specific estimates was an important contribution of this dissertation. 
Interesting differences in results by race were noted for both aims. For cigarette smoking-
HNC associations, ORs were elevated among both whites and African Americans. However, the 
magnitude of the ORs among African Americans was noticeably higher than among whites. 
Differences in cigarette smoking-HNC associations by race using CHANCE data have been previously 
identified and published (57). Briefly, elevated HNC ORs among African American cigarette smokers 
were noted even when accounting for frequency and duration of smoking, cigarette product 
preferences (e.g., mentholated vs. non-mentholated), and HNC tumor site (57).  Variation in gene-
environment interactions may contribute to racial differences in cigarette smoking-HNC associations 
(57); though I was not able to explore interactions between cigarette smoking and NER SNPs among 
African Americans in this dissertation. Additional studies on racial differences in gene-environment 
interactions, as well as smoking cessation patterns, are warranted (57). 
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With respect to treatment, no substantial racial differences in HRs for either survival 
outcome were noted, with the exception of radiation only. Specifically, radiation only compared to 
surgery only was significantly associated with worse overall and disease-specific survival among 
whites, but not among African Americans. For models of platinum based-chemotherapy (yes vs. no), 
HRs were similarly reduced among both whites and African Americans. Although African Americans 
have a much higher mortality rate than whites, few studies have examined treatment-survival 
associations by race. In particular, clinical trials tended to not stratify effect estimates by race (209-
211). Observational studies have presented mixed results. A study by Ragin et al. (212) reported 
modestly reduced overall survival among patients receiving radiation and/or chemotherapy and 
surgery with radiation and/or chemo compared to surgery only in the overall study population, 
though HRs were not statistically significant.  Unfortunately, this study did not stratify treatment-
survival HRs by race (212). However, the study did note that the proportions of patients receiving 
surgery only, radiation and/or chemotherapy only, and surgery with chemotherapy and/or radiation 
were similar between whites and African Americans (Χ2 p-value=0.23) (212). A study of HNC using 
SEER data noted no difference in disease-specific survival among white and African Americans when 
models were adjusted for treatment; however, overall survival was modestly improved among 
whites (213). Murdock et al. noted worse survival among African Americans compared to whites 
when adjusting for treatment, though no difference in survival was noted for surgery with/without 
radiation compared to other treatment (214).  
 For both aims, SNP-HNC associations varied by race. For HNC incidence, a SNP on ERCC3 
(XPB) was associated with elevated HNC risk among whites, while a single SNP on ERCC6 was 
associated with reduced HNC risk among African Americans. This finding illustrated how a variant 
genotype of one SNP may be harmful while the variant genotype of another SNP may be beneficial, 
and that the direction of associations can vary by race. Not only were the effects of SNPs on HNC 
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different by race, but the genes implicated have considerably different functions within NER. In 
particular, ERCC6 acts only on transcriptionally active DNA (123,124). Similarly, SNPs which 
appeared to be associated with survival among whites were not associated with survival among 
African Americans and vice-versa.  Specifically, 2 SNPs, which were in LD, on ERCC4 (XPF) and a 
single SNP on ERCC2 were suggestively associated with both overall and disease-specific survival 
among whites. In contrast, a single SNP on XPC was suggestively associated with both survival 
outcomes in African Americans. All three genes act during different phases of NER: XPC recognizes 
and binds to DNA adducts, ERCC2 operates as a component of the TFIIH subunit to denature the 
double helix surrounding the adduct, and ERCC4 creates an incision at the 5’ end of a damage site 
(123,124). Since this was only the second study to consider associations between NER SNPs and HNC 
risk (15), and the first to consider survival, among African Americans, additional studies which 
consider race-specific effects are required. 
5.3.2 “Double-Edged Sword” 
As previously described, NER genes are hypothesized to be a “double-edged sword” or 
“Janus, the two headed Roman god” (6). In this dissertation I did not find conclusive evidence for 
this assertion. First, most SNPs were not associated with HNC incidence or survival. Second, those 
SNPs that were associated with HNC incidence were not associated with HNC survival, or vice-versa. 
Yet, associations were generally in the direction expected based on the outcome.  
For HNC risk, variant genotypes of SNPs were generally hypothesized to be associated 
elevated HNC risk, though some may be associated with reduced HNC risk depending on the SNP.  
Among African Americans a single SNP was also associated with reduced HNC risk. Among whites, 
two SNPs on the same gene were associated with HNC, though one SNP was associated with 
elevated HNC risk and the other suggestively associated with reduced HNC risk demonstrating how 
the direction of associations can vary by SNP, gene, and race. While the function of many SNPs is 
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well understood (e.g., missense or nonsense mutations in the exon which are marked by amino acid 
changes) (215,216), a considerable portion of SNPs, including SNPs in this dissertation, occur in 
noncoding intronic regions. Although intronic SNPs can affect splicing (217), the exact consequence 
of each SNP is not always known. In particular, none of the SNPs associated with HNC outcomes in 
this dissertation have known function. It is also important to note that observed SNP-HNC 
associations may not be necessarily due to the specified SNP, but may rather reflect the effects of 
functional SNPs in LD with the specified SNP (218). As the complex interactions and function of 
genetic variants continue to be unraveled, our understanding of SNP-HNC associations, including 
direction of associations, will improve. 
For HNC survival, it was believed that referent genotypes may mitigate treatment effects 
resulting in worse survival, though again some SNPs may have the opposite effect. Of the three SNPs 
associated with overall and disease-specific survival among whites and the one SNP among African 
Americans, all were associated with reduced HRs indicating improved survival as hypothesized. 
Though again, understanding SNP-survival associations will benefit from mounting functional 
information. 
5.4 STRENGTHS AND LIMITATIONS 
5.4.1 Strengths 
The foremost strengths of this dissertation were the large, racially diverse study population 
and the broad evaluation of SNPs in NER genes. To my knowledge, this dissertation was the largest 
to evaluate both associations between SNPs in NER genes and HNC incidence and survival. Although 
two related studies included larger study populations to explore HNC incidence, these studies 
included a limited number of NER variant and defined the outcome as upper aero-digestive tract 
(UADT) cancers (HNC and esophageal cancers) (11,14). Most previous studies included only a couple 
hundred HNC cases and controls. Further, this dissertation was the first to report both NER SNP-HNC 
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risk and survival associations stratified by race (white and African American).  One previous study 
reported NER SNP-UADT associations among African Americans, but included only 157 African 
Americans (15).  As demonstrated in this dissertation, associations between NER variants and HNC 
incidence and survival vary by race, and were an important contribution to the literature.  
In addition to including more individuals than previous studies, this dissertation also 
examined more SNPs in NER genes than any previous study. Previous studies on HNC incidence have 
collectively examined around 50 SNPs in 10 NER genes (4,5,8-46).  For HNC survival, studies have 
considered even fewer SNPs, approximately 18 SNPs in 6 NER genes (7,47-55). This dissertation 
alone included 84 SNPs across 15 NER genes in whites and 79 SNPs across 14 genes in African 
Americans.   
 Other strengths of this dissertation project include utilization of hierarchical modeling and 
assessment of gene-environment interactions. Although the conventional approach to address 
multiple comparisons is to model one SNP at a time and then adjust the alpha level using the 
Bonferroni method, this approach is overly conservative and can result in false negatives because it 
assumes tests are independent, which is generally not the case with SNPs which may be in LD (164-
166). However, not correcting for multiple comparisons would likely results in false positives 
(160,166). Therefore, hierarchical modeling has been advocated as a method which addresses 
multiple testing of correlated exposures by incorporating a SNP-gene matrix to account for 
clustering of SNP data by gene (164,165,167,168). In this sense, hierarchical modeling allows biology 
to inform the statistical model (164,165,168). Further, previous literature can be used to inform the 
prior value placed on the variance of the error term (164,165,167,168). In this dissertation I used a 
semi-Bayes approach to set this variation (τ2) for SNP-HNC models to be 0.05, which corresponds to 
an expected OR between 0.6 to 1.6 (165). For joint effects of SNPs and cigarette smoking, τ2 was set 
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to 0.35 to allow for ORs between 0.3 and 3.0 (165). To my knowledge, this is the first study to use 
hierarchical modeling to explore associations between NER variants and HNC risk.  
 To consider SNP-cigarette joint effects, several studies have stratified main SNP effects 
models by ever/never or light heavy cigarette smoking (4,9,10,13,15,16,24,26,27,30,31,33,35-
38,40). In this dissertation, though, I formally calculated the RERI to assess interactions between 
SNPs and cigarette smoking. Further, several studies have assessed NER variant and survival 
associations within populations receiving the same treatment (47-51,53-55), but only one study has 
compared effects of a single NER SNP across strata of different treatment regimens (7). In this 
dissertation I considered joint effects of 84 SNPs and 6 treatment regimens. 
5.4.2 Limitations 
While exploration of gene-environment interactions was an asset to this dissertation, it was 
also limited.  Despite the large sample size of CHANCE, RERI estimates were imprecise among 
whites. Among African Americans, small sample sizes were too small to reliably consider joint effects 
(though joint effects among African Americans are presented in the appendix solely as an 
exploratory analysis). HNC tumor site-specific estimates among African Americans were also limited 
by sparse numbers.  
Another key limitation of this dissertation was incomplete capture of variation across some 
genes, especially among African Americans, since tagging SNPs were not selected for all genes and 
SNPs were selected based on the CEU population.  Based on HapMap data (129,143), the proportion 
of variation captured by SNPs in this dissertation ranged from 0% for CDK7 among CEU (Utah 
Residents with Northern and Western European Ancestry) and YRI (Yoruba in Ibadan, Nigeria) 
populations, to 76% and 53% for ERCC1 among the CEU and YRI populations, respectively. 
Therefore, it is possible that some potentially meaningful LD blocks were overlooked. In addition, I 
did not estimate haplotypes.  Further, some SNPs were excluded from analyses because the minor 
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allele frequency was less than 5%, though most of these SNPs were originally selected based on 
previous literature and not tagging. Therefore, the proportion of variation captures was likely not 
further compromised. 
In addition, I did not consider proxy interviews (52 cases and 17 controls) since these 
occurred for individuals who died prior to interview, and therefore did not provide a biologic 
sample. If SNPs were related to aggressive tumors, then estimates for SNP-risk and SNP-survival 
associations may be slightly attenuated to the null (82,153). When SNP-survival associations were 
stratified by stage, associations were strongest among cases with stage 3 and 4 tumors. 
For analyses of HNC survival, there were also limitations with respect to treatment, 
covariate and outcome measurements. While information on whether patients received (yes/no) 
surgery, radiation, and chemotherapy (including chemotherapy drug) was uniformly abstracted from 
patients’ medical records, information on duration of treatment (e.g., start and end dates) and 
timing of treatments combinations (e.g., induction, adjuvant, or concurrent chemotherapy) were 
not complete. For example, nearly a quarter of cases who received chemotherapy were missing end 
dates for that treatment (138). Information on radiation and chemotherapy dose was also not 
available. Since many previous studies focused on a single treatment, including restricting the study 
population to patients with comparable frequencies and durations of treatment (47-55), defining 
treatment based on combinations of dichotomous variables was considered sufficient to explore 
gene-environment interactions. However, frequency and duration of treatment would have allowed 
for assessment of dose-response trends of main effects, as well as more detailed exploration of SNP-
treatment join effects. Finally, treatment history beyond first course treatment was not available. 
Therefore, treatment was considered solely as the first-course combinations of 
dichotomous variables for surgery, radiation, and chemotherapy. However, first course treatment is 
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generally regarded as the best possibility for cure and subsequent treatments are considered less 
effective (65,67,72).  
With respect to covariates, survival models were adjusted for cigarette smoking and alcohol 
drinking information that was ascertained at baseline based on behaviors prior to diagnosis since 
information on behavioral risk factors following diagnosis was not uniformly available.  Further, 
CHANCE does not currently contain information on human papillomavirus (HPV) which is associated 
with improved survival among cases with oropharyngeal tumors (103). However, since HPV is 
unlikely to affect germline SNPs, it would not be considered a confounder of SNP main effects, 
though it may impact SNP-treatment joint effects. When SNP-survival associations were stratified by 
tumor site, estimates for oropharyngeal cancers were generally of the same direction and 
magnitude as overall HNC estimates, though oropharyngeal cancer estimates were imprecise due to 
low cell counts and were not statistically significant. There was not adequate sample size to stratify 
SNP-treatment joint effects by tumor site. Finally, with respect to outcome, CHANCE currently does 
not contain information on tumor recurrent disease so I was unable to consider disease-free or 
relapse-free survival.  
5.5 IMPLICATIONS AND CONCLUSIONS 
5.5.1 SNP Main Effects 
 As previously described, associations between NER genes and HNC incidence and survival 
are biologically plausible (3,6). Previous epidemiologic studies have varied with regard to which 
specific SNPs were investigated and often presented inconsistent evidence for associations between 
the same SNP and HNC incidence (4,5,8-46) and survival (7,47-55). For both HNC incidence and 
survival, SNPs on ERCC2, in particular rs13181, were the most commonly studied NER variants with 
mixed evidence for associations with HNC outcomes (4,5,9,10,16,17,19-21,24,29,30,32-
34,36,37,47,48,50,53,54).  
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 This dissertation evaluated more NER variants than all previous studies combined. While a 
few SNP-HNC associations were identified, results overall were mostly null. Specifically, I identified 1 
SNPs on ERCC3, rs4150403, among whites and 1 SNP on ERCC6, rs4253132, among African 
Americans which were associated with HNC risk. With respect to HNC survival, no SNPs were 
statistically significantly associated at a Bonferroni corrected level. However, rs3136038 and 
rs3136130 which are in LD on ERCC4 (XPF) and rs50871 on ERCC2 among whites and rs2607755 on 
XPC among African Americans were suggestively associated with both overall and disease-specific 
survival at an uncorrected 0.05 alpha level. The remaining 80 or so NER variants included in this 
dissertation did not appear to be associated with HNC outcomes.  
 Since many of the SNPs included in this dissertation had not been previously considered, 
additional studies of NER genes and HNC outcomes are needed to replicate the findings in this 
dissertation. In particular future studies should focus on ERCC3 and ERCC4 variants among whites 
and ERCC6 and XPC variants among African Americans rather than including only a few ERCC2 
variants among mostly European descent population as has been commonly done in the past.  With 
respect to ERCC2, though, future studies should consider rs1799793, as this SNP was associated with 
HNC risk in previous studies but was not included in this dissertation.  
 Further, studies should select SNPs based on tagging methods in CEU and YRI (or ASW 
African ancestry in Southwest USA) population separately (129). While this dissertation included the 
majority of genes in the NER pathway, it did not uniformly include tag SNPs to completely capture 
variation within given genes. Selection of tag SNPs would also allow for informative haplotype 
estimation. Finally, it is important that future studies note null associations. Identifying the lack of 
an association can be just as meaningful as detecting an association. Reporting null associations is 
important for following-up early positive associations, avoiding publication bias, and informing 
future meta-analyses (206). 
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5.5.2 SNP-Cigarette Smoking and SNP-Treatment Joint Effects 
 Cigarette smoking is strongly associated with increased risk of HNC (2), and a growing body 
of evidence suggests that cigarette smoking-HNC associations may be modified by NER genes  (4,8-
10,13,15,16,22,24,26-28,30,31,33,35-38,40,44). Further, cigarette smoking-HNC associations are 
marked by noticeably higher magnitude ORs among African Americans in comparison to whites, and 
racial variation in gene-environment interactions may contribute to such differences (57). However, 
only three suggestive SNP-cigarette interactions (rs4253132-smoking, rs2291120-smoking, and 
rs744154-smoking) were noted among whites in this dissertation. 
With respect to survival, treatment is a strong predictor of outcome following HNC diagnosis 
(65,72).  Historically HNC was treated with surgery and/or radiation therapy (65,72). However, 
following a series of clinical trials in the 1990s demonstrating survival benefits for treatment with 
radiation and chemotherapy following surgery, advanced tumors (stage 3 and 4) are increasingly 
treated with concurrent or induction chemotherapy (72). Both radiation and platinum-based 
chemotherapies irradiate cancerous cells by causing DNA adducts, among other forms of DNA 
damage (6,7,48).  Since NER genes remove such adducts, functional process may actually mitigate 
intended treatment effects (6). Although three SNP-treatment interactions (rs2972388-radiation, 
rs2972388-radiation and chemotherapy, and rs2974752-radiation and chemotherapy) were 
significant at a Bonferroni-corrected alpha level among whites in this dissertation, these interactions 
all involved SNPs with inconsistent HWE evidence.  
While the present study is the largest to date to consider SNP-cigarette smoking and SNP-
treatment joint effects on HNC outcomes, estimates were imprecise among whites and inestimable 
among African Americans. Therefore, studies among even larger, racially diverse populations are 
needed. Given the potential resource burden of individual large studies, larger sample sizes could be 
efficiently achieved through pooling efforts, such as those conducted by the INHANCE consortium.  
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This would require coordination among existing and future studies to not only administer 
questionnaires to ascertain demographic and behavorial information, but to uniformly collect DNA 
samples to ascertain genetic information, medical records to ascertain treatment information, and 
death records to ascertain survival outcomes. Larger studies would also allow for tumor site and 
stage specific estimation of interactions, which I was unable to evaluate in this dissertation. As 
noted, SNP-HNC associations were stronger for some tumor site and stages than others. Therefore, 
joint effects are also likely to vary tumor site and stage. Finally, studies of SNP and treatment effects 
on HNC survival would benefit from more detailed treatment information; namely, dose and 
duration of treatment which I was unable to analyse. 
5.5.3 Other Considerations for Future Studies 
Given the prominent role of NER genes in repairing DNA damage, especially the types of 
damage caused by cigarette smoking and treatment, variants in this pathway were prime suspects 
for associations with HNC. However, other DNA repair pathways are also believed to contribute to 
HNC outcomes. In particular, base excision repair (BER) genes have a similar function to NER genes, 
namely removing DNA adducts (123,124). While NER processes remove bulky adducts, (~30 
damaged nucleotides), BER genes repair smaller adducts (~1-13 damaged nucleotides) (123,124). 
Yet only about a dozen studies have investigated the effects of BER variants on HNC risk (131). 
Associations between XRCC1 variants and HNC risk were consistently noted (131). For HNC survival, 
only half a dozen studies have considered the effects of 3 variants in 2 BER genes and none of these 
studies investigated interactions between BER SNPs and treatment (47,48,53,54,219,220), though a 
separate study on XRCC1 expression did note important interactions with treatment (221). 
Therefore future studies, including the CHANCE study, could investigate associations between BER 
variants, particularly XRCC1, cigarette smoking, treatment, and HNC risk and survival. Other DNA 
repair pathways to be further investigated include homologous recombination and nonhomologous 
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end joining, as well as other specific DNA repair variants such as FGFR4 and CCND1 (131,222). 
Although future studies of other DNA repair variants may yield null results (similar to this 
dissertation), detecting null associations is important for sifting through biologically plausible 
genetic associations, as previously described. 
 The literature on genetics and HNC would further benefit from additional genome-wide 
association studies (GWAS). Previously, McKay et al. (81) conducted a GWAS for upper aerodigestive 
cancers (UADT); though, only 5% of cases included in this particular study had tumors of the 
esophagus. In the first phase of the study, associations between 294,620 SNPs and UADT cancers 
were examined in the Central Europe and ARCAGE study populations (2,230 UADT cases and 4,090 
controls) (81). In the second phase, the top 19 SNPs associated with UADT cancer, as identified in 
phase 1, were then replicated using data from the INHANCE study population (6,514 UADT cases 
and 7,892 controls) (81). Five SNPs were found to be significantly associated with UADT cancers in 
both phases: rs4767364 in ALDH2; rs1494961in HEL208 (related to the ADH genes); and rs1573496, 
rs1229984 and rs698 in ADH7, AHD1B,and ADH1C, respectively (81). All of these genes are known to 
function in alcohol metabolism, none in DNA repair (81).   
 Future GWAS studies should focus on more diverse populations, particularly African 
American populations. The McKay study included only 537 cases and 539 controls who were African 
American, which limited estimation among this population (81). In addition, GWAS studies assessing 
associations between common variants and HNC survival may yield informative results. Finally, it is 
important to keep in mind that even if GWAS or candidate gene studies do not detect a SNP main 
effect, that does not preclude important gene-environment interactions involving that SNP (223). 
Therefore, future GWAS and candidate gene studies should consider gene-environment 
interactions. 
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 Finally, future studies which consider associations between gene and protein expression and 
HNC risk and survival may enhance the literature. Previously, 4 studies have investigated 
associations between expression of 8 NER genes or proteins (ERCC3, XPA, XPC, ERCC6, ERCC5, 
ERCC4, ERCC2, ERCC1) and HNC risk (12,42,43,224).  In addition, 9 studies evaluated associations 
between expression of 2 genes or proteins (ERCC1 and ERCC4) and survival among HNC cases 
(49,52,55,225-230). Single nucleotide polymorphisms are known to impact gene expression (231). 
Therefore, assessing associations between gene and protein expression and HNC risk and outcomes 
will further inform functional and mechanistic understanding of the genetic etiology of this disease 
(231). In addition, studies which utilize DNA and RNA extracted directly from tumor tissues could 
offer additional insights regarding germline and somatic mutations and gene expression with 
respect to HNC, particularly for response to treatment. 
5.5.4 Public Health Implications  
 As described by the US National Institute for Environmental Health Sciences (232): 
 Almost all diseases result from a complex interaction between an individual’s genetic  
 make-up and environmental agents. Subtle differences in genetic factors cause people to 
 respond differently to the same environmental exposure. This explains why some individuals 
 have a fairly low risk of developing a disease as a result of an environmental insult, while 
 others  are much more vulnerable. As scientists learn more about how genetics and 
 environmental  factors work together to cause human diseases, they will be able to develop 
 new strategies for the prevention and treatment of many illnesses (232).  
A review in Nature Genetics by Hunter et al. (233) further discusses the public health significance of 
environmental and genetic research. The authors specifically assert that considering gene-
environment interactions will help identify susceptible individuals, understand disease mechanisms, 
and inform tailored interventions and treatments (233). 
 In the context of this dissertation, strong associations between cigarette smoking and HNC 
risk were already well established in the literature (2). However, few studies had considered racial 
differences in smoking-HNC associations (57). A previous CHANCE study indicated higher magnitude 
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ORs among African Americans compared to whites, and gene-environment interactions were 
hypothesized to play a role (57). Since carcinogens in cigarette smoke can cause DNA adducts and 
NER process remove DNA adducts (3,124), smoking-NER variants interactions are biologically 
plausible factors for racial differences in HNC risk. Further, characterizing gene-environment 
interactions may help further elucidate why some non-smokers develop HNC and some smokers 
never develop HNC (4,234).  
 Beyond specifically assessing interactions between cigarette smoking and NER variants with 
respect to HNC, research regarding gene-environment has value in further clarifying the underlying 
mechanisms of cancer etiology more broadly. Insights into how environmental exposures are 
modified by DNA repair processes may be translated to other public health concerns. For example, 
air pollution is known to contain some carcinogens similar to tobacco smoke, such as polycyclic 
aromatic hydrocarbons (234,235); therefore, research regarding air pollution-cancer associations 
could benefit from epidemiologic investigation of cigarette smoking-NER variants effects with 
respect to cancer outcomes. 
 Finally, with respect to HNC survival, there still remains debate about optimal treatment. 
Although a series of clinical trials indicated survival advantages for the addition of chemotherapy to 
radiation therapy (72), concerns regarding dosing and potential side-effects, especially for less 
aggressive tumors, still remain (236,237). Further, only a few studies have examined treatment-
survival associations among HNC cases by race (212-214). Again given the biologically established 
connection between treatment and the NER pathway (6), assessing treatment-NER variant 
interaction has the potential to inform mechanistic knowledge and help discern any racial 
differences in treatment response. Further research characterizing treatment response based on 
variants in biologically plausible pathways could have promising implications for targeted therapies 
(7,233). 
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5.5.5 Summary 
 In summary, this dissertation evaluated associations between 84 SNPs and HNC risk and 
survival among a large, racially diverse study population. SNP-HNC associations varied by race and 
outcome. The majority of SNPs were not associated with either HNC risk or survival, though two 
SNPs (one among whites and one among African Americans) were associated with HNC risk and four 
SNPs (three among whites and one among African Americans) were suggestively associated with 
HNC survival. A few suggestive SNP-cigarette or SNP-treatment interactions were also noted. Larger, 
perhaps pooled, studies are needed to confirm findings and more precisely estimate joint effects. In 
addition, future studies should include a larger number African Americans to estimate race-specific 
effects. Finally, studies which select SNPs to completely tag variation in genes and facilitate 
haplotype estimation, as well as studies of other DNA repair pathways are warranted. Characterizing 
independent and joint effects of behavorial/environmental and genetic exposures can help identify 
susceptible individuals, unravel disease mechanisms and etiology, and inform preventive and 
therapeutic strategies (233).
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APPENDIX A 
AIM 1 SUPPLEMENTAL TABLES REFERENCED IN CHAPTER 3  
  
Table 1S. Odds Ratios for Environmental Tobacco Smoke and Head and Neck Cancer in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study 
  Never Active Cigarette Smoking Ever Active Cigarette Smoking Whites African Americans 
Environmental 
Tobacco Smoke 
Controls Cases OR (95% I)a Controls Cases OR (95% I)a Controls Cases OR (95% I)a Controls Cases OR (95% I)a 
Never  130 47   83 84   159 89   54 42   
Ever 378 116 0.84 (0.54, 1.33) 733 979 0.92 (0.62, 1.37) 914 832 0.87 (0.63, 1.19) 197 263 0.91 (0.45, 1.82) 
Missing 0 0   1 1   1 1   0 0   
Work                         
Never  215 70   199 246   476 291   116 108   
Ever 293 93 1.02 (0.69, 1.53) 618 816 1.07 (0.82, 1.39) 597 630 1.02 (0.81, 1.30) 135 197 1.11 (0.67, 1.86) 
Missing 0 0   0 2   1 1   0 0   
Home                         
Never  279 89   313 310   317 209   97 107   
Ever 229 74 1.03 (0.67, 1.58) 503 753 1.03 (0.81, 1.30) 757 711 1.09 (0.87, 1.36) 154 198 0.82 (0.49, 1.37) 
Missing 0 0   1 1   0 2   0 0   
Work Duration 
(years)             
    
  
    
  
Never  215 70   199 246   317 209   97 107   
<10 84 27 0.96 (0.55, 1.68) 109 149 1.06 (0.73, 1.55) 155 128 0.94 (0.67, 1.33) 38 48 1.43 (0.67, 3.05) 
10-19 76 24 0.99 (0.54, 1.79) 147 138 0.80 (0.56, 1.15) 184 122 0.82 (0.59, 1.14) 39 40 0.85 (0.40, 1.84) 
20-29 69 21 0.93 (0.50, 1.73) 131 205 1.24 (0.88, 1.76) 164 181 1.19 (0.86, 1.64) 36 45 0.99 (0.48, 2.08) 
30+ 59 20 1.35 (0.69, 2.67) 223 305 1.13 (0.82, 1.55) 245 269 1.11 (0.82, 1.51) 37 56 1.33 (0.64, 2.77) 
Missing 5 1   8 21   9 13   4 9   
Ptrend     0.46     0.52     0.45     0.69 
Home Duration 
(years)             
    
        
Never  279 89   313 310   476 291   116 108   
<10 98 35 1.02 (0.61, 1.71) 224 324 0.94 (0.71, 1.24) 255 271 1.02 (0.78, 1.32) 67 88 0.78 (0.43, 1.42) 
10-19 50 17 1.31 (0.67, 2.57) 99 179 1.13 (0.79, 1.60) 114 140 1.27 (0.90, 1.79) 35 56 0.78 (0.38, 1.60) 
20-29 32 7 0.62 (0.24, 1.62) 74 113 1.01 (0.68, 1.51) 96 94 0.98 (0.67, 1.43) 10 26 1.26 (0.41, 3.88) 
30+ 49 15 1.07 (0.48, 2.39) 104 132 1.14 (0.79, 1.65) 131 121 1.18 (0.84, 1.68) 22 26 0.81 (0.32, 2.06) 
Missing 0 0   3 6   2 5   1 1   
Ptrend     0.87     0.52     0.38     0.87 
OR odds ratio, I interval estimates  
aOdds ratios adjusted for matching factors (age, sex, and race, including pairwise interactions), education, alcohol drinking, and cigarette smoking 
bP-value for linear trend obtained from modeling the continuous forms of the frequency, duration, and cumulative variables  
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Table 2S. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in ERCC3 and Head and 
Neck Cancer Tumor Sites Using Hierarchical Regression for SNPs by Gene, the Carolina 
Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Cases/Controls   
Tumor Site SNP AA AB + BB OR (95% I)a 
Orala rs4150496 228 392 279 682 0.79 (0.60,1.04) 
  rs1011019 240 548 267 526 0.98 (0.73,1.31) 
  rs4150434 308 670 199 404 0.99 (0.77,1.27) 
  rs4150416 210 481 297 593 0.97 (0.73,1.30) 
  rs4150407 175 311 332 763 1.01 (0.76,1.35) 
  rs4150403 394 904 113 170 1.32 (1.01,1.71) 
Pharynxb rs4150496 36 392 49 682 0.98 (0.66,1.46) 
  rs1011019 43 548 42 526 1.04 (0.70,1.53) 
  rs4150434 45 670 40 404 1.22 (0.79,1.87) 
  rs4150416 41 481 44 593 0.94 (0.63,1.38) 
  rs4150407 31 311 54 763 0.91 (0.60,1.36) 
  rs4150403 67 904 18 170 1.18 (0.79,1.78) 
Larynxc rs4150496 137 392 191 682 0.82 (0.61,1.12) 
  rs1011019 177 548 150 526 0.85 (0.62,1.17) 
  rs4150434 193 670 134 404 0.96 (0.73,1.27) 
  rs4150416 159 481 168 593 0.85 (0.62,1.16) 
  rs4150407 112 311 215 763 0.83 (0.60,1.13) 
  rs4150403 272 904 55 170 1.04 (0.77,1.40) 
Orald rs4150496 55 392 74 682 0.87 (0.61,1.25) 
  rs1011019 59 548 70 526 1.03 (0.72,1.47) 
  rs4150434 85 670 44 404 0.92 (0.63,1.34) 
  rs4150416 50 481 79 593 1.07 (0.75,1.54) 
  rs4150407 42 311 87 763 0.98 (0.67,1.42) 
  rs4150403 99 904 30 170 1.20 (0.84,1.72) 
Oropharynx3 rs4150496 123 392 137 682 0.77 (0.56,1.06) 
  rs1011019 125 548 134 526 0.98 (0.71,1.36) 
  rs4150434 149 670 110 404 1.09 (0.80,1.49) 
  rs4150416 110 481 149 593 0.97 (0.70,1.35) 
  rs4150407 92 311 167 763 1.01 (0.73,1.41) 
  rs4150403 204 904 55 170 1.19 (0.87,1.62) 
NOSf rs4150496 72 392 98 682 0.95 (0.67,1.34) 
  rs1011019 82 548 88 526 1.04 (0.73,1.47) 
  rs4150434 99 670 71 404 1.09 (0.77,1.54) 
  rs4150416 76 481 94 593 0.93 (0.66,1.31) 
  rs4150407 60 311 110 763 0.92 (0.65,1.31) 
  rs4150403 131 904 39 170 1.30 (0.92,1.83) 
OR odds ratio, I interval estimate 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions) 
and percent African ancestry 
aIncludes tumors with the following ICD codes:C01.9, C02.2, C02.4, C02.9, C03.0, C03.1, 
C03.9, C04.0, C04.9, C05.0, C05.1, C05.2, C05.3, C05.9, C06.0, C06.1, C06.2, C06.9, C09.0, 
C09.1, C09.9 
bIncludes tumors with the following ICD codes:C10.0, C10.9, C12.9, C13.0, C13.1, C13.9, 
C14.0 
cIncludes tumors with the following ICD codes: C32.0, C32.1, C32.2, C32,3, C32.9 
 dIncludes tumors with the following ICD codes: C02.2, C0.3.0, C03.1, C03.9, C04.0, C0.4.9,  
C05.0, C06.0, C06.1, C06.2, C06.9 
 eIncludes tumors with the following ICD codes: C01.9, C02.4, C05.1, C05.2, C09.0, C09.1, 
C09.9, C10.0, C10.9 
fIncludes tumors with the following ICD codes: C02.9, C05.9, C14.0 
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Table 3S. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in ERCC6 Genes and 
Laryngeal Cancer Using Hierarchical Regression for SNPs by Gene, the Carolina Head and 
Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Cases/Controls   
Tumor Site SNP AA AB + BB OR (95% I)a 
Larynxb rs2228529 87 189 26 60 0.84 (0.56,1.27) 
  rs2228527  81 175 33 76 0.88 (0.59,1.30) 
  rs4253132 73 125 41 126 0.65 (0.44,0.97) 
  rs2228528 79 182 34 69 0.91 (0.60,1.38) 
OR odds ratio, I interval estimates         
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions) 
and percent African ancestry 
bIncludes tumors with the following ICD codes: C32.0, C32.1, C32.2, C32,3, C32.9 
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Table 4S. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Head and Neck 
Cancer Using Conventional Logistic Regression for Individual SNPs, the Carolina Head and Neck Cancer Epidemiology (CHANCE) 
Study, Whites 
    Coded Allele Cases/Controls AB + BB vs AA 
Gene SNP 
Referent 
(A)  
Variant 
(B)  AA AB + BB OR (95% I)a p-valueb 
ERCC3 (XPB) rs4150496 G A 401 392 520 682 0.75 (0.63, 0.90) 0.002 
  rs1011019 C T 462 548 460 526 1.02 (0.85, 1.22) 0.81 
  rs4150434 G A 548 670 374 404 1.13 (0.94, 1.35) 0.21 
  rs4150416 T G 410 481 509 593 1.00 (0.83, 1.20) 0.99 
  rs4150407 A G 318 311 604 763 0.78 (0.64, 0.95) 0.01 
  rs4150403 G A 736 904 186 170 1.34 (1.06, 1.70) 0.01 
  rs4150402 G A 462 548 460 525 1.03 (0.86, 1.23) 0.78 
XPC rs2228001 A C 337 375 584 699 0.92 (0.77, 1.11) 0.40 
  rs3731143 T C 818 957 104 117 1.06 (0.80, 1.41) 0.70 
  rs2228000 C T 524 598 396 475 0.96 (0.80, 1.15) 0.64 
  rs3731124 A C 521 599 401 475 0.97 (0.81, 1.17) 0.78 
  rs13099160 A G 814 962 108 112 1.09 (0.82, 1.45) 0.56 
  rs3731093 T C 776 919 138 146 1.09 (0.84, 1.41) 0.52 
  rs3731089 G A 778 919 144 155 1.08 (0.84, 1.38) 0.56 
  rs2733537 A G 416 480 506 594 0.98 (0.82, 1.17) 0.82 
  rs3731068 C A 624 732 298 342 1.03 (0.85, 1.25) 0.77 
  rs2607755 T C 242 284 680 790 1.01 (0.82, 1.23) 0.95 
  rs1902658 G A 235 280 686 794 0.86 (0.70, 1.07) 0.17 
ERCC8 rs3117 T C 337 397 585 677 1.02 (0.84, 1.22) 0.87 
CDK7 rs2972388 A G 266 335 656 739 1.12 (0.92, 1.36) 0.25 
XPA rs3176757 C T 609 710 313 364 1.01 (0.83, 1.22) 0.95 
  rs3176748 A G 440 510 482 564 0.96 (0.80, 1.15) 0.66 
  rs2808667 C T 814 950 106 124 1.05 (0.79, 1.39) 0.73 
  rs2805835 G C 727 848 195 226 1.02 (0.82, 1.28) 0.84 
  rs3176689 A T 622 728 300 346 0.98 (0.81, 1.18) 0.80 
  rs3176683 T C 818 944 104 130 0.92 (0.70, 1.22) 0.57 
  rs3176658      C T 699 792 223 282 0.93 (0.76, 1.14) 0.49 
  rs1800975 G A 420 473 465 563 0.96 (0.80, 1.15) 0.64 
RAD23B rs1805330 C T 764 870 158 204 0.90 (0.71, 1.14) 0.39 
  rs1805329  C T 590 711 332 363 1.13 (0.93, 1.36) 0.21 
ERCC6 rs2228529 A G 597 661 313 396 0.88 (0.73, 1.06) 0.19 
  rs2228527  A G 598 665 324 409 0.89 (0.74, 1.07) 0.21 
  rs4253132 T C 723 829 199 245 0.95 (0.77, 1.18) 0.66 
  rs2228528 G A 637 746 284 328 1.01 (0.83, 1.22) 0.93 
DDB2 (XPE) rs2029298 A G 425 478 497 596 0.95 (0.80, 1.14) 0.62 
  rs4647709 C T 766 902 156 172 1.06 (0.83, 1.35) 0.62 
  rs2291120 T C 685 812 237 262 1.02 (0.83, 1.25) 0.87 
  rs1685404  G C 418 502 504 572 1.04 (0.87, 1.25) 0.65 
  rs2957873 A G 643 711 279 363 0.87 (0.72, 1.05) 0.15 
  rs326224 G A 683 761 239 313 0.88 (0.72, 1.08) 0.22 
  rs2306353 G A 696 762 226 312 0.82 (0.67, 1.00) 0.05 
  rs326222 C T 484 526 438 548 0.89 (0.74, 1.06) 0.20 
  rs901746 A G 485 528 437 546 0.89 (0.75, 1.07) 0.21 
ERCC5 (XPG) rs2296147 T C 280 303 637 765 0.90 (0.74, 1.09) 0.29 
  rs4771436  T G 563 659 359 415 1.03 (0.85, 1.23) 0.79 
  rs1047768 C T 319 377 603 696 1.03 (0.86, 1.25) 0.73 
  rs3818356 C T 563 659 357 413 1.03 (0.85, 1.23) 0.79 
  rs4150351 A C 595 692 327 382 0.99 (0.82, 1.20) 0.95 
  rs4150355 C T 402 428 520 646 0.85 (0.71, 1.02) 0.07 
  rs4150360 T C 275 316 647 758 0.79 (0.63, 1.00) 0.05 
  rs4150383 G A 630 749 292 325 1.08 (0.89, 1.31) 0.46 
  rs4150386 A C 724 836 198 237 0.96 (0.77, 1.19) 0.69 
  rs17655 C G 555 658 367 416 1.05 (0.88, 1.26) 0.59 
  rs873601       A G 464 539 458 535 1.00 (0.83, 1.19) 0.97 
  rs4150393 A G 702 844 220 230 1.15 (0.93, 1.42) 0.21 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions) and percent African ancestry 
bSignificant associations using the dominant genetic model (p<0.05) highlighted in gray. No associations significant at a Bonferroni 
corrected level (p<0.0006) 
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Table 4S cont. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Head and 
Neck Cancer Using Conventional Logistic Regression for Individual SNPs, the Carolina Head and Neck Cancer Epidemiology 
(CHANCE) Study, Whites 
    Coded Allele Cases/Controls AB + BB vs AA 
Gene SNP 
Referent 
(A)  
Variant 
(B)  AA AB + BB OR (95% I)a p-valueb 
 ERCC5 (XPG) rs876430 C T 465 540 457 534 1.00 (0.83, 1.19) 0.97 
  rs1051677 T C 735 858 186 216 1.00 (0.80, 1.25) 0.97 
  rs1051685 A G 736 832 185 242 0.90 (0.72, 1.12) 0.34 
ERCC4 (XPF) rs3136038 C T 402 490 520 584 1.07 (0.89, 1.28) 0.49 
  rs1799798 G A 757 901 165 173 1.15 (0.90, 1.46) 0.26 
  rs744154 C G 480 582 442 492 1.08 (0.90, 1.29) 0.41 
  rs3136085 G C 475 576 447 498 1.08 (0.90, 1.29) 0.41 
  rs3136130 G T 400 485 522 589 1.06 (0.88, 1.27) 0.54 
  rs1800067 G A 778 920 144 154 1.10 (0.86, 1.42) 0.44 
  rs3136172 A G 458 566 464 508 1.12 (0.93, 1.34) 0.23 
RAD23A rs2974752 A G 333 424 561 617 1.16 (0.96, 1.40) 0.11 
ERCC2 (XPD) rs13181 T G 381 437 534 633 0.95 (0.79, 1.14) 0.58 
  rs238418 C A 382 426 540 648 0.92 (0.77, 1.11) 0.38 
  rs1799787 C T 472 545 450 529 0.97 (0.81, 1.16) 0.75 
  rs3916874 G C 477 545 445 529 0.95 (0.80, 1.14) 0.60 
  rs238416 G A 369 468 552 604 1.17 (0.97, 1.40) 0.10 
  rs50872 C T 531 584 389 488 0.89 (0.74, 1.07) 0.20 
  rs50871 T G 242 258 680 815 0.89 (0.73, 1.10) 0.28 
  rs238407 A T 263 338 658 736 1.16 (0.95, 1.41) 0.14 
  rs3810366 C G 178 232 743 548 1.18 (0.94, 1.47) 0.15 
ERCC1 rs735482 A C 688 797 234 277 0.98 (0.80, 1.21) 0.86 
  rs2336219 G A 688 797 234 277 0.98 (0.80, 1.21) 0.86 
  rs3212964 G A 692 794 230 280 0.94 (0.77, 1.16) 0.57 
  rs3212955 A G 528 607 394 466 0.99 (0.82, 1.18) 0.90 
  rs3212948 C G 382 458 540 616 1.07 (0.89, 1.28) 0.49 
  rs3212930 T C 576 657 346 417 0.96 (0.80, 1.15) 0.63 
LIG1 rs156641 G A 370 440 552 634 1.01 (0.84, 1.22) 0.88 
  rs20580 C A 237 293 685 781 1.05 (0.86, 1.29) 0.63 
  rs20579 C T 691 826 231 248 1.09 (0.89, 1.35) 0.40 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions) and percent African ancestry 
bSignificant associations using the dominant genetic model (p<0.05) highlighted in gray. No associations significant at a Bonferroni 
corrected level (p<0.0006) 
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Table 5S. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Head and 
Neck Cancer Using Conventional Logistic Regression for Individual SNPs, the Carolina Head and Neck Cancer Epidemiology 
(CHANCE) Study, African Americans 
    Coded Allele Cases/Controls AB + BB vs AA 
Gene SNP 
Referent 
(A)  
Variant 
(B)  AA AB + BB OR (95% I)a p-valueb 
ERCC3 
(XPB) rs4150496 G A 178 136 125 115 0.80 (0.56, 1.14) 0.21 
  rs4150459 G A 190 164 115 87 1.23 (0.85, 1.78) 0.26 
  rs1011019 C T 183 143 122 108 0.84 (0.59, 1.19) 0.33 
  rs4150434 G A 232 186 73 65 1.00 (0.66, 1.50) 0.99 
  rs4150416 T G 85 76 219 175 1.13 (0.77, 1.65) 0.54 
  rs4150407 A G 84 68 221 183 0.97 (0.66, 1.43) 0.87 
  rs4150402 G A 183 143 122 108 0.84 (0.59, 1.19) 0.33 
XPC rs2228001 A C 180 134 125 117 0.82 (0.57, 1.16) 0.26 
  rs2228000 C T 251 205 54 46 0.98 (0.62, 1.55) 0.95 
  rs3731124 A C 252 212 53 39 1.06 (0.66, 1.70) 0.80 
  rs3731093 T C 263 208 38 41 0.75 (0.46, 1.24) 0.27 
  rs3731089 G A 263 208 42 43 0.79 (0.49, 1.28) 0.34 
  rs2733537 A G 212 164 93 87 0.85 (0.59, 1.24) 0.40 
  rs2607755 T C 111 109 194 142 1.35 (0.94, 1.93) 0.10 
  rs1902658 G A 300 51 5 200 0.69 (0.46, 1.03) 0.07 
ERCC8 rs3117 T C 126 94 179 157 0.82 (0.57, 1.17) 0.27 
CDK7 rs2972388 A G 160 132 145 119 1.05 (0.74, 1.49) 0.78 
CCNH rs2266691 A G 257 221 48 30 1.39 (0.84, 2.30) 0.20 
  rs2266692 G T 237 202 68 48 1.18 (0.77, 1.82) 0.45 
XPA rs3176757 C T 236 193 69 58 0.94 (0.62, 1.42) 0.77 
  rs3176753 T C 225 184 80 67 0.97 (0.65, 1.43) 0.87 
  rs3176748 A G 250 208 55 43 1.06 (0.66, 1.68) 0.82 
  rs3176658      C T 260 210 45 41 0.97 (0.60, 1.57) 0.92 
  rs1800975 G A 187 141 106 93 0.87 (0.60, 1.26) 0.47 
RAD23B rs1805330 C T 183 160 122 91 1.16 (0.81, 1.66) 0.43 
ERCC6 rs2228529 A G 234 189 69 60 0.93 (0.62, 1.40) 0.72 
  rs2228527  A G 218 175 87 76 0.91 (0.62, 1.33) 0.63 
  rs4253132 T C 191 125 114 126 0.55 (0.38, 0.79) 0.001 
  rs2228528 G A 212 182 92 69 1.19 (0.80, 1.75) 0.39 
DDB2 
(XPE) rs2029298 A G 90 88 215 163 1.26 (0.87, 1.82) 0.22 
  rs1685404  G C 164 140 141 111 1.12 (0.79, 1.60) 0.52 
  rs2957873 A G 90 82 214 169 1.11 (0.76, 1.61) 0.59 
  rs326224 G A 80 63 225 188 0.89 (0.60, 1.33) 0.58 
  rs2306353 G A 106 97 199 154 1.14 (0.80, 1.64) 0.47 
  rs326222 C T 54 50 251 201 1.15 (0.74, 1.80) 0.53 
  rs901746 A G 65 58 240 193 1.03 (0.67, 1.56) 0.90 
ERCC5 
(XPG) rs2296147 T C 193 148 111 102 0.86 (0.60, 1.24) 0.43 
  rs2296148 C T 228 190 76 61 1.07 (0.71, 1.60) 0.76 
  rs4771436  T G 204 172 101 79 1.03 (0.71, 1.49) 0.87 
  rs1047768 C T 116 115 189 136 1.27 (0.89, 1.80) 0.18 
  rs2020915 G A 205 144 100 107 0.70 (0.49, 1.00) 0.05 
  rs3818356 C T 206 172 99 79 1.00 (0.69, 1.45) 0.99 
  rs4150355 C T 218 175 87 76 0.98 (0.67, 1.45) 0.93 
  rs4150360 T C 19 17 286 232 0.95 (0.67, 1.36) 0.80 
  rs4150383 G A 242 200 63 51 0.98 (0.64, 1.51) 0.93 
  rs17655 C G 90 70 215 181 0.96 (0.65, 1.41) 0.82 
  rs873601       A G 30 30 275 221 1.29 (0.74, 2.27) 0.37 
  rs876430 C T 32 30 273 221 1.22 (0.70, 2.11) 0.49 
  rs1051677 T C 232 184 73 67 0.85 (0.57, 1.27) 0.44 
  rs1051685 A G 138 117 167 133 0.98 (0.69, 1.39) 0.89 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions) and percent African ancestry 
bSignificant associations using the dominant genetic model (p<0.05) highlighted in gray. No associations significant at a 
Bonferroni corrected level (p<0.0006) 
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Table 5S cont. Odds Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Head 
and Neck Cancer Using Conventional Logistic Regression for Individual SNPs, the Carolina Head and Neck Cancer Epidemiology 
(CHANCE) Study, African Americans 
    Coded Allele Cases/Controls AB + BB vs AA 
Gene SNP 
Referent 
(A)  
Variant 
(B)  AA AB + BB OR (95% I)a p-valueb 
ERCC4 
(XPF) rs3136038 C T 92 84 213 167 1.14 (0.79, 1.66) 0.48 
  rs744154 C G 221 174 84 77 0.91 (0.62, 1.34) 0.63 
  rs3136085 G C 173 146 132 105 1.16 (0.81, 1.65) 0.41 
  rs3136091 C G 255 199 50 52 0.73 (0.47, 1.14) 0.17 
  rs3136130 G T 75 65 230 186 1.11 (0.74, 1.65) 0.61 
  rs3136172 A G 216 171 89 80 0.94 (0.64, 1.37) 0.74 
  rs2020955  T C 193 165 112 86 1.10 (0.76, 1.58) 0.62 
RAD23A rs2974752 A G 77 62 216 170 1.06 (0.71, 1.59) 0.77 
  rs11558955 A G 256 214 49 37 1.18 (0.73, 1.92) 0.50 
ERCC2 
(XPD) rs13181 T G 173 140 131 109 0.95 (0.67, 1.35) 0.77 
  rs238418 C A 8 11 296 240 1.57 (0.59, 4.21) 0.37 
  rs1799787 C T 235 192 70 59 0.95 (0.63, 1.44) 0.82 
  rs3916874 G C 268 226 37 25 1.15 (0.65, 2.04) 0.62 
  rs238416 G A 243 208 61 41 1.34 (0.85, 2.13) 0.21 
  rs50872 C T 223 158 82 93 0.64 (0.44, 0.92) 0.02 
  rs50871 T G 229 195 76 56 1.20 (0.79, 1.84) 0.40 
  rs238407 A T 226 190 79 61 1.07 (0.71, 1.62) 0.73 
  rs3810366 C G 212 180 93 71 1.11 (0.75, 1.64) 0.59 
ERCC1 rs735482 A C 156 122 149 129 0.87 (0.62, 1.23) 0.44 
  rs2336219 G A 157 126 148 125 0.92 (0.65, 1.30) 0.64 
  rs3212964 G A 207 142 96 107 0.65 (0.45, 0.93) 0.02 
  rs3212955 A G 159 142 146 109 1.21 (0.85, 1.72) 0.30 
  rs3212948 C G 9 6 296 245 0.82 (0.26, 2.54) 0.73 
  rs3212935 A G 143 125 162 125 1.19 (0.84, 1.69) 0.34 
  rs3212930 T C 250 205 55 46 1.00 (0.64, 1.57) 1.00 
LIG1 rs156641 G A 234 192 71 59 1.07 (0.70, 1.64) 0.74 
  rs20580 C A 62 57 242 194 1.21 (0.79, 1.84) 0.38 
  rs20579 C T 150 128 155 123 1.03 (0.73, 1.46) 0.87 
  rs439132 A G 172 136 133 115 0.87 (0.61, 1.24) 0.43 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions) and percent African ancestry 
bSignificant associations using the dominant genetic model (p<0.05) highlighted in gray. No associations significant at a 
Bonferroni corrected level (p<0.0006) 
 
  
 
Table 6S. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Ever Environmental Tobacco 
Smoke on Head and Neck Cancer Risk Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Cases/Controls OR (95% I)d 
Gene SNP 
Referent (A)  / 
Variant (B)  
ETS=0, 
SNP=0 
ETS=0, 
SNP=1 
ETS=1, 
SNP=0 
ETS=1, 
SNP=1 ETS=1, SNP=0  ETS=0, SNP=1  ETS=1, SNP=1 RERI (95% CI) 
ERCC3 
(XPB) rs4150496 G A 46 58 43 101 355 334 476 580 0.65 (0.41, 1.04) 0.47 (0.26, 0.84) 0.51 (0.32, 0.80) 0.38 (0.03, 0.73) 
  rs1011019 C T 45 82 44 77 416 466 416 448 0.98 (0.63, 1.53) 1.40 (0.79, 2.49) 1.05 (0.67, 1.63) -0.34 (-1.15, 0.48) 
  rs4150434 G A 44 106 45 53 504 563 328 351 1.23 (0.80, 1.88) 2.20 (1.22, 3.95) 1.14 (0.74, 1.76) -1.29 (-2.63, 0.05) 
  rs4150416 T G 40 73 49 86 369 408 460 506 0.97 (0.61, 1.56) 1.32 (0.74, 2.36) 1.01 (0.63, 1.60) -0.29 (-1.07, 0.50) 
  rs4150407 A G 35 52 54 107 283 259 549 655 0.70 (0.42, 1.18) 0.57 (0.32, 1.04) 0.57 (0.35, 0.93) 0.29 (-0.13, 0.71) 
  rs4150403 G A 70 136 19 23 665 767 167 147 0.92 (0.64, 1.31) 1.89 (0.91, 3.95) 1.18 (0.77, 1.79) -0.63 (-2.03, 0.77) 
  rs4150402 G A 45 82 44 76 416 466 416 448 0.98 (0.63, 1.53) 1.43 (0.80, 2.54) 1.05 (0.67, 1.63) -0.37 (-1.20, 0.47) 
XPC rs2228001 A C 28 57 61 102 309 317 522 597 1.11 (0.64, 1.91) 1.28 (0.69, 2.36) 0.96 (0.56, 1.63) -0.43 (-1.31, 0.45) 
  rs3731143 T C 80 145 9 14 737 812 95 102 0.87 (0.62, 1.21) 1.29 (0.50, 3.34) 1.00 (0.63, 1.57) -0.16 (-1.42, 1.10) 
  rs2228000 C T 57 93 32 66 466 505 364 408 0.85 (0.56, 1.27) 0.92 (0.51, 1.65) 0.81 (0.53, 1.23) 0.05 (-0.53, 0.62) 
  rs3731124 A C 56 80 33 79 465 519 367 395 0.71 (0.47, 1.07) 0.65 (0.36, 1.17) 0.73 (0.48, 1.11) 0.37 (-0.04, 0.78) 
  rs13099160 A G 77 140 12 19 736 821 96 93 0.83 (0.59, 1.18) 0.95 (0.41, 2.23) 1.03 (0.65, 1.63) 0.24 (-0.63, 1.10) 
  rs3731093 T C 71 136 18 22 704 782 120 124 0.88 (0.62, 1.26) 1.45 (0.69, 3.06) 1.03 (0.66, 1.61) -0.30 (-1.41, 0.81) 
  rs3731089 G A 71 136 18 23 706 782 126 132 0.89 (0.63, 1.27) 1.43 (0.68, 2.99) 1.04 (0.67, 1.60) -0.28 (-1.36, 0.80) 
  rs2733537 A G 41 76 48 83 374 404 458 510 0.95 (0.59, 1.51) 1.20 (0.68, 2.14) 0.95 (0.60, 1.52) -0.20 (-0.92, 0.53) 
  rs3731068 C A 70 96 19 63 553 636 279 278 0.64 (0.44, 0.94) 0.43 (0.22, 0.83) 0.73 (0.49, 1.09) 0.66 (0.34, 0.97)* 
  rs2607755 T C 29 35 60 124 213 249 619 665 0.61 (0.34, 1.11) 0.68 (0.36, 1.30) 0.66 (0.37, 1.18) 0.37 (-0.07, 0.82) 
  rs1902658 G A 28 33 61 126 207 247 624 667 0.58 (0.31, 1.07) 0.66 (0.34, 1.28) 0.65 (0.36, 1.18) 0.41 (-0.02, 0.84) 
ERCC8 rs3117 T C 39 58 50 101 297 338 535 576 0.77 (0.47, 1.26) 0.83 (0.46, 1.48) 0.76 (0.47, 1.23) 0.17 (-0.35, 0.68) 
CDK7 rs2972388 A G 23 46 66 113 243 289 589 625 0.94 (0.51, 1.74) 1.28 (0.66, 2.48) 1.07 (0.59, 1.95) -0.15 (-0.97, 0.67) 
XPA rs3176757 C T 58 99 31 60 550 610 282 304 0.84 (0.57, 1.25) 0.98 (0.54, 1.77) 0.87 (0.57, 1.32) 0.05 (-0.56, 0.66) 
  rs3176748 A G 41 84 48 75 398 425 434 489 0.94 (0.60, 1.48) 1.13 (0.64, 2.02) 0.90 (0.57, 1.41) -0.18 (-0.87, 0.52) 
  rs2808667     C T 81 136 8 23 732 813 98 101 0.78 (0.56, 1.10) 0.62 (0.24, 1.61) 1.03 (0.65, 1.62) 0.62 (-0.05, 1.29) 
  rs2805835 G C 68 126 21 33 659 722 173 192 0.92 (0.64, 1.32) 1.31 (0.66, 2.60) 0.90 (0.59, 1.36) -0.34 (-1.27, 0.59) 
  rs3176689 A T 59 109 30 50 562 618 270 296 0.96 (0.65, 1.42) 1.33 (0.72, 2.46) 0.90 (0.60, 1.36) -0.39 (-1.25, 0.46) 
  rs3176683 T C 78 136 11 23 739 807 93 107 0.86 (0.61, 1.22) 1.00 (0.43, 2.30) 0.82 (0.52, 1.30) -0.04 (-0.92, 0.84) 
  rs3176658      C T 69 113 20 46 630 678 202 236 0.81 (0.56, 1.17) 0.78 (0.40, 1.51) 0.79 (0.52, 1.18) 0.20 (-0.36, 0.75) 
  rs1800975 G A 43 67 42 86 377 405 422 477 0.82 (0.51, 1.30) 0.88 (0.49, 1.60) 0.79 (0.50, 1.26) 0.09 (-0.47, 0.65) 
RAD23B rs1805330 C T 69 128 20 31 694 741 138 173 0.90 (0.63, 1.30) 1.09 (0.54, 2.18) 0.76 (0.49, 1.16) -0.24 (-1.05, 0.58) 
  rs1805329  C T 65 108 24 51 524 602 308 312 0.78 (0.54, 1.14) 0.82 (0.42, 1.57) 0.87 (0.59, 1.29) 0.27 (-0.28, 0.83) 
ERCC6 rs2228529 A G 54 98 34 61 542 563 279 334 0.96 (0.64, 1.44) 1.19 (0.66, 2.15) 0.86 (0.56, 1.32) -0.28 (-1.04, 0.47) 
  rs2228527  A G 54 98 35 61 543 567 289 347 0.96 (0.64, 1.44) 1.19 (0.66, 2.15) 0.86 (0.56, 1.31) -0.29 (-1.05, 0.47) 
  rs4253132 T C 77 117 12 42 645 711 187 203 0.76 (0.53, 1.08) 0.50 (0.24, 1.08) 0.74 (0.49, 1.11) 0.48 (0.05, 0.91) 
  rs2228528 G A 69 126 20 33 567 620 264 294 0.91 (0.63, 1.31) 1.25 (0.63, 2.51) 0.88 (0.60, 1.30) -0.28 (-1.18, 0.62) 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, cigarette smoking, and percent African ancestry. 124 individuals missing 
alcohol drinking or cigarette smoking, and therefore dropped from models. 
Interval estimates presented not corrected for multiple comparisons. 
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 6S cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Ever Environmental 
Tobacco Smoke on Head and Neck Cancer Risk Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Cases/Controls OR (95% I)d 
Gene SNP 
Referent (A)  / 
Variant (B)  
ETS=0, 
SNP=0 
ETS=0, 
SNP=1 
ETS=1, 
SNP=0 
ETS=1, 
SNP=1 ETS=1, SNP=0  ETS=0, SNP=1  ETS=1, SNP=1 RERI (95% CI) 
DDB2 
(XPE) rs2029298 A G 44 71 45 88 381 407 451 507 0.92 (0.59, 1.45) 1.03 (0.58, 1.84) 0.83 (0.53, 1.31) -0.12 (-0.77, 0.53) 
  rs4647709 C T 73 135 16 24 693 767 139 147 0.86 (0.60, 1.22) 1.10 (0.51, 2.36) 0.95 (0.62, 1.44) -0.01 (-0.88, 0.86) 
 rs2291120 T C 73 110 16 49 611 701 221 213 0.73 (0.50, 1.05) 0.53 (0.27, 1.08) 0.78 (0.52, 1.17) 0.52 (0.10, 0.93) 
  rs1685404  G C 39 76 50 83 378 425 454 489 0.86 (0.54, 1.37) 1.15 (0.64, 2.04) 0.98 (0.62, 1.55) -0.03 (-0.68, 0.63) 
  rs2957873 A G 66 108 23 51 576 603 256 311 0.90 (0.62, 1.31) 0.99 (0.52, 1.89) 0.77 (0.52, 1.15) -0.12 (-0.81, 0.56) 
  rs326224 G A 67 110 22 49 615 651 217 263 0.90 (0.62, 1.30) 1.07 (0.56, 2.03) 0.82 (0.55, 1.23) -0.14 (-0.87, 0.59) 
  rs2306353 G A 71 112 18 47 624 650 208 264 0.88 (0.61, 1.27) 0.88 (0.45, 1.74) 0.72 (0.48, 1.08) -0.04 (-0.70, 0.61) 
  rs326222 C T 44 75 45 84 439 451 393 463 1.01 (0.65, 1.57) 1.14 (0.64, 2.02) 0.82 (0.52, 1.28) -0.33 (-1.07, 0.41) 
  rs901746 A G 44 75 45 84 440 453 392 461 1.01 (0.65, 1.57) 1.14 (0.64, 2.02) 0.82 (0.52, 1.28) -0.33 (-1.06, 0.41) 
ERCC5 
(XPG) rs2296147 T C 26 43 63 114 254 260 573 650 0.79 (0.44, 1.43) 0.85 (0.45, 1.61) 0.74 (0.42, 1.31) 0.10 (-0.49, 0.70) 
  rs4771436 T G 58 100 31 59 504 559 328 355 0.88 (0.59, 1.31) 1.05 (0.58, 1.90) 0.86 (0.57, 1.29) -0.07 (-0.73, 0.59) 
  rs1047768 C T 30 57 59 102 288 320 544 593 0.96 (0.57, 1.63) 1.15 (0.63, 2.10) 0.93 (0.56, 1.55) -0.19 (-0.93, 0.55) 
  rs3818356 C T 58 100 31 59 504 559 326 353 0.88 (0.59, 1.31) 1.05 (0.58, 1.90) 0.86 (0.57, 1.30) -0.07 (-0.73, 0.59) 
  rs4150351 A C 60 101 29 58 534 591 298 323 0.84 (0.56, 1.24) 0.92 (0.50, 1.68) 0.83 (0.55, 1.25) 0.07 (-0.51, 0.66) 
  rs4150355 C T 39 63 50 96 363 364 469 550 0.80 (0.49, 1.30) 0.81 (0.45, 1.46) 0.74 (0.46, 1.19) 0.12 (-0.41, 0.65) 
  rs4150360 T C 26 49 63 110 248 267 584 647 1.01 (0.58, 1.77) 1.16 (0.62, 2.16) 0.92 (0.54, 1.59) -0.24 (-1.04, 0.55) 
  rs4150383 G A 60 111 29 48 569 638 263 276 0.92 (0.63, 1.35) 1.24 (0.67, 2.30) 0.90 (0.60, 1.36) -0.26 (-1.06, 0.54) 
  rs4150386 A C 71 123 18 36 652 712 180 201 0.82 (0.57, 1.18) 0.80 (0.40, 1.60) 0.79 (0.52, 1.19) 0.17 (-0.43, 0.77) 
  rs17655 C G 50 100 39 59 504 557 328 357 0.87 (0.57, 1.30) 1.08 (0.60, 1.94) 0.92 (0.60, 1.40) -0.03 (-0.68, 0.63) 
  rs873601 A G 42 81 47 78 421 457 411 457 0.84 (0.53, 1.32) 0.95 (0.53, 1.68) 0.83 (0.53, 1.30) 0.05 (-0.53, 0.62) 
  rs4150393 A G 73 123 16 36 628 721 204 193 0.80 (0.56, 1.15) 0.90 (0.44, 1.83) 0.98 (0.66, 1.48) 0.29 (-0.37, 0.95) 
  rs876430 C T 42 81 47 78 422 458 410 456 0.84 (0.53, 1.31) 0.95 (0.53, 1.68) 0.83 (0.53, 1.30) 0.05 (-0.53, 0.63) 
  rs1051677 T C 78 124 11 35 656 733 175 181 0.75 (0.53, 1.07) 0.49 (0.22, 1.12) 0.78 (0.52, 1.18) 0.54 (0.09, 0.99) 
  rs1051685 A G 69 119 20 40 666 712 165 202 0.81 (0.57, 1.17) 0.72 (0.37, 1.43) 0.71 (0.46, 1.08) 0.17 (-0.38, 0.72) 
ERCC4 
(XPF) rs3136038 C T 41 75 48 84 360 414 472 500 0.76 (0.48, 1.21) 0.91 (0.51, 1.62) 0.86 (0.54, 1.36) 0.19 (-0.34, 0.72) 
  rs1799798 G A 71 133 18 26 686 767 146 147 0.89 (0.63, 1.27) 1.36 (0.65, 2.87) 1.00 (0.65, 1.53) -0.26 (-1.30, 0.79) 
  rs744154 C G 48 85 41 74 431 496 401 418 0.76 (0.49, 1.17) 0.90 (0.51, 1.61) 0.89 (0.58, 1.38) 0.23 (-0.29, 0.75) 
  rs3136085 G C 47 84 42 75 427 491 405 423 0.75 (0.49, 1.17) 0.91 (0.51, 1.63) 0.90 (0.58, 1.39) 0.23 (-0.29, 0.75) 
  rs3136130 G T 39 75 50 84 360 409 472 505 0.80 (0.50, 1.29) 1.00 (0.56, 1.79) 0.90 (0.56, 1.43) 0.09 (-0.49, 0.68) 
  rs1800067 G A 78 137 11 22 699 782 133 132 0.81 (0.57, 1.14) 0.75 (0.31, 1.78) 0.93 (0.61, 1.42) 0.38 (-0.32, 1.07) 
  rs3136172 A G 46 82 43 77 411 483 421 431 0.74 (0.47, 1.15) 0.90 (0.50, 1.59) 0.90 (0.58, 1.40) 0.26 (-0.24, 0.77) 
RAD23A rs2974752 A G 31 65 54 87 301 359 507 529 0.89 (0.53, 1.48) 1.17 (0.64, 2.14) 0.97 (0.58, 1.60) -0.09 (-0.79, 0.62) 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, cigarette smoking, and percent African ancestry. 124 individuals missing 
alcohol drinking or cigarette smoking, and therefore dropped from models. 
Interval estimates presented not corrected for multiple comparisons. 
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 6S cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Ever Environmental 
Tobacco Smoke on Head and Neck Cancer Risk Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Cases/Controls OR (95% I)d 
Gene SNP 
Referent (A)  / 
Variant (B)  
ETS=0, 
SNP=0 
ETS=0, 
SNP=1 
ETS=1, 
SNP=0 
ETS=1, 
SNP=1 ETS=1, SNP=0  ETS=0, SNP=1  ETS=1, SNP=1 RERI (95% CI) 
ERCC2 
(XPD) rs13181 T G 36 61 53 96 344 376 481 536 0.84 (0.51, 1.38) 1.01 (0.56, 1.82) 0.85 (0.52, 1.38) 0 (-0.62, 0.62) 
  rs238418 C A 36 60 53 99 345 366 487 548 0.84 (0.51, 1.39) 0.96 (0.53, 1.74) 0.84 (0.51, 1.37) 0.03 (-0.57, 0.63) 
  rs1799787 C T 45 87 44 72 426 458 406 456 0.91 (0.59, 1.42) 1.19 (0.67, 2.12) 0.95 (0.61, 1.47) -0.15 (-0.86, 0.55) 
  rs3916874 G C 47 85 42 74 430 459 402 455 0.96 (0.62, 1.49) 1.14 (0.64, 2.03) 0.87 (0.56, 1.34) -0.24 (-0.95, 0.47) 
  rs238416 G A 30 68 59 91 339 400 492 512 0.99 (0.59, 1.65) 1.38 (0.76, 2.51) 1.10 (0.66, 1.82) -0.27 (-1.09, 0.55) 
  rs50872 C T 54 83 35 76 476 500 354 412 0.83 (0.55, 1.26) 0.83 (0.47, 1.50) 0.75 (0.49, 1.14) 0.08 (-0.46, 0.62) 
  rs50871 T G 23 36 66 123 218 222 614 691 1.07 (0.57, 2.02) 1.23 (0.63, 2.41) 0.98 (0.53, 1.80) -0.32 (-1.23, 0.59) 
  rs238407 A T 26 48 63 111 237 290 594 624 0.81 (0.45, 1.44) 1.01 (0.54, 1.90) 0.89 (0.51, 1.56) 0.07 (-0.56, 0.71) 
  rs3810366 C G 19 37 70 122 159 195 672 719 0.76 (0.39, 1.45) 0.95 (0.48, 1.87) 0.84 (0.45, 1.56) 0.14 (-0.50, 0.77) 
ERCC1 rs735482 A C 66 118 23 41 621 678 211 236 0.86 (0.60, 1.25) 0.99 (0.51, 1.91) 0.84 (0.56, 1.26) -0.01 (-0.70, 0.67) 
  rs2336219 G A 66 118 23 41 621 678 211 236 0.86 (0.60, 1.25) 0.99 (0.51, 1.91) 0.84 (0.56, 1.26) -0.01 (-0.70, 0.67) 
  rs3212964 G A 66 117 23 42 625 676 207 238 0.85 (0.59, 1.24) 0.92 (0.48, 1.79) 0.80 (0.53, 1.21) 0.03 (-0.62, 0.68) 
  rs3212955 A G 55 89 34 70 472 518 360 395 0.79 (0.52, 1.20) 0.87 (0.49, 1.56) 0.84 (0.55, 1.27) 0.17 (-0.36, 0.70) 
  rs3212948 C G 40 64 49 95 341 394 491 520 0.70 (0.43, 1.14) 0.82 (0.46, 1.46) 0.81 (0.51, 1.30) 0.29 (-0.18, 0.76) 
  rs3212930 T C 56 98 33 61 519 559 313 355 0.85 (0.57, 1.27) 1.00 (0.56, 1.81) 0.87 (0.58, 1.33) 0.02 (-0.60, 0.64) 
LIG1 rs156641 G A 36 54 53 105 334 385 498 529 0.64 (0.39, 1.06) 0.74 (0.41, 1.33) 0.76 (0.46, 1.24) 0.38 (-0.04, 0.81) 
  rs20580 C A 22 27 67 132 215 265 617 649 0.47 (0.24, 0.92) 0.63 (0.31, 1.27) 0.65 (0.34, 1.22) 0.55 (0.17, 0.92) 
  rs20579 C T 69 111 20 48 621 714 211 200 0.73 (0.51, 1.06) 0.73 (0.38, 1.41) 1.01 (0.67, 1.53) 0.54 (0.04, 1.05) 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, cigarette smoking, and percent African ancestry. 124 individuals missing 
alcohol drinking or cigarette smoking, and therefore dropped from models. 
Interval estimates presented not corrected for multiple comparisons. 
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/84=0.0006). 
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APPENDIX B 
AIM 1 SUPPLEMENTAL TABLES NOT REFERENCED IN CHAPTER 3 
 
  
Table 1A. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on Head 
and Neck Cancer Risk Using Exact Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a  
Gene SNP 
Referent (A) / 
Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1  Cigarette=1, SNP=0 
 Cigarette=0, 
SNP=1  Cigarette=1, SNP=1 RERI  
ERCC3 
(XPB) rs4150496 G A 7 52 6 47 171 84 119 68 14.99 (6.42, 40.82) 0.95 (0.24, 3.56) 12.86 (5.42, 35.48) -2.07 
  rs4150459 G A 9 66 4 33 181 98 111 54 13.44 (6.32, 32.04) 0.89 (0.19, 3.49) 14.89 (6.75, 36.6) 1.55 
  rs1011019 C T 10 60 3 39 173 83 119 69 12.40 (5.92, 28.59) 0.46 (0.08, 1.96) 10.25 (4.82, 23.96) -1.62 
  rs4150434 G A 9 68 4 31 223 118 69 34 14.19 (6.74, 33.52) 0.98 (0.20, 3.83) 15.06 (6.51, 38.58) 0.90 
  rs4150416 T G 6 34 7 65 79 42 212 110 10.50 (3.94, 33.09) 0.61 (0.16, 2.4) 10.85 (4.33, 32.59) 0.74 
  rs4150407 A G 3 24 10 75 81 44 211 108 14.48 (4.06, 79.27) 1.07 (0.25, 6.52) 15.51 (4.56, 82.27) 0.97 
  rs4150402 G A 10 60 3 39 173 83 119 69 12.40 (5.92, 28.59) 0.46 (0.08, 1.96) 10.25 (4.82, 23.96) -1.62 
XPC rs2228001 A C 6 50 7 49 174 84 118 68 17.11 (6.96, 50.79) 1.19 (0.32, 4.61) 14.3 (5.73, 42.99) -2.99 
  rs2228000 C T 11 83 2 16 240 122 52 30 14.75 (7.48, 31.87) 0.94 (0.09, 4.99) 12.85 (5.73, 31.1) -1.85 
  rs3731124 A C 9 86 4 13 243 126 49 26 18.32 (8.83, 42.81) 2.9 (0.57, 12.46) 17.61 (7.37, 46.51) -2.61 
  rs3731093 T C 12 84 1 13 251 124 37 28 14.09 (7.31, 29.45) 0.54 (0.01, 4.28) 9.1 (4, 22.01) -4.53 
  rs3731089 G A 12 84 1 15 251 124 41 28 14.09 (7.31, 29.45) 0.47 (0.01, 3.64) 10.07 (4.47, 24.21) -3.48 
  rs2733537 A G 10 67 3 32 202 97 90 55 13.85 (6.71, 31.55) 0.63 (0.1, 2.68) 10.84 (5.02, 25.66) -2.64 
  rs2607755 T C 6 45 7 54 105 64 187 88 12.17 (4.81, 36.90) 0.97 (0.26, 3.78) 15.8 (6.4, 47.04) 3.66 
  rs1902658 G A 3 25 10 74 50 26 242 126 15.59 (4.19, 88.13) 1.12 (0.26, 6.86) 15.9 (4.72, 83.86) 0.19 
ERCC8 rs3117 T C 5 34 8 65 121 60 171 92 13.55 (4.93, 46.65) 0.84 (0.22, 3.52) 12.54 (4.66, 42.48) -0.85 
CDK7 rs2972388 A G 9 52 4 47 151 80 141 72 10.81 (4.96, 26.28) 0.49 (0.1, 1.92) 11.21 (5.11, 27.38) 0.90 
CCNH rs2266691 A G 8 90 5 9 249 131 43 21 21.25 (9.93, 52.31) 6.09 (1.29, 27.15) 22.41 (8.84, 63.81) -3.93 
  rs2266692 G T 9 77 4 21 228 125 64 27 15.51 (7.43, 36.42) 1.62 (0.33, 6.56) 19.84 (8.42, 51.76) 3.70 
XPA rs3176757 C T 8 74 5 25 228 119 64 33 17.61 (8.13, 43.73) 1.84 (0.43, 7.09) 17.6 (7.36, 47.45) -0.85 
  rs3176753 T C 10 73 3 26 215 111 77 41 14.05 (6.88, 31.74) 0.84 (0.14, 3.63) 13.51 (6.13, 32.58) -0.38 
  rs3176748 A G 11 78 2 21 239 130 53 22 12.96 (6.57, 28.02) 0.68 (0.07, 3.48) 16.69 (7.2, 41.86) 4.05 
  rs3176658      C T 9 85 4 14 251 125 41 27 18.85 (9.08, 44.07) 2.67 (0.53, 11.32) 14.05 (5.82, 37.32) -6.47 
  rs1800975 G A 4 56 9 35 183 85 97 58 29.84 (10.52, 117.01) 3.55 (0.91, 17.02) 23.09 (7.93, 92.24) -9.31 
RAD23B rs1805330 C T 7 59 6 40 176 101 116 51 14.58 (6.33, 39.29) 1.26 (0.32, 4.75) 18.9 (7.91, 52.49) 4.06 
ERCC6 rs2228529 A G 12 77 1 21 222 112 68 39 12.64 (6.5, 26.62) 0.31 (0.01, 2.31) 11.03 (5.18, 25.16) -0.92 
  rs2228527  A G 11 72 2 27 207 103 85 49 13.07 (6.53, 28.55) 0.49 (0.05, 2.46) 11.22 (5.29, 25.79) -1.34 
  rs4253132 T C 9 50 4 49 182 75 110 77 13.36 (6.12, 32.5) 0.46 (0.1, 1.77) 7.87 (3.56, 19.31) -4.94 
  rs2228528 G A 7 74 6 25 205 108 86 44 19.92 (8.79, 53.07) 2.51 (0.63, 9.69) 20.33 (8.45, 56.81) -1.10 
DDB2 
(XPE) rs2029298 A G 2 31 11 68 88 57 204 95 23.58 (5.63, 211.02) 2.49 (0.5, 24.46) 32.98 (8.11, 290.14) 7.91 
  rs1685404  G C 8 51 5 48 156 89 136 63 11.09 (4.94, 28.3) 0.67 (0.16, 2.5) 13.61 (5.96, 35.23) 2.86 
  rs2957873 A G 5 33 8 66 85 49 206 103 11.29 (4.02, 39.49) 0.8 (0.21, 3.37) 13.1 (4.89, 44.28) 2.01 
  rs326224 G A 4 25 9 74 76 38 216 114 12.27 (3.86, 52.02) 0.76 (0.19, 3.69) 11.76 (3.93, 47.64) -0.27 
  rs2306353 G A 5 39 8 60 101 58 191 94 13.41 (4.91, 46.05) 1.04 (0.28, 4.35) 15.72 (5.92, 52.78) 2.27 
  rs326222 C T 2 18 11 81 52 32 240 120 14.28 (3.1, 135.06) 1.22 (0.23, 12.28) 17.88 (4.17, 161.4) 3.38 
  rs901746 A G 3 22 10 77 62 36 230 116 12.38 (3.38, 69.06) 0.95 (0.22, 5.85) 14.44 (4.21, 76.9) 2.11 
OR odds ratio, I interval estimates 
aCrude (not adjusted for matching factors or ancestry) 
1
8
8 
  
Table 1A cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on 
Head and Neck Cancer Risk Using Exact Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a 
Gene SNP 
Referent (A) / 
Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1  Cigarette=1, SNP=0 
 Cigarette=0, 
SNP=1  Cigarette=1, SNP=1 RERI  
ERCC5 
(XPG) rs2296147 T C 7 56 6 42 186 92 105 60 16.04 (6.93, 43.39) 1.14 (0.29, 4.3) 13.84 (5.81, 38.31) -2.35 
 rs2296148 C T 10 72 3 27 218 118 73 34 13.22 (6.48, 29.84) 0.8 (0.13, 3.44) 15.19 (6.78, 37.24) 2.17 
 rs4771436  T G 8 65 5 34 196 107 96 45 14.78 (6.74, 37.03) 1.19 (0.28, 4.52) 17.07 (7.37, 44.78) 2.10 
 rs1047768 C T 5 45 8 54 111 70 181 82 14.12 (5.27, 47.79) 1.33 (0.35, 5.55) 19.68 (7.46, 65.86) 5.23 
 rs2020915 G A 9 67 4 32 196 77 96 75 18.77 (8.77, 44.99) 0.93 (0.19, 3.66) 9.45 (4.33, 22.98) -9.26 
 rs3818356 C T 9 65 4 34 197 107 95 45 13.21 (6.23, 31.38) 0.85 (0.18, 3.33) 15.03 (6.7, 37.48) 1.97 
 rs4150355 C T 9 67 4 32 209 108 83 44 14.31 (6.77, 33.93) 0.93 (0.19, 3.66) 13.84 (6.14, 34.65) -0.40 
 rs4150360 T C 1 8 12 90 18 9 274 142 14.78 (1.59, 748.17) 1.07 (0.12, 51.22) 15.35 (2.02, 687.38) 0.50 
 rs4150383 G A 11 73 2 26 231 127 61 25 12 (6.05, 26.04) 0.51 (0.05, 2.59) 15.85 (6.97, 38.99) 4.34 
 rs17655 C G 5 35 8 64 85 35 207 117 16.66 (5.86, 59.04) 0.88 (0.23, 3.67) 12.3 (4.63, 41.34) -4.24 
 rs873601       A G 2 15 11 84 28 15 264 137 13.37 (2.59, 135.99) 0.98 (0.18, 10) 14.37 (3.27, 131.3) 1.01 
 rs876430 C T 2 15 11 84 30 15 262 137 14.32 (2.78, 145.25) 0.98 (0.18, 10) 14.26 (3.24, 130.31) -0.05 
 rs1051677 T C 10 71 3 28 222 113 70 39 13.86 (6.78, 31.33) 0.76 (0.13, 3.26) 12.55 (5.64, 30.51) -1.07 
 rs1051685 A G 6 47 7 51 132 70 160 82 14.62 (5.85, 43.92) 1.07 (0.29, 4.17) 15.14 (6.12, 45.17) 0.45 
 rs17655 C G 5 35 8 64 85 35 207 117 16.66 (5.86, 59.04) 0.88 (0.23, 3.67) 12.3 (4.63, 41.34) -4.24 
 rs873601       A G 2 15 11 84 28 15 264 137 13.37 (2.59, 135.99) 0.98 (0.18, 10) 14.37 (3.27, 131.3) 1.01 
 rs876430 C T 2 15 11 84 30 15 262 137 14.32 (2.78, 145.25) 0.98 (0.18, 10) 14.26 (3.24, 130.31) -0.05 
 rs1051677 T C 10 71 3 28 222 113 70 39 13.86 (6.78, 31.33) 0.76 (0.13, 3.26) 12.55 (5.64, 30.51) -1.07 
 rs1051685 A G 6 47 7 51 132 70 160 82 14.62 (5.85, 43.92) 1.07 (0.29, 4.17) 15.14 (6.12, 45.17) 0.45 
ERCC4 
(XPF) rs3136038 C T 4 31 9 68 88 53 204 99 12.69 (4.16, 52.24) 1.03 (0.26, 4.91) 15.84 (5.39, 63.48) 3.13 
  rs744154 C G 7 76 6 23 214 98 78 54 23.52 (10.37, 62.71) 2.8 (0.7, 10.87) 15.48 (6.49, 42.91) -9.84 
  rs3136085 G C 6 64 7 35 167 82 125 70 21.52 (8.86, 63.35) 2.12 (0.56, 8.28) 18.84 (7.67, 55.98) -3.79 
  rs3136091 C G 10 83 3 16 245 116 47 36 17.42 (8.61, 39.07) 1.55 (0.25, 6.98) 10.67 (4.69, 26.42) -7.3 
  rs3136130 G T 4 29 9 70 71 36 221 116 14.02 (4.45, 59.11) 0.93 (0.24, 4.48) 13.72 (4.66, 55.01) -0.23 
  rs3136172 A G 7 74 6 25 209 97 83 55 22.59 (9.94, 60.33) 2.51 (0.63, 9.69) 15.75 (6.62, 43.58) -8.36 
  rs2020955 T C 9 68 4 31 184 97 108 55 14.22 (6.7, 33.86) 0.98 (0.2, 3.83) 14.66 (6.65, 35.98) 0.46 
RAD23A rs2974752 A G 3 20 10 69 74 42 206 101 11.55 (3.16, 64.21) 0.97 (0.22, 5.98) 13.49 (3.87, 72.55) 1.98 
  rs11558955 A G 12 84 1 15 244 130 48 22 13.07 (6.79, 27.29) 0.47 (0.01, 3.64) 14.94 (6.54, 36.6) 2.41 
ERCC2 
(XPD) rs13181 T G 5 62 8 37 168 78 123 72 26.43 (10.17, 87.58) 2.66 (0.71, 11.13) 20.95 (7.99, 69.88) -7.14 
  rs238418 C A 1 5 12 94 7 6 284 146 5.33 (0.42, 314.49) 0.64 (0.06, 32.68) 9.68 (1.07, 461.59) 4.70 
  rs1799787 C T 6 76 7 23 229 116 63 36 24.83 (10.46, 71.87) 3.8 (0.98, 15.21) 21.73 (8.4, 67.27) -5.89 
  rs3916874 G C 13 91 0 8 255 135 37 17     
  rs238416 G A 9 82 4 15 234 126 57 26 16.82 (8.09, 39.39) 2.41 (0.48, 10.11) 19.53 (8.23, 51.28) 1.30 
  rs50872 C T 10 63 3 36 213 95 79 57 14.02 (6.77, 32.01) 0.53 (0.09, 2.23) 8.64 (3.97, 20.55) -4.91 
OR odds ratio, I interval estimates 
aCrude (not adjusted for matching factors or ancestry) 
1
8
9 
  
Table 1A cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on 
Head and Neck Cancer Risk Using Exact Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a  
Gene SNP 
Referent (A) / 
Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1  Cigarette=1, SNP=0 
 Cigarette=0, 
SNP=1  Cigarette=1, SNP=1 RERI  
ERCC2 
(XPD)  
rs50871 
T G 10 80 3 19 219 115 73 37 15.14 (7.45, 34.06) 1.26 (0.2, 5.57) 15.53 (7, 37.68) 0.13 
  rs238407 A T 8 77 5 22 218 113 74 39 18.44 (8.51, 45.81) 2.17 (0.51, 8.45) 17.95 (7.67, 47.57) -1.66 
  rs3810366 C G 8 72 5 27 204 108 88 44 16.88 (7.75, 42.11) 1.66 (0.39, 6.36) 17.72 (7.66, 46.48) 0.19 
ERCC1 rs735482 A C 10 38 3 61 146 84 146 68 6.56 (3.02, 15.55) 0.19 (0.03, 0.8) 8.09 (3.69, 19.32) 2.34 
  rs2336219 G A 10 40 3 59 147 86 145 66 6.79 (3.14, 16.03) 0.21 (0.03, 0.87) 8.71 (3.98, 20.76) 2.71 
  rs3212964 G A 12 51 1 47 195 91 95 60 9.05 (4.49, 19.58) 0.09 (0, 0.67) 6.67 (3.19, 14.91) -1.47 
  rs3212955 A G 7 55 6 44 152 87 140 65 13.61 (5.84, 37.01) 1.07 (0.28, 4.03) 16.73 (7.09, 45.98) 3.05 
  rs3212948 C G 13 2 0 97 9 4 283 148     
  rs3212935 A G 6 51 7 48 137 74 155 77 15.58 (6.29, 46.53) 1.24 (0.33, 4.8) 16.94 (6.86, 50.46) 1.13 
  rs3212930 T C 9 76 4 23 241 129 51 23 15.68 (7.52, 36.8) 1.46 (0.3, 5.87) 18.27 (7.54, 48.97) 2.13 
LIG1 rs156641 G A 9 78 4 21 225 114 67 38 16.99 (8.12, 39.97) 1.64 (0.34, 6.64) 15.03 (6.58, 38.06) -2.6 
  rs20580 C A 3 21 10 78 59 36 232 116 11.25 (3.05, 63.02) 0.9 (0.21, 5.53) 13.91 (4.03, 74.29) 2.76 
  rs20579 C T 8 46 5 53 142 82 150 70 9.88 (4.34, 25.44) 0.55 (0.13, 2.05) 12.2 (5.34, 31.57) 2.78 
  rs439132 A G 8 50 5 49 164 86 128 66 11.82 (5.25, 30.21) 0.64 (0.15, 2.4) 12 (5.25, 31.06) 0.53 
OR odds ratio, I interval estimates 
aCrude (not adjusted for matching factors or ancestry) 
 
1
90 
  
Table 2A. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on Head and 
Neck Cancer Risk Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a 
Gene SNP 
Referent (A)  / 
Variant (B) 
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 Cigarette=1, SNP=0 Cigarette=0, SNP=1 Cigarette=1, SNP=1 RERI (95% CI) 
ERCC3 (XPB) rs4150496 G A 7 52 6 47 171 84 119 68 10.62 (3.89, 28.98) 1.53 (0.42, 5.56) 7.64 (2.74, 21.31) -3.51 (-9.85, 2.82) 
  rs4150459 G A 9 66 4 33 181 98 111 54 7.25 (2.90, 18.13) 0.83 (0.21, 3.29) 7.34 (2.83, 19.01) 0.26 (-3.71, 4.24) 
  rs1011019 C T 10 60 3 39 173 83 119 69 5.64 (2.29, 13.92) 0.35 (0.08, 1.56) 5.21 (2.07, 13.14) 0.22 (-2.61, 3.05) 
  rs4150434 G A 9 68 4 31 223 118 69 34 6.60 (2.71, 16.05) 0.91 (0.22, 3.73) 11.11 (4.1, 30.08) 4.60 (-2.58, 11.78) 
  rs4150416 T G 6 34 7 65 79 42 212 110 5.15 (1.56, 17.00) 0.58 (0.15, 2.17) 5.56 (1.79, 17.24) 0.83 (-2.17, 3.84) 
  rs4150407 A G 3 24 10 75 81 44 211 108 11.7 (2.63, 52.03) 1.32 (0.28, 6.22) 8.81 (2.08, 37.26) -3.20 (-11.82, 5.41) 
  rs4150402 G A 10 60 3 39 173 83 119 69 5.64 (2.29, 13.92) 0.35 (0.08, 1.56) 5.21 (2.07, 13.14) 0.22 (-2.61, 3.05) 
XPC rs2228001 A C 6 50 7 49 174 84 118 68 9.83 (3.44, 28.05) 1.30 (0.35, 4.81) 7.7 (2.65, 22.41) -2.43 (-8.06, 3.20) 
  rs2228000 C T 11 83 2 16 240 122 52 30 6.76 (2.94, 15.57) 0.60 (0.11, 3.40) 8.51 (3.2, 22.66) 2.15 (-3.41, 7.70) 
  rs3731124 A C 9 86 4 13 243 126 49 26 10.85 (4.27, 27.53) 3.72 (0.75, 18.35) 11.01 (3.76, 32.29) -2.55 (-11.73, 6.63) 
  rs3731093 T C 12 84 1 13 251 124 37 28 7.71 (3.40, 17.51) 0.99 (0.09, 10.5) 6.48 (2.42, 17.34) -1.23 (-6.53, 4.08) 
  rs3731089 G A 12 84 1 15 251 124 41 28 7.65 (3.37, 17.35) 0.73 (0.07, 7.40) 6.87 (2.58, 18.29) -0.51 (-5.57, 4.55) 
  rs2733537 A G 10 67 3 32 202 97 90 55 6.64 (2.73, 16.14) 0.60 (0.13, 2.65) 6.75 (2.65, 17.19) 0.52 (-3.14, 4.17) 
  rs2607755 T C 6 45 7 54 105 64 187 88 8.39 (2.59, 27.14) 1.35 (0.35, 5.23) 9.99 (3.13, 31.93) 1.25 (-3.53, 6.03) 
  rs1902658 G A 3 25 10 74 50 26 242 126 7.35 (1.54, 34.99) 0.81 (0.17, 3.77) 6.28 (1.42, 27.78) -0.88 (-6.23, 4.47) 
ERCC8 rs3117 T C 5 34 8 65 121 60 171 92 8.36 (2.53, 27.66) 0.95 (0.24, 3.67) 7.01 (2.16, 22.73) -1.29 (-6.07, 3.48) 
CDK7 rs2972388 A G 9 52 4 47 151 80 141 72 4.36 (1.73, 11.00) 0.25 (0.06, 0.99) 4.35 (1.70, 11.12) 0.74 (-1.47, 2.95) 
CCNH rs2266691 A G 8 90 5 9 249 131 43 21 12.15 (4.63, 31.86) 6.33 (1.32, 30.29) 18.26 (5.64, 59.15) 0.78 (-14.86, 16.41) 
  rs2266692 G T 9 77 4 21 228 125 64 27 9.18 (3.64, 23.12) 2.27 (0.51, 10.04) 12.54 (4.34, 36.26) 2.09 (-6.43, 10.62) 
XPA rs3176757 C T 8 74 5 25 228 119 64 33 9.61 (3.77, 24.47) 2.01 (0.50, 8.09) 9.88 (3.53, 27.7) -0.73 (-7.26, 5.79) 
  rs3176753 T C 10 73 3 26 215 111 77 41 6.56 (2.77, 15.54) 0.52 (0.11, 2.38) 6.65 (2.64, 16.72) 0.57 (-3.21, 4.34) 
  rs3176748 A G 11 78 2 21 239 130 53 22 7.24 (3.13, 16.79) 0.80 (0.14, 4.67) 8.93 (3.13, 25.51) 1.89 (-4.54, 8.32) 
  rs3176658      C T 9 85 4 14 251 125 41 27 8.79 (3.70, 20.88) 1.91 (0.41, 8.88) 9.69 (3.48, 27.01) -0.01 (-6.94, 6.93) 
  rs1800975 G A 4 56 9 35 183 85 97 58 13.28 (3.90, 45.21) 2.7 (0.67, 10.97) 11.95 (3.45, 41.34) -3.03 (-11.46, 5.40) 
RAD23B rs1805330 C T 7 59 6 40 176 101 116 51 8.92 (3.33, 23.88) 1.58 (0.43, 5.81) 9.99 (3.65, 27.35) 0.48 (-4.73, 5.70) 
ERCC6 rs2228529 A G 12 77 1 21 222 112 68 39 7.34 (3.27, 16.46) 0.57 (0.06, 5.38) 7.33 (2.88, 18.67) 0.42 (-4.08, 4.93) 
  rs2228527  A G 11 72 2 27 207 103 85 49 7.43 (3.19, 17.32) 0.75 (0.14, 4.06) 7.13 (2.82, 17.98) -0.06 (-4.22, 4.10) 
  rs4253132 T C 9 50 4 49 182 75 110 77 6.64 (2.60, 16.95) 0.35 (0.09, 1.41) 4.04 (1.59, 10.31) -1.94 (-5.72, 1.84) 
  rs2228528 G A 7 74 6 25 205 108 86 44 12.88 (4.80, 34.58) 4.10 (1.05, 15.98) 12.00 (4.14, 34.80) -3.98 (-13.22, 5.26) 
DDB2 (XPE) rs2029298 A G 2 31 11 68 88 57 204 95 15.51 (2.98, 80.81) 3.70 (0.66, 20.72) 24.13 (4.74, 122.76) 5.91 (-7.28, 19.11) 
  rs1685404  G C 8 51 5 48 156 89 136 63 5.62 (2.16, 14.56) 0.46 (0.12, 1.80) 5.60 (2.12, 14.80) 0.52 (-2.39, 3.44) 
  rs2957873 A G 5 33 8 66 85 49 206 103 4.95 (1.52, 16.19) 0.57 (0.15, 2.17) 5.60 (1.81, 17.34) 1.08 (-1.75, 3.91) 
  rs326224 G A 4 25 9 74 76 38 216 114 6.62 (1.81, 24.27) 0.68 (0.16, 2.90) 5.78 (1.68, 19.92) -0.53 (-4.66, 3.61) 
  rs2306353 G A 5 39 8 60 101 58 191 94 6.82 (2.17, 21.48) 0.95 (0.25, 3.60) 7.91 (2.63, 23.82) 1.14 (-2.74, 5.02) 
  rs326222 C T 2 18 11 81 52 32 240 120 5.60 (1.01, 30.96) 0.78 (0.14, 4.55) 6.54 (1.27, 33.74) 1.15 (-2.55, 4.85) 
  rs901746 A G 3 22 10 77 62 36 230 116 5.38 (1.26, 22.88) 0.66 (0.14, 3.09) 5.77 (1.45, 22.91) 0.73 (-2.60, 4.06) 
ERCC5 (XPG) rs2296147 T C 7 56 6 42 186 92 105 60 10.37 (3.82, 28.13) 1.75 (0.48, 6.35) 8.94 (3.21, 24.86) -2.18 (-8.16, 3.8) 
  rs2296148 C T 10 72 3 27 218 118 73 34 6.90 (2.95, 16.10) 0.71 (0.15, 3.28) 8.35 (3.17, 22.00) 1.74 (-3.24, 6.73) 
OR odds ratio, I interval estimates  
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry 
1
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Table 2A cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on Head 
and Neck Cancer Risk Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a 
Gene SNP 
Referent (A)  / 
Variant (B) 
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 Cigarette=1, SNP=0 Cigarette=0, SNP=1 Cigarette=1, SNP=1 RERI (95% CI) 
 ERCC5 (XPG) rs4771436  T G 8 65 5 34 196 107 96 45 6.95 (2.73, 17.69) 0.85 (0.22, 3.25) 8.19 (3.03, 22.16) 1.39 (-3.00, 5.77) 
  rs1047768 C T 5 45 8 54 111 70 181 82 5.98 (1.97, 18.14) 0.95 (0.25, 3.57) 9.15 (3.04, 27.50) 3.22 (-1.42, 7.86) 
  rs2020915 G A 9 67 4 32 196 77 96 75 10.46 (4.08, 26.8) 0.92 (0.22, 3.89) 4.72 (1.79, 12.42) -5.67 (-12.75, 1.41) 
  rs3818356 C T 9 65 4 34 197 107 95 45 6.25 (2.55, 15.33) 0.60 (0.15, 2.42) 7.30 (2.79, 19.08) 1.45 (-2.45, 5.35) 
  rs4150355 C T 9 67 4 32 209 108 83 44 9.13 (3.53, 23.63) 1.64 (0.39, 6.91) 9.26 (3.39, 25.34) -0.51 (-6.19, 5.17) 
  rs4150360 T C 1 8 12 90 18 9 274 142 7.88 (0.65, 95.06) 0.86 (0.08, 9.64) 6.45 (0.65, 64.22) -1.29 (-11.17, 8.6) 
  rs4150383 G A 11 73 2 26 231 127 61 25 6.03 (2.55, 14.27) 0.44 (0.08, 2.53) 8.05 (2.94, 22.00) 2.58 (-2.70, 7.85) 
  rs17655 C G 5 35 8 64 85 35 207 117 8.95 (2.54, 31.53) 0.92 (0.24, 3.57) 6.91 (2.11, 22.66) -1.96 (-8.01, 4.08) 
  rs873601       A G 2 15 11 84 28 15 264 137 5.41 (0.81, 36.01) 0.57 (0.09, 3.71) 4.75 (0.83, 27.31) -0.23 (-5.13, 4.68) 
  rs876430 C T 2 15 11 84 30 15 262 137 5.85 (0.88, 38.86) 0.57 (0.09, 3.71) 4.71 (0.82, 27.07) -0.71 (-6.25, 4.83) 
  rs1051677 T C 10 71 3 28 222 113 70 39 7.06 (3.04, 16.40) 0.51 (0.10, 2.51) 5.75 (2.25, 14.67) -0.83 (-4.68, 3.03) 
  rs1051685 A G 6 47 7 51 132 70 160 82 9.22 (3.11, 27.30) 0.95 (0.26, 3.48) 6.53 (2.25, 18.92) -2.64 (-8.20, 2.92) 
ERCC4 (XPF) rs3136038 C T 4 31 9 68 88 53 204 99 6.60 (1.79, 24.31) 0.98 (0.24, 3.96) 8.24 (2.33, 29.17) 1.66 (-2.33, 5.64) 
  rs744154 C G 7 76 6 23 214 98 78 54 10.16 (3.92, 26.34) 1.98 (0.51, 7.62) 9.19 (3.39, 24.92) -1.95 (-8.10, 4.20) 
  rs3136085 G C 6 64 7 35 167 82 125 70 10.71 (3.86, 29.71) 2.38 (0.62, 9.06) 11.23 (4.07, 31.00) -0.85 (-7.17, 5.47) 
  rs3136091 C G 10 83 3 16 245 116 47 36 8.76 (3.66, 21.00) 1.12 (0.23, 5.40) 5.48 (2.03, 14.80) -3.40 (-8.99, 2.19) 
  rs3136130 G T 4 29 9 70 71 36 221 116 7.02 (1.93, 25.50) 0.95 (0.23, 3.97) 7.66 (2.26, 25.99) 0.70 (-3.54, 4.93) 
  rs3136172 A G 7 74 6 25 209 97 83 55 9.66 (3.71, 25.18) 1.86 (0.49, 7.11) 9.67 (3.57, 26.17) -0.85 (-6.67, 4.97) 
  rs2020955  T C 9 68 4 31 184 97 108 55 8.98 (3.62, 22.29) 1.06 (0.26, 4.37) 6.58 (2.59, 16.68) -2.46 (-7.50, 2.57) 
RAD23A rs2974752 A G 3 20 10 69 74 42 206 101 3.55 (0.78, 16.21) 0.45 (0.10, 2.14) 3.77 (0.88, 16.14) 0.76 (-1.37, 2.89) 
  rs11558955 A G 12 84 1 15 244 130 48 22 7.06 (3.09, 16.13) 0.51 (0.05, 4.91) 7.39 (2.80, 19.47) 0.82 (-4.38, 6.01) 
ERCC2 (XPD) rs13181 T G 5 62 8 37 168 78 123 72 14.78 (4.84, 45.09) 2.43 (0.65, 9.16) 10.13 (3.31, 31.03) -6.08 (-15.95, 3.78) 
  rs238418 C A 1 5 12 94 7 6 284 146 2.54 (0.14, 44.85) 0.34 (0.03, 4.63) 2.84 (0.23, 34.55) 0.96 (-2.82, 4.74) 
  rs1799787 C T 6 76 7 23 229 116 63 36 14.05 (5.09, 38.78) 3.54 (0.94, 13.38) 9.44 (3.16, 28.26) -7.14 (-17.63, 3.34) 
  rs3916874 G C 13 91 0 8 255 135 37 17     
  rs238416 G A 9 82 4 15 234 126 57 26 9.27 (3.76, 22.85) 3.54 (0.76, 16.46) 15.13 (5.36, 42.65) 3.32 (-7.24, 13.88) 
  rs50872 C T 10 63 3 36 213 95 79 57 7.03 (2.84, 17.4) 0.43 (0.09, 1.99) 4.38 (1.71, 11.23) -2.08 (-6.01, 1.85) 
  rs50871 T G 10 80 3 19 219 115 73 37 8.86 (3.61, 21.74) 1.60 (0.31, 8.30) 8.30 (3.04, 22.67) -1.16 (-6.77, 4.45) 
  rs238407 A T 8 77 5 22 218 113 74 39 10.86 (4.22, 27.95) 3.55 (0.87, 14.39) 12.62 (4.58, 34.77) -0.79 (-9.00, 7.41) 
  rs3810366 C G 8 72 5 27 204 108 88 44 9.22 (3.55, 23.96) 2.18 (0.55, 8.65) 11.99 (4.37, 32.87) 1.59 (-5.15, 8.32) 
ERCC1 rs735482 A C 10 38 3 61 146 84 146 68 2.84 (1.10, 7.36) 0.13 (0.03, 0.59) 3.95 (1.51, 10.29) 1.98 (-0.01, 3.97) 
  rs2336219 G A 10 40 3 59 147 86 145 66 2.87 (1.11, 7.43) 0.13 (0.03, 0.60) 3.98 (1.53, 10.36) 1.98 (-0.02, 3.98) 
  rs3212964 G A 12 51 1 47 195 91 95 60 3.72 (1.54, 8.99) 0.05 (0.01, 0.46) 3.08 (1.25, 7.64) 0.31 (-1.55, 2.16) 
  rs3212955 A G 7 55 6 44 152 87 140 65 6.86 (2.48, 18.95) 0.72 (0.19, 2.75) 6.37 (2.27, 17.89) -0.21 (-3.84, 3.41) 
  rs3212948 C G 13 2 0 97 9 4 283 148     
  rs3212935 A G 6 51 7 48 137 74 155 77 10.26 (3.40, 30.93) 1.91 (0.5, 7.28) 11.62 (3.86, 35.05) 0.45 (-5.37, 6.28) 
  rs3212930 T C 9 76 4 23 241 129 51 23 8.26 (3.29, 20.76) 1.24 (0.30, 5.17) 8.71 (3, 25.28.00) 0.21 (-5.77, 6.18) 
OR odds ratio, I interval estimates  
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry 
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Table 2A cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on 
Head and Neck Cancer Risk Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a 
Gene SNP 
Referent (A)  / 
Variant (B) 
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 Cigarette=1, SNP=0 Cigarette=0, SNP=1 Cigarette=1, SNP=1 RERI (95% CI) 
LIG1 rs156641 G A 9 78 4 21 225 114 67 38 9.37 (3.89, 22.60) 2.22 (0.51, 9.64) 9.12 (3.45, 24.15) -1.47 (-7.97, 5.02) 
  rs20580 C A 3 21 10 78 59 36 232 116 4.68 (1.10, 19.95) 0.6 (0.13, 2.81) 5.43 (1.37, 21.59) 1.15 (-1.81, 4.10) 
  rs20579 C T 8 46 5 53 142 82 150 70 4.87 (1.85, 12.82) 0.49 (0.13, 1.89) 6.72 (2.55, 17.71) 2.36 (-0.92, 5.63) 
  rs439132 A G 8 50 5 49 164 86 128 66 7.67 (2.91, 20.20) 0.73 (0.20, 2.71) 5.71 (2.13, 15.35) -1.69 (-5.88, 2.49) 
OR odds ratio, I interval estimates  
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry 
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Table 3A. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on Head 
and Neck Cancer Risk Using Hierarchical Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a  
Gene SNP 
Referent (A) / 
Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1  Cigarette=1, SNP=0 
 Cigarette=0, 
SNP=1  Cigarette=1, SNP=1 RERI  
ERCC3 
(XPB) 
rs4150496 
G A 7 52 6 47 171 84 119 68 9.51 (3.78, 23.93) 1.24 (0.41, 3.73) 7.08 (2.66, 18.86) -2.68 
  rs4150459 G A 9 66 4 33 181 98 111 54 7.42 (3.09, 17.80) 0.88 (0.28, 2.77) 7.45 (2.91, 19.06) 0.15 
  rs1011019 C T 10 60 3 39 173 83 119 69 6.29 (2.63, 15.05) 0.49 (0.15, 1.57) 5.61 (2.23, 14.07) -0.17 
  rs4150434 G A 9 68 4 31 223 118 69 34 7.04 (2.98, 16.63) 1.10 (0.34, 3.51) 11.43 (4.21, 31.04) 4.29 
  rs4150416 T G 6 34 7 65 79 42 212 110 5.90 (1.98, 17.56) 0.69 (0.22, 2.14) 6.17 (2.10, 18.16) 0.58 
  rs4150407 A G 3 24 10 75 81 44 211 108 9.87 (2.88, 33.79) 1.08 (0.32, 3.70) 7.64 (2.20, 26.52) -2.31 
  rs4150402 G A 10 60 3 39 173 83 119 69 6.29 (2.63, 15.05) 0.49 (0.15, 1.57) 5.61 (2.23, 14.07) -0.17 
XPC rs2228001 A C 6 50 7 49 174 84 118 68 9.05 (3.47, 23.60) 1.13 (0.37, 3.41) 7.25 (2.63, 19.99) -1.93 
  rs2228000 C T 11 83 2 16 240 122 52 30 7.17 (3.17, 16.20) 0.80 (0.22, 2.94) 8.64 (3.22, 23.13) 1.66 
  rs3731124 A C 9 86 4 13 243 126 49 26 9.34 (3.97, 21.96) 2.31 (0.63, 8.48) 10.22 (3.59, 29.12) -0.42 
  rs3731093 T C 12 84 1 13 251 124 37 28 7.63 (3.44, 16.94) 0.90 (0.18, 4.48) 6.46 (2.41, 17.28) -1.08 
  rs3731089 G A 12 84 1 15 251 124 41 28 7.75 (3.49, 17.21) 0.82 (0.17, 3.84) 6.90 (2.59, 18.39) -0.67 
  rs2733537 A G 10 67 3 32 202 97 90 55 7.02 (2.98, 16.52) 0.71 (0.22, 2.35) 6.98 (2.75, 17.70) 0.24 
  rs2607755 T C 6 45 7 54 105 64 187 88 8.18 (2.85, 23.46) 1.30 (0.42, 4.05) 9.79 (3.31, 28.93) 1.31 
  rs1902658 G A 3 25 10 74 50 26 242 126 7.49 (2.03, 27.60) 0.82 (0.24, 2.88) 6.38 (1.71, 23.76) -0.94 
ERCC8 rs3117 T C 5 34 8 65 121 60 171 92 8.15 (2.79, 23.78) 0.91 (0.29, 2.85) 6.87 (2.31, 20.47) -1.19 
CDK7 rs2972388 A G 9 52 4 47 151 80 141 72 5.19 (2.12, 12.70) 0.38 (0.12, 1.16) 4.89 (1.91, 12.49) 0.32 
CCNH rs2266691 A G 8 90 5 9 249 131 43 21 10.25 (4.26, 24.66) 3.85 (1.08, 13.75) 17.3 (5.48, 54.65) 4.20 
  rs2266692 G T 9 77 4 21 228 125 64 27 8.65 (3.64, 20.54) 1.92 (0.56, 6.54) 12.23 (4.29, 34.89) 2.66 
XPA rs3176757 C T 8 74 5 25 228 119 64 33 8.87 (3.71, 21.24) 1.64 (0.51, 5.28) 9.49 (3.46, 26.03) -0.02 
  rs3176753 T C 10 73 3 26 215 111 77 41 6.98 (3.02, 16.14) 0.65 (0.20, 2.18) 6.86 (2.73, 17.28) 0.23 
  rs3176748 A G 11 78 2 21 239 130 53 22 7.51 (3.32, 17.00) 0.95 (0.25, 3.63) 9.00 (3.14, 25.81) 1.54 
  rs3176658      C T 9 85 4 14 251 125 41 27 8.35 (3.65, 19.06) 1.58 (0.45, 5.59) 9.54 (3.45, 26.44) 0.62 
  rs1800975 G A 4 56 9 35 183 85 97 58 10.56 (3.67, 30.41) 1.93 (0.61, 6.05) 10.02 (3.26, 30.8) -1.48 
RAD23B rs1805330 C T 7 59 6 40 176 101 116 51 8.50 (3.40, 21.25) 1.44 (0.47, 4.34) 9.66 (3.65, 25.57) 0.73 
ERCC6 rs2228529 A G 12 77 1 21 222 112 68 39 7.56 (3.41, 16.77) 0.76 (0.17, 3.32) 7.39 (2.89, 18.89) 0.07 
  rs2228527  A G 11 72 2 27 207 103 85 49 7.58 (3.34, 17.23) 0.83 (0.23, 3.03) 7.20 (2.86, 18.12) -0.21 
  rs4253132 T C 9 50 4 49 182 75 110 77 7.10 (2.90, 17.41) 0.41 (0.13, 1.30) 4.23 (1.68, 10.66) -2.29 
  rs2228528 G A 7 74 6 25 205 108 86 44 10.57 (4.33, 25.79) 2.64 (0.84, 8.32) 10.62 (3.87, 29.18) -1.59 
DDB2 
(XPE) rs2029298 A G 2 31 11 68 88 57 204 95 11.57 (3.23, 41.41) 2.64 (0.74, 9.44) 18.6 (5.03, 68.86) 5.40 
  rs1685404  G C 8 51 5 48 156 89 136 63 6.22 (2.50, 15.47) 0.58 (0.19, 1.79) 6.00 (2.30, 15.71) 0.20 
  rs2957873 A G 5 33 8 66 85 49 206 103 5.74 (1.94, 17.00) 0.70 (0.22, 2.17) 6.29 (2.13, 18.52) 0.85 
  rs326224 G A 4 25 9 74 76 38 216 114 7.05 (2.25, 22.11) 0.74 (0.22, 2.45) 6.07 (1.94, 19.01) -0.71 
  rs2306353 G A 5 39 8 60 101 58 191 94 7.09 (2.50, 20.17) 1.01 (0.33, 3.11) 8.16 (2.87, 23.18) 1.06 
  rs326222 C T 2 18 11 81 52 32 240 120 6.53 (1.62, 26.26) 0.93 (0.23, 3.68) 7.47 (1.82, 30.65) 1.01 
  rs901746 A G 3 22 10 77 62 36 230 116 6.23 (1.79, 21.73) 0.79 (0.22, 2.78) 6.53 (1.87, 22.82) 0.50 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry 
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Table 3A cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on 
Head and Neck Cancer Risk Using Exact Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a 
Gene SNP 
Referent (A) / 
Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1  Cigarette=1, SNP=0 
 Cigarette=0, 
SNP=1  Cigarette=1, SNP=1 RERI  
ERCC5 
(XPG) rs2296147 T C 7 56 6 42 186 92 105 60 9.37 (3.73, 23.51) 1.44 (0.48, 4.32) 8.34 (3.13, 22.25) -1.46 
  rs2296148 C T 10 72 3 27 218 118 73 34 7.22 (3.16, 16.49) 0.85 (0.25, 2.89) 8.50 (3.21, 22.46) 1.43 
  rs4771436 T G 8 65 5 34 196 107 96 45 7.24 (2.97, 17.63) 0.94 (0.31, 2.88) 8.40 (3.14, 22.49) 1.22 
  rs1047768 C T 5 45 8 54 111 70 181 82 6.55 (2.34, 18.31) 1.09 (0.35, 3.36) 9.82 (3.40, 28.37) 3.18 
  rs2020915 G A 9 67 4 32 196 77 96 75 9.57 (3.99, 22.95) 0.73 (0.22, 2.44) 4.44 (1.75, 11.28) -4.86 
  rs3818356 C T 9 65 4 34 197 107 95 45 6.73 (2.83, 15.99) 0.74 (0.23, 2.31) 7.61 (2.92, 19.88) 1.15 
  rs4150355 C T 9 67 4 32 209 108 83 44 8.57 (3.54, 20.72) 1.41 (0.43, 4.65) 8.90 (3.35, 23.67) -0.07 
  rs4150360 T C 1 8 12 90 18 9 274 142 7.67 (1.49, 39.42) 0.84 (0.16, 4.47) 6.31 (1.15, 34.62) -1.20 
  rs4150383 G A 11 73 2 26 231 127 61 25 6.71 (2.91, 15.50) 0.68 (0.19, 2.45) 8.40 (3.05, 23.13) 2.01 
  rs17655 C G 5 35 8 64 85 35 207 117 8.58 (2.82, 26.09) 0.88 (0.28, 2.73) 6.69 (2.24, 20.03) -1.76 
  rs873601 A G 2 15 11 84 28 15 264 137 6.54 (1.51, 28.37) 0.69 (0.16, 2.93) 5.55 (1.28, 24.13) -0.68 
  rs876430 C T 2 15 11 84 30 15 262 137 6.81 (1.58, 29.36) 0.66 (0.16, 2.80) 5.33 (1.24, 22.99) -1.14 
  rs1051677 T C 10 71 3 28 222 113 70 39 7.34 (3.23, 16.69) 0.60 (0.17, 2.11) 5.84 (2.28, 14.94) -1.10 
  rs1051685 A G 6 47 7 51 132 70 160 82 8.76 (3.25, 23.58) 0.87 (0.29, 2.63) 6.28 (2.29, 17.19) -2.35 
ERCC4 
(XPF) rs3136038 C T 4 31 9 68 88 53 204 99 7.01 (2.21, 22.28) 1.06 (0.33, 3.39) 8.66 (2.69, 27.87) 1.59 
  rs744154 C G 7 76 6 23 214 98 78 54 9.20 (3.80, 22.28) 1.57 (0.50, 4.89) 8.65 (3.29, 22.72) -1.12 
  rs3136085 G C 6 64 7 35 167 82 125 70 9.46 (3.74, 23.93) 1.87 (0.61, 5.77) 10.28 (3.94, 26.81) -0.04 
  rs3136091 C G 10 83 3 16 245 116 47 36 8.28 (3.61, 19.00) 0.90 (0.25, 3.26) 5.36 (2.00, 14.37) -2.82 
  rs3136130 G T 4 29 9 70 71 36 221 116 7.27 (2.34, 22.60) 0.99 (0.30, 3.25) 7.88 (2.56, 24.26) 0.62 
  rs3136172 A G 7 74 6 25 209 97 83 55 8.92 (3.66, 21.73) 1.55 (0.50, 4.80) 9.20 (3.51, 24.15) -0.26 
  rs2020955 T C 9 68 4 31 184 97 108 55 8.63 (3.64, 20.42) 0.94 (0.29, 3.07) 6.42 (2.58, 15.96) -2.15 
RAD23A rs2974752 A G 3 20 10 69 74 42 206 101 4.69 (1.25, 17.64) 0.62 (0.17, 2.23) 4.77 (1.25, 18.13) 0.46 
  rs11558955 A G 12 84 1 15 244 130 48 22 7.43 (3.32, 16.63) 0.73 (0.17, 3.23) 7.48 (2.82, 19.81) 0.31 
ERCC2 
(XPD) rs13181 T G 5 62 8 37 168 78 123 72 11.83 (4.43, 31.54) 1.69 (0.56, 5.12) 8.55 (3.07, 23.77) -3.97 
  rs238418 C A 1 5 12 94 7 6 284 146 5.53 (0.92, 33.25) 0.66 (0.10, 4.49) 5.14 (0.71, 37.23) -0.05 
  rs1799787 C T 6 76 7 23 229 116 63 36 11.13 (4.49, 27.61) 2.20 (0.71, 6.75) 8.23 (2.92, 23.20) -4.09 
  rs3916874 G C 13 91 0 8 255 135 37 17         
  rs238416 G A 9 82 4 15 234 126 57 26 8.52 (3.66, 19.86) 2.70 (0.76, 9.56) 14.58 (5.25, 40.51) 4.35 
  rs50872 C T 10 63 3 36 213 95 79 57 7.35 (3.1, 17.43) 0.49 (0.14, 1.66) 4.51 (1.78, 11.42) -2.33 
  rs50871 T G 10 80 3 19 219 115 73 37 8.35 (3.6, 19.41) 1.30 (0.35, 4.90) 8.00 (2.99, 21.40) -0.65 
  rs238407 A T 8 77 5 22 218 113 74 39 9.45 (3.96, 22.56) 2.5 (0.77, 8.16) 11.64 (4.37, 30.98) 0.69 
  rs3810366 C G 8 72 5 27 204 108 88 44 8.62 (3.54, 20.96) 1.86 (0.58, 5.95) 11.49 (4.31, 30.64) 2.01 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry 
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Table 3A cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Cigarette Smoking on 
Head and Neck Cancer Risk Using Exact Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a  
Gene SNP 
Referent (A) / 
Variant (B)  
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1  Cigarette=1, SNP=0 
 Cigarette=0, 
SNP=1  Cigarette=1, SNP=1 RERI  
ERCC1 rs735482 A C 10 38 3 61 146 84 146 68 3.86 (1.54, 9.69) 0.28 (0.09, 0.88) 4.85 (1.86, 12.65) 1.71 
  rs2336219 G A 10 40 3 59 147 86 145 66 3.89 (1.56, 9.75) 0.28 (0.09, 0.89) 4.88 (1.87, 12.71) 1.70 
  rs3212964 G A 12 51 1 47 195 91 95 60 4.74 (2.00, 11.24) 0.17 (0.05, 0.61) 3.55 (1.42, 8.85) -0.37 
  rs3212955 A G 7 55 6 44 152 87 140 65 7.13 (2.76, 18.44) 0.78 (0.25, 2.39) 6.55 (2.40, 17.86) -0.36 
  rs3212948 C G 13 2 0 97 9 4 283 148         
  rs3212935 A G 6 51 7 48 137 74 155 77 9.34 (3.46, 25.21) 1.64 (0.53, 5.04) 10.81 (3.85, 30.35) 0.83 
  rs3212930 T C 9 76 4 23 241 129 51 23 8.11 (3.40, 19.35) 1.18 (0.36, 3.87) 8.64 (3.00, 24.91) 0.36 
LIG1 rs156641 G A 9 78 4 21 225 114 67 38 8.64 (3.75, 19.89) 1.69 (0.49, 5.79) 8.80 (3.37, 22.96) -0.53 
  rs20580 C A 3 21 10 78 59 36 232 116 5.72 (1.63, 20.16) 0.76 (0.21, 2.71) 6.42 (1.82, 22.69) 0.93 
  rs20579 C T 8 46 5 53 142 82 150 70 5.62 (2.22, 14.19) 0.67 (0.22, 2.03) 7.42 (2.84, 19.39) 2.14 
  rs439132 A G 8 50 5 49 164 86 128 66 7.69 (3.09, 19.14) 0.74 (0.24, 2.23) 5.72 (2.18, 15.02) -1.70 
OR odds ratio, I interval estimates 
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry 
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Table 4A. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Ever Environmental Tobacco 
Smoke on Head and Neck Cancer Risk  Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a 
Gene SNP 
Referent (A)  / 
Variant (B) 
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 Cigarette=1, SNP=0 Cigarette=0, SNP=1 Cigarette=1, SNP=1 RERI (95% CI) 
ERCC3 (XPB) rs4150496 G A 20 26 22 28 158 110 103 87 1.43 (0.53, 3.85) 1.57 (0.44, 5.65) 0.93 (0.34, 2.54) -1.07 (-3.52, 1.38) 
  rs4150459 G A 27 44 15 10 163 120 100 77 0.95 (0.42, 2.15) 0.99 (0.23, 4.21) 0.88 (0.37, 2.11) -0.05 (-1.59, 1.48) 
  rs1011019 C T 26 31 16 23 157 112 106 85 0.78 (0.32, 1.89) 0.61 (0.16, 2.29) 0.77 (0.32, 1.88) 0.38 (-0.53, 1.29) 
  rs4150434 G A 30 34 12 20 202 152 61 45 1.11 (0.48, 2.53) 2.18 (0.56, 8.45) 1.53 (0.59, 3.98) -0.76 (-3.65, 2.14) 
  rs4150416 T G 14 22 28 32 71 54 191 143 0.75 (0.25, 2.27) 0.76 (0.21, 2.75) 0.81 (0.29, 2.25) 0.29 (-0.75, 1.34) 
  rs4150407 A G 10 18 32 36 74 50 189 147 1.76 (0.46, 6.69) 1.59 (0.37, 6.72) 1.16 (0.32, 4.16) -1.19 (-4.29, 1.92) 
  rs4150402 G A 26 31 16 23 157 112 106 85 0.78 (0.32, 1.89) 0.61 (0.16, 2.29) 0.77 (0.32, 1.88) 0.38 (-0.53, 1.29) 
XPC rs2228001 A C 25 22 17 32 155 112 108 85 0.90 (0.32, 2.49) 0.84 (0.23, 3.09) 0.79 (0.28, 2.23) 0.05 (-1.20, 1.30) 
  rs2228000 C T 34 46 8 8 217 159 46 38 0.92 (0.44, 1.93) 1.00 (0.13, 7.83) 0.96 (0.39, 2.33) 0.04 (-2.10, 2.19) 
  rs3731124 A C 37 43 5 11 215 169 48 28 0.70 (0.33, 1.52) 0.28 (0.05, 1.56) 1.00 (0.38, 2.59) 1.01 (0.22, 1.81) 
  rs3731093 T C 38 43 2 10 225 165 36 31 0.74 (0.35, 1.58) 0.08 (0.01, 0.75) 0.78 (0.29, 2.06) 0.95 (0.36, 1.54) 
  rs3731089 G A 38 43 4 11 225 165 38 32 0.73 (0.34, 1.56) 0.21 (0.03, 1.28) 0.76 (0.29, 1.99) 0.82 (0.17, 1.47) 
  rs2733537 A G 30 37 12 17 182 127 81 70 0.84 (0.37, 1.90) 0.61 (0.14, 2.60) 0.79 (0.34, 1.86) 0.34 (-0.67, 1.35) 
  rs2607755 T C 17 24 25 30 94 85 169 112 0.74 (0.27, 2.06) 0.86 (0.24, 3.04) 0.94 (0.35, 2.56) 0.35 (-0.70, 1.40) 
  rs1902658 G A 5 11 37 43 48 40 215 157 2.15 (0.4, 11.63) 2.04 (0.36, 11.52) 1.58 (0.32, 7.90) -1.61 (-6.18, 2.97) 
ERCC8 rs3117 T C 24 24 18 30 102 70 161 127 0.68 (0.26, 1.78) 0.44 (0.12, 1.60) 0.64 (0.26, 1.60) 0.52 (-0.18, 1.22) 
CDK7 rs2972388 A G 21 36 21 18 139 96 124 101 1.80 (0.72, 4.51) 3.50 (0.92, 13.35) 1.31 (0.52, 3.28) -2.99 (-8.01, 2.03) 
CCNH rs2266691 A G 34 52 8 2 223 169 40 28 1.24 (0.59, 2.58)    
  rs2266692 G T 31 43 11 10 206 159 57 38 0.86 (0.39, 1.85) 1.12 (0.20, 6.18) 1.35 (0.53, 3.42) 0.38 (-1.60, 2.36) 
XPA rs3176757 C T 30 38 12 16 206 155 57 42 0.69 (0.30, 1.57) 0.47 (0.12, 1.91) 0.99 (0.38, 2.55) 0.83 (0, 1.66) 
  rs3176753 T C 30 38 12 16 195 146 68 51 1.04 (0.47, 2.30) 1.33 (0.31, 5.65) 0.90 (0.37, 2.20) -0.47 (-2.51, 1.58) 
 rs3176748 A G 37 42 5 12 213 166 50 31 0.70 (0.32, 1.53) 0.33 (0.06, 1.68) 1.00 (0.37, 2.67) 0.97 (0.13, 1.82) 
  rs3176658 C T 37 44 5 10 223 166 40 31 0.77 (0.35, 1.69) 0.51 (0.10, 2.57) 1.02 (0.38, 2.72) 0.74 (-0.29, 1.77) 
  rs1800975 G A 26 26 15 25 161 115 91 68 0.42 (0.14, 1.21) 0.29 (0.07, 1.17) 0.53 (0.18, 1.57) 0.82 (0.38, 1.25)* 
RAD23B rs1805330 C T 21 33 21 21 162 127 101 70 1.25 (0.50, 3.14) 2.10 (0.57, 7.73) 1.38 (0.53, 3.60) -0.97 (-3.73, 1.79) 
ERCC6 rs2228529 A G 35 37 7 16 199 152 62 44 0.68 (0.31, 1.51) 0.28 (0.06, 1.35) 0.85 (0.33, 2.17) 0.89 (0.24, 1.55) 
  rs2228527 A G 34 35 8 19 184 140 79 57 0.67 (0.29, 1.50) 0.32 (0.07, 1.45) 0.81 (0.33, 2.00) 0.82 (0.19, 1.45) 
  rs4253132 T C 27 30 15 24 164 95 99 102 1.02 (0.40, 2.61) 0.63 (0.18, 2.24) 0.54 (0.21, 1.41) -0.10 (-1.29, 1.09) 
  rs2228528 G A 30 37 12 17 182 145 80 52 0.86 (0.37, 1.97) 0.98 (0.24, 4.00) 1.17 (0.45, 3.01) 0.33 (-1.09, 1.74) 
DDB2 (XPE) rs2029298 A G 9 18 33 36 81 70 182 127 1.80 (0.49, 6.66) 3.09 (0.72, 13.27) 2.28 (0.64, 8.12) -1.61 (-5.78, 2.57) 
  rs1685404 G C 18 24 24 30 146 116 117 81 0.66 (0.21, 2.12) 0.56 (0.14, 2.15) 0.58 (0.18, 1.92) 0.36 (-0.52, 1.25) 
  rs2957873 A G 14 22 28 32 76 60 186 137 0.59 (0.19, 1.87) 0.57 (0.16, 2.13) 0.69 (0.23, 2.04) 0.52 (-0.24, 1.29) 
  rs326224 G A 12 14 30 40 68 49 195 148 0.63 (0.18, 2.23) 0.58 (0.15, 2.30) 0.64 (0.19, 2.11) 0.43 (-0.45, 1.31) 
  rs2306353 G A 17 25 25 29 89 72 174 125 0.44 (0.15, 1.24) 0.39 (0.11, 1.41) 0.64 (0.24, 1.72) 0.81 (0.33, 1.29) 
  rs326222 C T 8 14 34 40 46 36 217 161 1.03 (0.25, 4.24) 1.44 (0.33, 6.24) 1.26 (0.34, 4.65) -0.21 (-2.21, 1.80) 
  rs901746 A G 12 15 30 39 53 43 210 154 0.52 (0.15, 1.82) 0.60 (0.15, 2.30) 0.70 (0.22, 2.20) 0.58 (-0.16, 1.33) 
OR odds ratio, I interval estimates  
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry 
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/79=0.0006).
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Table 4A cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Ever Environmental 
Tobacco Smoke on Head and Neck Cancer Risk  Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a 
Gene SNP 
Referent (A)  / 
Variant (B) 
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 Cigarette=1, SNP=0 Cigarette=0, SNP=1 Cigarette=1, SNP=1 RERI (95% CI) 
ERCC5 (XPG) rs2296147 T C 27 29 15 25 166 119 96 77 0.62 (0.24, 1.56) 0.45 (0.12, 1.66) 0.72 (0.28, 1.88) 0.65 (-0.01, 1.32) 
  rs2296148 C T 30 42 12 12 198 148 64 49 1.39 (0.63, 3.06) 4.74 (1.09, 20.68) 1.32 (0.53, 3.29) -3.80 (-10.86, 3.25) 
  rs4771436 T G 24 35 18 19 180 137 83 60 0.98 (0.41, 2.37) 1.25 (0.34, 4.64) 1.11 (0.43, 2.86) -0.13 (-1.82, 1.56) 
  rs1047768 C T 12 24 30 30 104 91 159 106 1.24 (0.4, 3.88) 2.01 (0.53, 7.70) 1.65 (0.53, 5.09) -0.60 (-3.09, 1.89) 
  rs2020915 G A 33 37 9 17 172 107 91 90 0.87 (0.37, 2.04) 0.32 (0.07, 1.35) 0.42 (0.17, 1.05) 0.24 (-0.55, 1.02) 
  rs3818356 C T 24 35 18 19 182 137 81 60 1 (0.41, 2.41) 1.25 (0.34, 4.63) 1.06 (0.41, 2.74) -0.20 (-1.91, 1.52) 
  rs4150355 C T 29 32 13 22 189 143 74 54 0.55 (0.22, 1.36) 0.39 (0.10, 1.45) 0.88 (0.32, 2.36) 0.94 (0.31, 1.57) 
  rs4150360 T C 1 6 41 48 18 11 245 184     
  rs4150383 G A 32 40 10 14 210 160 53 37 0.78 (0.35, 1.74) 0.62 (0.14, 2.66) 1.03 (0.39, 2.67) 0.63 (-0.43, 1.69) 
  rs17655 C G 12 22 30 32 78 48 185 149 1.70 (0.51, 5.74) 1.54 (0.40, 5.98) 1.09 (0.35, 3.45) -1.15 (-3.98, 1.67) 
  rs873601 A G 4 11 38 43 26 19 237 178 1.77 (0.27, 11.63) 1.43 (0.24, 8.51) 1.20 (0.23, 6.39) -1.00 (-4.82, 2.82) 
  rs876430 C T 4 11 38 43 28 19 235 178 1.95 (0.3, 12.64) 1.43 (0.24, 8.56) 1.19 (0.22, 6.35) -1.19 (-5.33, 2.96) 
  rs1051677 T C 34 39 8 15 198 145 65 52 1.07 (0.49, 2.36) 1.22 (0.26, 5.85) 0.70 (0.29, 1.72) -0.59 (-2.70, 1.52) 
  rs1051685 A G 21 30 21 23 117 87 146 110 0.63 (0.23, 1.74) 0.38 (0.10, 1.38) 0.51 (0.19, 1.39) 0.50 (-0.15, 1.15) 
ERCC4 (XPF) rs3136038 C T 14 21 28 33 78 63 185 134 0.72 (0.22, 2.34) 0.84 (0.22, 3.19) 0.89 (0.29, 2.79) 0.33 (-0.74, 1.40) 
  rs744154 C G 37 42 5 12 184 132 79 65 0.88 (0.41, 1.9) 0.78 (0.13, 4.74) 0.93 (0.41, 2.11) 0.26 (-1.23, 1.76) 
  rs3136085 G C 18 28 24 26 155 118 108 79 1.01 (0.4, 2.58) 1.42 (0.40, 5.00) 1.24 (0.47, 3.26) -0.19 (-1.97, 1.58) 
  rs3136091 C G 41 46 1 8 214 153 49 44 0.91 (0.44, 1.89) 0.12 (0.01, 2.37) 0.64 (0.27, 1.51) 0.60 (-0.02, 1.23) 
  rs3136130 G T 5 15 37 39 70 50 193 147 1.46 (0.31, 6.89) 1.92 (0.38, 9.72) 1.62 (0.36, 7.27) -0.75 (-3.79, 2.29) 
  rs3136172 A G 37 41 5 13 179 130 84 67 0.85 (0.40, 1.83) 0.77 (0.13, 4.69) 0.98 (0.43, 2.24) 0.36 (-1.10, 1.82) 
  rs2020955  T C 17 32 25 22 176 133 87 64 1.1 (0.44, 2.76) 1.19 (0.33, 4.25) 0.82 (0.31, 2.20) -0.47 (-2.23, 1.30) 
RAD23A rs2974752 A G 10 16 31 34 67 46 185 136 1.50 (0.36, 6.17) 1.76 (0.39, 7.96) 1.30 (0.34, 4.99) -0.96 (-3.97, 2.05) 
 rs11558955 A G 37 47 5 7 219 167 44 30 0.92 (0.44, 1.94) 0.94 (0.14, 6.20) 0.93 (0.36, 2.41) 0.06 (-1.83, 1.96) 
ERCC2 (XPD) rs13181 T G 23 36 18 18 150 104 113 91 1.44 (0.55, 3.73) 1.61 (0.45, 5.79) 1.01 (0.39, 2.60) -1.03 (-3.46, 1.40) 
  rs238418 C A 42 3 0 51 8 8 254 189     
  rs1799787 C T 31 45 11 9 204 147 59 50 1.23 (0.55, 2.76) 1.99 (0.46, 8.56) 0.85 (0.34, 2.08) -1.38 (-4.49, 1.74) 
  rs3916874 G C 40 48 2 6 228 178 35 19 0.85 (0.41, 1.76) 0.30 (0.03, 2.81) 0.75 (0.26, 2.13) 0.60 (-0.34, 1.55) 
  rs238416 G A 35 41 7 12 208 167 54 29 0.68 (0.31, 1.48) 0.54 (0.09, 3.06) 1.84 (0.71, 4.80) 1.63 (0.09, 3.16) 
  rs50872 C T 34 30 8 24 189 128 74 69 0.83 (0.37, 1.87) 0.30 (0.07, 1.33) 0.52 (0.22, 1.23) 0.40 (-0.29, 1.09) 
  rs50871 T G 34 39 8 15 195 156 68 41 0.78 (0.35, 1.77) 0.61 (0.14, 2.72) 0.93 (0.37, 2.37) 0.54 (-0.48, 1.56) 
  rs238407 A T 35 40 7 14 191 150 72 47 0.76 (0.34, 1.71) 0.77 (0.16, 3.70) 1.28 (0.51, 3.19) 0.74 (-0.53, 2.02) 
  rs3810366 C G 33 38 9 16 179 142 84 55 0.86 (0.38, 1.95) 1.26 (0.29, 5.52) 1.32 (0.54, 3.24) 0.20 (-1.62, 2.02) 
OR odds ratio, I interval estimates  
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry 
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/79=0.0006). 
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Table 4A cont. Odds Ratios and Relative Excess Risk Estimates for Joint Effects of Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Ever Environmental 
Tobacco Smoke on Head and Neck Cancer Risk  Using Conventional Logistic Regression, the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Cases/Controls OR (95% I)a 
Gene SNP 
Referent (A)  / 
Variant (B) 
Cigarette=0, 
SNP=0 
Cigarette=0, 
SNP=1 
Cigarette=1, 
SNP=0 
Cigarette=1, 
SNP=1 Cigarette=1, SNP=0 Cigarette=0, SNP=1 Cigarette=1, SNP=1 RERI (95% CI) 
ERCC1 rs735482 A C 22 26 20 28 134 96 129 101 1.02 (0.40, 2.55) 1.33 (0.37, 4.82) 1.10 (0.43, 2.79) -0.25 (-2.00, 1.50) 
  rs2336219 G A 22 27 20 27 135 99 128 98 1.01 (0.40, 2.52) 1.33 (0.37, 4.83) 1.11 (0.44, 2.83) -0.23 (-1.98, 1.52) 
  rs3212964 G A 32 31 9 22 175 111 87 85 0.59 (0.24, 1.42) 0.18 (0.04, 0.73) 0.49 (0.19, 1.23) 0.72 (0.31, 1.14) 
  rs3212955 A G 18 33 24 21 141 109 122 88 1.90 (0.73, 4.94) 3.03 (0.81, 11.38) 1.22 (0.47, 3.21) -2.71 (-7.23, 1.80) 
  rs3212948 C G 1 54 41 0 8 6 255 191     
  rs3212935 A G 24 29 18 25 119 96 144 100 0.89 (0.35, 2.27) 1.11 (0.30, 4.11) 1.08 (0.42, 2.73) 0.08 (-1.38, 1.54) 
  rs3212930 T C 33 47 9 7 217 158 46 39 1.29 (0.60, 2.77) 3.79 (0.75, 19.18) 0.89 (0.35, 2.23) -3.19 (-9.50, 3.13) 
LIG1 rs156641 G A 33 39 9 15 201 153 62 44 0.69 (0.30, 1.55) 0.45 (0.10, 1.94) 1.00 (0.39, 2.58) 0.87 (0.03, 1.70) 
  rs20580 C A 13 9 28 45 49 48 214 149 0.40 (0.09, 1.70) 0.50 (0.11, 2.29) 0.62 (0.16, 2.45) 0.73 (0.13, 1.32) 
  rs20579 C T 23 27 19 27 127 101 136 96 1.14 (0.44, 2.99) 1.84 (0.51, 6.60) 1.39 (0.53, 3.68) -0.59 (-2.89, 1.71) 
  rs439132 A G 24 30 18 24 148 106 115 91 1.01 (0.41, 2.50) 0.88 (0.24, 3.27) 0.74 (0.29, 1.89) -0.15 (-1.53, 1.23) 
OR odds ratio, I interval estimates  
aOdds ratios adjusted for matching factors (age and sex including pairwise interactions), education, alcohol drinking, and percent African ancestry 
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/79=0.0006).
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Table 7S. Hazard Ratios for Select Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and and Survival by Stage 
among Head and Neck Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study 
      
Overall Deaths / Deaths from HNC / 
Alive Overall Survival Disease-Specific Survival 
Gene SNP Stage AA AB + BB HR (95% CI)
a
 p-value HR (95% CI)
a
 p-value 
Whites                         
ERCC4 (XPF) rs3136038 1 29 8 65 37 8 90 1.16 (0.71, 1.91) 0.56 0.75 (0.27, 2.05) 0.58 
    2 33 16 39 40 16 55 0.98 (0.61, 1.59) 0.95 0.78 (0.38, 1.59) 0.49 
    3 32 13 36 33 15 56 0.71 (0.42, 1.21) 0.21 0.82 (0.37, 1.82) 0.63 
    4 90 49 78 89 44 120 0.67 (0.49, 0.91) 0.01 0.63 (0.41, 0.96) 0.03 
  rs3136130 1 30 8 64 36 8 91 1.09 (0.66, 1.79) 0.74 0.71 (0.26, 1.94) 0.51 
    2 32 16 38 41 16 56 0.96 (0.59, 1.55) 0.86 0.73 (0.36, 1.49) 0.39 
    3 32 13 37 33 15 55 0.74 (0.44, 1.25) 0.25 0.84 (0.38, 1.87) 0.68 
    4 90 49 77 89 44 121 0.65 (0.48, 0.88) 0.01 0.62 (0.41, 0.93) 0.02 
ERCC2 (XPD) rs50871 1 17 5 32 49 11 123 0.68 (0.38, 1.21) 0.19 0.65 (0.22, 1.97) 0.45 
    2 20 11 32 53 21 62 0.98 (0.56, 1.72) 0.95 0.77 (0.34, 1.71) 0.52 
    3 23 10 20 42 18 72 0.61 (0.35, 1.05) 0.07 0.49 (0.21, 1.14) 0.10 
    4 50 29 48 129 64 150 0.84 (0.6, 1.17) 0.30 0.71 (0.45, 1.11) 0.14 
African Americans                         
ERCC4 (XPF) rs2607755 1 8 0 12 10 1 28 1.19 (0.39, 3.6) 0.76     
    2 10 3 7 18 3 18 0.62 (0.26, 1.49) 0.29 0.21 (0.01, 3.16) 0.26 
    3 9 8 8 19 4 18 1.04 (0.42, 2.59) 0.93 0.62 (0.15, 2.65) 0.52 
    4 43 20 14 45 19 38 0.62 (0.45, 0.86) 0.004 0.5 (0.26, 0.96) 0.04 
HR hazards ratio, CI confidence interval 
a) HR for dominant genetic model (AB + BB vs AA). HRs adjusted for matching factors (age, sex, including pairwise interactions) and ancestry (% 
African ancestry) 
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Table 8S. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
 
  Coded Allele Died/Alive 
Gene SNP 
Referent (A) / 
Variant (B) 
Surgery, 
Referent 
Genotype 
Surgery, 
Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery 
and 
Radiation, 
Referent 
Genotype 
Surgery 
and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherap
y, Referent 
Genotype 
Radiation and 
Chemotherapy
, Variant 
Genotype 
Surgery, 
Radiation, 
Chemotherapy
, Referent 
Genotype 
Surgery, 
Radiation, 
Chemotherapy
, Variant 
Genotype 
ERCC3 
(XPB) rs4150496 G A 31 64 37 80 37 30 40 53 35 50 50 55 40 53 62 65 22 36 21 51 
  rs1011019 C T 32 62 36 82 40 45 37 38 46 52 39 54 49 69 53 49 17 42 26 45 
  rs4150434 G A 48 86 20 58 41 53 36 30 50 58 35 48 63 64 39 54 24 56 19 31 
  rs4150416 T G 28 58 40 86 35 43 42 40 40 46 45 59 41 62 60 56 15 35 28 51 
  rs4150407 A G 23 55 45 89 28 27 49 56 26 38 59 68 35 41 67 77 19 26 24 61 
  rs4150403 G A 49 110 19 34 61 67 16 16 70 88 15 18 81 100 21 18 35 67 8 20 
  rs4150402 G A 32 62 36 82 40 45 37 38 46 52 39 54 49 69 53 49 17 42 26 45 
XPC rs2228001 A C 25 56 43 88 32 33 45 50 27 41 58 64 37 45 65 73 12 26 31 61 
  rs3731143 T C 60 128 8 16 59 80 18 3 75 92 10 14 91 105 11 13 40 79 3 8 
  rs2228000 C T 37 77 31 67 42 51 35 32 47 63 37 43 52 62 49 56 29 58 14 29 
  rs3731124 A C 43 82 25 62 43 43 34 40 54 56 31 50 51 73 51 45 23 52 20 35 
  rs13099160 A G 59 128 9 16 66 76 11 7 77 94 8 12 89 105 13 13 37 75 6 12 
  rs3731093 T C 56 118 12 24 61 73 15 9 73 91 12 14 87 102 13 15 37 70 6 17 
  rs3731089 G A 56 119 12 25 61 73 16 10 73 91 12 15 87 103 15 15 37 70 6 17 
  rs2733537 A G 29 56 39 88 33 46 44 37 35 51 50 55 41 52 61 66 24 44 19 43 
  rs3731068 C A 48 99 20 45 54 52 23 31 63 70 22 36 61 85 41 33 28 61 15 26 
  rs2607755 T C 20 30 48 114 14 20 63 63 31 29 54 77 21 34 81 84 13 29 30 58 
  rs1902658 G A 19 28 49 116 14 20 63 63 31 26 54 80 21 33 81 85 13 29 30 57 
ERCC8 rs3117 T C 19 52 49 92 28 32 49 51 27 40 58 66 33 42 69 76 15 44 28 43 
CDK7 rs2972388 A G 20 33 48 111 15 30 62 53 26 27 59 79 29 39 73 79 18 27 25 60 
XPA rs3176757 C T 48 101 20 43 60 53 17 30 55 65 30 41 60 80 42 38 28 54 15 33 
  rs3176748 A G 34 67 34 77 35 42 42 41 46 46 39 60 46 55 56 63 19 47 24 40 
  rs2808667     C T 59 120 9 24 68 69 9 14 75 94 9 12 95 106 6 12 40 79 3 8 
  rs2805835 G C 53 114 15 30 54 63 23 20 64 89 21 17 84 93 18 25 39 66 4 21 
  rs3176689 A T 43 95 25 49 60 56 17 27 61 72 24 34 68 81 34 37 31 50 12 37 
  rs3176683 T C 57 129 11 15 70 71 7 12 79 91 6 15 89 105 13 13 39 79 4 8 
  rs3176658      C T 54 102 14 42 57 61 20 22 61 78 24 28 85 95 17 23 29 68 14 19 
  rs1800975 G A 38 66 29 74 40 33 36 44 38 41 43 61 45 61 51 54 18 35 24 46 
RAD23B rs1805330 C T 54 116 14 28 64 66 13 17 67 90 18 16 84 106 18 12 31 79 12 8 
  rs1805329  C T 48 95 20 49 51 49 26 34 55 63 30 43 65 66 37 52 34 59 9 28 
ERCC6 rs2228529 A G 46 101 21 42 55 56 22 25 53 60 31 44 64 74 36 42 29 53 14 33 
  rs2228527  A G 46 101 22 43 54 57 23 26 53 60 32 46 64 75 38 43 29 53 14 34 
  rs4253132 T C 54 112 14 32 55 65 22 18 68 88 17 18 76 91 26 27 34 73 9 14 
  rs2228528 G A 51 95 17 49 45 56 32 27 59 78 26 28 78 83 23 35 28 60 15 27 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry (% African ancestry), education, cigarette smoking, and alcohol drinking  
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 8S cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
 
  Coded Allele Died/Alive 
Gene SNP 
Referent (A) / 
Variant (B) 
Surgery, 
Referent 
Genotype 
Surgery, 
Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery 
and 
Radiation, 
Referent 
Genotype 
Surgery 
and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherap
y, Referent 
Genotype 
Radiation and 
Chemotherapy
, Variant 
Genotype 
Surgery, 
Radiation, 
Chemotherapy
, Referent 
Genotype 
Surgery, 
Radiation, 
Chemotherapy
, Variant 
Genotype 
DDB2 
(XPE) rs2029298 A G 29 60 39 84 34 40 43 43 38 51 47 55 48 58 54 60 19 45 24 42 
  rs4647709 C T 57 118 11 26 65 69 12 14 73 92 12 14 85 97 17 21 32 72 11 15 
  rs2291120 T C 50 113 18 31 62 50 15 33 59 87 26 19 76 84 26 34 30 68 13 19 
  rs1685404 G C 34 72 34 72 37 37 40 46 40 49 45 57 41 48 61 70 17 40 26 47 
  rs2957873 A G 46 102 22 42 53 59 24 24 56 74 29 32 66 85 36 33 33 65 10 22 
  rs326224 G A 51 103 17 41 57 65 20 18 60 73 25 33 71 93 31 25 36 69 7 18 
  rs2306353 G A 51 106 17 38 57 67 20 16 62 77 23 29 71 93 31 25 36 71 7 16 
  rs326222 C T 30 76 38 68 36 39 41 44 44 56 41 50 53 68 49 50 25 54 18 33 
  rs901746 A G 30 77 38 67 36 39 41 44 44 56 41 50 53 68 49 50 25 54 18 33 
ERCC5 
(XPG) rs2296147 T C 24 35 44 108 21 18 56 65 26 30 58 76 41 40 60 77 15 27 27 60 
  rs4771436 T G 34 92 34 52 52 54 25 29 47 59 38 47 63 76 39 42 28 54 15 33 
  rs1047768 C T 20 60 48 84 27 33 50 50 24 30 61 76 32 45 70 73 16 29 27 58 
  rs3818356 C T 34 92 34 51 52 54 25 29 47 59 38 47 63 76 38 42 28 54 15 33 
  rs4150351 A C 42 91 26 53 51 46 26 37 64 68 21 38 62 76 40 42 30 60 13 27 
  rs4150355 C T 35 51 33 93 29 37 48 46 33 46 52 60 58 51 44 67 18 39 25 48 
  rs4150360 T C 16 52 52 92 21 28 56 55 23 26 62 80 29 39 73 79 14 24 29 63 
  rs4150383 G A 38 106 30 38 56 60 21 23 54 68 31 38 71 83 31 35 31 57 12 30 
  rs4150386 A C 55 111 13 33 56 62 21 21 70 90 15 16 84 98 18 20 32 58 11 29 
  rs17655 C G 45 94 23 50 42 54 35 29 48 62 37 44 55 71 47 47 26 51 17 36 
  rs873601 A G 40 81 28 63 36 43 41 40 39 51 46 55 44 60 58 58 25 39 18 48 
  rs4150393 A G 49 105 19 39 61 56 16 27 73 82 12 24 76 90 26 28 32 73 11 14 
  rs876430 C T 40 81 28 63 36 43 41 40 39 51 46 55 45 60 57 58 25 39 18 48 
  rs1051677 T C 53 113 15 31 49 66 28 17 79 84 6 21 82 97 20 21 33 71 10 16 
  rs1051685 A G 53 116 15 27 63 65 14 18 63 84 22 22 82 98 20 20 34 70 9 17 
ERCC4 
(XPF) rs3136038 C T 35 54 33 90 30 33 47 50 44 42 41 64 54 51 48 67 18 38 25 49 
  rs1799798 G A 56 114 12 30 66 70 11 13 67 86 18 20 89 95 13 23 37 71 6 16 
  rs744154 C G 37 76 31 68 41 42 36 41 47 48 38 58 60 59 42 59 19 46 24 41 
  rs3136085 G C 37 75 31 69 39 42 38 41 46 49 39 57 60 59 42 59 19 44 24 43 
  rs3136130 G T 35 53 33 91 29 33 48 50 45 42 40 64 54 51 48 67 18 37 25 50 
  rs1800067 G A 55 126 13 18 64 73 13 10 71 86 14 20 91 96 11 22 35 74 8 13 
  rs3136172 A G 35 75 33 69 37 41 40 42 43 47 42 59 57 58 45 60 19 41 24 46 
RAD23A rs2974752 A G 29 46 38 95 33 33 43 47 25 32 56 70 30 54 67 62 14 32 28 52 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry (% African ancestry), education, cigarette smoking, and alcohol drinking  
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 8S. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
 
  Coded Allele Died/Alive 
Gene SNP 
Referent (A) / 
Variant (B) 
Surgery, 
Referent 
Genotype 
Surgery, 
Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery 
and 
Radiation, 
Referent 
Genotype 
Surgery 
and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherap
y, Referent 
Genotype 
Radiation and 
Chemotherapy
, Variant 
Genotype 
Surgery, 
Radiation, 
Chemotherapy
, Referent 
Genotype 
Surgery, 
Radiation, 
Chemotherapy
, Variant 
Genotype 
ERCC2 
(XPD) rs13181 T G 25 61 42 83 29 41 46 42 40 38 45 67 40 50 61 67 14 37 28 50 
  rs238418 C A 26 60 42 84 30 41 47 42 40 39 45 67 39 49 63 69 15 37 28 50 
  rs1799787 C T 34 72 34 72 38 48 39 35 46 52 39 54 53 56 49 62 19 47 24 40 
  rs3916874 G C 39 74 29 70 42 31 35 52 44 55 41 51 58 58 44 60 23 49 20 38 
  rs238416 G A 26 58 42 86 37 35 40 48 29 43 56 63 40 48 62 69 18 33 25 54 
  rs50872 C T 40 71 28 72 42 49 35 33 52 62 33 44 55 70 47 48 31 53 12 34 
  rs50871 T G 15 36 53 108 22 23 55 60 27 21 58 85 33 26 69 92 11 26 32 61 
  rs238407 A T 21 32 47 112 23 23 54 59 29 33 56 73 29 28 73 90 16 26 27 61 
  rs3810366 C G 13 24 55 120 13 17 64 66 18 20 67 86 22 18 80 100 10 20 33 66 
ERCC1 rs735482 A C 53 111 15 33 58 68 19 15 58 76 27 30 71 98 31 20 31 57 12 30 
  rs2336219 G A 53 111 15 33 58 68 19 15 58 76 27 30 71 98 31 20 31 57 12 30 
  rs3212964 G A 53 111 15 33 58 68 19 15 59 77 26 29 71 99 31 19 32 57 11 30 
  rs3212955 A G 35 74 33 70 39 51 38 32 48 59 37 47 59 75 43 43 23 59 20 28 
  rs3212948 C G 27 55 41 89 30 42 47 41 35 40 50 66 42 56 60 62 16 35 27 52 
  rs3212930 T C 42 79 26 65 46 54 31 29 55 61 30 45 67 79 35 39 25 61 18 26 
LIG1 rs156641 G A 25 51 43 93 35 32 42 51 25 49 60 57 39 47 63 71 23 39 20 48 
  rs20580 C A 12 31 56 113 26 27 51 56 17 28 68 78 24 27 78 91 16 27 27 60 
  rs20579 C T 51 101 17 43 58 65 19 18 72 73 13 33 73 90 29 28 34 68 9 19 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry (% African ancestry), education, cigarette smoking, and alcohol drinking  
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 8S cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
  HR (95% CI)
a
 
Gene SNP 
Surgery, Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery and 
Radiation, 
Referent 
Genotype 
Surgery and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Radiation and 
Chemotherapy, 
Variant 
Genotype 
Surgery, 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Surgery, 
Radiation, and 
Chemotherapy, 
Variant 
Genotype 
ERCC3 
(XPB) rs4150496 0.72 (0.43, 1.19) 1.23 (0.71, 2.12) 1.36 (0.80, 2.32) 1.00 (0.58, 1.71) 0.94 (0.56, 1.56) 0.94 (0.53, 1.68) 0.95 (0.57, 1.60) 1.17 (0.62, 2.22) 0.60 (0.32, 1.12) 
  rs1011019 0.93 (0.57, 1.53) 1.72 (1.01, 2.93) 1.36 (0.81, 2.30) 1.14 (0.69, 1.88) 1.14 (0.68, 1.9) 1.02 (0.61, 1.72) 1.24 (0.72, 2.12) 0.66 (0.34, 1.29) 1.24 (0.68, 2.25) 
  rs4150434 0.73 (0.42, 1.27) 1.21 (0.75, 1.95) 1.75 (1.07, 2.89) 1.13 (0.71, 1.79) 0.97 (0.59, 1.59) 1.03 (0.64, 1.67) 1.03 (0.61, 1.75) 0.79 (0.44, 1.41) 0.96 (0.51, 1.80) 
  rs4150416 1.13 (0.68, 1.87) 1.77 (1.01, 3.10) 1.64 (0.96, 2.79) 1.24 (0.72, 2.12) 1.29 (0.77, 2.17) 1.11 (0.64, 1.94) 1.34 (0.77, 2.32) 0.73 (0.36, 1.50) 1.32 (0.72, 2.41) 
  rs4150407 0.87 (0.51, 1.49) 1.19 (0.64, 2.21) 1.64 (0.94, 2.85) 1.04 (0.56, 1.92) 1.07 (0.63, 1.84) 1.16 (0.62, 2.18) 1.00 (0.57, 1.75) 1.41 (0.70, 2.83) 0.67 (0.35, 1.29) 
  rs4150403 1.26 (0.71, 2.25) 1.86 (1.20, 2.89) 1.22 (0.64, 2.32) 1.23 (0.81, 1.87) 1.26 (0.68, 2.33) 1.14 (0.73, 1.78) 1.64 (0.88, 3.03) 1.05 (0.63, 1.77) 0.86 (0.38, 1.95) 
  rs4150402 0.93 (0.57, 1.53) 1.72 (1.01, 2.93) 1.36 (0.81, 2.30) 1.14 (0.69, 1.88) 1.14 (0.68, 1.90) 1.02 (0.61, 1.72) 1.24 (0.72, 2.12) 0.66 (0.34, 1.29) 1.24 (0.68, 2.25) 
XPC rs2228001 1.08 (0.64, 1.82) 1.49 (0.83, 2.66) 1.81 (1.05, 3.12) 0.88 (0.48, 1.63) 1.45 (0.87, 2.43) 1.14 (0.64, 2.05) 1.21 (0.70, 2.10) 0.90 (0.43, 1.89) 1.04 (0.56, 1.92) 
  rs3731143 0.96 (0.43, 2.13) 1.39 (0.91, 2.10) 3.53 (1.84, 6.77) 1.14 (0.76, 1.71) 1.35 (0.66, 2.78) 1.18 (0.76, 1.82) 0.96 (0.46, 2.02) 0.99 (0.60, 1.63) 0.60 (0.18, 2.00) 
  rs2228000 0.96 (0.58, 1.58) 1.58 (0.96, 2.59) 1.52 (0.89, 2.59) 1.13 (0.70, 1.85) 1.15 (0.69, 1.92) 1.05 (0.62, 1.76) 1.21 (0.71, 2.06) 0.95 (0.53, 1.70) 0.92 (0.46, 1.82) 
  rs3731124 0.85 (0.50, 1.43) 1.65 (1.00, 2.72) 1.38 (0.84, 2.27) 1.36 (0.85, 2.17) 0.82 (0.49, 1.39) 0.90 (0.54, 1.50) 1.38 (0.83, 2.28) 0.92 (0.51, 1.67) 0.88 (0.48, 1.64) 
  rs13099160 1.10 (0.52, 2.33) 1.57 (1.04, 2.37) 1.64 (0.80, 3.37) 1.21 (0.81, 1.79) 0.93 (0.43, 2.02) 1.08 (0.69, 1.67) 1.86 (0.95, 3.62) 0.93 (0.56, 1.54) 1.12 (0.45, 2.75) 
  rs3731093 1.05 (0.54, 2.01) 1.47 (0.97, 2.25) 1.93 (1.03, 3.64) 1.19 (0.79, 1.79) 1.11 (0.57, 2.16) 1.08 (0.69, 1.68) 1.54 (0.79, 3.02) 1.00 (0.60, 1.68) 0.75 (0.31, 1.84) 
  rs3731089 1.03 (0.53, 1.97) 1.48 (0.97, 2.26) 2.01 (1.08, 3.72) 1.19 (0.79, 1.79) 1.04 (0.53, 2.02) 1.07 (0.69, 1.67) 1.70 (0.89, 3.23) 1.00 (0.60, 1.66) 0.75 (0.31, 1.83) 
  rs2733537 0.92 (0.56, 1.53) 1.43 (0.82, 2.49) 1.57 (0.93, 2.66) 1.08 (0.62, 1.86) 1.14 (0.69, 1.90) 0.92 (0.52, 1.63) 1.24 (0.72, 2.13) 1.00 (0.53, 1.87) 0.83 (0.43, 1.59) 
  rs3731068 0.93 (0.54, 1.59) 1.78 (1.11, 2.84) 1.29 (0.75, 2.22) 1.32 (0.85, 2.04) 0.80 (0.45, 1.44) 0.93 (0.57, 1.51) 1.61 (0.95, 2.72) 0.87 (0.50, 1.53) 1.03 (0.53, 2.01) 
  rs2607755 0.72 (0.42, 1.24) 1.17 (0.55, 2.50) 1.26 (0.72, 2.23) 1.21 (0.64, 2.27) 0.81 (0.46, 1.43) 0.68 (0.34, 1.36) 1.01 (0.56, 1.83) 0.81 (0.37, 1.79) 0.74 (0.38, 1.41) 
  rs1902658 0.74 (0.43, 1.29) 1.20 (0.56, 2.58) 1.29 (0.73, 2.30) 1.31 (0.69, 2.49) 0.81 (0.45, 1.45) 0.71 (0.35, 1.43) 1.03 (0.57, 1.88) 0.83 (0.37, 1.86) 0.76 (0.39, 1.48) 
ERCC8 rs3117 1.23 (0.71, 2.15) 1.37 (0.72, 2.59) 2.22 (1.24, 3.97) 1.05 (0.56, 2.00) 1.53 (0.87, 2.68) 1.07 (0.56, 2.03) 1.45 (0.81, 2.60) 0.97 (0.46, 2.06) 1.15 (0.59, 2.21) 
CDK7 rs2972388 0.57 (0.33, 0.99) 0.61 (0.28, 1.29) 1.25 (0.72, 2.16) 0.77 (0.41, 1.44) 0.76 (0.44, 1.33) 0.58 (0.30, 1.11) 0.87 (0.49, 1.54) 0.95 (0.46, 1.94) 0.51 (0.26, 0.98) 
XPA rs3176757 0.98 (0.57, 1.68) 1.75 (1.13, 2.72) 1.15 (0.62, 2.12) 1.18 (0.75, 1.85) 1.13 (0.68, 1.87) 1.02 (0.63, 1.66) 1.33 (0.80, 2.22) 0.99 (0.56, 1.73) 0.88 (0.46, 1.69) 
  rs3176748 0.93 (0.57, 1.53) 1.44 (0.85, 2.43) 1.61 (0.96, 2.69) 1.23 (0.75, 2.02) 1.03 (0.62, 1.71) 1.12 (0.66, 1.89) 1.11 (0.66, 1.88) 0.71 (0.38, 1.35) 1.21 (0.66, 2.22) 
  rs2808667     0.55 (0.27, 1.14) 1.50 (1.00, 2.26) 1.04 (0.46, 2.34) 1.03 (0.69, 1.54) 1.17 (0.56, 2.47) 1.03 (0.67, 1.59) 0.90 (0.37, 2.20) 0.86 (0.52, 1.41) 0.78 (0.24, 2.61) 
  rs2805835 1.19 (0.65, 2.19) 1.50 (0.97, 2.33) 2.08 (1.19, 3.63) 1.11 (0.73, 1.70) 1.54 (0.89, 2.67) 1.21 (0.77, 1.91) 1.04 (0.56, 1.94) 1.18 (0.72, 1.96) 0.29 (0.09, 0.97) 
  rs3176689 1.10 (0.65, 1.84) 1.86 (1.17, 2.96) 1.21 (0.66, 2.21) 1.24 (0.80, 1.93) 1.11 (0.63, 1.95) 1.17 (0.72, 1.90) 1.25 (0.72, 2.15) 1.22 (0.70, 2.13) 0.66 (0.32, 1.32) 
  rs3176683 1.29 (0.67, 2.51) 1.69 (1.13, 2.54) 1.36 (0.53, 3.45) 1.31 (0.88, 1.96) 0.64 (0.27, 1.54) 1.23 (0.79, 1.91) 1.04 (0.53, 2.06) 0.99 (0.60, 1.64) 0.91 (0.31, 2.61) 
  rs3176658      0.61 (0.33, 1.12) 1.41 (0.92, 2.16) 1.35 (0.74, 2.44) 1.02 (0.67, 1.56) 1.04 (0.61, 1.79) 1.01 (0.64, 1.57) 1.05 (0.55, 2.00) 0.76 (0.44, 1.30) 1.11 (0.55, 2.24) 
  rs1800975 0.66 (0.40, 1.10) 1.47 (0.88, 2.46) 1.17 (0.69, 1.96) 1.03 (0.61, 1.74) 0.83 (0.50, 1.37) 0.77 (0.45, 1.32) 1.02 (0.61, 1.72) 0.78 (0.41, 1.48) 0.77 (0.42, 1.42) 
RAD23B rs1805330 1.56 (0.85, 2.88) 1.72 (1.13, 2.62) 1.69 (0.85, 3.37) 1.20 (0.79, 1.83) 1.43 (0.79, 2.60) 1.14 (0.73, 1.80) 1.69 (0.93, 3.09) 0.85 (0.50, 1.45) 1.66 (0.83, 3.33) 
  rs1805329  0.81 (0.47, 1.40) 1.49 (0.95, 2.34) 1.46 (0.85, 2.52) 1.20 (0.77, 1.88) 0.96 (0.58, 1.60) 1.08 (0.67, 1.72) 1.12 (0.67, 1.89) 0.99 (0.58, 1.70) 0.70 (0.32, 1.49) 
ERCC6 rs2228529 0.89 (0.52, 1.54) 1.53 (0.97, 2.44) 1.47 (0.84, 2.58) 1.23 (0.78, 1.95) 0.99 (0.59, 1.66) 0.97 (0.59, 1.57) 1.49 (0.86, 2.57) 1.14 (0.65, 1.99) 0.68 (0.34, 1.34) 
  rs2228527  0.94 (0.55, 1.60) 1.58 (1.00, 2.51) 1.50 (0.85, 2.63) 1.25 (0.79, 1.99) 1.02 (0.61, 1.69) 0.99 (0.61, 1.61) 1.48 (0.86, 2.54) 1.15 (0.66, 2.02) 0.68 (0.34, 1.34) 
  rs4253132 0.90 (0.48, 1.68) 1.41 (0.92, 2.17) 1.99 (1.14, 3.48) 1.11 (0.73, 1.68) 1.20 (0.67, 2.15) 1.17 (0.75, 1.81) 0.95 (0.53, 1.67) 0.93 (0.55, 1.55) 0.90 (0.42, 1.94) 
  rs2228528 0.65 (0.36, 1.18) 1.30 (0.83, 2.03) 1.66 (0.98, 2.79) 0.99 (0.64, 1.51) 1.23 (0.73, 2.08) 1.04 (0.66, 1.64) 0.98 (0.55, 1.75) 0.86 (0.50, 1.48) 0.86 (0.44, 1.65) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry (% African ancestry), education, cigarette smoking, and alcohol drinking  
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 8S cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
  HR (95% CI)
a
 
Gene SNP 
Surgery, Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery and 
Radiation, 
Referent 
Genotype 
Surgery and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Radiation and 
Chemotherapy, 
Variant 
Genotype 
Surgery, 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Surgery, 
Radiation, and 
Chemotherapy, 
Variant 
Genotype 
DDB2 
(XPE) rs2029298 0.76 (0.46, 1.27) 1.20 (0.68, 2.10) 1.46 (0.88, 2.44) 0.93 (0.55, 1.58) 1.06 (0.64, 1.75) 0.93 (0.54, 1.61) 1.02 (0.61, 1.72) 0.68 (0.35, 1.30) 0.96 (0.52, 1.77) 
  rs4647709 0.88 (0.43, 1.81) 1.54 (1.02, 2.34) 1.59 (0.80, 3.16) 1.12 (0.74, 1.67) 1.35 (0.68, 2.69) 1.14 (0.73, 1.78) 1.08 (0.57, 2.02) 0.81 (0.48, 1.37) 1.79 (0.84, 3.80) 
  rs2291120 1.14 (0.65, 1.99) 1.87 (1.22, 2.86) 0.93 (0.47, 1.86) 1.01 (0.65, 1.57) 2.02 (1.18, 3.45) 1.17 (0.73, 1.88) 1.24 (0.70, 2.18) 0.95 (0.55, 1.64) 1.09 (0.54, 2.20) 
  rs1685404 0.99 (0.60, 1.65) 1.70 (1.00, 2.89) 1.45 (0.85, 2.45) 1.22 (0.72, 2.06) 1.11 (0.67, 1.85) 0.96 (0.55, 1.67) 1.30 (0.76, 2.21) 0.88 (0.45, 1.71) 1.01 (0.55, 1.86) 
  rs2957873 1.08 (0.64, 1.84) 1.59 (1.01, 2.49) 1.68 (0.96, 2.96) 1.17 (0.75, 1.83) 1.23 (0.73, 2.08) 1.10 (0.68, 1.78) 1.33 (0.78, 2.26) 0.99 (0.58, 1.71) 0.91 (0.43, 1.92) 
  rs326224 0.81 (0.45, 1.45) 1.43 (0.93, 2.21) 1.73 (0.97, 3.10) 1.12 (0.73, 1.72) 1.07 (0.63, 1.82) 0.99 (0.63, 1.58) 1.38 (0.80, 2.37) 0.92 (0.54, 1.54) 0.79 (0.34, 1.84) 
  rs2306353 0.81 (0.45, 1.45) 1.40 (0.91, 2.17) 1.87 (1.05, 3.35) 1.13 (0.74, 1.73) 1.04 (0.60, 1.80) 1.00 (0.63, 1.59) 1.38 (0.80, 2.37) 0.90 (0.53, 1.52) 0.88 (0.38, 2.05) 
  rs326222 1.13 (0.68, 1.87) 1.69 (0.98, 2.92) 1.67 (1.00, 2.80) 1.34 (0.80, 2.23) 1.15 (0.69, 1.93) 1.15 (0.67, 1.98) 1.29 (0.76, 2.18) 0.96 (0.52, 1.78) 1.07 (0.56, 2.06) 
  rs901746 1.13 (0.68, 1.88) 1.69 (0.98, 2.93) 1.67 (1.00, 2.81) 1.34 (0.80, 2.24) 1.15 (0.69, 1.93) 1.16 (0.67, 1.99) 1.29 (0.76, 2.19) 0.97 (0.52, 1.79) 1.08 (0.56, 2.06) 
ERCC5 
(XPG) rs2296147 0.75 (0.44, 1.27) 1.28 (0.66, 2.50) 1.31 (0.77, 2.22) 1.20 (0.65, 2.23) 0.86 (0.50, 1.48) 1.02 (0.56, 1.85) 0.88 (0.49, 1.56) 0.81 (0.39, 1.69) 0.74 (0.39, 1.40) 
  rs4771436 1.28 (0.78, 2.11) 1.89 (1.16, 3.08) 1.53 (0.85, 2.77) 1.02 (0.73, 1.97) 1.47 (0.87, 2.47) 1.24 (0.74, 2.07) 1.36 (0.78, 2.40) 1.15 (0.64, 2.06) 0.94 (0.47, 1.90) 
  rs1047768 1.36 (0.79, 2.36) 1.79 (0.95, 3.37) 2.10 (1.16, 3.79) 1.26 (0.66, 2.40) 1.56 (0.88, 2.75) 1.29 (0.67, 2.48) 1.53 (0.84, 2.79) 1.34 (0.63, 2.82) 1.12 (0.57, 2.18) 
  rs3818356 1.29 (0.78, 2.13) 1.90 (1.16, 3.09) 1.53 (0.85, 2.77) 1.20 (0.73, 1.98) 1.47 (0.87, 2.47) 1.25 (0.75, 2.09) 1.34 (0.76, 2.36) 1.14 (0.63, 2.06) 0.95 (0.47, 1.90) 
  rs4150351 0.94 (0.56, 1.58) 2.01 (1.24, 3.24) 1.09 (0.63, 1.87) 1.21 (0.77, 1.91) 0.92 (0.52, 1.63) 1.07 (0.65, 1.76) 1.15 (0.68, 1.94) 0.90 (0.52, 1.56) 0.96 (0.47, 1.95) 
  rs4150355 0.73 (0.44, 1.21) 1.07 (0.61, 1.89) 1.54 (0.94, 2.54) 1.08 (0.62, 1.86) 0.94 (0.58, 1.54) 1.17 (0.69, 1.98) 0.78 (0.45, 1.36) 0.77 (0.40, 1.48) 0.86 (0.46, 1.59) 
  rs4150360 1.40 (0.78, 2.50) 1.63 (0.81, 3.29) 2.27 (1.23, 4.19) 1.49 (0.75, 2.95) 1.51 (0.83, 2.75) 1.37 (0.68, 2.74) 1.53 (0.82, 2.88) 1.43 (0.64, 3.19) 1.14 (0.57, 2.27) 
  rs4150383 1.54 (0.93, 2.55) 1.96 (1.24, 3.11) 1.54 (0.84, 2.85) 1.27 (0.79, 2.03) 1.58 (0.93, 2.69) 1.34 (0.82, 2.19) 1.38 (0.78, 2.45) 1.24 (0.70, 2.18) 0.93 (0.45, 1.90) 
  rs4150386 1.22 (0.64, 2.31) 1.53 (1.00, 2.36) 2.07 (1.15, 3.70) 1.14 (0.75, 1.72) 1.64 (0.88, 3.07) 1.12 (0.72, 1.77) 1.50 (0.81, 2.77) 1.06 (0.62, 1.79) 0.79 (0.39, 1.63) 
  rs17655 1.05 (0.62, 1.78) 1.39 (0.86, 2.24) 2.03 (1.21, 3.41) 1.12 (0.70, 1.78) 1.27 (0.77, 2.10) 1.14 (0.70, 1.87) 1.19 (0.71, 2.01) 0.99 (0.55, 1.77) 0.91 (0.48, 1.71) 
  rs873601 0.92 (0.55, 1.53) 1.36 (0.81, 2.27) 1.73 (1.04, 2.86) 1.02 (0.62, 1.69) 1.23 (0.76, 1.99) 1.08 (0.64, 1.82) 1.13 (0.68, 1.88) 1.12 (0.62, 2.03) 0.73 (0.39, 1.38) 
  rs4150393 0.98 (0.56, 1.69) 1.89 (1.22, 2.95) 0.99 (0.54, 1.83) 1.24 (0.81, 1.89) 0.81 (0.41, 1.59) 1.07 (0.67, 1.71) 1.29 (0.74, 2.25) 0.83 (0.49, 1.42) 1.41 (0.66, 2.98) 
  rs876430 0.92 (0.55, 1.53) 1.36 (0.81, 2.27) 1.73 (1.04, 2.86) 1.02 (0.62, 1.69) 1.23 (0.76, 1.99) 1.10 (0.65, 1.86) 1.10 (0.66, 1.84) 1.12 (0.62, 2.03) 0.73 (0.39, 1.38) 
  rs1051677 0.84 (0.46, 1.54) 1.32 (0.84, 2.07) 1.97 (1.17, 3.31) 1.25 (0.83, 1.86) 0.46 (0.18, 1.18) 1.14 (0.73, 1.78) 0.97 (0.53, 1.79) 0.85 (0.51, 1.44) 1.22 (0.58, 2.57) 
  rs1051685 0.96 (0.53, 1.73) 1.58 (1.03, 2.41) 1.37 (0.70, 2.70) 1.08 (0.70, 1.67) 1.40 (0.79, 2.45) 1.11 (0.70, 1.75) 1.19 (0.63, 2.21) 0.91 (0.54, 1.55) 1.01 (0.45, 2.28) 
ERCC4 
(XPF) rs3136038 0.63 (0.38, 1.04) 1.20 (0.70, 2.06) 1.30 (0.80, 2.12) 1.16 (0.72, 1.88) 0.73 (0.44, 1.22) 1.10 (0.67, 1.83) 0.74 (0.44, 1.25) 0.76 (0.39, 1.46) 0.74 (0.41, 1.33) 
  rs1799798 0.85 (0.45, 1.62) 1.55 (1.02, 2.35) 1.39 (0.65, 2.95) 1.10 (0.72, 1.67) 1.30 (0.73, 2.33) 1.16 (0.74, 1.83) 0.89 (0.45, 1.78) 0.98 (0.59, 1.64) 0.61 (0.21, 1.77) 
  rs744154 1.00 (0.60, 1.66) 1.59 (0.97, 2.63) 1.58 (0.95, 2.63) 1.39 (0.86, 2.22) 0.95 (0.57, 1.59) 1.36 (0.84, 2.22) 0.91 (0.54, 1.55) 0.88 (0.47, 1.67) 0.99 (0.55, 1.79) 
  rs3136085 0.99 (0.59, 1.64) 1.51 (0.91, 2.50) 1.65 (1.00, 2.72) 1.36 (0.85, 2.18) 0.96 (0.58, 1.60) 1.37 (0.84, 2.23) 0.90 (0.53, 1.52) 0.92 (0.49, 1.74) 0.96 (0.53, 1.73) 
  rs3136130 0.62 (0.38, 1.03) 1.15 (0.67, 1.98) 1.32 (0.81, 2.14) 1.19 (0.73, 1.92) 0.70 (0.42, 1.17) 1.11 (0.67, 1.85) 0.73 (0.43, 1.23) 0.76 (0.40, 1.47) 0.73 (0.41, 1.32) 
  rs1800067 1.31 (0.70, 2.45) 1.58 (1.04, 2.41) 2.26 (1.16, 4.40) 1.28 (0.85, 1.94) 1.00 (0.53, 1.91) 1.26 (0.81, 1.97) 0.86 (0.41, 1.78) 0.98 (0.58, 1.64) 1.07 (0.47, 2.41) 
  rs3136172 1.05 (0.64, 1.74) 1.51 (0.90, 2.54) 1.72 (1.04, 2.85) 1.38 (0.85, 2.25) 1.02 (0.61, 1.69) 1.37 (0.83, 2.27) 0.97 (0.57, 1.64) 0.98 (0.52, 1.87) 0.95 (0.53, 1.72) 
RAD23A rs2974752 0.67 (0.40, 1.12) 1.49 (0.84, 2.63) 1.15 (0.68, 1.95) 0.81 (0.44, 1.49) 0.93 (0.56, 1.56) 0.59 (0.32, 1.09) 1.06 (0.61, 1.82) 0.62 (0.30, 1.28) 0.77 (0.42, 1.42) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry (% African ancestry), education, cigarette smoking, and alcohol drinking  
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 8S cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
  HR (95% CI)
a
 
Gene SNP 
Surgery, Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery and 
Radiation, 
Referent 
Genotype 
Surgery and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Radiation and 
Chemotherapy, 
Variant 
Genotype 
Surgery, 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Surgery, 
Radiation, and 
Chemotherapy, 
Variant 
Genotype 
ERCC2 
(XPD) rs13181 1.20 (0.71, 2.03) 1.50 (0.83, 2.73) 1.88 (1.07, 3.30) 1.48 (0.84, 2.59) 1.16 (0.67, 2.01) 1.34 (0.74, 2.43) 1.19 (0.67, 2.12) 0.74 (0.34, 1.57) 1.19 (0.64, 2.23) 
  rs238418 1.17 (0.70, 1.96) 1.56 (0.87, 2.81) 1.91 (1.10, 3.32) 1.50 (0.86, 2.61) 1.13 (0.66, 1.95) 1.33 (0.74, 2.41) 1.21 (0.68, 2.13) 0.80 (0.38, 1.67) 1.19 (0.64, 2.22) 
  rs1799787 1.09 (0.66, 1.81) 1.56 (0.92, 2.66) 1.78 (1.04, 3.03) 1.31 (0.78, 2.19) 1.15 (0.68, 1.95) 1.40 (0.81, 2.42) 1.04 (0.60, 1.80) 0.80 (0.41, 1.56) 1.21 (0.66, 2.24) 
  rs3916874 0.68 (0.41, 1.14) 1.51 (0.93, 2.44) 1.13 (0.67, 1.90) 1.04 (0.65, 1.68) 0.90 (0.55, 1.48) 0.98 (0.59, 1.62) 0.95 (0.57, 1.58) 0.79 (0.44, 1.42) 0.80 (0.43, 1.51) 
  rs238416 1.09 (0.65, 1.81) 1.78 (1.01, 3.13) 1.57 (0.92, 2.69) 0.99 (0.55, 1.78) 1.37 (0.82, 2.27) 1.13 (0.64, 2.00) 1.26 (0.73, 2.17) 1.22 (0.63, 2.37) 0.86 (0.46, 1.63) 
  rs50872 0.71 (0.42, 1.19) 1.28 (0.77, 2.11) 1.84 (1.11, 3.07) 0.95 (0.59, 1.54) 1.03 (0.61, 1.73) 0.95 (0.57, 1.59) 0.98 (0.58, 1.66) 0.87 (0.49, 1.54) 0.64 (0.31, 1.30) 
  rs50871 1.20 (0.65, 2.20) 1.72 (0.85, 3.48) 1.81 (0.97, 3.37) 2.19 (1.10, 4.34) 1.11 (0.60, 2.05) 1.48 (0.73, 2.96) 1.24 (0.66, 2.35) 1.04 (0.44, 2.43) 1.10 (0.55, 2.19) 
  rs238407 0.65 (0.38, 1.11) 1.26 (0.65, 2.47) 1.30 (0.74, 2.27) 0.76 (0.41, 1.43) 0.89 (0.52, 1.53) 0.97 (0.51, 1.84) 0.80 (0.45, 1.40) 0.80 (0.39, 1.63) 0.61 (0.32, 1.17) 
  rs3810366 0.85 (0.45, 1.61) 0.95 (0.40, 2.30) 1.49 (0.77, 2.86) 1.09 (0.50, 2.39) 1.00 (0.52, 1.91) 1.29 (0.60, 2.80) 0.94 (0.48, 1.84) 0.81 (0.33, 1.97) 0.83 (0.40, 1.73) 
ERCC1 rs735482 1.19 (0.64, 2.18) 1.55 (1.01, 2.39) 1.93 (1.07, 3.51) 1.21 (0.78, 1.86) 1.22 (0.72, 2.07) 1.10 (0.70, 1.75) 1.45 (0.84, 2.51) 1.02 (0.60, 1.74) 0.91 (0.46, 1.84) 
  rs2336219 1.19 (0.64, 2.18) 1.55 (1.01, 2.39) 1.93 (1.07, 3.51) 1.21 (0.78, 1.86) 1.22 (0.72, 2.07) 1.10 (0.70, 1.75) 1.45 (0.84, 2.51) 1.02 (0.60, 1.74) 0.91 (0.46, 1.84) 
  rs3212964 1.19 (0.65, 2.19) 1.55 (1.01, 2.39) 1.93 (1.06, 3.51) 1.21 (0.79, 1.86) 1.22 (0.72, 2.07) 1.09 (0.69, 1.72) 1.51 (0.87, 2.60) 1.05 (0.62, 1.79) 0.85 (0.41, 1.74) 
  rs3212955 1.07 (0.65, 1.76) 1.57 (0.93, 2.65) 1.71 (1.00, 2.91) 1.13 (0.69, 1.86) 1.33 (0.78, 2.26) 1.16 (0.68, 1.95) 1.25 (0.71, 2.18) 0.79 (0.42, 1.48) 1.32 (0.70, 2.49) 
  rs3212948 1.11 (0.67, 1.85) 1.55 (0.87, 2.78) 1.77 (1.03, 3.04) 1.25 (0.71, 2.19) 1.23 (0.72, 2.09) 1.26 (0.71, 2.25) 1.19 (0.68, 2.08) 0.89 (0.43, 1.84) 1.08 (0.58, 2.02) 
  rs3212930 0.79 (0.48, 1.31) 1.54 (0.95, 2.48) 1.26 (0.73, 2.18) 1.14 (0.72, 1.81) 0.91 (0.53, 1.56) 1.04 (0.64, 1.69) 1.03 (0.60, 1.79) 0.70 (0.39, 1.26) 1.21 (0.64, 2.29) 
LIG1 rs156641 0.85 (0.51, 1.43) 1.39 (0.78, 2.45) 1.44 (0.84, 2.47) 0.84 (0.46, 1.53) 1.17 (0.70, 1.97) 0.90 (0.50, 1.63) 1.12 (0.65, 1.93) 0.87 (0.46, 1.66) 0.83 (0.42, 1.62) 
  rs20580 1.15 (0.61, 2.17) 1.51 (0.72, 3.15) 1.87 (0.97, 3.61) 1.01 (0.46, 2.22) 1.38 (0.72, 2.64) 1.17 (0.55, 2.51) 1.28 (0.65, 2.51) 1.15 (0.52, 2.58) 0.99 (0.47, 2.09) 
  rs20579 0.95 (0.54, 1.66) 1.68 (1.07, 2.63) 1.32 (0.72, 2.41) 1.28 (0.84, 1.95) 0.76 (0.40, 1.47) 1.07 (0.68, 1.70) 1.34 (0.77, 2.31) 1.02 (0.60, 1.74) 0.70 (0.31, 1.55) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry (% African ancestry), education, cigarette smoking, and alcohol drinking  
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected level (0.05/84=0.0006). 
 
2
0
7
 
  
Table 8S cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) 
Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the Carolina Head and Neck 
Cancer Epidemiology (CHANCE) Study, Whites 
  RERI (95% CI)
a
 
Gene SNP Radiation x SNP 
Radiation and 
Surgery x SNP 
Radiation and 
Chemotherapy x 
SNP 
Surgery, Radiation 
and Chemotherapy 
x SNP 
ERCC3 (XPB) rs4150496 0.42 (-0.33, 1.16) 0.23 (-0.35, 0.81) 0.30 (-0.25, 0.84) -0.29 (-1.09, 0.52) 
  rs1011019 -0.29 (-1.25, 0.67) 0.07 (-0.62, 0.76) 0.29 (-0.35, 0.92) 0.65 (-0.06, 1.36) 
  rs4150434 0.81 (-0.02, 1.65) 0.11 (-0.54, 0.75) 0.27 (-0.32, 0.86) 0.43 (-0.24, 1.11) 
  rs4150416 -0.25 (-1.3, 0.80) -0.08 (-0.87, 0.72) 0.10 (-0.63, 0.82) 0.45 (-0.34, 1.24) 
  rs4150407 0.57 (-0.23, 1.37) 0.16 (-0.52, 0.84) -0.03 (-0.74, 0.69) -0.61 (-1.66, 0.45) 
  rs4150403 -0.91 (-2.13, 0.32) -0.24 (-1.25, 0.78) 0.24 (-0.82, 1.30) -0.45 (-1.49, 0.59) 
  rs4150402 -0.29 (-1.25, 0.67) 0.07 (-0.62, 0.76) 0.29 (-0.35, 0.92) 0.65 (-0.06, 1.36) 
XPC rs2228001 0.24 (-0.71, 1.18) 0.49 (-0.19, 1.16) -0.01 (-0.74, 0.72) 0.06 (-0.78, 0.89) 
  rs3731143 2.19 (0, 4.37) 0.25 (-0.94, 1.43) -0.18 (-1.19, 0.84) -0.34 (-1.46, 0.78) 
  rs2228000 -0.01 (-0.93, 0.90) 0.06 (-0.65, 0.77) 0.21 (-0.44, 0.85) 0.01 (-0.76, 0.79) 
  rs3731124 -0.12 (-1.03, 0.78) -0.38 (-1.15, 0.38) 0.63 (0.02, 1.24) 0.12 (-0.61, 0.84) 
  rs13099160 -0.03 (-1.45, 1.39) -0.37 (-1.49, 0.74) 0.68 (-0.65, 2.01) 0.09 (-1.18, 1.35) 
  rs3731093 0.41 (-0.90, 1.72) -0.13 (-1.12, 0.86) 0.42 (-0.68, 1.53) -0.30 (-1.30, 0.70) 
  rs3731089 0.51 (-0.80, 1.81) -0.18 (-1.14, 0.78) 0.6 (-0.51, 1.72) -0.27 (-1.26, 0.71) 
  rs2733537 0.21 (-0.64, 1.06) 0.14 (-0.53, 0.82) 0.39 (-0.20, 0.98) -0.09 (-0.85, 0.67) 
  rs3731068 -0.42 (-1.4, 0.57) -0.45 (-1.24, 0.35) 0.75 (0, 1.50) 0.23 (-0.57, 1.03) 
  rs2607755 0.37 (-0.47, 1.21) -0.12 (-0.88, 0.65) 0.61 (0.13, 1.09) 0.20 (-0.49, 0.89) 
  rs1902658 0.35 (-0.51, 1.22) -0.24 (-1.08, 0.60) 0.58 (0.09, 1.08) 0.19 (-0.53, 0.90) 
ERCC8 rs3117 0.62 (-0.38, 1.62) 0.24 (-0.55, 1.03) 0.15 (-0.61, 0.92) -0.06 (-0.97, 0.86) 
CDK7 rs2972388 1.07 (0.55, 1.60)* 0.43 (-0.07, 0.92) 0.72 (0.33, 1.10)* -0.01 (-0.72, 0.70) 
XPA rs3176757 -0.58 (-1.59, 0.42) -0.03 (-0.78, 0.73) 0.33 (-0.38, 1.04) -0.08 (-0.89, 0.73) 
  rs3176748 0.23 (-0.62, 1.09) -0.14 (-1.07, 0.79) 0.06 (-0.59, 0.71) 0.56 (-0.16, 1.28) 
  rs2808667     -0.02 (-1.01, 0.97) 0.59 (-0.33, 1.50) 0.32 (-0.56, 1.19) 0.37 (-0.65, 1.39) 
  rs2805835 0.38 (-0.85, 1.62) 0.24 (-0.76, 1.24) -0.37 (-1.33, 0.59) -1.09 (-2.12, -0.06) 
  rs3176689 -0.75 (-1.85, 0.35) -0.23 (-1.05, 0.60) -0.02 (-0.79, 0.75) -0.66 (-1.58, 0.26) 
  rs3176683 -0.63 (-2.19, 0.94) -0.96 (-2.08, 0.16) -0.48 (-1.56, 0.61) -0.38 (-1.67, 0.92) 
  rs3176658      0.33 (-0.55, 1.20) 0.41 (-0.23, 1.05) 0.44 (-0.26, 1.13) 0.75 (-0.04, 1.53) 
  rs1800975 0.03 (-0.76, 0.82) 0.14 (-0.45, 0.72) 0.59 (0.11, 1.07) 0.33 (-0.27, 0.93) 
RAD23B rs1805330 -0.59 (-2.06, 0.88) -0.33 (-1.57, 0.90) -0.01 (-1.26, 1.23) 0.25 (-1.11, 1.61) 
  rs1805329  0.16 (-0.73, 1.05) -0.05 (-0.75, 0.65) 0.24 (-0.41, 0.89) -0.11 (-0.88, 0.66) 
ERCC6 rs2228529 0.04 (-0.91, 0.99) -0.13 (-0.88, 0.61) 0.63 (-0.09, 1.35) -0.36 (-1.18, 0.47) 
  rs2228527  -0.02 (-0.99, 0.95) -0.17 (-0.93, 0.58) 0.55 (-0.16, 1.27) -0.42 (-1.26, 0.43) 
  rs4253132 0.68 (-0.45, 1.81) 0.20 (-0.66, 1.05) -0.12 (-0.87, 0.64) 0.08 (-0.81, 0.97) 
  rs2228528 0.07 (-0.15, 1.56) 0.59 (-0.08, 1.26) 0.29 (-0.35, 0.94) 0.34 (-0.34, 1.03) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry 
(% African ancestry), education, cigarette smoking, and alcohol drinking. 
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected 
level (0.05/84=0.0006). 
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Table 8S cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) 
Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the Carolina Head and Neck 
Cancer Epidemiology (CHANCE) Study, Whites 
  RERI (95% CI)
a
 
Gene SNP Radiation x SNP 
Radiation and 
Surgery x SNP 
Radiation and 
Chemotherapy x 
SNP 
Surgery, Radiation 
and Chemotherapy 
x SNP 
DDB2 (XPE) rs2029298 0.51 (-0.22, 1.24) 0.36 (-0.20, 0.93) 0.33 (-0.22, 0.88) 0.52 (-0.08, 1.13) 
  rs4647709 0.17 (-1.04, 1.39) 0.36 (-0.69, 1.42) 0.06 (-0.82, 0.94) 1.1 (-0.25, 2.45) 
  rs2291120 -1.07 (-2.19, 0.04) 0.87 (-0.16, 1.90) -0.07 (-0.92, 0.78) 0 (-0.95, 0.95) 
  rs1685404 -0.25 (-1.22, 0.72) -0.10 (-0.85, 0.66) 0.35 (-0.28, 0.98) 0.14 (-0.61, 0.89) 
  rs2957873 0.01 (-1.04, 1.06) -0.02 (-0.83, 0.79) 0.15 (-0.63, 0.92) -0.17 (-1.07, 0.73) 
  rs326224 0.50 (-0.53, 1.52) 0.15 (-0.58, 0.87) 0.58 (-0.17, 1.33) 0.07 (-0.76, 0.90) 
  rs2306353 0.66 (-0.42, 1.74) 0.10 (-0.63, 0.83) 0.57 (-0.18, 1.32) 0.17 (-0.70, 1.04) 
  rs326222 -0.15 (-1.15, 0.86) -0.31 (-1.15, 0.52) 0 (-0.75, 0.76) -0.02 (-0.87, 0.83) 
  rs901746 -0.15 (-1.16, 0.86) -0.32 (-1.16, 0.51) 0 (-0.76, 0.75) -0.02 (-0.88, 0.83) 
ERCC5 (XPG) rs2296147 0.27 (-0.55, 1.10) -0.09 (-0.84, 0.66) 0.12 (-0.48, 0.71) 0.17 (-0.50, 0.84) 
  rs4771436 -0.64 (-1.79, 0.51) -0.01 (-0.85, 0.84) -0.15 (-0.98, 0.67) -0.48 (-1.45, 0.49) 
  rs1047768 -0.05 (-1.23, 1.14) -0.07 (-1.00, 0.87) -0.12 (-1.03, 0.78) -0.58 (-1.75, 0.59) 
  rs3818356 -0.66 (-1.82, 0.50) -0.03 (-0.88, 0.82) -0.20 (-1.03, 0.63) -0.49 (-1.46, 0.48) 
  rs4150351 -0.86 (-1.93, 0.20) -0.23 (-0.99, 0.52) 0.14 (-0.52, 0.81) 0.11 (-0.69, 0.91) 
  rs4150355 0.73 (0.02, 1.44) 0.13 (-0.50, 0.76) -0.12 (-0.76, 0.52) 0.36 (-0.26, 0.97) 
  rs4150360 0.24 (-0.95, 1.43) -0.38 (-1.50, 0.73) -0.24 (-1.23, 0.75) -0.69 (-1.99, 0.62) 
  rs4150383 -0.96 (-2.24, 0.33) -0.22 (-1.21, 0.78) -0.49 (-1.48, 0.49) -0.85 (-1.97, 0.26) 
  rs4150386 0.31 (-1.00, 1.62) 0.29 (-0.88, 1.46) 0.15 (-0.92, 1.23) -0.48 (-1.50, 0.54) 
  rs17655 0.60 (-0.43, 1.62) 0.11 (-0.66, 0.87) 0.01 (-0.73, 0.75) -0.12 (-0.95, 0.71) 
  rs873601 0.45 (-0.43, 1.33) 0.29 (-0.38, 0.95) 0.13 (-0.52, 0.78) -0.30 (-1.12, 0.51) 
  rs4150393 -0.88 (-1.92, 0.17) -0.41 (-1.24, 0.43) 0.24 (-0.54, 1.01) 0.60 (-0.47, 1.66) 
  rs876430 0.45 (-0.43, 1.33) 0.29 (-0.38, 0.95) 0.08 (-0.58, 0.74) -0.30 (-1.12, 0.51) 
  rs1051677 0.81 (-0.20, 1.81) -0.63 (-1.44, 0.18) -0.01 (-0.76, 0.73) 0.53 (-0.44, 1.49) 
  rs1051685 -0.16 (-1.25, 0.93) 0.36 (-0.51, 1.23) 0.12 (-0.70, 0.95) 0.15 (-0.81, 1.10) 
ERCC4 (XPF) rs3136038 0.48 (-0.21, 1.16) -0.06 (-0.66, 0.54) 0.01 (-0.55, 0.57) 0.35 (-0.22, 0.93) 
  rs1799798 -0.02 (-1.19, 1.16) 0.35 (-0.50, 1.20) -0.12 (-0.95, 0.71) -0.22 (-1.15, 0.70) 
  rs744154 -0.01 (-0.95, 0.93) -0.43 (-1.23, 0.37) -0.45 (-1.21, 0.32) 0.11 (-0.65, 0.88) 
  rs3136085 0.15 (-0.77, 1.06) -0.38 (-1.17, 0.40) -0.46 (-1.23, 0.31) 0.05 (-0.73, 0.82) 
  rs3136130 0.55 (-0.12, 1.22) -0.11 (-0.72, 0.51) -0.01 (-0.57, 0.55) 0.35 (-0.23, 0.92) 
  rs1800067 0.37 (-1.22, 1.96) -0.59 (-1.65, 0.46) -0.72 (-1.79, 0.35) -0.22 (-1.38, 0.94) 
  rs3136172 0.16 (-0.77, 1.09) -0.42 (-1.23, 0.40) -0.46 (-1.25, 0.33) -0.08 (-0.90, 0.73) 
RAD23A rs2974752 0 (-0.82, 0.81) 0.45 (-0.09, 0.98) 0.80 (0.36, 1.24)* 0.48 (-0.06, 1.03) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry 
(% African ancestry), education, cigarette smoking, and alcohol drinking  
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected 
level (0.05/84=0.0006). 
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Table 8S cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) 
Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the Carolina Head and Neck 
Cancer Epidemiology (CHANCE) Study, Whites 
  RERI (95% CI)
a
 
Gene SNP Radiation x SNP 
Radiation and 
Surgery x SNP 
Radiation and 
Chemotherapy x 
SNP 
Surgery, Radiation 
and Chemotherapy 
x SNP 
ERCC2 (XPD) rs13181 0.17 (-0.82, 1.17) -0.52 (-1.48, 0.43) -0.35 (-1.24, 0.53) 0.25 (-0.54, 1.05) 
  rs238418 0.18 (-0.82, 1.17) -0.54 (-1.48, 0.41) -0.30 (-1.15, 0.56) 0.23 (-0.57, 1.02) 
  rs1799787 0.12 (-0.84, 1.09) -0.25 (-1.06, 0.56) -0.46 (-1.30, 0.39) 0.31 (-0.47, 1.09) 
  rs3916874 -0.06 (-0.84, 0.73) 0.18 (-0.41, 0.77) 0.29 (-0.24, 0.83) 0.33 (-0.28, 0.95) 
  rs238416 -0.29 (-1.33, 0.75) 0.29 (-0.41, 1.00) 0.04 (-0.68, 0.76) -0.45 (-1.40, 0.51) 
  rs50872 0.86 (0.01, 1.70) 0.37 (-0.22, 0.95) 0.32 (-0.23, 0.87) 0.06 (-0.59, 0.71) 
  rs50871 -0.11 (-1.29, 1.07) -1.28 (-2.87, 0.31) -0.43 (-1.47, 0.62) -0.14 (-1.17, 0.90) 
  rs238407 0.39 (-0.40, 1.18) 0.48 (-0.02, 0.98) 0.18 (-0.41, 0.77) 0.16 (-0.47, 0.79) 
  rs3810366 0.69 (-0.11, 1.48) 0.06 (-0.78, 0.90) -0.21 (-1.16, 0.75) 0.17 (-0.62, 0.97) 
ERCC1 rs735482 0.19 (-1.06, 1.45) -0.17 (-1.10, 0.76) 0.16 (-0.75, 1.08) -0.29 (-1.28, 0.69) 
  rs2336219 0.19 (-1.06, 1.45) -0.17 (-1.10, 0.76) 0.16 (-0.75, 1.08) -0.29 (-1.28, 0.69) 
  rs3212964 0.19 (-1.06, 1.44) -0.18 (-1.10, 0.75) 0.23 (-0.70, 1.15) -0.40 (-1.39, 0.59) 
  rs3212955 0.06 (-0.90, 1.03) 0.12 (-0.63, 0.88) 0.02 (-0.70, 0.74) 0.45 (-0.36, 1.26) 
  rs3212948 0.11 (-0.86, 1.08) -0.13 (-0.93, 0.68) -0.18 (-0.96, 0.60) 0.08 (-0.73, 0.89) 
  rs3212930 -0.07 (-0.92, 0.79) -0.02 (-0.69, 0.64) 0.2 (-0.39, 0.80) 0.72 (-0.01, 1.45) 
LIG1 rs156641 0.20 (-0.62, 1.02) 0.48 (-0.10, 1.06) 0.36 (-0.20, 0.92) 0.10 (-0.59, 0.80) 
  rs20580 0.21 (-0.81, 1.23) 0.22 (-0.61, 1.04) -0.04 (-0.93, 0.84) -0.31 (-1.38, 0.75) 
  rs20579 -0.31 (-1.35, 0.73) -0.46 (-1.28, 0.36) 0.32 (-0.45, 1.08) -0.27 (-1.12, 0.58) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry 
(% African ancestry), education, cigarette smoking, and alcohol drinking  
Highlighting indicates RERI significant at 0.05 level. Asterisks indicate RERI significant at a Bonferroni corrected 
level (0.05/84=0.0006). 
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Table 9S. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Platinum-Based Chemotherapy on Overall Survival among Head and Neck Cancer 
Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Died/Alive HR (95% CI)a   
Gene SNP 
Referent (A) / 
Variant (B) 
No Platinum-
Based 
Chemotherapy, 
Referent 
Genotype 
No Platinum-
Based 
Chemotherapy, 
Variant 
Genotype 
Platinum-Based 
Chemotherapy, 
Referent 
Genotype 
Platinum-Based 
Chemotherapy, 
Variant 
Genotype 
No Platinum-
Based 
Chemotherapy, 
Variant 
Genotype 
Platinum-Based 
Chemotherapy, 
Referent 
Genotype 
Platinum-Based 
Chemotherapy, 
Variant 
Genotype RERI (95% CI) 
ERCC3 
(XPB) rs4150496 G A 107 144 132 191 61 89 83 114 0.91 (0.69, 1.19) 0.74 (0.50, 1.11) 0.63 (0.44, 0.90) -0.02 (-0.39, 0.34) 
  rs1011019 C T 125 159 114 177 66 112 78 91 0.86 (0.66, 1.13) 0.55 (0.38, 0.80) 0.78 (0.54, 1.13) 0.37 (0.05, 0.69) 
  rs4150434 G A 144 200 95 136 86 118 58 85 1.01 (0.76, 1.33) 0.69 (0.49, 0.98) 0.72 (0.49, 1.07) 0.02 (-0.35, 0.40) 
  rs4150416 T G 109 147 130 188 56 98 87 104 0.99 (0.75, 1.30) 0.58 (0.39, 0.87) 0.81 (0.56, 1.17) 0.24 (-0.11, 0.58) 
  rs4150407 A G 79 120 160 216 52 67 92 136 1.08 (0.81, 1.43) 0.89 (0.58, 1.37) 0.68 (0.47, 0.99) -0.29 (-0.75, 0.17) 
  rs4150403 G A 188 267 51 69 115 166 29 37 0.90 (0.65, 1.26) 0.66 (0.48, 0.91) 0.84 (0.53, 1.34) 0.28 (-0.18, 0.74) 
  rs4150402 G A 125 159 114 177 66 112 78 91 0.86 (0.66, 1.13) 0.55 (0.38, 0.80) 0.78 (0.54, 1.13) 0.37 (0.05, 0.69) 
XPC rs2228001 A C 88 131 151 204 47 71 97 132 1.27 (0.95, 1.68) 0.73 (0.48, 1.11) 0.84 (0.59, 1.22) -0.15 (-0.60, 0.29) 
  rs3731143 T C 202 303 37 33 131 182 13 21 1.46 (0.99, 2.15) 0.77 (0.56, 1.05) 0.52 (0.28, 0.97) -0.70 (-1.36, -0.04) 
  rs2228000 C T 131 193 107 143 82 118 61 85 0.98 (0.75, 1.28) 0.68 (0.48, 0.97) 0.71 (0.49, 1.05) 0.05 (-0.30, 0.41) 
  rs3731124 A C 142 183 97 153 73 123 71 80 0.80 (0.61, 1.06) 0.54 (0.37, 0.79) 0.75 (0.52, 1.08) 0.40 (0.10, 0.71) 
  rs13099160 A G 211 301 28 35 124 178 20 25 0.93 (0.61, 1.42) 0.66 (0.48, 0.90) 1.02 (0.61, 1.71) 0.43 (-0.19, 1.05) 
  rs3731093 T C 199 285 39 47 122 170 20 32 1.05 (0.73, 1.51) 0.69 (0.50, 0.95) 0.80 (0.48, 1.34) 0.06 (-0.48, 0.60) 
  rs3731089 G A 199 286 40 50 122 171 22 32 1.04 (0.73, 1.48) 0.68 (0.50, 0.93) 0.85 (0.52, 1.40) 0.14 (-0.40, 0.67) 
  rs2733537 A G 102 155 137 181 65 94 79 109 1.02 (0.77, 1.33) 0.67 (0.45, 0.98) 0.74 (0.51, 1.08) 0.06 (-0.30, 0.42) 
  rs3731068 C A 168 223 71 113 89 144 55 59 0.81 (0.60, 1.09) 0.56 (0.39, 0.79) 0.85 (0.58, 1.25) 0.49 (0.14, 0.84) 
  rs2607755 T C 66 81 173 255 34 61 110 142 0.82 (0.61, 1.11) 0.52 (0.32, 0.83) 0.65 (0.45, 0.94) 0.31 (-0.01, 0.62) 
  rs1902658 G A 65 76 174 260 34 60 110 142 0.80 (0.59, 1.08) 0.52 (0.32, 0.83) 0.64 (0.44, 0.93) 0.32 (0.01, 0.63) 
ERCC8 rs3117 T C 78 125 161 211 48 86 96 117 1.38 (1.03, 1.84) 0.71 (0.47, 1.10) 0.93 (0.64, 1.34) -0.17 (-0.63, 0.30) 
CDK7 rs2972388 A G 65 92 174 244 45 64 99 139 0.99 (0.73, 1.34) 0.64 (0.41, 1.00) 0.72 (0.49, 1.06) 0.10 (-0.27, 0.47) 
XPA rs3176757 C T 168 220 71 116 88 133 56 70 0.87 (0.65, 1.17) 0.63 (0.44, 0.89) 0.74 (0.50, 1.09) 0.24 (-0.11, 0.59) 
  rs3176748 A G 119 156 120 180 64 101 80 102 0.96 (0.73, 1.26) 0.65 (0.45, 0.94) 0.73 (0.51, 1.05) 0.13 (-0.22, 0.47) 
  rs2808667     C T 211 286 27 50 134 183 9 20 0.71 (0.46, 1.09) 0.68 (0.50, 0.92) 0.61 (0.30, 1.24) 0.22 (-0.30, 0.75) 
  rs2805835 G C 179 269 60 67 122 157 22 46 1.32 (0.97, 1.80) 0.82 (0.59, 1.12) 0.51 (0.30, 0.86) -0.62 (-1.15, -0.10) 
  rs3176689 A T 171 224 68 112 96 131 48 72 0.85 (0.63, 1.15) 0.68 (0.49, 0.96) 0.64 (0.43, 0.95) 0.1 (-0.25, 0.46) 
  rs3176683 T C 215 294 24 42 127 182 17 21 0.80 (0.51, 1.26) 0.70 (0.51, 0.95) 0.61 (0.35, 1.06) 0.11 (-0.38, 0.60) 
  rs3176658      C T 180 244 59 92 114 161 30 42 0.85 (0.62, 1.16) 0.66 (0.48, 0.91) 0.76 (0.48, 1.20) 0.25 (-0.16, 0.67) 
  rs1800975 G A 120 141 112 181 64 95 73 99 0.75 (0.57, 0.99) 0.55 (0.37, 0.80) 0.66 (0.45, 0.96) 0.36 (0.07, 0.65) 
RAD23B rs1805330 C T 192 275 47 61 114 183 30 20 1.27 (0.91, 1.79) 0.65 (0.47, 0.89) 1.11 (0.72, 1.71) 0.19 (-0.40, 0.78) 
  rs1805329  C T 156 209 83 127 101 124 43 79 0.91 (0.69, 1.22) 0.71 (0.51, 0.99) 0.62 (0.41, 0.94) 0 (-0.37, 0.36) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), education, cigarette smoking, alcohol drinking, stage, ancestry (% African ancestry), surgery and/or radiation 
treatment.  
Highlighting indicates RERI significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 9S cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Platinum-Based Chemotherapy on Overall Survival among Head and Neck 
Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Died/Alive HR (95% CI)a   
Gene SNP 
Referent (A) / 
Variant (B) 
No Platinum-
Based 
Chemotherapy, 
Referent 
Genotype 
No Platinum-
Based 
Chemotherapy, 
Variant 
Genotype 
Platinum-Based 
Chemotherapy, 
Referent 
Genotype 
Platinum-Based 
Chemotherapy, 
Variant 
Genotype 
No Platinum-
Based 
Chemotherapy, 
Variant 
Genotype 
Platinum-Based 
Chemotherapy, 
Referent 
Genotype 
Platinum-Based 
Chemotherapy, 
Variant 
Genotype RERI (95% CI) 
ERCC6 rs2228529 A G 158 218 79 113 94 127 48 73 0.90 (0.67, 1.21) 0.65 (0.46, 0.92) 0.72 (0.49, 1.08) 0.17 (-0.19, 0.53) 
  rs2228527  A G 157 219 82 117 94 128 50 75 0.91 (0.68, 1.22) 0.66 (0.46, 0.93) 0.72 (0.48, 1.06) 0.15 (-0.21, 0.51) 
  rs4253132 T C 184 268 55 68 110 161 34 42 1.15 (0.83, 1.59) 0.75 (0.55, 1.04) 0.62 (0.40, 0.96) -0.29 (-0.75, 0.18) 
  rs2228528 G A 160 230 79 106 105 142 38 61 1.07 (0.80, 1.43) 0.72 (0.52, 1.01) 0.70 (0.46, 1.06) -0.10 (-0.52, 0.33) 
DDB2 
(XPE) rs2029298 A G 104 152 135 184 66 103 78 100 1.04 (0.79, 1.37) 0.64 (0.43, 0.94) 0.79 (0.55, 1.13) 0.11 (-0.26, 0.48) 
  rs4647709 C T 201 281 38 55 116 168 28 35 1.09 (0.75, 1.59) 0.68 (0.50, 0.94) 0.87 (0.54, 1.40) 0.10 (-0.45, 0.64) 
  rs2291120 T C 177 253 62 83 106 149 38 54 1.12 (0.82, 1.52) 0.72 (0.51, 1.00) 0.74 (0.49, 1.14) -0.09 (-0.54, 0.36) 
  rs1685404 G C 113 161 126 175 59 85 85 118 0.95 (0.72, 1.25) 0.62 (0.42, 0.92) 0.73 (0.50, 1.07) 0.17 (-0.17, 0.50) 
  rs2957873 A G 160 238 79 98 97 148 47 55 1.08 (0.81, 1.44) 0.69 (0.49, 0.97) 0.79 (0.53, 1.17) 0.02 (-0.40, 0.44) 
  rs326224 G A 174 244 65 92 105 160 39 43 1.00 (0.74, 1.35) 0.66 (0.48, 0.92) 0.83 (0.54, 1.26) 0.17 (-0.27, 0.60) 
  rs2306353 G A 176 253 63 83 105 162 39 41 1.01 (0.74, 1.37) 0.66 (0.48, 0.92) 0.85 (0.55, 1.29) 0.17 (-0.27, 0.62) 
  rs326222 C T 114 173 125 163 76 121 68 82 0.97 (0.74, 1.28) 0.64 (0.44, 0.93) 0.75 (0.52, 1.09) 0.14 (-0.21, 0.50) 
  rs901746 A G 114 174 125 162 76 121 68 82 0.97 (0.74, 1.28) 0.64 (0.44, 0.93) 0.75 (0.52, 1.09) 0.14 (-0.22, 0.50) 
ERCC5 
(XPG) rs2296147 T C 73 83 165 252 57 67 85 135 0.81 (0.60, 1.08) 0.64 (0.41, 0.98) 0.57 (0.38, 0.84) 0.12 (-0.21, 0.46) 
  rs4771436  T G 138 208 101 128 89 128 55 75 1.11 (0.84, 1.45) 0.72 (0.51, 1.01) 0.75 (0.51, 1.11) -0.07 (-0.47, 0.32) 
  rs1047768 C T 76 125 163 211 46 72 98 131 1.21 (0.90, 1.62) 0.74 (0.47, 1.14) 0.83 (0.57, 1.21) -0.12 (-0.56, 0.33) 
  rs3818356 C T 138 208 101 127 89 128 54 75 1.11 (0.84, 1.46) 0.72 (0.51, 1.02) 0.74 (0.50, 1.10) -0.09 (-0.49, 0.31) 
  rs4150351 A C 162 208 77 128 92 133 52 70 0.74 (0.56, 1.00) 0.63 (0.45, 0.89) 0.63 (0.42, 0.93) 0.25 (-0.06, 0.56) 
  rs4150355 C T 101 134 138 202 76 91 68 112 0.96 (0.73, 1.26) 0.77 (0.52, 1.13) 0.62 (0.42, 0.91) -0.11 (-0.50, 0.27) 
  rs4150360 T C 65 108 174 228 41 61 103 142 1.18 (0.87, 1.6) 0.75 (0.47, 1.20) 0.80 (0.55, 1.18) -0.13 (-0.59, 0.33) 
  rs4150383 G A 155 237 84 99 100 138 44 65 1.17 (0.88, 1.55) 0.74 (0.53, 1.04) 0.73 (0.48, 1.09) -0.19 (-0.62, 0.25) 
  rs4150386 A C 186 264 53 72 118 156 26 47 1.34 (0.97, 1.87) 0.74 (0.53, 1.02) 0.76 (0.48, 1.21) -0.32 (-0.89, 0.24) 
  rs17655 C G 143 212 96 124 80 120 64 83 1.17 (0.88, 1.54) 0.75 (0.52, 1.06) 0.75 (0.51, 1.10) -0.16 (-0.58, 0.25) 
  rs873601       A G 122 177 117 159 68 97 76 106 1.10 (0.84, 1.45) 0.78 (0.53, 1.13) 0.70 (0.48, 1.02) -0.18 (-0.58, 0.23) 
  rs4150393 A G 188 246 51 90 108 160 36 43 0.73 (0.53, 1.01) 0.62 (0.45, 0.86) 0.74 (0.48, 1.15) 0.39 (0.03, 0.76) 
  rs876430 C T 122 177 117 159 69 97 75 106 1.10 (0.84, 1.45) 0.79 (0.54, 1.15) 0.69 (0.48, 1.00) -0.20 (-0.61, 0.21) 
  rs1051677 T C 187 266 52 69 116 166 28 37 0.95 (0.68, 1.32) 0.71 (0.52, 0.97) 0.63 (0.39, 1.02) -0.02 (-0.45, 0.40) 
  rs1051685 A G 186 267 53 68 116 167 28 36 1.05 (0.76, 1.45) 0.70 (0.51, 0.96) 0.74 (0.47, 1.19) -0.01 (-0.47, 0.46) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), education, cigarette smoking, alcohol drinking, stage, ancestry (% African ancestry), surgery and/or radiation 
treatment.  
Highlighting indicates RERI significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 9S cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Platinum-Based Chemotherapy on Overall Survival among Head and Neck 
Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, Whites 
    Coded Allele Died/Alive HR (95% CI)a   
Gene SNP 
Referent (A) / 
Variant (B) 
No Platinum-
Based 
Chemotherapy, 
Referent 
Genotype 
No Platinum-
Based 
Chemotherapy, 
Variant 
Genotype 
Platinum-Based 
Chemotherapy, 
Referent 
Genotype 
Platinum-Based 
Chemotherapy, 
Variant 
Genotype 
No Platinum-
Based 
Chemotherapy, 
Variant 
Genotype 
Platinum-Based 
Chemotherapy, 
Referent 
Genotype 
Platinum-Based 
Chemotherapy, 
Variant 
Genotype RERI (95% CI) 
ERCC4 
(XPF) rs3136038 C T 113 129 126 207 71 89 73 114 0.75 (0.57, 0.98) 0.68 (0.47, 0.99) 0.53 (0.37, 0.77) 0.11 (-0.20, 0.42) 
  rs1799798 G A 196 272 43 64 124 165 20 38 0.98 (0.69, 1.40) 0.73 (0.53, 1.00) 0.56 (0.32, 0.97) -0.15 (-0.63, 0.32) 
  rs744154 C G 129 166 110 170 79 106 65 97 0.87 (0.66, 1.14) 0.73 (0.51, 1.05) 0.59 (0.40, 0.85) -0.01 (-0.35, 0.33) 
  rs3136085 G C 126 166 113 170 79 104 65 99 0.90 (0.69, 1.19) 0.76 (0.53, 1.09) 0.59 (0.40, 0.85) -0.07 (-0.43, 0.28) 
  rs3136130 G T 113 128 126 208 71 88 73 115 0.74 (0.56, 0.97) 0.69 (0.47, 1.00) 0.53 (0.36, 0.77) 0.10 (-0.20, 0.41) 
  rs1800067 G A 198 288 41 48 124 168 20 35 1.11 (0.78, 1.59) 0.73 (0.53, 1.00) 0.64 (0.38, 1.07) -0.2 (-0.72, 0.32) 
  rs3136172 A G 119 163 120 173 76 100 68 103 0.94 (0.72, 1.24) 0.77 (0.53, 1.11) 0.61 (0.42, 0.89) -0.10 (-0.47, 0.27) 
RAD23A rs2974752 A G 90 111 142 215 45 87 93 111 0.84 (0.63, 1.12) 0.45 (0.28, 0.70) 0.72 (0.50, 1.04) 0.44 (0.15, 0.73) 
ERCC2 
(XPD) rs13181 T G 99 141 137 194 55 86 87 116 1.00 (0.76, 1.32) 0.69 (0.46, 1.02) 0.70 (0.49, 1.02) 0.01 (-0.36, 0.39) 
  rs238418 C A 101 141 138 195 55 85 89 118 0.98 (0.75, 1.28) 0.69 (0.46, 1.02) 0.70 (0.48, 1.01) 0.03 (-0.33, 0.40) 
  rs1799787 C T 123 174 116 162 73 102 71 101 1.00 (0.77, 1.31) 0.74 (0.51, 1.07) 0.67 (0.46, 0.97) -0.08 (-0.45, 0.29) 
  rs3916874 G C 128 162 111 174 81 106 63 97 0.78 (0.60, 1.03) 0.63 (0.43, 0.90) 0.62 (0.43, 0.90) 0.21 (-0.09, 0.51) 
  rs238416 G A 94 136 145 200 58 81 86 121 1.14 (0.87, 1.51) 0.78 (0.52, 1.16) 0.75 (0.52, 1.09) -0.17 (-0.59, 0.25) 
  rs50872 C T 142 184 97 150 84 121 60 82 0.98 (0.74, 1.30) 0.67 (0.47, 0.95) 0.63 (0.42, 0.93) -0.02 (-0.39, 0.34) 
  rs50871 T G 65 81 174 255 45 51 99 152 0.87 (0.64, 1.17) 0.70 (0.45, 1.10) 0.61 (0.42, 0.90) 0.05 (-0.34, 0.43) 
  rs238407 A T 76 89 163 246 45 53 99 150 0.97 (0.72, 1.30) 0.77 (0.50, 1.18) 0.59 (0.41, 0.86) -0.15 (-0.56, 0.27) 
  rs3810366 C G 47 61 192 275 32 38 112 164 1.03 (0.72, 1.47) 0.85 (0.52, 1.42) 0.68 (0.45, 1.04) -0.20 (-0.73, 0.33) 
ERCC1 rs735482 A C 177 256 62 80 101 154 43 49 1.10 (0.81, 1.51) 0.69 (0.49, 0.95) 0.80 (0.53, 1.20) 0.01 (-0.44, 0.45) 
  rs2336219 G A 177 256 62 80 101 154 43 49 1.10 (0.81, 1.51) 0.69 (0.49, 0.95) 0.80 (0.53, 1.20) 0.01 (-0.44, 0.45) 
  rs3212964 G A 178 257 61 79 102 155 42 48 1.10 (0.81, 1.51) 0.69 (0.50, 0.95) 0.80 (0.53, 1.21) 0.01 (-0.44, 0.46) 
  rs3212955 A G 126 187 113 149 83 132 61 71 1.14 (0.87, 1.51) 0.70 (0.49, 1.00) 0.81 (0.56, 1.19) -0.03 (-0.44, 0.37) 
  rs3212948 C G 96 138 143 198 58 90 86 113 1.07 (0.82, 1.41) 0.74 (0.49, 1.10) 0.73 (0.51, 1.05) -0.08 (-0.48, 0.31) 
  rs3212930 T C 147 197 92 139 94 138 50 65 0.84 (0.63, 1.11) 0.64 (0.45, 0.90) 0.69 (0.46, 1.02) 0.21 (-0.12, 0.54) 
LIG1 rs156641 G A 90 134 149 202 61 85 83 118 1.08 (0.82, 1.44) 0.69 (0.47, 1.02) 0.77 (0.53, 1.13) 0 (-0.39, 0.39) 
  rs20580 C A 57 87 182 249 40 53 104 150 1.28 (0.93, 1.77) 0.86 (0.54, 1.37) 0.82 (0.55, 1.23) -0.31 (-0.84, 0.22) 
  rs20579 C T 187 241 52 95 107 156 37 47 0.78 (0.56, 1.08) 0.65 (0.47, 0.91) 0.68 (0.44, 1.04) 0.25 (-0.12, 0.61) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), education, cigarette smoking, alcohol drinking, stage, ancestry (% African ancestry), surgery and/or radiation 
treatment.  
Highlighting indicates RERI significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/84=0.0006). 
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Table 5A. Hazard Ratios for Select Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and and Survival by Tumor Site among 
Head and Neck Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study 
      
Overall Deaths / Deaths from HNC / 
Alive Overall Survival Disease-Specific Survival 
Gene SNP Tumor Site AA AB + BB HR (95% CI)
a
 p-value HR (95% CI)
a
 p-value 
Whites                         
ERCC4 (XPF) rs3136038 oral cavity 88 42 123 103 47 193 0.79 (0.59, 1.05) 0.10 0.73 (0.48, 1.11) 0.14 
    pharynx 31 12 12 15 2 28 0.27 (0.12, 0.57) 0.001 0.12 (0.02, 0.66) 0.01 
    larynx 65 32 83 81 34 100 1.09 (0.78, 1.52) 0.63 0.85 (0.52, 1.40) 0.53 
    oral cavity b 24 12 32 40 17 33 1.66 (0.97, 2.84) 0.06 1.43 (0.66, 3.13) 0.37 
    oropharynx 35 13 67 47 21 111 0.78 (0.49, 1.23) 0.28 0.89 (0.43, 1.83) 0.75 
    hypopharynx 17 6 1 8 2 8 0.06 (0.01, 0.32) 0.001 0.11 (0.00, 2.96) 0.19 
    HNC NOS 43 23 35 23 9 69 0.34 (0.20, 0.58) 0.0001 0.25 (0.11, 0.56) 0.001 
  rs3136130 oral cavity 88 42 122 103 47 194 0.78 (0.58, 1.04) 0.09 0.72 (0.47, 1.10) 0.13 
    pharynx 31 12 13 15 2 27 0.28 (0.13, 0.60) 0.001 0.13 (0.02, 0.68) 0.02 
    larynx 65 32 81 81 34 102 1.06 (0.76, 1.48) 0.74 0.84 (0.51, 1.37) 0.48 
    oral cavity b 24 12 32 40 17 33 1.66 (0.97, 2.84) 0.06 1.43 (0.66, 3.13) 0.37 
    oropharynx 35 13 68 47 21 110 0.79 (0.50, 1.24) 0.30 0.90 (0.44, 1.87) 0.78 
    hypopharynx 17 6 1 8 2 8 0.06 (0.01, 0.32) 0.001 0.11 (0.00, 2.96) 0.19 
    HNC NOS 43 23 34 23 9 70 0.33 (0.19, 0.56) 5.00E-05 0.24 (0.11, 0.54) 0.001 
ERCC2 (XPD) rs50871 oral cavity 51 29 80 140 60 236 0.91 (0.66, 1.26) 0.57 0.67 (0.43, 1.05) 0.08 
    pharynx 12 3 10 34 11 30 1.40 (0.64, 3.07) 0.40 2.05 (0.4, 10.35) 0.39 
    larynx 47 23 42 99 43 141 0.60 (0.42, 0.87) 0.01 0.51 (0.29, 0.87) 0.01 
    oral cavity b 12 6 15 52 23 50 1.14 (0.59, 2.21) 0.69 0.99 (0.39, 2.54) 0.99 
    oropharynx 23 13 42 59 21 136 0.88 (0.54, 1.46) 0.63 0.50 (0.25, 1.02) 0.06 
    hypopharynx 10 3 3 15 5 6 1.22 (0.40, 3.73) 0.73 0.88 (0.05, 14.72) 0.93 
    HNC NOS 18 10 30 48 22 74 1.09 (0.60, 1.96) 0.78 0.84 (0.38, 1.87) 0.68 
African 
Americans                         
ERCC4 (XPF) rs2607755 oral cavity 36 13 17 47 20 49 0.56 (0.35, 0.90) 0.02 0.69 (0.32, 1.47) 0.34 
    pharynx 11 7 5 17 6 9 0.54 (0.21, 1.41) 0.21 0.35 (0.10, 1.23) 0.10 
    larynx 23 7 19 28 5 44 0.73 (0.40, 1.33) 0.31 0.43 (0.13, 1.42) 0.17 
    oral cavity b 15 5 2 12 4 14 0.07 (0.02, 0.24) 2.43E-05 0.09 (0.01, 0.67) 0.02 
    oropharynx 17 6 7 29 14 20 1.13 (0.56, 2.28) 0.74 1.03 (0.33, 3.15) 0.96 
    hypopharynx 5 4 2 9 3 5 0.30 (0.02, 4.57) 0.39     
    HNC NOS 10 5 11 14 5 19 0.74 (0.31, 1.72) 0.48 0.48 (0.13, 1.76) 0.27 
HR hazards ratio, CI confidence interval, HNC head and neck cancer, NOS not otherwise specified 
a) HR for dominant genetic model (AB + BB vs AA). HRs adjusted for matching factors (age, sex, including pairwise interactions) and ancestry (% African ancestry) 
See Table 2S in Appendix A for ICD codes used to categorize sites. 
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Table 6A. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the 
Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Died/Alive 
Gene SNP 
Referent (A) / 
Variant (B) 
Surgery, 
Referent 
Genotype 
Surgery, 
Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery and 
Radiation, 
Referent 
Genotype 
Surgery and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Radiation and 
Chemotherapy, 
Variant 
Genotype 
Surgery, 
Radiation, 
Chemotherapy, 
Referent 
Genotype 
Surgery, 
Radiation, 
Chemotherapy, 
Variant 
Genotype 
ERCC3 
(XPB) rs4150496 G A 16 15 10 15 13 16 10 15 28 21 10 11 29 22 26 14 7 9 9 3 
  rs4150459 G A 18 18 8 13 17 21 7 10 24 21 14 11 31 21 24 15 9 7 7 5 
  rs1011019 C T 10 22 16 9 16 19 8 12 19 19 19 13 35 22 20 14 12 6 4 6 
  rs4150434 G A 25 23 1 8 17 24 7 7 30 18 8 14 39 30 16 6 12 10 4 2 
  rs4150416 T G 5 11 21 20 9 9 15 22 8 11 29 21 12 12 43 24 4 2 12 10 
  rs4150407 A G 9 8 17 23 6 10 18 21 11 9 27 23 13 10 42 26 3 4 13 8 
  rs4150402 G A 10 22 16 9 16 19 8 12 19 19 19 13 35 22 20 14 12 6 4 6 
XPC rs2228001 A C 17 22 9 9 11 16 13 15 26 24 12 8 26 19 29 17 8 8 8 4 
  rs2228000 C T 26 25 0 6 22 28 2 3 29 22 9 10 43 29 12 7 16 9 0 3 
  rs3731124 A C 23 23 3 8 20 26 4 5 33 26 5 6 46 31 9 5 13 9 3 3 
  rs3731093 T C 20 28 4 3 22 27 2 4 33 28 4 4 52 28 3 8 11 11 5 0 
  rs3731089 G A 20 28 6 3 22 27 2 4 33 28 5 4 52 28 3 8 11 11 5 1 
  rs2733537 A G 20 22 6 9 20 25 4 6 24 19 14 13 40 22 15 14 11 8 5 4 
  rs2607755 T C 9 5 17 26 6 10 18 21 15 6 23 26 27 14 28 22 12 5 4 7 
  rs1902658 G A 3 2 23 29 3 5 21 26 6 3 32 29 12 11 43 25 5 1 11 11 
ERCC8 rs3117 T C 8 13 18 18 13 15 11 16 19 13 19 19 24 10 31 26 6 2 10 10 
CDK7 rs2972388 A G 11 17 15 14 11 17 13 14 16 17 22 15 28 27 27 9 10 5 6 7 
CCNH rs2266691 A G 24 23 2 8 21 27 3 4 33 25 5 7 47 32 8 4 12 10 4 2 
  rs2266692 G T 21 23 5 8 17 21 7 10 32 24 6 8 46 25 9 11 15 10 1 2 
XPA rs3176757 C T 21 25 5 6 18 25 6 6 29 23 9 9 44 27 11 9 11 9 5 3 
  rs3176753 T C 18 19 8 12 18 25 6 6 30 23 8 9 42 25 13 11 12 9 4 3 
  rs3176748 A G 24 21 2 10 18 27 6 4 33 27 5 5 45 33 10 3 11 9 5 3 
  rs3176658      C T 23 26 3 5 23 24 1 7 31 27 7 5 46 33 9 3 16 9 0 3 
  rs1800975 G A 18 22 6 9 16 19 7 12 20 18 16 13 33 21 20 11 11 7 5 5 
RAD23B rs1805330 C T 10 17 16 14 16 19 8 12 24 18 14 14 31 24 24 12 10 11 6 1 
ERCC6 rs2228529 A G 18 23 8 7 18 23 6 8 30 28 8 4 42 30 13 5 12 7 4 5 
  rs2228527  A G 17 20 9 11 17 23 7 8 30 26 8 6 37 27 18 9 11 7 5 5 
  rs4253132 T C 15 16 11 15 15 25 9 6 22 23 16 9 34 21 21 15 9 8 7 4 
  rs2228528 G A 17 24 9 7 16 19 8 12 28 25 10 7 33 26 21 10 12 10 4 2 
DDB2 
(XPE) rs2029298 A G 6 8 20 23 12 8 12 23 13 9 25 23 10 15 45 21 2 7 14 5 
  rs1685404  G C 20 21 6 10 11 15 13 16 21 16 17 16 27 20 28 16 6 5 10 7 
  rs2957873 A G 6 8 20 23 7 9 16 22 12 9 26 23 16 11 39 25 7 4 9 8 
  rs326224 G A 5 9 21 22 5 6 19 25 12 8 26 24 15 11 40 25 5 3 11 9 
  rs2306353 G A 8 10 18 21 10 11 14 20 15 9 23 23 19 12 36 24 7 4 9 8 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry (% African ancestry), education, cigarette smoking, and alcohol drinking 
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006). 
2
16 
  
Table 6A cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in 
the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Died/Alive 
Gene SNP 
Referent (A) / 
Variant (B) 
Surgery, 
Referent 
Genotype 
Surgery, 
Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery and 
Radiation, 
Referent 
Genotype 
Surgery and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Radiation and 
Chemotherapy, 
Variant 
Genotype 
Surgery, 
Radiation, 
Chemotherapy, 
Referent 
Genotype 
Surgery, 
Radiation, 
Chemotherapy, 
Variant 
Genotype 
  rs326222 C T 1 3 25 28 5 6 19 25 6 6 32 26 11 9 44 27 3 4 13 8 
  rs901746 A G 3 5 23 26 7 6 17 25 8 6 30 26 13 9 42 27 3 4 13 8 
ERCC5 
(XPG) rs2296147 T C 21 20 5 11 13 23 11 8 20 20 17 12 36 21 19 15 9 7 7 5 
  rs2296148 C T 19 24 7 7 18 21 6 10 30 28 8 4 41 23 13 13 12 9 4 3 
  rs4771436  T G 21 16 5 15 20 20 4 11 22 23 16 9 37 25 18 11 8 10 8 2 
  rs1047768 C T 12 7 14 24 8 12 16 19 15 12 23 20 24 14 31 22 5 5 11 7 
  rs2020915 G A 15 26 11 5 17 20 7 11 26 17 12 15 33 29 22 7 11 9 5 3 
  rs3818356 C T 21 17 5 14 20 20 4 11 22 23 16 9 37 26 18 10 8 10 8 2 
  rs4150355 C T 20 21 6 10 16 20 8 11 26 24 12 8 42 25 13 11 12 8 4 4 
  rs4150360 T C 2 0 24 31 1 5 23 26 5 0 33 32 0 2 55 34 3 1 13 11 
  rs4150383 G A 23 22 3 9 21 23 3 8 29 25 9 7 44 30 11 6 11 10 5 2 
  rs17655 C G 3 9 23 22 6 13 18 18 15 8 23 24 14 13 41 23 6 2 10 10 
  rs873601       A G 1 4 25 27 2 5 22 26 6 2 32 30 2 4 53 32 3 1 13 11 
  rs876430 C T 1 4 25 27 2 5 22 26 6 2 32 30 3 5 52 31 3 1 13 11 
  rs1051677 T C 19 27 7 4 19 25 5 6 25 23 13 9 36 30 19 6 14 10 2 2 
  rs1051685 A G 8 9 18 22 12 13 12 18 19 11 19 21 30 21 25 15 7 7 9 5 
ERCC4 
(XPF) rs3136038 C T 3 9 23 22 10 9 14 22 11 10 27 22 13 16 42 20 4 4 12 8 
  rs744154 C G 19 21 7 10 16 26 8 5 23 23 15 9 41 29 14 7 12 7 4 5 
  rs3136085 G C 18 19 8 12 12 25 12 6 19 14 19 18 30 16 25 20 11 7 5 5 
  rs3136091 C G 22 27 4 4 18 28 6 3 30 27 8 5 46 31 9 5 12 10 4 2 
  rs3136130 G T 5 10 21 21 9 8 15 23 9 5 29 27 12 10 43 26 3 3 13 9 
  rs3136172 A G 18 21 8 10 16 26 8 5 23 23 15 9 40 27 15 9 12 6 4 6 
  rs2020955  T C 20 23 6 8 13 25 11 6 23 17 15 15 31 18 24 18 12 9 4 3 
RAD23
A rs2974752 A G 5 11 20 20 6 4 17 27 11 12 24 19 13 11 40 21 2 5 14 7 
  rs11558955 A G 20 28 6 3 20 25 4 6 32 28 6 4 46 31 9 5 14 8 2 4 
ERCC2 
(XPD) 
rs13181 
T G 11 20 15 11 14 21 10 9 20 20 18 12 31 19 24 17 8 6 8 6 
  rs238418 C A 1 1 25 30 1 1 23 30 1 7 37 24 1 1 54 35 1 0 15 12 
  rs1799787 C T 16 26 10 5 17 27 7 4 28 25 10 7 45 26 10 10 12 10 4 2 
  rs3916874 G C 22 29 4 2 22 27 2 4 33 28 5 4 49 30 6 6 14 11 2 1 
  rs238416 G A 23 21 3 10 16 24 7 7 27 29 11 3 49 31 6 5 11 8 5 4 
  rs50872 C T 17 23 9 8 17 25 7 6 27 27 11 5 41 24 14 12 11 7 5 5 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry (% African ancestry), education, cigarette smoking, and alcohol drinking 
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006). 
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Table 6A cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in 
the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
    Coded Allele Died/Alive 
Gene SNP 
Referent (A) / 
Variant (B) 
Surgery, 
Referent 
Genotype 
Surgery, 
Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery and 
Radiation, 
Referent 
Genotype 
Surgery and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Radiation and 
Chemotherapy, 
Variant 
Genotype 
Surgery, 
Radiation, 
Chemotherapy, 
Referent 
Genotype 
Surgery, 
Radiation, 
Chemotherapy, 
Variant 
Genotype 
  rs50871 T G 19 25 7 6 16 20 8 11 25 25 13 7 46 31 9 5 13 7 3 5 
  rs238407 A T 17 23 9 8 14 23 10 8 24 27 14 5 47 30 8 6 10 8 6 4 
  rs3810366 C G 17 22 9 9 14 21 10 10 22 25 16 7 44 27 11 9 9 8 7 4 
ERCC1 rs735482 A C 13 13 13 18 13 20 11 11 20 18 18 14 25 17 30 19 10 4 6 8 
  rs2336219 G A 13 13 13 18 13 20 11 11 20 18 18 14 25 17 30 19 11 4 5 8 
  rs3212964 G A 19 18 7 13 16 24 8 7 28 25 8 7 33 20 22 16 12 8 4 4 
  rs3212955 A G 10 19 16 12 11 15 13 16 19 16 19 16 32 20 23 16 9 7 7 5 
  rs3212948 C G 0 1 36 30 0 0 24 31 3 0 35 32 1 2 54 34 1 1 15 11 
  rs3212935 A G 12 16 14 15 11 17 13 14 20 13 18 19 27 12 28 24 9 4 7 8 
  rs3212930 T C 19 25 7 6 18 25 6 6 33 28 5 4 47 30 8 6 12 10 4 2 
LIG1 rs156641 G A 19 22 7 9 17 20 7 11 29 25 9 7 48 30 7 6 13 7 3 5 
  rs20580 C A 3 6 23 25 5 5 19 25 6 5 32 27 17 11 38 25 1 2 15 10 
  rs20579 C T 9 15 17 16 13 13 11 18 21 15 17 17 33 18 22 18 7 6 9 6 
  rs439132 A G 14 17 12 14 13 15 11 16 26 21 12 11 23 23 32 13 10 7 6 5 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), stage, anatomic site, ancestry (% African ancestry), education, cigarette smoking, and alcohol drinking 
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006). 
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Table 6A cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the Carolina Head and Neck 
Cancer Epidemiology (CHANCE) Study, African Americans 
  HR (95% CI)
a
 
Gene SNP 
Surgery, Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery and 
Radiation, 
Referent 
Genotype 
Surgery and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Radiation and 
Chemotherapy, 
Variant 
Genotype 
Surgery, 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Surgery, 
Radiation, and 
Chemotherapy, 
Variant 
Genotype 
ERCC3 (XPB) rs4150496 0.76 (0.31, 1.84) 0.85 (0.36, 1.97) 0.78 (0.32, 1.91) 1.02 (0.51, 2.03) 0.83 (0.35, 1.96) 0.76 (0.37, 1.55) 1.16 (0.54, 2.47) 0.43 (0.16, 1.17) 1.17 (0.44, 3.14) 
  rs4150459 0.59 (0.24, 1.48) 0.80 (0.37, 1.71) 0.90 (0.32, 2.57) 0.80 (0.40, 1.59) 1.13 (0.49, 2.58) 0.74 (0.35, 1.55) 0.91 (0.43, 1.92) 0.61 (0.23, 1.63) 0.58 (0.22, 1.55) 
  rs1011019 1.71 (0.74, 4.00) 1.38 (0.57, 3.33) 1.20 (0.43, 3.41) 1.23 (0.53, 2.85) 1.80 (0.78, 4.15) 1.48 (0.66, 3.36) 1.07 (0.44, 2.61) 1.32 (0.51, 3.43) 0.49 (0.12, 1.94) 
  rs4150434 0.20 (0.03, 1.58) 0.72 (0.34, 1.50) 1.36 (0.50, 3.65) 1.15 (0.62, 2.13) 0.58 (0.24, 1.38) 0.82 (0.44, 1.53) 0.95 (0.43, 2.08) 0.64 (0.28, 1.48) 0.75 (0.23, 2.40) 
  rs4150416 1.09 (0.38, 3.12) 1.11 (0.34, 3.70) 1.02 (0.33, 3.13) 0.78 (0.23, 2.61) 1.36 (0.47, 3.88) 0.85 (0.26, 2.80) 1.18 (0.41, 3.41) 1.15 (0.27, 4.85) 0.75 (0.23, 2.48) 
  rs4150407 0.68 (0.29, 1.59) 0.61 (0.19, 1.91) 0.83 (0.34, 2.06) 0.68 (0.26, 1.77) 0.90 (0.40, 2.03) 0.65 (0.25, 1.72) 0.76 (0.33, 1.74) 0.35 (0.08, 1.48) 0.64 (0.24, 1.68) 
  rs4150402 1.71 (0.74, 4.00) 1.38 (0.57, 3.33) 1.20 (0.43, 3.41) 1.23 (0.53, 2.85) 1.80 (0.78, 4.15) 1.48 (0.66, 3.36) 1.07 (0.44, 2.61) 1.32 (0.51, 3.43) 0.49 (0.12, 1.94) 
XPC rs2228001 0.92 (0.38, 2.25) 0.78 (0.32, 1.89) 1.11 (0.49, 2.53) 1.01 (0.52, 1.98) 1.07 (0.47, 2.42) 0.76 (0.36, 1.60) 1.12 (0.56, 2.22) 0.75 (0.29, 1.95) 0.66 (0.25, 1.78) 
  rs2228000 
 
0.82 (0.42, 1.61) 0.60 (0.13, 2.75) 0.93 (0.51, 1.68) 0.62 (0.25, 1.53) 0.79 (0.42, 1.45) 0.80 (0.35, 1.80) 0.64 (0.30, 1.38) 
   rs3731124 0.47 (0.13, 1.62) 0.86 (0.43, 1.73) 0.94 (0.29, 3.07) 0.93 (0.50, 1.73) 0.97 (0.33, 2.82) 0.86 (0.46, 1.61) 0.81 (0.30, 2.16) 0.61 (0.27, 1.40) 0.77 (0.20, 2.94) 
  rs3731093 1.68 (0.51, 5.56) 1.19 (0.59, 2.44) 0.82 (0.17, 4.06) 1.22 (0.64, 2.33) 1.50 (0.46, 4.92) 1.25 (0.65, 2.38) 0.21 (0.04, 1.06) 0.67 (0.27, 1.63) 
   rs3731089 1.91 (0.71, 5.17) 1.17 (0.58, 2.39) 0.80 (0.16, 3.93) 1.17 (0.62, 2.21) 1.72 (0.57, 5.18) 1.20 (0.63, 2.27) 0.21 (0.04, 1.03) 0.63 (0.26, 1.53) 1.79 (0.60, 5.34) 
  rs2733537 0.74 (0.28, 1.96) 0.94 (0.45, 1.96) 0.82 (0.26, 2.61) 0.99 (0.50, 1.95) 0.97 (0.43, 2.16) 1.00 (0.51, 1.95) 0.65 (0.28, 1.48) 0.62 (0.25, 1.51) 0.83 (0.27, 2.56) 
  rs2607755 0.31 (0.12, 0.79) 0.45 (0.14, 1.41) 0.39 (0.15, 1.04) 1.05 (0.40, 2.80) 0.28 (0.11, 0.72) 0.55 (0.21, 1.45) 0.25 (0.10, 0.68) 0.28 (0.09, 0.85) 0.21 (0.05, 0.79) 
  rs1902658 0.46 (0.12, 1.72) 0.55 (0.10, 3.04) 0.50 (0.13, 1.89) 1.24 (0.27, 5.75) 0.48 (0.13, 1.78) 0.32 (0.07, 1.36) 0.53 (0.14, 2.02) 0.68 (0.13, 3.62) 0.29 (0.07, 1.24) 
ERCC8 rs3117 1.33 (0.52, 3.40) 1.30 (0.47, 3.56) 1.13 (0.40, 3.19) 1.48 (0.59, 3.69) 1.20 (0.47, 3.07) 1.39 (0.54, 3.56) 1.06 (0.43, 2.66) 1.05 (0.32, 3.42) 0.82 (0.28, 2.43) 
CDK7 rs2972388 1.33 (0.57, 3.08) 0.93 (0.37, 2.37) 1.52 (0.60, 3.84) 1.06 (0.46, 2.47) 1.44 (0.64, 3.24) 0.80 (0.35, 1.87) 1.76 (0.78, 4.00) 1.35 (0.47, 3.87) 0.57 (0.19, 1.72) 
CCNH rs2266691 0.41 (0.09, 1.90) 0.83 (0.41, 1.68) 0.86 (0.23, 3.20) 0.97 (0.54, 1.76) 0.68 (0.22, 2.14) 0.81 (0.43, 1.51) 1.19 (0.48, 2.95) 0.55 (0.24, 1.27) 1.23 (0.38, 3.97) 
  rs2266692 0.83 (0.28, 2.44) 1.04 (0.49, 2.20) 0.86 (0.33, 2.27) 1.01 (0.55, 1.87) 1.39 (0.49, 3.92) 1.09 (0.58, 2.03) 0.61 (0.24, 1.56) 0.84 (0.38, 1.85) 0.24 (0.03, 1.87) 
XPA rs3176757 1.62 (0.55, 4.75) 0.97 (0.47, 2.01) 2.04 (0.67, 6.20) 1.15 (0.61, 2.17) 1.24 (0.53, 2.91) 1.16 (0.61, 2.20) 0.67 (0.26, 1.71) 0.75 (0.32, 1.77) 0.89 (0.30, 2.65) 
  rs3176753 0.85 (0.35, 2.07) 1.00 (0.48, 2.06) 0.69 (0.21, 2.25) 1.09 (0.58, 2.05) 0.82 (0.31, 2.18) 0.86 (0.45, 1.68) 1.14 (0.49, 2.64) 0.78 (0.34, 1.84) 0.53 (0.16, 1.79) 
  rs3176748 0.20 (0.04, 0.93) 0.67 (0.32, 1.38) 1.04 (0.38, 2.83) 0.85 (0.46, 1.56) 0.53 (0.18, 1.54) 0.66 (0.35, 1.26) 0.99 (0.42, 2.31) 0.48 (0.20, 1.16) 0.65 (0.22, 1.93) 
  rs3176658      0.70 (0.15, 3.21) 1.15 (0.59, 2.25) 0.22 (0.03, 1.70) 0.98 (0.53, 1.79) 1.52 (0.57, 4.04) 0.87 (0.47, 1.60) 1.54 (0.61, 3.89) 0.79 (0.37, 1.70) 
   rs1800975 1.40 (0.45, 4.35) 1.16 (0.53, 2.53) 1.02 (0.36, 2.87) 1.03 (0.51, 2.09) 1.59 (0.75, 3.36) 1.11 (0.56, 2.22) 1.20 (0.55, 2.60) 0.91 (0.37, 2.21) 0.78 (0.26, 2.36) 
RAD23B rs1805330 1.45 (0.61, 3.42) 1.35 (0.54, 3.39) 1.06 (0.38, 2.98) 1.70 (0.76, 3.79) 0.97 (0.38, 2.45) 1.05 (0.46, 2.39) 1.46 (0.61, 3.48) 0.69 (0.25, 1.90) 1.85 (0.59, 5.73) 
ERCC6 rs2228529 1.24 (0.48, 3.23) 0.93 (0.44, 2.01) 1.26 (0.43, 3.68) 1.07 (0.54, 2.09) 1.27 (0.50, 3.22) 0.90 (0.45, 1.82) 1.51 (0.65, 3.54) 0.92 (0.38, 2.23) 0.54 (0.16, 1.78) 
  rs2228527  0.93 (0.36, 2.42) 0.89 (0.40, 1.96) 1.15 (0.41, 3.25) 1.08 (0.53, 2.18) 0.94 (0.37, 2.42) 0.83 (0.39, 1.78) 1.22 (0.55, 2.72) 0.77 (0.30, 1.94) 0.62 (0.20, 1.91) 
  rs4253132 0.97 (0.42, 2.23) 0.92 (0.41, 2.07) 1.11 (0.42, 2.88) 0.92 (0.44, 1.91) 1.40 (0.64, 3.06) 0.98 (0.47, 2.04) 1.01 (0.45, 2.24) 0.58 (0.22, 1.5) 1.18 (0.41, 3.44) 
  rs2228528 1.14 (0.47, 2.77) 1.10 (0.49, 2.44) 0.98 (0.37, 2.60) 0.98 (0.50, 1.91) 1.99 (0.81, 4.88) 0.82 (0.40, 1.68) 1.42 (0.65, 3.13) 0.80 (0.34, 1.89) 0.65 (0.17, 2.56) 
DDB2 (XPE) rs2029298 1.36 (0.50, 3.71) 2.20 (0.69, 7.03) 0.97 (0.33, 2.86) 1.41 (0.49, 4.01) 1.38 (0.53, 3.61) 0.88 (0.28, 2.79) 1.41 (0.53, 3.73) 0.31 (0.06, 1.62) 1.42 (0.48, 4.24) 
  rs1685404  0.71 (0.27, 1.85) 0.80 (0.32, 1.99) 0.99 (0.46, 2.17) 1.20 (0.60, 2.39) 0.82 (0.39, 1.71) 0.77 (0.38, 1.56) 1.07 (0.53, 2.15) 0.55 (0.18, 1.66) 0.75 (0.31, 1.80) 
  rs2957873 1.24 (0.46, 3.31) 1.30 (0.39, 4.34) 1.01 (0.35, 2.93) 1.48 (0.52, 4.20) 1.18 (0.44, 3.14) 1.00 (0.33, 3.01) 1.14 (0.44, 2.97) 0.98 (0.28, 3.44) 0.77 (0.25, 2.37) 
  rs326224 2.17 (0.70, 6.76) 2.38 (0.58, 9.70) 1.62 (0.49, 5.33) 2.07 (0.63, 6.82) 1.87 (0.60, 5.81) 1.33 (0.39, 4.54) 1.87 (0.62, 5.66) 1.21 (0.27, 5.4) 1.33 (0.39, 4.56) 
  rs2306353 1.24 (0.49, 3.15) 1.63 (0.56, 4.69) 0.90 (0.32, 2.54) 1.59 (0.62, 4.11) 1.06 (0.42, 2.67) 0.96 (0.35, 2.61) 1.12 (0.47, 2.71) 0.96 (0.29, 3.19) 0.76 (0.26, 2.20) 
  rs326222 2.17 (0.27, 17.58) 2.29 (0.23, 22.95) 2.04 (0.24, 17.15) 3.34 (0.36, 31.39) 2.07 (0.26, 16.40) 2.23 (0.25, 19.79) 1.98 (0.24, 16.16) 0.98 (0.09, 10.77) 1.73 (0.21, 14.60) 
  rs901746 1.50 (0.43, 5.30) 2.05 (0.47, 8.98) 1.27 (0.34, 4.77) 2.73 (0.66, 11.33) 1.34 (0.38, 4.69) 1.43 (0.37, 5.58) 1.32 (0.38, 4.61) 0.68 (0.12, 3.8) 1.18 (0.31, 4.52) 
ERCC5 (XPG) rs2296147 0.63 (0.23, 1.77) 0.76 (0.35, 1.64) 1.27 (0.51, 3.17) 0.78 (0.39, 1.55) 1.35 (0.66, 2.76) 0.99 (0.51, 1.93) 0.81 (0.37, 1.75) 0.76 (0.29, 1.97) 0.65 (0.25, 1.70) 
  rs2296148 1.77 (0.68, 4.59) 1.18 (0.57, 2.47) 0.80 (0.25, 2.59) 1.09 (0.57, 2.07) 1.81 (0.72, 4.58) 1.50 (0.76, 2.94) 0.59 (0.25, 1.39) 0.78 (0.33, 1.84) 0.88 (0.27, 2.87) 
  rs4771436  0.42 (0.15, 1.20) 0.86 (0.42, 1.76) 0.51 (0.14, 1.80) 0.77 (0.39, 1.53) 1.00 (0.48, 2.08) 0.74 (0.38, 1.44) 0.90 (0.42, 1.90) 0.44 (0.17, 1.13) 0.95 (0.35, 2.53) 
  rs1047768 0.48 (0.21, 1.14) 0.56 (0.21, 1.50) 0.75 (0.31, 1.82) 0.91 (0.40, 2.07) 0.62 (0.28, 1.34) 0.68 (0.30, 1.51) 0.63 (0.29, 1.37) 0.36 (0.11, 1.15) 0.56 (0.21, 1.47) 
  rs2020915 1.71 (0.72, 4.06) 1.33 (0.60, 2.97) 0.95 (0.35, 2.57) 1.58 (0.78, 3.19) 0.94 (0.41, 2.13) 1.02 (0.50, 2.10) 1.61 (0.73, 3.53) 0.84 (0.34, 2.10) 0.99 (0.33, 2.94) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), education, cigarette smoking, alcohol drinking, stage, and ancestry (% African ancestry).  
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006). 
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Table 6A cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall Survival among Head and Neck Cancer Cases in the Carolina Head and Neck 
Cancer Epidemiology (CHANCE) Study, African Americans 
  HR (95% CI)
a
 
Gene SNP 
Surgery, Variant 
Genotype 
Radiation, 
Referent 
Genotype 
Radiation, 
Variant 
Genotype 
Surgery and 
Radiation, 
Referent 
Genotype 
Surgery and 
Radiation, 
Variant 
Genotype 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Radiation and 
Chemotherapy, 
Variant 
Genotype 
Surgery, 
Radiation and 
Chemotherapy, 
Referent 
Genotype 
Surgery, 
Radiation, and 
Chemotherapy, 
Variant 
Genotype 
 ERCC5 (XPG) rs3818356 0.46 (0.16, 1.30) 0.88 (0.43, 1.82) 0.53 (0.15, 1.88) 0.79 (0.40, 1.57) 1.03 (0.50, 2.15) 0.73 (0.38, 1.42) 1.01 (0.47, 2.14) 0.46 (0.18, 1.17) 0.98 (0.36, 2.61) 
  rs4150355 0.88 (0.33, 2.34) 1.06 (0.49, 2.30) 0.84 (0.33, 2.14) 0.88 (0.45, 1.71) 1.60 (0.71, 3.61) 0.89 (0.45, 1.74) 1.06 (0.45, 2.49) 0.76 (0.32, 1.81) 0.59 (0.18, 1.92) 
 rs4150360          
  rs4150383 0.45 (0.13, 1.59) 0.92 (0.46, 1.85) 0.50 (0.11, 2.24) 0.94 (0.50, 1.75) 0.93 (0.39, 2.23) 0.8 (0.43, 1.49) 1.24 (0.53, 2.92) 0.58 (0.25, 1.36) 0.97 (0.29, 3.20) 
  rs17655 1.61 (0.43, 6.03) 1.08 (0.23, 5.03) 1.59 (0.43, 5.95) 2.21 (0.60, 8.21) 1.29 (0.35, 4.76) 1.04 (0.27, 4.01) 1.61 (0.46, 5.73) 1.60 (0.33, 7.75) 0.94 (0.23, 3.77) 
  rs873601       2.33 (0.29, 18.84) 1.62 (0.13, 19.61) 2.23 (0.28, 17.87) 2.87 (0.31, 26.61) 2.32 (0.29, 18.23) 1.44 (0.11, 18.15) 2.20 (0.28, 17.28) 2.90 (0.27, 31.76) 1.52 (0.18, 12.79) 
  rs876430 2.34 (0.29, 18.92) 1.62 (0.13, 19.7) 2.24 (0.28, 17.95) 2.88 (0.31, 26.62) 2.33 (0.30, 18.30) 1.58 (0.15, 17.00) 2.22 (0.28, 17.42) 2.92 (0.27, 31.94) 1.52 (0.18, 12.83) 
  rs1051677 1.51 (0.56, 4.05) 1.12 (0.55, 2.30) 0.91 (0.24, 3.35) 1.07 (0.55, 2.08) 1.56 (0.72, 3.37) 0.91 (0.47, 1.79) 1.50 (0.69, 3.24) 0.91 (0.40, 2.11) 0.52 (0.11, 2.36) 
  rs1051685 0.87 (0.35, 2.16) 1.02 (0.37, 2.83) 0.81 (0.30, 2.20) 1.53 (0.61, 3.85) 0.71 (0.29, 1.78) 0.86 (0.34, 2.16) 0.88 (0.34, 2.27) 0.61 (0.19, 1.92) 0.74 (0.25, 2.23) 
ERCC4 (XPF) rs3136038 2.40 (0.65, 8.81) 3.04 (0.74, 12.56) 1.52 (0.39, 5.91) 1.97 (0.50, 7.71) 2.35 (0.65, 8.50) 1.15 (0.28, 4.74) 2.62 (0.71, 9.68) 1.56 (0.31, 7.84) 1.50 (0.37, 6.19) 
  rs744154 0.87 (0.35, 2.19) 0.80 (0.37, 1.74) 1.34 (0.50, 3.60) 0.87 (0.44, 1.74) 1.49 (0.68, 3.24) 0.84 (0.42, 1.68) 1.22 (0.54, 2.73) 0.82 (0.34, 1.98) 0.47 (0.13, 1.71) 
  rs3136085 0.59 (0.23, 1.53) 0.63 (0.28, 1.44) 1.38 (0.55, 3.50) 1.00 (0.49, 2.07) 0.84 (0.40, 1.78) 0.92 (0.45, 1.90) 0.66 (0.30, 1.44) 0.68 (0.27, 1.68) 0.51 (0.16, 1.55) 
  rs3136091 1.21 (0.40, 3.65) 0.91 (0.44, 1.86) 1.61 (0.56, 4.65) 1.05 (0.57, 1.96) 1.52 (0.62, 3.75) 0.97 (0.51, 1.83) 1.21 (0.50, 2.94) 0.74 (0.32, 1.73) 0.84 (0.23, 3.08) 
  rs3136130 1.31 (0.45, 3.85) 1.52 (0.43, 5.34) 1.10 (0.36, 3.37) 1.84 (0.54, 6.32) 1.25 (0.43, 3.59) 1.10 (0.33, 3.69) 1.29 (0.43, 3.89) 0.91 (0.15, 5.33) 0.93 (0.28, 3.09) 
  rs3136172 0.94 (0.39, 2.29) 0.81 (0.37, 1.78) 1.37 (0.51, 3.70) 0.89 (0.44, 1.79) 1.52 (0.69, 3.35) 0.86 (0.42, 1.74) 1.22 (0.54, 2.75) 0.93 (0.38, 2.25) 0.40 (0.11, 1.46) 
  rs2020955  0.82 (0.30, 2.22) 0.82 (0.38, 1.78) 1.42 (0.56, 3.64) 1.21 (0.61, 2.38) 0.88 (0.42, 1.88) 1.09 (0.55, 2.18) 0.76 (0.36, 1.59) 0.74 (0.31, 1.75) 0.62 (0.19, 2.00) 
RAD23A rs2974752 1.52 (0.55, 4.20) 2.56 (0.72, 9.09) 1.13 (0.38, 3.33) 1.39 (0.46, 4.25) 1.56 (0.57, 4.28) 1.24 (0.41, 3.77) 1.61 (0.59, 4.41) 1.83 (0.31, 10.67) 1.05 (0.34, 3.24) 
  rs11558955 1.68 (0.54, 5.21) 1.11 (0.56, 2.23) 0.81 (0.22, 3.02) 1.21 (0.66, 2.22) 0.90 (0.33, 2.45) 0.97 (0.52, 1.81) 1.36 (0.52, 3.52) 0.92 (0.42, 2.02) 0.23 (0.03, 1.79) 
ERCC2 (XPD) rs13181 2.40 (1.05, 5.48) 1.33 (0.54, 3.23) 1.73 (0.66, 4.51) 1.47 (0.66, 3.24) 1.91 (0.84, 4.34) 1.6 (0.71, 3.58) 1.34 (0.60, 2.99) 1.04 (0.37, 2.92) 1.2 (0.43, 3.32) 
  rs238418                   
  rs1799787 2.72 (1.11, 6.68) 1.06 (0.49, 2.32) 2.26 (0.80, 6.39) 1.36 (0.68, 2.71) 1.92 (0.78, 4.70) 1.41 (0.70, 2.85) 0.87 (0.35, 2.20) 0.96 (0.4, 2.29) 1.18 (0.31, 4.47) 
  rs3916874 1.79 (0.54, 5.93) 1.12 (0.56, 2.24) 0.85 (0.18, 4.07) 1.23 (0.67, 2.28) 0.93 (0.32, 2.70) 1.06 (0.56, 2.00) 1.08 (0.40, 2.93) 0.79 (0.35, 1.8) 0.87 (0.18, 4.22) 
  rs238416 0.48 (0.14, 1.69) 0.78 (0.36, 1.67) 0.98 (0.37, 2.58) 0.74 (0.40, 1.38) 2.54 (1.11, 5.77) 0.83 (0.44, 1.57) 0.83 (0.30, 2.28) 0.75 (0.32, 1.76) 0.47 (0.16, 1.38) 
  rs50872 1.36 (0.56, 3.32) 0.86 (0.39, 1.90) 1.98 (0.70, 5.60) 1.17 (0.60, 2.28) 1.19 (0.49, 2.87) 1.22 (0.61, 2.46) 0.72 (0.30, 1.76) 0.77 (0.31, 1.90) 0.95 (0.31, 2.92) 
  rs50871 1.65 (0.65, 4.20) 1.15 (0.54, 2.47) 1.04 (0.40, 2.74) 1.12 (0.58, 2.16) 1.44 (0.65, 3.19) 1.03 (0.54, 1.98) 1.42 (0.57, 3.54) 1.00 (0.44, 2.29) 0.48 (0.13, 1.81) 
  rs238407 1.51 (0.63, 3.62) 0.87 (0.38, 2.02) 1.46 (0.61, 3.51) 1.01 (0.51, 2.00) 1.89 (0.85, 4.21) 1.10 (0.56, 2.15) 1.05 (0.42, 2.65) 1.03 (0.42, 2.53) 0.68 (0.24, 1.90) 
  rs3810366 1.35 (0.56, 3.21) 0.92 (0.39, 2.14) 1.22 (0.52, 2.90) 0.94 (0.47, 1.88) 1.81 (0.84, 3.93) 1.06 (0.53, 2.12) 1.03 (0.45, 2.36) 0.99 (0.39, 2.51) 0.71 (0.26, 1.90) 
ERCC1 rs735482 0.74 (0.32, 1.69) 0.65 (0.27, 1.59) 1.10 (0.45, 2.72) 0.85 (0.38, 1.9) 0.96 (0.43, 2.18) 0.83 (0.36, 1.87) 0.81 (0.36, 1.82) 1.00 (0.37, 2.68) 0.40 (0.13, 1.20) 
  rs2336219 0.73 (0.32, 1.69) 0.65 (0.26, 1.57) 1.11 (0.45, 2.74) 0.85 (0.38, 1.91) 0.96 (0.43, 2.18) 0.82 (0.36, 1.86) 0.81 (0.36, 1.82) 1.06 (0.40, 2.80) 0.34 (0.11, 1.09) 
  rs3212964 0.54 (0.22, 1.34) 0.67 (0.30, 1.48) 1.08 (0.42, 2.75) 0.78 (0.4, 1.52) 1.02 (0.43, 2.43) 0.77 (0.38, 1.54) 0.75 (0.34, 1.62) 0.60 (0.25, 1.45) 0.53 (0.16, 1.76) 
  rs3212955 2.10 (0.90, 4.86) 1.36 (0.53, 3.48) 1.56 (0.61, 4.00) 2.14 (0.93, 4.92) 1.23 (0.54, 2.84) 1.83 (0.82, 4.07) 1.03 (0.44, 2.43) 1.10 (0.41, 2.95) 1.10 (0.37, 3.29) 
  rs3212948                   
  rs3212935 1.02 (0.44, 2.32) 0.83 (0.34, 2.07) 1.12 (0.44, 2.87) 1.12 (0.51, 2.45) 1.03 (0.45, 2.37) 1.17 (0.52, 2.6) 0.84 (0.38, 1.85) 1.02 (0.37, 2.79) 0.56 (0.20, 1.62) 
  rs3212930 1.97 (0.76, 5.12) 1.03 (0.49, 2.15) 1.64 (0.57, 4.77) 1.30 (0.70, 2.41) 0.87 (0.27, 2.77) 1.13 (0.59, 2.15) 0.92 (0.35, 2.39) 0.81 (0.35, 1.87) 0.95 (0.26, 3.50) 
LIG1 rs156641 0.99 (0.37, 2.64) 1.12 (0.53, 2.40) 0.83 (0.30, 2.26) 1.14 (0.60, 2.19) 0.94 (0.38, 2.32) 1.02 (0.53, 1.93) 0.78 (0.29, 2.08) 0.97 (0.42, 2.26) 0.34 (0.09, 1.30) 
  rs20580 1.28 (0.36, 4.60) 1.03 (0.19, 5.64) 1.29 (0.35, 4.80) 1.47 (0.34, 6.40) 1.32 (0.38, 4.65) 0.93 (0.24, 3.64) 1.33 (0.37, 4.75) 1.06 (0.1, 11.74) 0.90 (0.23, 3.54) 
  rs20579 1.76 (0.72, 4.29) 1.81 (0.65, 5.04) 1.17 (0.44, 3.12) 1.46 (0.62, 3.42) 1.64 (0.67, 4.01) 1.49 (0.62, 3.57) 1.31 (0.53, 3.27) 1.01 (0.34, 2.97) 1.08 (0.37, 3.19) 
  rs439132 0.92 (0.39, 2.13) 0.93 (0.40, 2.17) 0.93 (0.37, 2.38) 1.18 (0.58, 2.43) 0.77 (0.32, 1.86) 0.70 (0.32, 1.55) 1.31 (0.60, 2.88) 0.84 (0.34, 2.10) 0.58 (0.19, 1.78) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), education, cigarette smoking, alcohol drinking, stage, and ancestry (% African ancestry).  
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006). 
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 Table 6A cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall 
Survival among Head and Neck Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
  RERI (95% CI)
a
 
Gene SNP 
Surgery, Variant 
Genotype 
Radiation, Referent 
Genotype 
Radiation, Variant 
Genotype 
Surgery and 
Radiation, Referent 
Genotype 
ERCC3 (XPB) rs4150496 0.17 (-0.86, 1.20) 0.05 (-0.97, 1.08) 0.64 (-0.19, 1.47) 0.99 (-0.13, 2.11) 
  rs4150459 0.52 (-0.51, 1.55) 0.74 (-0.14, 1.61) 0.59 (-0.15, 1.33) 0.38 (-0.47, 1.22) 
  rs1011019 -0.89 (-2.86, 1.08) -0.15 (-1.77, 1.47) -1.13 (-3.00, 0.75) -1.55 (-3.72, 0.63) 
  rs4150434 1.44 (0.08, 2.79) 0.22 (-0.62, 1.07) 0.93 (0.19, 1.68) 0.90 (-0.04, 1.85) 
  rs4150416 -0.18 (-1.78, 1.42) 0.48 (-0.60, 1.57) 0.24 (-0.89, 1.36) -0.49 (-2.46, 1.47) 
  rs4150407 0.55 (-0.30, 1.40) 0.55 (-0.19, 1.28) 0.43 (-0.28, 1.14) 0.61 (-0.11, 1.33) 
  rs4150402 -0.89 (-2.86, 1.08) -0.15 (-1.77, 1.47) -1.13 (-3.00, 0.75) -1.55 (-3.72, 0.63) 
XPC rs2228001 0.41 (-0.77, 1.60) 0.13 (-1.01, 1.28) 0.43 (-0.50, 1.37) -0.01 (-1.15, 1.12) 
  rs2228000     
  rs3731124 0.61 (-0.61, 1.84) 0.58 (-0.58, 1.73) 0.48 (-0.43, 1.40) 0.69 (-0.45, 1.83) 
  rs3731093 -1.05 (-3.6, 1.49) -0.41 (-3.04, 2.22) -1.72 (-4.09, 0.65)  
  rs3731089 -1.29 (-3.72, 1.14) -0.36 (-2.88, 2.16) -1.91 (-4.16, 0.34) 0.24 (-2.15, 2.63) 
  rs2733537 0.14 (-1.09, 1.37) 0.24 (-0.76, 1.24) -0.09 (-1.06, 0.88) 0.48 (-0.62, 1.58) 
  rs2607755 0.63 (0.10, 1.16) -0.09 (-1.16, 0.98) 0.39 (-0.20, 0.97) 0.61 (0.16, 1.05) 
  rs1902658 0.49 (-0.47, 1.44) -0.22 (-2.12, 1.68) 0.75 (0.29, 1.21) 0.14 (-1.17, 1.46) 
ERCC8 rs3117 -0.5 (-2.24, 1.23) -0.61 (-2.30, 1.07) -0.66 (-2.3, 0.98) -0.56 (-2.28, 1.15) 
CDK7 rs2972388 0.27 (-1.19, 1.73) 0.05 (-1.24, 1.34) 0.63 (-0.50, 1.76) -1.1 (-3.01, 0.82) 
CCNH rs2266691 0.62 (-0.68, 1.92) 0.30 (-0.73, 1.33) 0.97 (-0.15, 2.09) 1.27 (-0.20, 2.74) 
  rs2266692 -0.01 (-1.32, 1.3) 0.54 (-1.03, 2.12) -0.31 (-1.45, 0.83) -0.44 (-1.67, 0.79) 
XPA rs3176757 0.45 (-2.11, 3.01) -0.53 (-2.49, 1.44) -1.11 (-3.06, 0.84) -0.48 (-2.42, 1.46) 
  rs3176753 -0.16 (-1.38, 1.06) -0.11 (-1.27, 1.05) 0.42 (-0.62, 1.47) -0.10 (-1.21, 1.01) 
  rs3176748 1.17 (0.13, 2.21) 0.48 (-0.22, 1.17) 1.12 (0.38, 1.87) 0.96 (0.23, 1.70) 
  rs3176658      -0.63 (-2.06, 0.80) 0.84 (-0.90, 2.58) 0.98 (-0.64, 2.59)  
  rs1800975 -0.54 (-2.48, 1.40) 0.16 (-1.58, 1.89) -0.31 (-2.02, 1.41) -0.53 (-2.38, 1.32) 
RAD23B rs1805330 -0.74 (-2.56, 1.08) -1.17 (-3.05, 0.70) -0.03 (-1.36, 1.29) 0.71 (-1.16, 2.58) 
ERCC6 rs2228529 0.08 (-1.65, 1.80) -0.04 (-1.59, 1.51) 0.37 (-1.08, 1.81) -0.62 (-2.17, 0.93) 
  rs2228527  0.34 (-1.08, 1.76) -0.06 (-1.32, 1.19) 0.46 (-0.60, 1.52) -0.07 (-1.28, 1.14) 
  rs4253132 0.22 (-1.05, 1.48) 0.51 (-0.56, 1.58) 0.05 (-0.95, 1.05) 0.63 (-0.66, 1.92) 
  rs2228528 -0.26 (-1.74, 1.23) 0.87 (-0.84, 2.59) 0.47 (-0.73, 1.67) -0.29 (-1.71, 1.14) 
DDB2 (XPE) rs2029298 -1.6 (-4.55, 1.35) -0.39 (-2.15, 1.37) 0.16 (-1.13, 1.44) 0.75 (-0.51, 2.02) 
  rs1685404  0.49 (-0.59, 1.56) -0.09 (-1.15, 0.97) 0.59 (-0.25, 1.43) 0.49 (-0.47, 1.44) 
  rs2957873 -0.52 (-2.42, 1.38) -0.54 (-2.29, 1.21) -0.09 (-1.43, 1.24) -0.45 (-2.16, 1.26) 
  rs326224 -1.93 (-5.93, 2.07) -1.37 (-4.39, 1.66) -0.63 (-2.86, 1.61) -1.05 (-3.85, 1.76) 
  rs2306353 -0.96 (-3.05, 1.13) -0.77 (-2.56, 1.03) -0.07 (-1.33, 1.19) -0.44 (-2.07, 1.19) 
  rs326222 -1.42 (-7.13, 4.28) -2.44 (-10.25, 5.36) -1.42 (-6.73, 3.89) -0.42 (-3.91, 3.07) 
  rs901746 -1.29 (-4.67, 2.10) -1.90 (-6.03, 2.24) -0.61 (-2.85, 1.63) 0 (-1.78, 1.78) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), education, cigarette smoking, alcohol drinking, stage, and 
ancestry (% African ancestry).  
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006). 
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Table 6A cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall 
Survival among Head and Neck Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
  RERI (95% CI)
a
 
Gene SNP 
Surgery, Variant 
Genotype 
Radiation, Referent 
Genotype 
Radiation, Variant 
Genotype 
Surgery and 
Radiation, Referent 
Genotype 
ERCC5 (XPG) rs2296147 0.88 (-0.33, 2.08) 0.94 (-0.06, 1.93) 0.18 (-0.69, 1.06) 0.25 (-0.79, 1.3) 
  rs2296148 -1.15 (-3.22, 0.92) -0.05 (-2.16, 2.07) -1.67 (-3.78, 0.44) -0.66 (-2.63, 1.31) 
  rs4771436  0.22 (-0.69, 1.14) 0.80 (0.04, 1.56) 0.73 (0.05, 1.42) 1.08 (0.15, 2.00) 
  rs1047768 0.71 (-0.01, 1.44) 0.23 (-0.56, 1.01) 0.47 (-0.14, 1.07) 0.72 (0.10, 1.33) 
  rs2020915 -1.09 (-3.05, 0.86) -1.35 (-3.29, 0.59) -0.12 (-1.74, 1.49) -0.56 (-2.37, 1.25) 
  rs3818356 0.19 (-0.77, 1.14) 0.78 (-0.02, 1.58) 0.82 (0.07, 1.56) 1.06 (0.10, 2.03) 
  rs4150355 -0.10 (-1.38, 1.17) 0.83 (-0.46, 2.13) 0.29 (-0.79, 1.37) -0.05 (-1.25, 1.14) 
  rs4150360     
  rs4150383 0.13 (-0.94, 1.19) 0.55 (-0.43, 1.52) 1.00 (-0.06, 2.05) 0.94 (-0.28, 2.16) 
  rs17655 -0.10 (-2.18, 1.97) -1.54 (-4.94, 1.87) -0.04 (-1.77, 1.69) -1.27 (-4.65, 2.10) 
  rs873601       -0.71 (-5.20, 3.78) -1.88 (-8.45, 4.69) -0.56 (-4.64, 3.52) -2.72 (-11.21, 5.78) 
  rs876430 -0.72 (-5.24, 3.79) -1.88 (-8.46, 4.69) -0.70 (-4.89, 3.49) -2.74 (-11.28, 5.81) 
  rs1051677 -0.73 (-2.68, 1.23) -0.02 (-1.74, 1.71) 0.08 (-1.58, 1.74) -0.90 (-2.75, 0.94) 
  rs1051685 -0.08 (-1.33, 1.18) -0.69 (-2.29, 0.91) 0.15 (-0.78, 1.08) 0.26 (-0.75, 1.27) 
ERCC4 (XPF) rs3136038 -2.92 (-8.41, 2.56) -1.03 (-4.18, 2.13) 0.06 (-1.95, 2.07) -1.46 (-5.15, 2.23) 
  rs744154 0.67 (-0.75, 2.09) 0.74 (-0.40, 1.89) 0.50 (-0.54, 1.54) -0.22 (-1.44, 0.99) 
  rs3136085 1.16 (-0.03, 2.35) 0.25 (-0.63, 1.12) 0.15 (-0.65, 0.94) 0.24 (-0.65, 1.13) 
  rs3136091 0.49 (-1.49, 2.48) 0.25 (-1.54, 2.05) 0.03 (-1.57, 1.62) -0.11 (-1.86, 1.64) 
  rs3136130 -0.73 (-2.99, 1.52) -0.91 (-3.34, 1.53) -0.12 (-1.60, 1.36) -0.29 (-2.25, 1.67) 
  rs3136172 0.62 (-0.84, 2.08) 0.69 (-0.48, 1.86) 0.43 (-0.62, 1.47) -0.47 (-1.76, 0.82) 
  rs2020955  0.78 (-0.59, 2.14) -0.15 (-1.31, 1.02) -0.16 (-1.24, 0.92) 0.06 (-1.09, 1.20) 
RAD23A rs2974752 -1.95 (-5.56, 1.66) -0.35 (-2.15, 1.44) -0.14 (-1.72, 1.44) -1.29 (-4.81, 2.22) 
  rs11558955 -0.98 (-3.26, 1.29) -0.99 (-3.16, 1.17) -0.29 (-2.48, 1.90) -1.38 (-3.51, 0.75) 
ERCC2 (XPD) rs13181 -1.00 (-3.33, 1.33) -0.95 (-3.12, 1.21) -1.65 (-3.96, 0.65) -1.24 (-3.5, 1.02) 
  rs238418 0.13 (-0.94, 1.19) 0.55 (-0.43, 1.52) 1.00 (-0.06, 2.05) 0.94 (-0.28, 2.16) 
  rs1799787 -0.52 (-3.50, 2.47) -1.16 (-3.88, 1.55) -2.26 (-5.03, 0.52) -1.50 (-4.31, 1.31) 
  rs3916874 -1.06 (-3.63, 1.52) -1.09 (-3.52, 1.34) -0.76 (-3.07, 1.54) -0.71 (-3.25, 1.84) 
  rs238416 0.73 (-0.36, 1.81) 2.32 (0.36, 4.27) 0.52 (-0.49, 1.53) 0.24 (-0.69, 1.17) 
  rs50872 0.76 (-1.27, 2.79) -0.34 (-1.88, 1.20) -0.86 (-2.41, 0.69) -0.18 (-1.72, 1.37) 
  rs50871 -0.76 (-2.59, 1.07) -0.33 (-2.11, 1.46) -0.26 (-2.11, 1.60) -1.16 (-3.03, 0.70) 
  rs238407 0.07 (-1.57, 1.72) 0.36 (-1.33, 2.06) -0.56 (-2.17, 1.05) -0.87 (-2.55, 0.81) 
  rs3810366 -0.04 (-1.53, 1.46) 0.53 (-0.99, 2.05) -0.38 (-1.79, 1.03) -0.63 (-2.17, 0.91) 
ERCC1 rs735482 0.72 (-0.23, 1.67) 0.38 (-0.49, 1.24) 0.24 (-0.55, 1.04) -0.33 (-1.54, 0.88) 
  rs2336219 0.73 (-0.22, 1.68) 0.38 (-0.49, 1.24) 0.25 (-0.55, 1.04) -0.45 (-1.72, 0.82) 
  rs3212964 0.88 (-0.16, 1.91) 0.70 (-0.25, 1.65) 0.44 (-0.23, 1.11) 0.39 (-0.44, 1.22) 
  rs3212955 -0.89 (-3.06, 1.27) -2.01 (-4.56, 0.55) -1.90 (-4.23, 0.44) -1.09 (-3.21, 1.02) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), education, cigarette smoking, alcohol drinking, stage, and 
ancestry (% African ancestry).  
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006). 
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Table 6A cont. Hazard Ratios for Single Nucleotide Polymorphisms (SNPs) in Nucleotide Excision Repair (NER) Genes and Treatment on Overall 
Survival among Head and Neck Cancer Cases in the Carolina Head and Neck Cancer Epidemiology (CHANCE) Study, African Americans 
  RERI (95% CI)
a
 
Gene SNP 
Surgery, Variant 
Genotype 
Radiation, Referent 
Genotype 
Radiation, Variant 
Genotype 
Surgery and 
Radiation, Referent 
Genotype 
ERCC1 rs3212948 0.27 (-0.93, 1.47) -0.10 (-1.26, 1.06) -0.35 (-1.52, 0.83) -0.47 (-1.85, 0.91) 
  rs3212935 -0.35 (-2.84, 2.14) -1.40 (-3.60, 0.80) -1.18 (-3.24, 0.88) -0.83 (-3.04, 1.38) 
  rs3212930 -0.29 (-1.69, 1.12) -0.20 (-1.53, 1.14) -0.22 (-1.45, 1.00) -0.62 (-1.98, 0.73) 
LIG1 rs156641 -0.02 (-1.92, 1.89) -0.42 (-2.67, 1.83) 0.12 (-1.29, 1.53) -0.44 (-3.31, 2.44) 
  rs20580 -1.39 (-3.85, 1.07) -0.57 (-2.37, 1.22) -0.93 (-2.80, 0.93) -0.68 (-2.56, 1.20) 
  rs20579 0.09 (-1.05, 1.23) -0.33 (-1.50, 0.84) 0.69 (-0.18, 1.57) -0.18 (-1.32, 0.97) 
  rs439132 0.27 (-0.93, 1.47) -0.10 (-1.26, 1.06) -0.35 (-1.52, 0.83) -0.47 (-1.85, 0.91) 
HR hazards ratio, CI confidence interval 
a) HRs adjusted for matching factors (age and sex, including pairwise interactions), education, cigarette smoking, alcohol drinking, stage, and 
ancestry (% African ancestry).  
Highlighting indicates significant at 0.05 level. None significant at a Bonferroni corrected level (0.05/79=0.0006). 
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